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ABSTRACT	
Tissue	engineering	has	emerged	as	a	practical	approach	to	tackle	with	the	prosthetic	
industry	 limitations.	 Its	 methods	 merge	 aspects	 from	 developmental	 biology,	
engineering,	material	sciences	and	medicine,	with	the	aim	to	produce	fully-functional	
bone	tissue	ex	vivo,	to	further	replacement	or	regeneration	of	real	bone	injuries	and/	or	
defects.	Traditional	bone	tissue	engineering	cell	culture	technique,	includes	the	seeding	
of	SCs	in	three-dimensional	matrices,	cultured	in	fed-batch	rotating	bioreactors,	working	
jointly	with	biological	cues	to	produce	biomimics.	Nonetheless,	fed-batch	bioprocessing	
has	found	some	difficulties.	Namely,	mass	transport	limitations	in	the	seeded	scaffolds	
and	accumulation	of	cellular	waste,	yielding	poor	nutrition	and	oxygenation	of	the	cells.	
Thus	producing	heterogeneous	distributed	cell/	bone	constructs.	Perfusion	of	media	has	
been	 proven	 to	 improve	mass	 transport	 in	 the	 culture	 system,	 along	with	 removing	
cellular	waste.	To	overcome	heterogeneity,	finding	the	adequate	cells	and	proper	cues	
to	 drive	 osteogenic	 differentiation,	 are	 as	 important	 as	 the	 bioprocess	 to	 host	 the	
culture.	hDPSCs	are	a	promising	 source	of	 stem	cells	 for	 the	production	of	bioactive	
biomaterial	 for	 skeletal	 tissue	 reconstruction.	 They	 lodge	 immunosuppressive	 and	
regenerative	functions,	high	proliferation	rates	and	ease	in	access.	Their	source	and	the	
subtle	nature	of	the	extraction	procedure,	harbour	less	moral	concerns	and	variability	
than	ESCs	and	most	of	the	MSCs.	
In	this	study,	the	characterisation	of	hDPSCs	as	MSCs	under	the	minimal	criteria	set	by	
The	International	Society	for	Cellular	Therapy	was	performed.	Further,	the	osteogenic	
differentiation	 of	 hDPSCs	 encapsulated	 in	 alginate/	 gelatin	 hydrogel	 subjected	 to	
suspended	culture	in	a	novel	perfusion-RWV	bioreactor	was	studied,	and	compared	with	
traditional	fed-batch	and	static	culture	methodologies.	Finally,	the	effect	of	osteogenic	
cues	 as	 physiological	 BMP2	 and	 simvastatin	 were	 studied	 to	 enhance	 the	 designed	
bioprocess.	
The	characterisation	results	demonstrated	that	passage	4	donor	hDPSCs	were	ideal	to	
perform	the	3D	osteogenic	differentiation.	These	cells,	allowing	enough	production	of	
cells	while	maintaining	the	multipotent	phenotype	of	the	parental	cells	under	several	
conditions,	including	highly	dense	long-term	culture.	These	cells	were	able	to	undergo	
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osteogenesis	 in	 2D	 and	 3D.	 The	 novel	 high	 throughput	 perfusion-RWV	 bioreactor	
bioprocessing,	demonstrated	to	be	successful	in	the	mitigation	of	nutrient	and	oxygen	
transport	limitations,	external	to	three-dimensional	cell/alginate	constructs,	performing	
above	 fed-batch	 RWV	 bioreactor	 and	 static	 culture,	 and	 able	 to	 produce	 more	
homogeneous,	denser	and	functional	bone	constructs,	rich	in	mature	osteoblasts	and	
mineralising	 osteocytes.	 Both	 BMP2	 and	 simvastatin,	 demonstrated	 to	 enhance	 the	
quality	 of	 bone	 constructs	 produced	 by	 the	 perfusion-RWV	 unit,	 yielding	 more	
homogeneous	constructs,	with	higher	alkaline	phosphatase	activity,	mineralisation	and	
showing	a	more	mature	gene	pattern.	Interestingly.	BMP2	produced	constructs	rich	in	
mature	osteoblast,	while	simvastatin,	constructs	 rich	 in	osteocytes.	 In	particular,	 this	
experiment	proved	effective	in	producing	osteogenic	differentiation	with	minimal	use	
of	BMP2,	offering	a	potential	mean	to	avoid	dosage	dependant	safety	risks	of	BMP2.	
In	 conclusion,	 this	 thesis	 reports	 the	 development	 of	 a	 novel	 bioprocess	 to	 produce	
homogeneous	bone	tissue	constructs	able	to	support	the	transfer	of	the	“on	the	bench”	
research,	to	the	clinical	facility.	
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Overview	
The	need	for	bone	tissue	engineering	
In	the	United	Kingdom,	the	number	of	bone	fractures	reaches	approximately	2.3	million	
annually.	70,000/	100,000	hip	and	knee	replacement	surgeries	respectively,	are	carried	
out	yearly.	The	use	of	surgical	engraftment	implants	and	bone	screws	for	bone	failure	is	
increasing	 every	 year.	 A	 report	 from	 Global	 Industry	 Analysts	 (GIA),	 “Orthopaedic	
Prosthetics:	A	Global	Strategic	Business	Report”,	sets	the	global	orthopaedic	prosthetic	
market	 at	 £12.7	 billion	 and	 projects	 by	 2017	 the	market	 reaching	 £15.2	 billion.	 Yet,	
prosthetic	 replacement	 failure	 (e.g.	 peri-implant	 bone	 loss,	 infections	 and	 allergic	
reactions)	is	frequent.	This	is	due	to	implants	not	being	able	to	undergo	physiological	
remodelling	along	with	the	host	bones	(Yuan	et	al.,	2011).	Around	5%	of	all	prosthetic	
replacements	will	fail	eventually.	This	occurs	as	a	result	of	implant	rejection,	corrosive	
attack,	wear	and	mechanical	 loading,	and	due	 to	 lack	of	osseointegration	or	delayed	
union.	These	numbers	dramatically		rise	to	20%	for	high-impact	fractures	(NHFD,	2012,	
Brydone	 et	 al.,	 2010,	 Yuan	 et	 al.,	 2011).	 Furthermore,	 infections	 and	 rejections	 of	
implants	 could	 result	 in	 additional	 loss	 of	 bone,	 cartilage,	 muscle	 and	 tendon	mass	
(Brydone	et	al.,	2010);	and	ultimately,	in	the	requirement	for	secondary	implant.	If	we	
consider	the	size	of	the	prosthetics	industry	and	their	limitations,	it	is	clear	that	there	is	
a	necessity	for	further	development	into	an	actual	cure.	
Tissue	engineering	(TE)	encompasses	a	toolset	capable	of	tackling	with	the	prosthetic	
industry	limitations	using	a	more	biological	approach.	It	studies	embryo	development	
and	adult	healing	phenomena,	to	further	pioneer	materials	to	reconstruct	and	mimic	
not	 only	 the	 mechanical	 characteristics	 of	 bone,	 but	 also	 the	 functionality	 of	 the	
damaged	tissue.	TE	uses	cell	therapy	and	the	development	of	biomimetic	biomaterials	
to	provide	solutions	for	these	problems	with	greater	safety	and	long-term	durability	(see	
Figure	7	The	Tissue	Engineering	principles,	for	a	schematic	view).		
Research	in	this	field	has	been	able	to	provide	a	wide	variety	of	stem	cell	sources,	with	
bone	 mimicry	 potential.	 Including	 embryonic	 (ESCs),	 hematopoietic	 (HSCs),	 bone	
marrow-derived	(BM-MSCs),	umbilical	cord	blood-derived	(UCB-MSCs),	adipose	tissue	
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(ADSCs),	muscle	(MDSCs),	and	dental	pulp	(DPSCs)	(Seong	et	al.,	2010,	Peng	et	al.,	2009,	
Polak	 et	 al.,	 2008,	 Placzek	 et	 al.,	 2009);	 and	 by	 designing	 and	 using	 different	
bioprocessing	 systems,	 has	 been	 able	 to	 study	 the	 pathways	 associated	 with	
development,	as	well	as	to	produce	different	kinds	of	tissue	mimics.	Tissue	such	as	skin,	
neurons,	pigment	cells,	cardiac	muscle,	bone,	teeth,	cartilage,	tubule	cells,	pancreatic	
cells,	thyroid	cells	and	lung	cells,	able	to	promote	and	foster	in	vivo	tissue	regeneration	
(Placzek	et	al.,	2009,	Hwang	et	al.,	2009,	Pagkalos	et	al.,	2010b,	 Itskovitz-Eldor	et	al.,	
2000,	Peng	et	al.,	2009).		
	
	
	
Figure	1	Tissue	engineering	approach	
Human	dental	pulp	stem	cells	(hDPSCs)	are	a	promising	new	source	of	stem	cells	for	the	
production	of	bioactive	biomaterial	for	skeletal	tissue	reconstruction.	As	MSCs-like	cells,	
they	lodge	immunosuppressive	and	regenerative	functions.	They	are	multipotent	ecto-
mesenchymal	 stem	 cell	 (MSCs	 from	 the	 neural	 crest),	 capable	 of	 differentiating	 into	
	 18	
osteoblasts,	 osteocytes,	 odontoblasts,	 adipocytes,	 chondrocytes	 and	 neural	 cells	
(Grottkau	 et	 al.,	 2010).	With	 high	 proliferation	 rates	 and	 ease	 in	 access.	 DPSCs	 are	
located	 in	the	cell-rich	zone	of	the	dental	pulp	of	adults’	teeth	(similar	to	the	human	
exfoliated	deciduous	stem	cells	(SHEDs)	in	babies).	Their	source	and	the	subtle	nature	
of	 the	 extraction	 procedure,	 harbour	 less	 moral	 concerns	 than	 their	 predecessors’	
embryonic	stem	cells	(ESCs)	and	most	of	the	MSCs.		
Cells	from	impacted,	wisdom	and	exfoliated	teeth	were	previously	discarded	as	medical	
waste.	Now	they	have	an	upcycled	clinical	use	for	understanding	regenerative	cues	of	
the	 body	 and	 implementing	 regenerative	 medicine.	 They	 can	 be	 suitable	 for	 bone	
therapy,	 as	 they	 can	differentiate	 into	all	 the	 cells	 in	 the	osteoblastic	 and	osteocytic	
lineages,	as	well	as	synthesise	and	secrete	most	of	the	extracellular	matrix	secreted	by	
the	cells	they	would	replace.	
The	variability	and	low	potency	of	adult	MSCs	(in	comparison	with	immortalised	cells	
and	other	murine	stem	cells)	hinders	their	clinical	potential	and	classical	static	culture	
processing	has	not	been	able	to	aid.	Hence,	a	better	bioprocessing	 is	essential.	MSCs	
culture	requires	to	comply	with	several	specific	processing	requirements	to	be	of	clinical	
use	(quantity,	quality,	etc.)	and	the	TE	approach	not	only	can	tackle	these	requirements,	
but	also	optimise	them.		
This	PhD	thesis	summarises	the	efforts	carried	out	in	the	past	four	years.	The	aim	is	to	
support	the	use	of	perfusion	rotating	wall	vessel	systems	as	a	platform	for	bone	tissue	
engineering	 of	 hDPSCs,	 with	 the	 use	 of	 minimal	 growth	 factors.	 In	 particular,	 the	
characterisation	of	hDPSCs	as	MSCs-like	cells,	was	carried	out,	to	further	study	the	use	
of	different	bioprocesses,	as	a	tool	to	bypass	classical	bioprocessing	weaknesses	in	bone	
regeneration,	as	well	as	the	biological	cues	to	produce	all	the	osteoblastic	and	osteocytic	
lineage	cells.				
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Novelty	
I	will	be	discussing	how	a	novel	rotating	wall	vessel	system,	coupled	with	perfusion	flow	
of	culture	media,	with	minimal	use	of	growth	factors	(physiological	level)	or	drugs,	can	
achieve	 bone	 mimicry,	 starting	 from	 undifferentiated	 hDPSCs	 in	 a	 3D	 environment.	
Ultimately,	 leading	 to	 the	 induction	 of	 the	 whole	 range	 of	 cells	 in	 the	 osteoblastic	
phenotype,	 from	 pre-osteoblasts	 to	 the	 terminally	 differentiated	 osteocytic	 cells	 to	
produce	cells	for	clinical	uses.		
Similar	 platforms	 have	 been	 used	 to	 study	 osteoblastic	 differentiation	 of	 ESCs	 and	
different	MSCs	with	the	use	of	growth	factors,	but	using	concentrations	of	several	orders	
of	magnitude	higher	(Liu	et	al.,	2007,	Ghodadra	and	Singh,	2008,	Karbanova	et	al.,	2010).	
In	addition,	 the	ex-vivo	differentiation	of	hDPSCs	 in	three-dimensional	constructs	has	
never	 been	 followed	 and	 characterised	 till	 this	 extent,	 studies	 will	 normally	 pre-
differentiate	cells	to	then	move	to	an	in	vivo	platform.	
The	importance	on	reducing	the	concentration	of	growth	factors	proceeds	from	the	risk	
of	cancer	associated	to	their	use	(Singh	and	Morris,	2010,	Carragee	et	al.,	2013a)	and	
their	high	price.	The	production	of	all	cell	types	associated	with	bone,	ensures	that	the	
constructs	will	be	able	to	generate	functional	bone,	once	it	is	used	as	implants.		
In	addition,	a	fully	differentiated	human	bone-like	construct	represents	a	great	step	in	
regenerative	medicine,	as	it	would	allow	researchers	to	perform	preclinical	studies	for	
mechano-biology	and	drug	delivery	 in	a	cheaper	platform,	with	the	potential	 to	bear	
closer	similarities	(bioequivalence)	to	the	human	body.	Rather	than	performing	studies	
in	vivo.	Testing	of	new	drugs	in	an	ex	vivo	tissue,	to	minimise	the	generation	and	use	of	
human-animal	chimeras,	as	well	as	avoiding	animal	sacrifice	in	preclinical	trials,	should	
be	our	moral	aim.	Although	in	vivo	studies	are	considered	to	be	the	“gold	standard”;	in	
vitro	studies,	if	improved,	could	exceed	in	biological	value.	Reduced	costs,	more	direct	
assessing	 of	 product	 performance	 and	 less	 ethical	 considerations,	 are	 some	 of	 the	
advantages.	But	more	importantly,	avoiding	the	low	bioequivalence	of	highly	variable	
drug	testing	studies	 in	vivo.	 In	vitro	mimicry	of	tissues	can	in	time	provide	a	cheaper,	
more	defined	and	ethically	accepted	platform	for	stem	cells	research.	
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1.1 Bone	
Bone	tissue	refers	to	a	heterogeneous	family,	constituted	by	hierarchically	structured	
composite	 biomaterials	 of	 organic	 and	mineral	 nature.	 These	 share	 a	 basic	 building	
block,	 the	 hydroxyapatite	 crystals	 and	 the	 mineralised	 collagen	 fibrils.	 The	 most	
important	members	of	the	family	are	all	the	tissues	normally	called	bones;	but	cartilage,	
enamel,	dentin,	 cementum	and	mineralised	 tendons,	also	 form	part	of	 the	 family.	 In	
general,	bones	will	differ	in	the	proportions	of	the	common	components	(collagen	fibrils,	
hydroxyapatite	 crystals	 and	water)	 and	 in	 their	 structural	motifs/	 architecture	 at	 all	
levels	 of	 complexity.	 The	 diversity	 of	 structures	 they	 present,	 reflects	 their	 specific	
functionality,	 as	mechanical	 support	 and	 as	 reservoirs	 of	 calcium	 and	 phosphate	 for	
metabolic	functions	(Weiner	and	Wagner,	1998,	Jager	and	Fratzl,	2000).	
Bones	 are	 composed	 in	 20-30%	 in	 weight	 of	 an	 organic	 phase,	 60-70%	 of	 mineral	
substances	 and	 the	 remaining	 is	 water.	 The	 organic	 phase	 consists	 of	 mineralised	
collagen	fibrils,	non	collagenous	proteins	(around	200	different	types,	less	than	10%	of	
the	 total	 protein	 content),	 functional	 bone	 cells	 (osteocytes),	 bone	 forming	 cells	
(osteoblasts),	bone	resorbing	cells	(osteoclasts)	and	osteoinductive	growth	factors	and	
molecules.	Assemblies	of	parallel	and	staggered	molecules	of	type	 I	collagen	protein,	
form	channels,	where	 the	 reminder	compounds	will	be	allocated.	The	mineral	phase	
consists	only	of	hydroxyapatite	crystals	(𝐶𝑎# 𝑃𝑂&, 𝐶𝑂( ( 𝑂𝐻 ).		
The	skeleton	has	mainly	two	arranged	macro-architectural	 forms,	cancellous/	spongy	
bone	 (around	 20%	 of	 total	 bone)	 and	 cortical/	 compact	 bone	 (the	 remaining	 80%),	
different	proportions	of	these	two	structures	will	be	present	in	the	different	bone	family	
members.	
To	understand	the	complexity	of	the	tissue	in	discussion,	the	next	section	describes	the	
micro	and	macro	bone	structure	in	a	more	detailed	manner.	
1.1.1 Structure	of	bone	
The	main	components	in	bone	are	hydroxyapatite	crystals,	type	I	collagen	fibrils,	non-
collagenous	proteins	and	water.	Factors	that	determine	the	properties	and	function	of	
different	bones	are:	a)	the	proportion	and	organisation	of	crystals	and	water,	b)	the	size	
of	the	crystals,	c)	the	structures	these	form	with	the	collagen	fibrils,	d)	the	orientation	
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and	porosity	of	the	construct	and	e)	how	these	constructs	organise	 into	higher	order	
structures	(Weiner	and	Wagner,	1998,	Jager	and	Fratzl,	2000).	Bone	relative	proportions	
vary	systematically	between	bone	types.	Although	the	collagen	concentration	is	almost	
constant,	 the	 increase	 of	 minerals	 proportion	 occurs	 at	 expense	 of	 water	 content.	
Furthermore,	 the	 mineral	 phase	 will	 increase	 with	 ageing	 as	 the	 crystals	 continue	
growing	 over	 time	 (by	 thermodynamic	 factors).	 How	 they	 build	 in	 higher	 and	more	
complex	structures,	establish	the	different	characteristics	of	the	overall	biomaterial.	
Mineralised	Collagen	fibril	form	arrays	in	parallel	alignment	(fibres):	collagen	fibrils	can	
fuse	with	a	contiguous	fibril,	forming	fibres.	However,	there	will	be	coexistence	between	
mineralised	 and	 un-mineralised	 fibrils,	 producing	 local	 alignment	 of	 crystal	 layers	 in	
adjacent	fibrils	(Weiner	and	Wagner,	1998).	The	fibres	organise	in	a	variety	of	pattern	
depending	 on	 their	 direction,	 the	 formation	 of	 clusters	 and	 how	 packed	 they	 are,	
namely:	 arrays	 of	 parallel	 fibrils	 (lamellae),	 Woven	 fibre	 structure,	 plywood-like	
structure	(e.g.	sementum)	and	radial	fibril	arrays	(e.g.	dentin).	
Cylindrical	motifs,	osteons	and	canaliculi:	remodelling	and	regeneration	of	bones	results	
in	the	formation	of	cylindrical	motifs.	Osteoclast	resorption	of	bone	tissue	generates	a	
matrix	of	 tunnels.	 These	are	 then	 refilled	by	 lamellar	bone	produced	by	osteoblasts,	
leaving	minuscule	channels	 that	work	as	blood	vessels	called	osteons	and	a	group	of	
even	 smaller	 channels	 called	 canaliculi,	 in	 them	 we	 find	 osteocytes	 with	 secretory	
function	that	will	exchange	nutrients	through	the	bones.		
Cortical	 and	 cancellous	 bone:	 macro-structurally,	 there	 are	 two	 types	 of	 bone,	 the	
cortical	(or	compact)	and	the	cancellous	(or	spongy,	trabecular).	Normally,	bones	have	
a	dense	cortical	outer	layer,	and	a	spongy	cancellous	structure	within	its	interior.		These	
are	recognized	by	the	degree	of	porosity,	or	how	fenestrated	they	are.	
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Figure	2	Structure	of	compact	bones.	
Cancellous	 bone	 has	 a	 microstructure	 rich	 in	 irregular,	 unorganized	 and	 unpacked	
bundles	of	lamellae,	meanwhile	trabecular	bone	has	an	organized,	cylindrically	shaped	
and	packed	lamellae	(Rho	et	al.,	1998).	
A	whole	bone	is	a	construct	of	all	the	described	levels	structured	to	perform	a	specific	
function.	As	a	result,	each	bone	type	will	have	a	characteristic	porosity;	crystals,	osteons	
and	canaliculi	distribution;	and	mechanical	resistance.	
1.1.2 Bone	cells	
There	are	three	different	types	of	cells	in	bone	tissue:	Osteoblasts,	or	bone	forming	cells;	
Osteocytes,	or	bone	functional	cells;	and	Osteoclasts,	or	bone	resorbing	cells.	
Osteoblasts	secrete	the	organic	bone	matrix.	They	can	grow	and	will	be	active	in	all	areas	
where	bone	growth,	regeneration	or	remodelling	is	proceeding.	They	are	allocated	on	
the	 surface	 of	 bone.	When	 these	 get	 surrounded	 and	 isolated	 by	 bone	matrix,	 they	
develop	into	osteocytes.	
Osteocytes	are	mature	osteoblasts.	They	are	 found	within	 the	bone	matrix,	confined	
inside	 lacunae.	 These	 communicate	 to	 each	 other	 through	 processes	 running	within	
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canaliculi.	They	control	the	formation	and	resorption	of	new	and	old	bone	respectively	
and	work	 in	signalling	events	between	the	rest	of	the	organism.	Thus,	they	deal	with	
metabolic	requirements	and	mineral	homeostasis	of	bone.	
Osteoclasts	perform	extracellular	bone	matrix	resorption.	The	joint	labour	of	these	and	
osteoblasts	ensures	 the	equilibrium	 in	bone	structure,	 constituents	and	density.	This	
fine	equilibrium	is	managed	by	Osteocytes.	
1.1.3 Osteogenesis	
The	skeleton	develops	from	three	different	mesenchymal	cell	lineages.	The	somites	(or	
primitive	 segment),	 precursor	 of	 the	 axial	 skeleton;	 the	 lateral	 plate	 mesoderm,	
precursor	of	limb	skeleton;	and	the	cranial	neural	crest,	precursor	of	the	branchial	arch,	
craniofacial	 bone	 and	 cartilage.	 Osteogenesis	 can	 occur	 following	 two	 different	
mechanisms:	 intramembranous	 ossification	 (IO),	 where	 mesenchyme	 differentiate	
directly	 into	 vascularised	 osteoblasts	 at	 ossification	 centres;	 or	 endochondral	
ossification	(EO),	 in	which	the	formation	of	mineralised	bone	 is	 intermediated	by	the	
development	 of	 a	 cartilaginous	 scaffold	 (Gilbert	 et	 al.,	 2000).	 Both	mechanisms	 are	
accompanied	 by	 the	 secretion	 of	 a	 complex	 extracellular	 matrix	 (collagen,	 bone	
sialoprotein,	 proteoglycans,	 other	 proteins	 and	 crystalline	 salts),	 that	 initiates	 tissue	
mineralisation	to	form	the	calcified	bone	(Heng	et	al.,	2004b).	
In	general,	bone	development	 involves	four	phases:	1)	the	migration	of	mesenchyme	
with	 osteogenic	 potential	 to	 the	 skeletogenesis	 spot,	 2)	 mesenchymal–epithelial	
interactions,	condensation	(or	the	aggregation)	and	commitment	of	mesenchymal	cells,	
and	the	successive	differentiation	into	chondrogenic	and/	or	osteogenic	lineage.		
In	the	next	section,	the	two	mechanisms	of	osteogenesis	will	be	described	 in	a	more	
detailed	manner.	
1.1.3.1 Intramembranous	ossification	
IO	 starts	 in	 the	 second	 month	 of	 embryogenesis,	 and	 is	 characteristic	 of	 the	
development	 of	 flat	 bones	 of	 the	 skull	 (e.g.	 frontal,	 parietal,	 occipital,	 and	 temporal	
bones)	 and	 the	 clavicles.	 Mesenchyme	 from	 the	 neural	 crest	 proliferates	 and	
differentiates	forming	dense	clusters	of	cells	called	“Ossification	Centres”.	The	cells	will	
have	 two	possible	paths,	develop	 into	capillaries,	or	change	their	 shape	and	become	
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osteoid	secreting	osteoblasts	(pre-bone),	a	collagen-proteoglycan	matrix.	This	matrix	is	
able	to	bind	with	calcium	salts,	 letting	the	pre-bone	get	calcified.	The	osteoblasts	left	
trapped	 between	 osteoid	will	 become	 osteocytes	 and	 develop	 secretory	 properties.	
From	these	nodules	of	osteoblasts,	calcified	spicules	will	start	to	spread.	Furthermore	
the	area	will	be	enclosed	by	new	layers	of	compact	mesenchyme	(periosteum)	that	will	
differentiate	into	osteoblasts	and	secrete	a	new	layer	of	calcified	matrix	in	parallel	to	
the	spicules,	and	in	due	process,	propagating	the	bone	formation	(Gilbert	et	al.,	2000),	
and	thus,	the	growth	of	the	bone.	Bones	developed	at	this	stage,	are	woven-like	bones.	
With	further	development,	the	woven	bone	will	be	replaced	by	mature	lamellar	bone.	
In	the	most	inner	part	of	the	new	bone,	spongy	bone	will	persist.	Blood	vessels	are	going	
to	 infiltrate	 the	 spongy	 bone	 and	 trabeculae	 will	 be	 formed	 around	 them.	 The		
vascularised	tissue	will	become	red	marrow	(Marieb	and	Hoehn,	2013).		
In	Figure	3	Structure	of	flat	bones,	the	layout	produced	by	IO	can	be	seen	with	compact	
bone	in	the	exterior,	spongy	bone	in	the	inner	part,	and	blood	vessels	and	red	marrow	
in	the	interstice	between	the	trabeculae.	
	
Figure	3	Structure	of	flat	bones.	
1.1.3.2 Endochondral	ossification	
EO	 starts	 in	 the	 second	 month	 of	 embryonic	 development	 and	 will	 result	 in	 the	
formation	of	all	the	bones	of	a	human	being,	but	the	flat	bones	of	the	skull	and	clavicles	
(formed	 by	 IO).	 Bones	 are	 developed	 through	mesenchyme	 formation	 of	 a	 cartilage	
model,	 and	 its	 further	 breakdown	 and	 gradual	 replacement	with	 bone	 during	 foetal	
development	and	postnatal	growth	(Mackie	et	al.,	2008).	The	process	happens	in	five	
distinguishable	 stages.	 In	 the	 first	 stage,	 mesenchyme	 will	 proliferate,	 and	 get	
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committed	 to	differentiate	 into	hyaline	 cartilage	 (articular).	 In	 the	 second	 stage,	 the	
committed	 cells	 will	 flatten	 and	 aggregate	 into	 clusters	 and	 differentiate	 into	
chondrocytes	 (cartilage	 forming	 cells).	 In	 the	 third	 stage,	 the	 chondrocytes	 will	
proliferate	and	arrange	in	the	form	of	the	specific	bone	they	will	build.	The	cells	start	
secreting	cartilage	specific	extracellular	matrix.	In	stage	four,	the	chondrocytes	stop	the	
proliferation	 and	 start	 to	 grow.	 Increasing	 their	 volume	 dramatically,	 becoming	
hypertrophic	 chondrocytes.	 The	 matrix	 they	 secrete,	 contain	 collagen	 X	 and	 more	
fibronectin.	This	matrix	will	be	mineralised	with	carbonate	calcium.	In	the	fifth	stage,	
the	 cartilage	 scaffold	will	 be	 infiltrated	 by	 cells	 from	 the	 periosteum	 (layer	 of	 tissue	
surrounding	the	bone):	blood	vessels,	osteoclasts	(bone-resorbing	cells),	and	cells	with	
osteogenic	 (osteoblasts)	 and	 hematopoietic	 (bone	 marrow)	 properties.	 This	
“Ossification	 Front”	 forms	 the	 periosteal	 bud.	 The	 hypertrophic	 chondrocytes	 start	
dying	by	autophagic	cell	dead	and	are	resorbed	by	the	osteoclasts.	Later,	this	area	will	
become	 yellow	 bone	 marrow.	 Mesenchymal	 cells	 from	 the	 periosteum	 and	 the	
periosteal	 bud,	 start	 proliferating	 and	 secreting	 extracellular	 bone	 matrix	 (osteoid)	
attached	to	the	remnants	of	the	hyaline	cartilage	scaffold	left	by	the	osteoclasts.	The	
process	 starts	 from	 the	 centre	 (primary	 ossification	 centres),	 and	 propagates	 to	 the	
longitudinal	ends	(secondary	ossification	centres),	allowing	ossification	centres	to	form	
in	 the	 space	 where	 once	 cartilage	 was.	 Eventually	 all	 the	 cartilage	 is	 replaced	 by	
trabecular	bones,	except	at	the	articular	surfaces.	Where	hyaline	cartilage	remains	and	
the	 inner	part	where	the	marrow	cavity	 is	 formed	(Gilbert	et	al.,	2000,	Mackie	et	al.,	
2008).	 Further	development	makes	 the	external	 layers	 to	become	cortical	bone.	The	
remaining	 cartilage	 in	 the	 articular	 surfaces,	 will	 allow	 for	 the	 bone	 to	 grow	
longitudinally	during	post-natal	development	(Mackie	et	al.,	2008).		
See	 Figure	 4	 Endochondral	 Ossification	 (Marieb	 and	 Hoehn,	 2013),	 for	 a	 schematic	
representation	of	the	five	stages	of	EO.		
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Figure	4	Endochondral	Ossification	(Marieb	and	Hoehn,	2013)	
1.1.3.3 In	vitro	bone	ontogenesis	
The	 in	 vitro	 mechanism	 followed	 by	 MSCs	 to	 commit	 to	 osteogenic	 lineage	 and	 to	
produce	the	histo-architecture	of	neo-tissular	bone	recapitulates	and	is	closely	related	
to	its	analogue	in	vivo	mechanism.	It	is	governed	by	the	intrinsic	capabilities	of	the	cells	
and	the	expression	of	several	signalling,	growth	factors	and	cytokines	in	an	orchestrated	
cross-talking	to	regulate	its	key	stages	(Veillette	and	McKee,	2007,	Caplan,	1988).	It	will	
require	 the	 commitment	 of	 the	 undifferentiated	multipotent	 cells	 to	 the	 osteogenic	
lineage,	 and	 the	 differentiation	 into	 pre-osteoblasts	 (osteoinduction)	 (Urist,	 1965,	
Albrektsson	 and	 Johansson,	 2001).	 Signalling	 pathways	 normally	 associated	 with	
osteoinduction	 are:	 WNT	 Signalling,	 TGF-β	 Signalling,	 FGF	 Signalling	 and	 Bone	
Morphogenetic	proteins	signalling,	being	the	last	one,	one	of	the	most	studied.	In	Figure	
5,	a	scheme	of	this	cross-talk	can	be	seen.	
1.1.3.3.1 Regulation	of	osteogenesis	by	Bone	morphogenetic	proteins	signalling	
The	bone	morphogenetic	proteins	(BMP)	family,	is	a	secreted	cytokine/	growth	factor	
subfamily	of	the	transforming	growth	factor-β	(TGF-β)	superfamily	of	signals.	They	are	
multifunctional	 cytokines	 regulators	 of	 development,	 proliferation,	 differentiation,	
adhesion	and	apoptosis	in	different	cell	types	at	embryonic	and	adult	ages	(Kirkbride	et	
al.,	2008,	Miyazono,	2000).	Abundant	in	lung,	spleen	and	colon,	and	in	low	but	significant	
levels	in	heart,	brain,	placenta,	liver,	skeletal	muscle,	kidney,	pancreas,	prostate,	ovary	
and	small	intestine.	
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The	BMPs	signalling	pathway	has	widely	been	recognized	as	the	main	player	in	a	series	
of	developmental	processes	in	the	body,	and	the	disruption	of	them	has	been	connected	
to	 a	number	of	 bone	diseases	 (Chen	et	 al.,	 2012).	 They	 induce	and	are	essential	 for	
cartilage,	 tooth	 and	 bone	 formation,	 crystallisation	 and	 maturation,	 having	 major	
relevance	in	the	differentiation	of	stem	cells	in	vitro	and	in	vivo	into	osteogenic	lineage,	
through	 the	 induction	 of	 the	 expression	 of	 gene	 Runx2	 in	 early	 stage	 osteogenesis	
(preosteoblasts),	and	subsequently	with	the	expression	of		Osteocalcin	(BGLAP)	in	late	
state	osteogenesis	(osteoblasts)		(Wozney,	2002,	Chen	et	al.,	2004,	Bei	and	Maas,	1998).	
Both	BMP2	and	BMP7	have	been	approved	by	the	US	Food	and	Drug	Administration	
(FDA)	and	the	European	Medicines	Agency	(EMEA)	for	the	use	in	certain	types	of	bone	
fracture,	making	these	two	growth	factors	really	important	in	the	regenerative	medicine	
field	(Ghodadra	and	Singh,	2008,	Starman	et	al.,	2012).	
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Figure	 5	 The	 BMP	 and	 TGFβ	 canonical	 signalling	 pathways:	 BMPs	 contact	 surface	
receptor	BMPR-II,	forming	an	heterodimeric	complex	with	surface	receptor	BMPR-I,	
BMPR-I	gets	phosphorylated	and	interacts	with	the	transcription	regulators	R-SMADS	
(SMAD1/5/8)	 that	 react	 propagating	 the	 signal	 through	 C-SMAD	 (SMAD4)	 and	
translocate	to	the	nucleus,	then	they	interact	with	DNA	binding	proteins,	to	regulate	
gene	expression,	in	a	cascade	of	genes	(Runx2,	dlx5,	Msx2	will	trigger	Osterix)	that	will	
end	 up	 in	 osteoblasts	 differentiation.	 The	 TGFβ	 contact	 TGFβR-II,	 forming	 an	
heterodimeric	complex	with	TGFβR-I,	TGFβR-I	gets	phosphorylated	and	interacts	with	
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R-SMADS	 (SMAD2/3)	 that	 react	 propagating	 the	 signal	 through	 SMAD4	 and	
translocate	to	the	nucleus,	then	they	interact	with	DNA	binding	proteins,	to	regulate	
gene	 expression,	 in	 a	 cascade	 of	 genes	 (Runx2)	 that	 will	 lead	 to	 osteoblasts	
differentiation	 (Cai	 et	 al.,	 2012,	 Song	 et	 al.,	 2009,	 Yavropoulou	 and	 Yovos,	 2007).	
Dexamethasone	 through	 interacting	with	 the	glucocorticoid	 receptor	 (GCR)	protein	
suppressing	the	inhibitory	action	of	NFkB	(by	suppressing	TNF-α	signalling	inhibitory	
effect	and	its	NFkB	activation)	on	BMPs	induced	osteoblastic	differentiation	
BMPs	 and	 TGF-β	 signalling	 pathways	 are	 two	 highly	 interactive	 pathways,	 and	 their	
cross-talk	is	fundamental	in	the	osteoblastogenesis	and	osteoclastogenesis	(Chen	et	al.,	
2012).	Both	pathways	share	inhibitors	and	activators.	The	central	signal	messengers	for	
BMP	 and	 TGF-β	 are	 the	 Smad	 proteins.	 There	 are	 three	 subclasses	 of	 Smads:	 the	
pathway	restricted	Smads	(R-Smads,	i.e.	Smad1/2/3/5/8),	the	common	mediator	Smads	
(C-Smads,	i.e.	Smad4)	and	the	inhibitory	Smads	(I-Smads,	i.e.	Smad6/7).	BMPs	and	TGF-
β	are	mediated	by	Smad4	and	inhibited	by	Smad7.	A	diagram	of	the	canonical	pathway	
can	be	seen	in	Figure	5.		
The	 BMP	 signal	 transduction	 requires	 the	 interaction	 between	 two	 distinct	 types	 of	
transmembrane	 receptors	 forming	 a	 complex	 (BMPR-II,	 a	 high	 affinity	 receptor	 for	
ligand	binding	and	BMPR-I,	an	activator	of	the	signal	transduction),	that	will	spread	the	
signal	 through	 the	 cytoplasm	 by	 the	 interaction	 of	 pathway	 restricted	 Smads	
(Smad1/5/8	or	 r-Smads)	and	common	mediator	Smads	 (Smad4	or	c-Smads)	 to	 finally	
translocate	 the	 signal	 to	 the	 nucleus	 and	 regulate/	 generate	 a	 cascade	 of	 gene	
expression	that	will	end	up	in	osteoblastic	differentiation.	The	binding	of	BMPs	to	BMPR-
II	 results	 in	transphosphorylation	and	activation	of	the	BMPR-I	by	BMPR-II,	activating	
the	 BMPR-I	 and	 the	 subsequent	 signalling	 by	 the	 heterodimeric	 receptor	 complex.	
BMPR-I	 will	 bind,	 phosphorylate	 and	 then	 activate	 the	 Smad1/5/8	 transcriptional	
regulator,	 which	 as	 well	 will	 bind	 and	 form	 a	 complex	with	 Smad4	 to	 subsequently	
translocate	 into	 the	 nucleus.	 Inside	 the	 nucleus,	 the	 r-Smad/c-Smad	 complex	 will	
directly	 interact	 with	 DNA	 as	 well	 as	 with	 DNA-binding	 proteins	 directing	 the	
transcription	 of	 the	 targeted	 genes.	 The	 gene	 cascade	 will	 start	 with	 Runt-related	
transcription	factor	2	(Runx2	or	CBFA1),	followed	by	expression	of	collagen	I	(Col1)	and	
osteopontin	 (OPN	 or	 Spp1),	 osterix	 (OSX)	 in	 the	 preosteoblast	 stage	 (Komori,	 2010,	
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Matsubara	et	al.,	2008).	Mature	osteoblasts	keep	expressing	Col1	and	start	expressing	
osteocalcin	 (Bglap),	 but	 Runx2	 is	 kept	 in	 a	 constant	 level.	 The	 non-canonical,	 smad	
independent	signalling	pathway	(not	described	here),	 through	a	different	mechanism	
converges	to	the	same	gene,	Runx2.	
Runx2,	Sp7	transcriptional	factor	(SP7)	and	canonical	Wnt	signalling	will	be	determinant	
for	osteoblastic	differentiation.	After	BMPs	signalling	triggers	the	 induction	of	Runx2,	
the	initial	transcriptional	factor	to	form	a	preosteoblast,	Runx2	and	Wnt	signalling	finally	
direct	 the	 preosteoblast	 to	 a	 mature	 stage	 (Komori,	 2010).	 After	 commitment	 to	
osteoblasts	lineage,	cells	will	express	different	bone	matrix	protein	genes,	depending	on	
the	stage	of	the	cell	development,	immature	preosteoblasts	will	weakly	express	collagen	
I	 (Col1)	 and	 in	 a	 higher	 level	 osteopontin	 (OPN	 or	 Spp1)	 and	 osterix	 (OSX),	 forming	
unpacked	woven	bone	(Komori,	2010,	Matsubara	et	al.,	2008).	Mature	osteoblasts	will	
strongly	express	Col1	and	osteocalcin	(Bglap),	forming	a	densely	packed	lamellar	bone.	
Finally,	 when	 osteoblasts	 become	 osteocytes,	 they	 will	 express	 dentin	matrix	 acidic	
phosphoprotein	(Dmp1),	sclerostin	(SOST)	and	podoplanin	(E11).		
A	scheme	showing	the	transformations	from	MSC	to	osteocyte	can	be	seen	in	Figure	6.		
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Figure	 6	 Genes	 acting	 in	 the	 maturation	 of	 osteoblasts:	 from	 mesenchyme	 to	
osteocyte.	Modified	from	(Compton	and	Lee,	2014).	
1.1.4 Summary	and	Conclusions	of	this	section	
Bone	is	a	heterogeneous	tissue	with	high	structural	complexity.	The	composition	of	the	
major	components	will	ulteriorly	define	its	function.	This	complexity	is	accompanied	by	
a	convoluted	net	of	developmental	pathways,	that	will	allow	all	the	different	structural	
patterns	 in	 bone	 to	 be	 generated.	 In	 order	 to	 bio-mimic	 this	 tissue	 in	 vitro,	 these	
developmental	 pathways	 need	 to	 be	 studied,	 understood	 and	 controlled.	 A	 proper	
system	has	to	be	used	to	create	the	adequate	microenvironment,	that	will	enable	this	
to	happen.	Tissue	engineering	has	proven	to	be	a	discipline	with	all	the	tools	required	
to	 face	 the	 challenges	 involved,	 and	 is	 slowly	 becoming	 a	 leading	 actor	 in	 the	
development	of	bone	related	clinical	appliances	and	implants.					
In	the	next	section,	tissue	engineering	and	the	multidisciplinary	approach	it	can	provide	
to	tackle	bone	regeneration,	will	be	described.	
biomineralisation		
phosphate	excretion	
ECM	producing		
osteoid	producing		
osteoid	embeding		
dendritic	projections		
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1.2 Bone	tissue	engineering	
Regeneration	has	been	of	great	interest	to	investigators	since	long	ago.	Research	has	
been	 done	 with	 the	 focus	 in	 understanding	 the	 biological	 mechanisms	 beneath	 the	
development	and	regeneration	of	biological	tissues,	and	the	tools	this	knowledge	could	
engineer/	pioneer	to	help	medicine	and	the	prosthetic	industry.	That’s	how	in	the	last	
twenty	years,	the	advances	on	medicine	and	biological	sciences	guided	engineering	in	
the	footpath	of	Tissue	Engineering	(TE).	
Langer	and	Vacanti	defined	TE	as	“an	integrated	research	field	that	applies	the	principia	
of	engineering	and	 life	 sciences	 for	 the	development	of	biological	 replacements	 that	
restore	damaged	tissue	function”	(Langer	and	Vacanti,	1993).	Furthermore	the	nature	
of	 TE	 research,	 positions	 improve	 functionality	 of	 tissues	 at	 a	 glance	 (Salgado	 et	 al.,	
2004).	 From	 a	 clinical	 perspective	 this	 encompasses	 the	 production	 of	 in	 vitro	
engineered	tissues	for	in	vivo	transplantation.				
Bone	tissue	is	a	major	focus	of	interests	for	TE.	Its	complexity	has	drawn	the	attention	
of	many	researchers	with	the	believe	that	bone	could	be	recovered	through	enhancing	
regenerability	or	by	biomimicry,	rather	than	using	prosthetics.	
The	 orthopaedic	 industry,	 studying	 complex	 materials	 and	 designing	 devices,	 has	
produced	spare	bone	substitutes	able	to	partially	recover	damaged	bone.	Nevertheless,	
its	focus	has	not	been	to	find	cures,	but	design	putative	spare	devices.	Commonly,	bone	
cements,	metals	and	screws	are	used	to	fill	or	pin	gaps	and	replace	portions	of	bone;	
autologous	 and	 allogeneic	 engraftments	 are	 used	 to	 help	 healing	 of	 fractures	 with	
partial	success.	These	methodologies	work	for	the	most	common	and	simple	cases,	but	
as	mentioned	in	the	previous	section,	there	is	an	important	number	of	cases	in	which	
they	 fail.	 For	 these	cases,	graft	 surface	enhancement	with	bioactive	osteoconductive	
growth	 factors,	has	been	 tried,	but	with	 limited	 success.	 The	 lack	of	 functional	 cells,	
hinders	 the	 inclusion	of	 the	grafts	 to	 the	metabolic	normal	mechanisms	of	 the	bone	
environment,	and	 in	due	process	 its	maturation	 towards	 functional	 tissue.	Thus,	 it	 is	
required	to	find	a	better	answer	for	those	questions	(Navarro	et	al.,	2008,	Hench	and	
Polak,	2002).		
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Figure	7	The	Tissue	Engineering	principles	
Bone	 TE	 envisions	 new	 horizons:	 Going	 the	 logical	 one-step	 above	 the	 prosthetic	
industry,	trying	to	produce	in	vitro	engineered	bone	tissue	for	in	vivo	transplantation,	
studying	the	bone	healing	process.	And	in	due	process,	providing	the	next	generation	of	
tailor-made	biomaterials	that	mimic	bone	tissue.	Also,	offering	alternatively	to	repair	or	
regenerate	failing	bone	as	a	much	viable	method	of	accomplishing	its	goals.	
The	 use	 of	 living	 cells	 to	 produce	 biological	 substitutes	 to	 replace,	 repair	 and/	 or	
regenerate	 failing	 bone	 with	 functional	 living	 bone-alike	 constructs	 requires	 the	
growing/	fabrication/	implantation	of	bone	ex	vivo,	and/	or	the	growth	in	vivo	(Polak	et	
al.,	 2008).	 From	a	 cellular	perspective,	 the	actors	 involved	 in	bone	 regeneration	are:	
cells,	 extra	 cellular	 matrix	 (ECM),	 signalling,	 cellular	 dynamics	 and	 the	 interactions	
between	them.	
The	constant	research	in	TE,	has	lead	to	the	finding	of	a	variety	of	cell	sources	for	its	
purposes,	including:	embryonic	stem	cells	(ESCs),	hematopoietic	stem	cells	(HSCs),	adult	
stem	cells	(ASCs),	bone	marrow-derived	mesenchymal	stem	cells	(BM-MSCs),	umbilical	
cord	blood-derived	mesenchymal	stem	cells	(UCB-MSCs),	adipose	tissue-derived	stem	
cells	 (ADSCs),	muscle-derived	stem	cells	 (MDSCs),	and	dental	pulp	stem	cells	 (DPSCs)	
(Seong	 et	 al.,	 2010,	 Peng	 et	 al.,	 2009,	 Polak	 et	 al.,	 2008,	 Placzek	 et	 al.,	 2009);	 and	
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manipulating	these	cells	in	vitro	and	in	2D	static	systems	it	has	been	possible	to	mimic	
different	 types	 of	 tissues:	 bone	 cells,	 teeth	 cells,	 cartilage	 cells,	 skin	 cells,	 neurons,	
pigment	cells,	cardiac	muscle,	,	tubule	cells,	pancreatic	cells,	thyroid	cells	and	lung	cells	
(Placzek	et	al.,	2009,	Hwang	et	al.,	2009,	Pagkalos	et	al.,	2010b,	 Itskovitz-Eldor	et	al.,	
2000,	Peng	et	al.,	2009).	
However,	 researching	 cells	 on	 its	 own	 cannot	provide	 a	 comprehensive	 and	 suitable	
solution	 for	 bone	 regeneration.	 Bone	 cells	 are	 enclosed	 in	 a	 3D	 complex	
microarchitecture	coordinated	by	intricate	signalling	dynamics.	This	3D	environment	is	
subjected	to	mechanical	stresses	and	in	constant	interaction	with	adjunct	tissues.	
This	reasoning	has	led	bone	TE	bioprocessing	methodology	to	be	involved	in	four	areas	
of	 research:	 cells,	 scaffolding,	 nutrition/	 signalling	 and	 bioprocessing.	 These	 four	
components	are	key	to	emulate	the	conditions	in	which	the	body	normally	regenerates/	
develops	bone.	The	proper	healthy	cells	(type	and	source)	must	be	chosen,	seeded	and	
grown	in	order	to	produce	sufficient	amount	of	bone	cells;	the	scaffolding	to	provide	the	
microenvironment	required	to	support	the	cell	growth,	to	develop	and	mature	into	bone	
and	to	interact	and	integrate	with	the	surrounding	tissues	after	implantation;	signals	to	
stimulate	the	correct	response	from	the	cells	(growth	factors	or	ECM);	and	finally,	the	
system	 to	 seed	 the	 cells/	 scaffolds	 and	 provide	 the	 fluid	 dynamics/	 mass	 transfer/	
mechanical	stress	to	deliver	the	signalling	properly	(Polak	et	al.,	2008).		
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Figure	8	Scheme	for	in	vitro	development	of	bone	
In	Figure	8	Scheme	for	in	vitro	development	of	bone,		in	A)	the	static	and	B)	the	dynamic	
path	for	developing	bone	tissue	 in	vitro	can	be	seen,	where	cells	are	expanded,	then	
encapsulated	to	finally	be	scaled	up	and	differentiated	in	the	selected	platform.	
In	the	next	sections	each	of	the	four	areas	of	study	will	be	reviewed	in	a	more	thorough	
manner.	What	type	of	cells	is	suitable	for	bone,	which	scaffold	will	provide	the	milieu	
for	the	bone	cells	and	ECM	deposition,	what	cues	will	foster	bone	differentiation	and	
finally	what	platform	should	be	used	to	deliver	the	cues	and	to	sustain	a	healthy	cellular	
growth.	
1.2.1 Cell	sources	for	bone	Tissue	Engineering	
Cells	with	potential	for	bone	TE	can	be	supplied	exogenously	by	donors	or	by	biopsies	
from	the	patients	(autologous),	then	expanded	and	differentiated	in	vitro,	to	further	be	
transplanted.	To	accomplish	this,	it	is	necessary	to	find	a	reliable	and	renewable	source	
of	 healthy	 cells,	 that	 could	 be	 easily	 isolated	 and	 expanded	 into	 required	 quantities	
(quality	 is	 age	 dependant),	 that	 is	 compatible	 with	 humans,	 and	 that	 with	 the	
appropriate	cues,	 is	capable	of	enhancing	the	body’s	 regeneration,	 to	 finally	become	
part	of	it	(Boheler	and	Fiszman,	1999).		
B)
A)
encapsulation
seeding passaging collectingencapsulating differentiationSupplements and factors for 
osteogenic
differentiation
encapsulation
	 37	
The	 natural	 choice	 of	 cells	 with	 bone	 TE	 potential	 are	 Osteoblasts.	 These	 wouldn’t	
present	 an	 immunogenic	 reaction	 from	 the	 body	 when	 acquired	 autologously	 and	
further	 expanded	 in	 vitro,	 they	 wouldn’t	 require	 differentiation	 and	 they	 would	 be	
expected	to	be	fully	functional	bone	cells.	However,	these	cells	come	with	a	series	of	
limitations:	the	invasive	extraction	is	time	consuming	and	damaging	for	the	patient	or	
donor,	low	number	cell	extraction	yield	and	with	poor	expansion.	The	scale-up	of	these	
cells,	 comes	 followed	by	 senescence	and	 the	 loss	of	 their	phenotypes	 (Luyten	et	 al.,	
2001).	Additionally,	cells	could	have	compromised	their	quality	if	the	donors	present	an	
impaired	functionality	of	osteoblasts	product	of	bone	diseases.		
Xenogeneic	cell	(non-human)	could	cope	with	the	low	number	of	cells.	However,	they	
come	 with	 immunogenic	 reactions	 and	 phenotypic	 mismatch,	 ultimately	 leading	 to	
rejection	of	the	tissue	and	further	health	complications.		
The	 early	 development	 of	 embryos	 and	 the	 self-repair	 mechanisms	 of	 the	 body,	
together	harbour	a	source	of	cells	that	complies	the	requirements	of	TE,	the	stem	cells.	
These	have	the	remarkable	potential	 to	expand	and	give	rise	to	all	 the	tissues	 in	 the	
body.	Being	in	charge	of	the	development	of	the	body	at	early	stage,	and	the	growth	
and	 regenerative	 processes	 after	 birth.	 Since	 their	 discovery,	 they	 have	 become	 an	
obvious	place	 to	 research	 for	alternative	 treatments	 to	 tackle	 the	disadvantages	and	
weaknesses	of	the	prosthetic	industry.	If	properly	handled	and	guided,	they	posses	the	
key	 to	 empowering	 the	 regenerability	 of	 the	 body,	 and	 ultimately	 of	 curing	 many	
different	diseases	and	injuries.	
To	choose	the	proper	source	of	cells,	it	has	to	be	considered:	1)	The	immune	response	
of	 the	 body	 towards	 them,	 2)	 Its	 ability	 to	 proliferate,	 3)	 Its	 location	 and	 ease	 of	
extraction,	and	3)	the	feasibility	to	differentiate	into	specific	functional	cell	types.	This	is	
a	huge	advantage	for	stem	cells	(SCs),	especially	the	embryonic	stem	cells	(ESCs),	over	
any	kind	of	somatic	cells.	As	SCs	are	normally	involved	in	repairing	damage	tissue,	they	
do	not	need	to	be	local,	they	have	certain	level	of	ubiquity	in	their	use,	although	some	
of	them	are	subjected	to	specific	cell	lines	or	a	closely	related	family.	It	will	depend	on	
the	potency	of	the	cells:	
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• Totipotent	 stem	 cells:	 cells	with	 the	 ability	 to	 give	 rise	 to	 all	 the	 cell	 lineages	 of	 an	
organism	(embryonic,	somatic,	and	germ	cells),	being	able	to	produce	a	hole	organism;	
in	mammalians	only	the	zygote	and	the	first	cleavage	blastomeres	are	totipotent.	
• Pluripotent	 stem	 cells:	 cells	 with	 the	 ability	 to	 give	 rise	 to	 the	 three	 germ	 layers	
(endoderm,	 mesoderm,	 ectoderm).	 In	 this	 group	 of	 cells	 we	 find	 the	 ESCs	 and	 the	
induced	pluripotent	stem	cells	(IPSs).	
• Multipotent	stem	cells:	adult	cells	with	the	ability	to	give	rise	to	multiple	cell	types	of	
one	 lineage.	 Good	 examples	 are	 the	 bone	marrow-derived	mesenchymal	 stem	 cells	
(BMSCs).	
• Unipotent	 stem	 cells:	 cells	 able	 to	 give	 rise	 only	 to	 one	 cell	 type.	 Good	 example	 is	
spermatogonial	stem	cells	(can	only	generate	sperm).	
• Somatic	cells:	cells	that	form	every	tissue	from	the	body	of	an	organism,	different	from	
a	gamete	or	any	kind	of	stem	cells.	
	
Figure	9:	Cell	sources	(Seong	et	al.,	2010)	
1.2.2 Pluripotent	stem	cells		
SCs	are	clonal	precursors	able	 to	self-renew	or	 to	differentiate	 into	other	specialised	
cells.	There	are	different	types	of	stem	cells,	presenting	unique	challenges	and	benefits	
for	the	manufacture	of	therapeutics	for	the	clinic	(Placzek	et	al.,	2009).	
1.2.2.1 Embryonic	stem	cells		
SCs	of	embryonic	origin	comprise:	embryonic	stem	cells	(ESCs)	that	are	derived	from	the	
inner	cell	mass	of	blastocyst-stage	embryos;	as	well	as	embryonic	germ	(EG)	cells,	that	
are	 cells	 derived	 from	 the	 developing	 foetal	 gonadal	 ridge.	 Additionally,	 embryonal	
carcinoma	 (EC)	 cells	 that	develop	 from	 testicular	 tumour	 can	be	 considered	as	ESCs,	
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although	this	 is	controversial	 (Heng	et	al.,	2004a,	Vallier	et	al.,	2009).	These	cells	are	
capable	of	indefinite	expansion	and	can	give	rise	to	any	cell	lineages	(pluripotent).	An	
early	study	made	by	Smith	et	al.	showed	that	murine	ESCs	in	absence	of	heterogeneous	
feeder	cells	can	sustain	undifferentiated	growth,	when	 in	presence	of	cytokines	with	
differentiation	inhibitory	activity	(DIA),	as	Leukemia	Inhibitory	Factor	(LIF)	(Smith	et	al.,	
1988).	 In	 the	 absence	 of	 these	 conditions,	 ESCs	 lose	 its	 self-renewal	 capacity	 and	
pluripotency	and	do	not	persist	more	than	a	small	number	of	days.	Similar	observations	
were	made	by	Watanabe	et	al.	when	studying	human	ESCs	and	the	use	of	Rho	kinase	
(ROCK)	 inhibitor,	 when	 cultured	 with	 or	 without	 a	 growth	 inactivated	 feeder	 layer	
(Watanabe	et	al.,	2007,	Claassen	et	al.,	2009).	Therefore,	under	the	proper	conditions,	
ESCs	 can	 be	 maintained	 in	 an	 unlimited	 self-renewal	 undifferentiated	 state,	 or	 be	
differentiated	into	any	cell	lineage	in	vivo	and	in	vitro.	
Table	1:	The	different	signalling	pathways	involved	in	self-renewal	and	pluripotency	
of	hESCs	
Genetic	factor	 Name	 Family	 Function	
Oct	 4	 (Oct-3,	 Oct-
3/4,	Pou5f1)	
Octamer	 binding	
factor	 POU	
initial	development	and	maintainance	
of	pluripotency	
STAT3	
Signal	 transducers	
and	 activators	 of	
transcription	
DNA-
binding	
activation	 via	 LIF	 and	 glucoprotein	
130	 is	 esencial	 for	 maintaining	
pluripotency	
Nanog	 	 Homebox		
maintain	ESC	self	renewal	in	absence	
of	LIF/gp130/STAT3	
Sox	2	
Tex	 determining	
region	Y	box	2	 HMG	 self	renewal	growth	
	
In	Table	1,	some	of	the	signalling	pathways	associated	with	growth	and	pluripotency	can	
be	seen,	a	thorough	description	can	be	seen	in	Figure	10	Stem	cell	pathways	(Walia	et	
al.,	 2012)	 where	 all	 the	 known	 pathways	 associated	 with	 pluripotency	 and	
differentiation	are	shown.	
None	of	these	pathways	suffice	to	sustain	the	self-renewal	and	pluripotency	of	hESCs,	
and	 hence	 prevent	 spontaneous	 differentiation.	 Factors	 and	 signalling	 remain	 to	 be	
elucidated	in	further	studies	(Humphrey	et	al.,	2004,	Daheron	et	al.,	2004).	
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These	characteristics	of	ESCs	allow	them	to	be	one	of	the	most	useful	cell	sources	for	TE	
and	 regenerative	 medicine.	 Lineage	 specific	 differentiation	 of	 ESCs	 can	 be	 directed	
under	specific	culture	conditions	and	by	manipulating	the	microenvironment.	Recently,	
substantial	attention	has	been	given	 to	directing	ESCs	differentiation	 into	osteogenic	
lineage	and	other	lineages	of	the	human	body	(Seong	et	al.,	2010).	
Currently,	efforts	are	being	made	to	produce	patient-tailored	ESC	lines	that	overcome	
immunological	rejections.	However,	ESCs	have	negative	aspects	to	consider:	they	are	
capable	of	 teratoma	 formation,	 the	differentiated	 fate	 they	 follow	 is	very	difficult	 to	
control,	 and	 they	 elicit	 ethical	 considerations	 due	 to	 the	 destruction	 of	 the	 embryo	
(Placzek	et	al.,	2009).	All	these	factors	hinder	the	application	of	ESCs	in	cell	therapy.	And	
in	the	process	to	cope	with	them,	the	induced	pluripotent	stem	cells	were	developed	
(Takahashi	et	al.,	2007).	
1.2.2.2 Induced	Pluripotent	Stem	cells	
Induced	pluripotent	stem	cells	(iPSCs)	are	adult	somatic	cells	reprogrammed	in	vitro	to	
an	embryonic-like	pluripotent	state	by	 the	 introduction	and	 forced	expression	of	 the	
main	genes	and	factors	associated	with	pluripotent	cells	(Walia	et	al.,	2012).	Mouse	and	
human	fibroblasts	can	be	reprogrammed	by	transduction	with	a	complex	combination	
of	transcriptional	factors	(Oct	3/4,	Sox2,	Klf4,	and	c-Myc	or	alternatively	Oct3/4,	Sox2,	
Nanog,	 and	 Lin28).	 Yamanaka	 et	 al.	 reprogrammed	 fibroblasts	 by	 defined	 factors,	
without	the	use	of	vectors	(Takahashi	et	al.,	2007,	Yamanaka,	2007).	The	cells	resulting	
from	the	reprogramming,	attain	an	ESCs-like	state	able	of	indefinite	proliferation,	with	
the	sustained	capacity	to	differentiate	into	cell	types	characteristic	of	all	the	three	germ	
layers	 in	 vitro	 and	 in	 vivo.	 These	 express	 most	 of	 the	 markers	 associated	 with	
pluripotency,	 having	 epigenetic	 and	morphological	 characteristics	 similar	 to	 those	 of	
ESCs.	Although	 the	potential	of	 iPSCs	compared	with	 that	of	ESC	 fluctuates	between	
similar	 to	 less	 effective	 depending	 on	 the	 cell	 lines	 tested	 and	 the	 differentiation	
analyses	performed	(Bilousova	et	al.,	2011).	However,	 it	remains	to	be	demonstrated	
whether	both	 cell	 types	 rely	on	 similar	mechanisms	 to	maintain	pluripotency	and	 to	
drive	their	differentiation	(Vallier	et	al.,	2009).	
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The	 known	 molecular	 pathways	 acting	 in	 maintenance	 of	 pluripotency	 and	
differentiation	can	be	seen	in	the	Figure	10	Stem	cell	pathways	(Walia	et	al.,	2012).	
Although	iPSCs	do	not	elicit	ethical	considerations	as	their	close	relatives,	the	ESCs;	they	
have	lower	expansion	and	differentiation	rates.	But	most	importantly,	they	still	lack	in	
safety	standards.	Not	only	they	carry	the	possibility	of	producing	teratogenesis	in	the	
hosts	 as	 ESCs,	but	 also	 they	 introduce	a	new	negative	 factor	 to	 consider,	 the	use	of	
dangerous	vectors	(lentiviruses,	retroviruses,	adenoviruses,	plasmids,	transposons	and	
recombinant	proteins)	required	to	achieve	cell	reprogramming	(Das	and	Pal,	2010).	
	
	
Figure	10	Stem	cell	pathways	(Walia	et	al.,	2012)	
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1.2.3 Multipotent	stem	cells	
Multipotent	 stem	 cells	 or	 adult	 mesenchymal	 stem	 cells	 (MDCs)	 are	 anchorage-
dependent,	 fibroblastic	 spindle-shaped,	 undifferentiated	 cells	 found	 throughout	 the	
adult	body.	They	belong	to	specific	niches	in	different	organs,	playing	a	critical	role	in	
postnatal	tissue	development	and	healing	(Yu	et	al.,	2007).	These	cells	heal	damaged	
tissue	and	replace	dying	cells.	They	present	an	immunomodulatory	effect,	in	vitro	and	
in	vivo	studies	have	demonstrated	that	these	cells	can	suppress	T	cells	proliferation	and	
decrease	the	production	of	various	 inflammatory	cytokines	(Fibbe	et	al.,	2007).	Adult	
stem	cells	have	been	used	clinically	 since	1950s,	when	stem	cell	 transplantation	was	
introduced	for	the	first	time,	using	bone	marrow-derived	stem	cells.	Since	then,	many	
types	of	MSCs	have	been	identified	in	the	body,	offering	alternative	possibilities,	which	
originate	from	easier	to	harvest	and	less	invasive	cell	sources,	such	as	fat,	skin,	olfactory	
cells	and	peripheral	blood	(PB)	(Placzek	et	al.,	2009).	
MSCs	have	been	isolated	from	the	connective	tissue	of	almost	every	organ,	suggesting	
a	role	as	a	storage	and	regenerative	pool	for	the	various	mesenchymal	tissues.	Several	
studies	have	been	successful	in	evaluating	the	capability	of	MSCs	for	their	feasibility	and	
efficacy	 in	 healing	 cartilaginous,	 osseous,	 tendon	defects	 or	 even	 in	 treating	 genetic	
disorders	such	as	osteogenesis	imperfecta	or	Duchenne’s	muscular	dystrophy	(Schultz	
et	al.,	2000).	
MSCs	 sources,	 bone	 marrow-derived	 mesenchymal	 stem	 cells	 (BM-MSCs),	 umbilical	
cord	blood-derived	mesenchymal	stem	cells	(UCB-MSCs),	adipose	tissue-derived	stem	
cells	 (ADSCs),	muscle-derived	stem	cells	 (MDSCs),	and	dental	pulp	stem	cells	 (DPSCs)	
(Seong	 et	 al.,	 2010,	 Peng	 et	 al.,	 2009,	 Polak	 et	 al.,	 2008,	 Placzek	 et	 al.,	 2009);	 and	
manipulating	this	cells	they	have	been	able	to	produce	different	kinds	of	cell	 tissues.	
When	 stem	 cells	 are	 supplemented	 with	 hydrocortisone,	 insulin,	 T3,	 EGF,	 VD3	 and	
ascorbic	 acid,	 they	 differentiate	 into	 skin	 cells	 when	 grown	 in	 collagen/	 poly(l-lactic	
acid)–co-poly(3-caprolactone)	nanofibrous	scaffolds	(Jin	et	al.,	2011).	Moue	and	human	
SCs	 in	 vitro	 can	 be	 differentiated	 to	 neural	 cells,	 when	 cultured	 in	 growth-factor-
minimized	medium,	in	what	is	called	intrinsic	transition	(Kamiya	et	al.,	2011).	pigment	
cells,	cardiac	muscle,	bone	cells,	teeth	cells,	cartilage	cells,	tubule	cells,	pancreatic	cells,	
thyroid	 cells	 and	 lung	 cells	 are	 other	 examples	 of	 cells	 that	 have	 been	 produced	
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bioprocessing	stem	cells	(Placzek	et	al.,	2009,	Hwang	et	al.,	2009,	Pagkalos	et	al.,	2010b,	
Itskovitz-Eldor	et	al.,	2000,	Peng	et	al.,	2009).	
In	 the	postnatal	 state,	 cells	with	osteogenic	potential	persist	 in	 the	bone	marrow,	 in	
dental	 pulp	 and	 in	 other	 cell	 niches.	 They	 play	 an	 integral	 part	 in	 bone	 growth	 and	
remodelling,	as	well	as	in	bone	repair	during	postnatal	life	(Heng	et	al.,	2004b).	These	
cells	 continuously	 replicate,	 while	 some	 become	 committed	 to	 cell	 lineages	 such	 as	
bone,	 cartilage,	 tendon,	 ligament,	 and	muscle.	 The	 differentiation	 of	 these	 cells	 is	 a	
complex	multistep	pathway	involving	distinct	cellular	transitions.	Progression	depends	
on	the	presence	of	specific	bioactive	factors,	nutrients,	and	other	microenvironmental	
cues	whose	controlled	action	orchestrate	the	differentiation	phenomenon	(Bruder	et	
al.,	1994).	
The	International	Society	for	Cell	Therapy	(ISCT)	proposes	as	sufficient	criteria	to	define	
a	 human	 MSCs	 the	 following:	 MSC	 must	 be	 plastic-adherent	 when	 maintained	 in	
standard	culture	conditions,	must	express	the	surface	markers	CD105,	CD73	and	CD90,	
and	 lack	expression	of	CD45,	CD34,	CD14	or	CD11b,	CD79alpha	or	CD19	and	HLA-DR	
when	measured	in	flow	cytometry.	They	must	differentiate	to	osteoblasts,	adipocytes	
and	chondroblasts	in	vitro.	These	panel	of	criteria	represents	the	commonly	used	and	
allows	a	standardised	study	of	MSCs		(Dominici	et	al.,	2006).	
1.2.3.1 Dental	pulp	stem	cells.	
Dental	pulp	stem	cells	(DPSCs)	are	an	interesting	and	particular	source	for	adult	stem	
cells.	 They	 have	 ease	 in	 access	 and	 extraction,	 a	 high	 proliferation	 ability	 and	
multipotency	and	they	do	not	elicit	ethical	considerations	as	their	extraction	is	one	of	
the	less	invasive	between	SCs.	
DPSCs	are	particular,	they	come	from	a	family	of	MSCs	called	the	ectomesenchyme,	as	
it	can	be	seen	in	Figure	11	Stem	cell	fate.	In	embryonary	development,	they	arise	from	
the	neural	crest,	which	 is	committed	to	ectomesenchyme	by	order	of	FGFs	signalling	
upon	entering	the	pharyngeal	arches.	Hence	it	is	directed	by	epithelial	cues	within	the	
arches,	making	the	cells	STRO-1	positive,	as	many	mesenchymal	stem	cells.	These	cells	
comply	with	the	minimal	criteria	for	MSCs	set	by	the	ISCT	as	well	as	being	positive	for	
pluripotent	markers	like	SSEA4,	OCT3/4,	NANOG,	SOX2,	LIN28	(Blentic	et	al.,	2008).		
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They	can	be	used	as	a	source	of	cells	for	bone	tissue,	dental/	periodontal	or	non-bone	
tissue	 regeneration	 therapies,	 DPSCs	 are	 self-renewing	 and	 able	 to	 express	markers	
of	 bone,	 cartilage,	 teeth,	 vascular	 and	neural	 tissues,	 suggesting	 their	multipotential	
capacity	(Karbanova	et	al.,	2011,	Shi	and	Gronthos,	2003,	Kawashima,	2012,	Wei	et	al.,	
2007).	
	
Figure	11	Stem	cell	fate	
Previous	 studies	 have	 shown	 the	 capability	 of	 DPSCs	 to	 regenerate	 their	
microenvironments	 with	 outstanding	 fidelity,	 including	 the	 surrounding	 mineralised	
structures	of	bone	and	dentin	(Shi	and	Gronthos,	2003),	being	able	to	differentiate	into	
bone-like	 constructs	 and	 dentin-pulp-like	 tissues	 when	 cultured	 with	 media	
supplemented	 with	 dexamethasone,	 ascorbic	 acid	 2-phosphate	 and	 inorganic	
phosphate	(Gronthos	et	al.,	2000,	Yu	et	al.,	2007,	Duailibi	et	al.,	2008,	Lee	et	al.,	2011,	
Ito	et	al.,	2011,	Liu	et	al.,	2011,	Mangano	et	al.,	2010,	Khanna-Jain	et	al.,	2010),	and	into	
cartilage	and	into	muscular	tissue		(Zainal	Ariffin	et	al.,	2012,	Lizier	et	al.,	2012).	
Research	 has	 been	 done	 in	 search	 of	 the	 proper	 techniques	 for	 directing	 the	
differentiation	 of	 DPSCs	 taking	 in	 consideration	 the	 effect	 of	 different	 growth/	
transcriptional	factors,	cytokines	and	other	biological	compounds	in	monolayer	culture.	
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Results	 have	 shown	 that	 transforming	 growth	 factor	 (TGF-β)	 and	 5-Aza-20-
deoxycytidine	(DNA	demethylation	agent)	have	myogenic	action	(Maeda	et	al.,	2004,	
Nakatsuka	et	al.,	2010,	Song	et	al.,	2012,	d'Aquino	et	al.,	2007),	fibroblast	growth	factor	
β	 (bFGF)	 and	 epithelial	 growth	 factor	 (EGF),	 neural	 differentiability	 (d'Aquino	 et	 al.,	
2007,	 Bei	 and	Maas,	 1998,	 Bilousova	 et	 al.,	 2011);	 and	 bone	 morphogenetic	 factor	
(BMPs),	 dexamethasone	 and	 natural	 polysacaride	 biomaterials	 as	 chitosan	 and	
glucosamine	have	osteogenic	and	odontogenic	capability	 (Aberg	et	al.,	1997,	Bei	and	
Maas,	1998,	d'Aquino	et	al.,	2007,	Huang	et	al.,	2010).	
	
Figure	12	DPSCs	multipotency	(stemsaveblog.com,	2012)	
Collections	 of	 DPSCs	 have	 been	 evaluated	 as	 potential	 subjects	 for	 iPSCs	 banks	 by	
retroviral	 transduction	 of	 the	 conventional	 reprogramming	 transcriptional	 factors:	
Oct3/4,	Sox2,	Klf4	and	c-Myc,	with	positive	results,	and	with	the	effective		generation	of	
iPSCs	even	without	the	use	of	c-Myc	that	is	an	oncogen	with	tumorgenicity	(Tamaoki	et	
al.,	2010,	Takahashi	et	al.,	2007).	
As	hDPSCs	harbour	the	potential	 to	overcome	many	of	 the	difficulties	 that	other	SCs	
present,	 and	 as	 their	 quality	 as	 SCs	 is	 not	 hindered	 by	 difficult	 access	 or	 ethical	
considerations,	 they	 should	 be	 exhaustively	 researched	 for	 further	 engineer	 cell	
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therapeutics	to	be	applied	in	bone	regenerative	medicine	and	stem	cell	healing	products	
in	general.	
	
1.2.4 Human	dental	pulp	stem	cell	3D	bioprocessing	
Traditionally,	cells	have	been	grown	in	2D	static	monolayered	culture	systems,	where	
cells	are	grown	attached	to	a	supportive	plane	in	their	basal	surface	and	are	exposed	to	
culture	media	in	their	upper	face.	Consequently,	cells	in	the	basal	area	receive	limited	
contact	 with	 nutrients	 and	 signals,	 developing	 heterogeneously.	 Cells	 allocated	 into	
planar	cell	culture	flasks	become	flatter,	divide	abnormally	and	lose	their	differentiated	
phenotype	 (Baker	 and	Chen,	 2012).	 Thus,	many	 findings	 in	 2D	 static	 culture	 are	 not	
reproducible	 in	 vivo	 or	 in	 tissue	 explants.	 The	 efforts	 to	 solve	 the	 gap	 between	 the	
culture	techniques	and	the	in	vivo	tissue	have	derived	into	the	development	of	3D	static	
and	 dynamic	 culture	 systems.	 These	 try	 to	mimic	 the	 host	 tissue	microenvironment	
more	accurately.	Adding	a	scaffolding	machinery,	mechanical	stimulus	and	perfusion	of	
culture	media	through	the	cells.	Enhancing	the	exchange	of	nutrients	and	removal	of	
waste	 between	 the	 cells	 and	 the	 media	 required	 for	 proper	 cell	 expansion	 and	
differentiation.	It	has	already	been	seen	by	several	researchers	that	the	3D	environment	
allows	the	cells	to	maintain	most	of	their	characteristics	and	markers	under	prolonged	
culture	periods	(Godara	et	al.,	2008,	Baker	and	Chen,	2012,	Sailon	et	al.,	2009).		
In	this	section	scaffolds,	cell	culture	systems,	nutrient	requirements	and	environmental	
conditions	will	be	reviewed.	
1.2.5 Scaffolds	
In	vivo,	bone	cells	are	contained	in	a	tissue	specific	3D	environment	that	hosts	the	cells	
and	 their	 interactions.	 Herein,	 water,	 nutrients,	 cytokines	 and	 growth	 factors	 are	
delivered	to	the	cells.	To	regain	functionality	of	damaged	bone,	this	microenvironment	
has	 to	be	 temporarily	 reproduced	 in	 the	 form	of	a	 scaffold.	These	matrices	 supply	a	
supporting	microarchitecture	for	the	cells	to	grow	and	adhere.	Providing	a	template	for	
normal	cell-cell	interactions	and	the	mass	transfer	for	nutrients	and	signalling	delivery.	
In	other	words,	 the	scaffold	plays	 the	role	of	an	artificial	3D	ECM	(Hutmacher,	2000,	
Sheridan	et	al.,	2000).	
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SCs	can	be	seeded	into	3D	biocompatible	and	bioresorbable	scaffold,	allowing	the	slow	
resorption	of	the	scaffolding	while	the	growth	of	cells	and	development	of	the	tissue	
happens	either	ex	or	in	vivo.		
A	scaffold	has	to	be	designed	considering	the	restrictive	semi-permeable	properties	of	
the	materials	in	use,	as	cells	get	physically	isolated	from	the	exterior.	It	has	to	allow	the	
essential	molecules	required	by	the	cells	to	diffuse	through	its	pores,	and	leave	outside	
the	undesired	particles	(Uludag	et	al.,	2000).	The	permeability	and	size	of	pores	won’t	
allow	access	 to	bigger	molecules.	Accordingly,	we	have	 to	 consider	 its	mass	 transfer	
properties	and	the	particular	needs	of	the	cell	type.	
After	 transplanting	 the	 new	 grown	 tissue,	 osseointegration,	 osteoinduction,	
osteoconduction,	 	 and	 fast/	abundant	vascularisation	 is	on	demand;	otherwise	 there	
could	be	a	negative	immune	response,	or	the	lack	of	oxygenation	could	hinder,	or	even	
kill	the	cells	(Abbah	et	al.,	2006,	Sheridan	et	al.,	2000).	
In	general,	the	fabrication	of	a	scaffold	for	bone	tissue	requires	a	highly	biocompatible	
material,	hence	not	having	any	potential	immune	response	(osseointegration).	It	has	to	
allow	 the	 migration	 of	 cells	 from	 the	 surroundings	 to	 inhabit	 the	 scaffold	
(osteoconduction)	and	aid	their	osteogenic	commitment	(osteoinduction).	Moreover,	it	
has	to	be	bioresorbable	in	a	controlled	rate,	allowing	the	cells	to	replenish	the	area	with	
bone	ECM	and	in	the	process,	to	generate	a	new	organically	generated	neotissue.	The	
rate	of	biodegradability	should	be	tightly	similar	with	the	time	required	for	the	injury	to	
be	regenerated.	
Metals,	ceramics	and	polymers	from	natural	and	synthetic	origin	have	been	studied	as	
possible	bone	scaffolds.	Nevertheless,	metals	and	most	of	the	ceramics	cannot	be	used	
for	this	purposes,	as	they	are	not	bioresorbable.	
Bioceramics	and	bioglasses	commonly	used	are:	 the	natural	coralline	hydroxylapatite	
(HA)	or	synthetic	as	calcium	phosphate(CaP),		synthetically	produced	HA	or	β-tricalcium	
phosphate	 (β-TCP),	 SiO2,	 CaO,	 Na2O	 and	 45S5	 bioglass®.	 All	 of	 them	 being	
biodegradable,	osteoconductive	and	osteoinductive.	However,	these	materials	present	
several	limitations.	They	are	brittle	and	have	poor	mechanical	features	and	in	vivo	they	
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can	be	degraded	unexpectedly	by	osteoclastic	activity,	hence	compromising	their	quality	
(Rezwan	et	al.,	2006).		
	There	 is	 a	 wide	 range	 of	 regulatory	 approved	 biodegradable	 and	 bioresorbable	
polymers	 used	 in	 manufacturing	 scaffolds	 with	 osteoconductive	 and	 osteoinductive	
features.	These	include	natural-based	materials,	with	a	polysaccharide/protein	nature,	
such	as:	alginate,	collagen,	chitosan,	starch;	and	the	synthetics-based	materials,	such	as:	
poly(α-hydroxy	 acids)	 (PHA),	 polylactic	 acid	 (PLA),	 poliglycolide	 (PGA),	 poly(lactic	 co-
glycolic	acid)	(PLGA),	poly(ε-caprolactone)	(PCL).	These	polymers	undergo	degradation	
and	 allow	 the	 vascularization	 of	 the	 engineered	 tissue	 in	 transplants.	 Bioactive	
compounds	(as	growth	factors)	can	be	embedded	in	these	polymers	and	slowly	secreted	
along	 with	 the	 degradation	 of	 the	 polymers	 (Hutmacher,	 2000,	 Augst	 et	 al.,	 2006).	
However,	 the	 biopolimers	 have	 poor	 mechanical	 properties	 and	 variable	 physical	
properties,	depending	on	the	sources	of	the	protein	matrices.	A	feasible	method	to	cope	
with	these	drawbacks	has	been	the	use	of	hydrogel	microcapsules.	
Hydrogel	microcapsules	with	a	diameter	of	0.3-1.5	mm	are	suitable	for	encapsulation	of	
cells	and	in	vivo	transplantation.	Hydrogels	are	highly	hydrated	polymer	materials,	able	
to	overcome	the	drawbacks	of	their	solid	biopolymers	counterparts	(Drury	and	Mooney,	
2003).	They	provide	a	large	surface	area	to	volume	ratio,	hence	high	mass	transport.	The	
interstitial	 space	between	microcapsules	allows	angiogenesis,	and	 the	appearance	of	
blood	vessels	 in	the	neo-tissule	is	fundamental	to	properly	heal	bone.	They	are	more	
resistible	 to	 mechanical	 stress	 than	 ceramic	 scaffolds,	 a	 desirable	 feature	 for	 3D	
bioprosessing.	 Encapsulation	 of	 cells	 can	 be	 achieved	 by	 reacting	 polymers	 with	
different	charges	and	forming	an	aqueous	biocompatible	matrix	(Uludag	et	al.,	2000).	
However,	 the	 use	 of	 highly	 toxic	 solvents	 in	 the	 polymerisation	 methods	 is	
disadvantageous	 for	 the	 encapsulated	 cells.	 As	well,	 the	 difficulties	 in	 the	 technique	
make	difficult	to	incorporate	bioactive	compounds	in	most	of	the	polymeric	scaffolds.	
Alginates	are	biopolymers	widely	utilised	in	the	industry	and	in	clinical	studies.	Alginates	
are	 found	 in	 natural	 sources	 as	 an	 heterogeneous	 population	 of	 polymers,	 they	 are	
purified	 from	 different	 species	 of	 seaweed,	 brown	 algae	 and	 bacteria	 (Augst	 et	 al.,	
2006).	 They	 have	 a	 number	 of	 useful	 features	 as	 biodegradability,	 osteoinductivity,	
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osteoconductivity	and	osseointegration.	They	can	be	bead	shaped	with	microcapsule	
size,	as	well	as	being	easily	produced	hydrogels	without	the	use	of	solvents.	they	are	
frequently	used	clinically	as	a	delivery	carrier	for	proteins	and	cytokines,	to	stimulate	
healing	of	tissue,	as	a	vehicle	for	cell	transplantation	and	as	an	immunological	wall.	
1.2.5.1 Alginate	scaffolds	 	
Alginates	 are	 natural	 hetero-polysaccharides	 isolated	 from	 brown	 algae	 such	 as	
Laminaria	 hyperborea	 and	 lessonia.	 Alginic	 acid	 is	 constituted	 by	 an	 heterogeneous	
mixture	of	guluronic	acid	(G),	D-manuronic	acid	(M),	with	different	concentration	ratio	
depending	 on	 the	 source	 (Augst	 et	 al.,	 2006).	 They	 are	 linear	 and	 unbranched	
copolymers,	ionically	and	covalently	linked	in	varying	sequences	(i.e.	GGGG,	MMMM	or	
GMGM).	These	can	be	stabilised	with	Na+	forming	sodium	alginate,	and	then	gelified	by	
cross-linkage	with	multivalent	cations	(e.g.	Ca2+,	Ba2+	or	Sr2+).	Using	different	alginates	
(arrangement	and	 ratio	of	 the	G/M-blocks)	 as	well	 as	 the	 type	and	 concentration	of	
cations	will	produce	gels	with	different	properties.		
The	 mechanical	 properties	 of	 the	 hydrogel	 beads,	 stiffness	 and	 swelling,	 can	 be	
controlled	 by	 physical	 factors	 as	 alginate	 solution	 concentration,	G/M	 ratio,	 and	 the	
cross-linking	density	(time,	temperature	and	stirring	dependant).	Normally	the	higher	
the	concentration	of	polymer,	the	stiffer	the	gel.	However,	the	viscosity	of	the	pre-gelled	
solution	will	 be	 higher	 as	 well	 and	 the	mechanical	 stress	 produced	 by	 handling	 the	
solution	 could	 damage	 the	 cell	 content.	 Managing	 the	 elasticity	 of	 the	 beads	 and	
avoiding	 high	 levels	 of	 viscosity	 product	 of	 the	 concentration,	 can	 be	 achieved	 by	
manipulating	 the	 G/M	 ratio	 and	 by	 addition	 chelating	 agents.	 Gelling	 at	 lower	
temperatures	 allows	 a	 more	 organized	 structure	 and	 hence	 enhancing	 mechanical	
properties.	The	composition	of	the	pre-gelling	solution	affects	the	swelling	properties	
and	the	pore	size	(ranging	from	5-18	nm	in	beads	of	80-120	µm,	with	a	density	of	1,06-
1.12	g/cm3)	(Klein	et	al.,	1983,	Hutmacher,	2000).	Remarkably,	the	gelling	process	and	
the	resulting	beads	produced,	is	highly	reproducible	when	same	conditions	and	regents	
are	used.	
Alginate	microcapsules	have	been	used	for	cell	culture	and	bone	tissue	engineering,	on	
its	own	and	as	 composites,	with	other	materials	as	gelatin,	 chitosan,	 collagen.	Many	
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researchers	have	reported	bone	regeneration	using	this	scaffold	loaded	with	SCs	with	
success.	When	using	alginate	as	a	drug	delivery	system	with	BMPs,	they	have	been	able	
to	produce	mature	osteoblasts	(Saito	et	al.,	2005,	Li	et	al.,	2005).	Adding	Gelatin	to	the	
scaffolds	 has	 been	 considered	 to	 strengthen	 the	 hydrogel	 to	 be	 used	 in	 long	 term	
culture.	As	alginate	alone,	when	ionically	cross-linked,	loses	Ca2+	ions	and	could	collapse	
(Basmanav	et	al.,	2008).	Furthermore,	cell	adherence	and	proliferation	has	been	seen	to	
significantly	improve.	(Venkatesan	et	al.,	2015).		
Alginate	microcapsules	can	fill	irregularly	shaped	areas	and	be	implanted	in	vivo	with	a	
minimally	 invasive	 procedure.	 These	 can	 host	 different	 types	 of	 MSCs	 and	 be	
cryopreserved	maintaining	cell	viability	 for	banking	 for	 future	use	 (Venkatesan	et	al.,	
2015).	 In	 vivo	 studies	 have	 demonstrated	 alginate	 osseointegration,	 osteoinductivity	
and	osteoconductivity	(Alsberg	et	al.,	2001).		
	
Figure	13:	Guluronic	acid	(G)	and		Manuronic	acid	(M)	acids	
When	cells	are	grown	in	alginate	hydrogels	(or	most	of	the	3D	scaffolds)	on	standard	
static	culture	flasks,	the	morphology	of	the	cells	and	the	environment	for	cells	to	grow,	
in	comparison	to	the	traditional	monolayered	static	culture,	is	closer	to	the	one	found	
in	vivo.	Nevertheless,	the	transport	of	oxygen,	nutrients,	metabolites,	wastes	and	other	
important	 molecules	 through	 the	 scaffold	 occurs	 by	 diffusion.	 This	 has	 negative	
repercussions	in	the	culture,	as	the	high	metabolic	demand	by	the	cells	is	not	achieved,	
ultimately	forcing	the	starving	cells	to	migrate	from	the	inner	scaffold,	to	the	surface,	or	
dying.	If	the	culture	is	prolonged,	cells	from	the	surface	of	the	scaffold	travel	to	the	flask	
surface.	 This	 phenomenon	 hinders	 the	 osteogenicity	 and	 osteoinductivity	 of	 the	
scaffold,	and	renders	poor	osteoconduction	when	transplanted	in	vivo.	The	cells	leaving	
the	scaffold	would	become	flattened	with	all	the	implications	previously	discussed.		The	
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dynamics	 of	 the	 in	 vivo	 environment	 cannot	 be	 achieved	 by	 this	 setting	 alone.	
Mechanical	stimulation	caused	by	hydrostatic	pressure	and	shear	stress	have	a	pivotal	
action	in	osteocyte	functionality,	osteoblast	growth	and	mineralisation.	
The	requirement	of	a	bioprocessing	dealing	with	the	local	and	global	transport	and	the	
dynamic	 characteristics	of	bone,	becomes	unavoidable	and	 fundamental.	 In	 the	next	
section,	this	will	be	described	in	detail.	
1.2.6 Stem	Cells	Bioprocessing	
Bone	tissue	is	a	complex	structure	subjected	to	active	 interactions,	between	multiple	
cell	types	under	mechanical	stresses,	and	a	dynamic	3D	micro	and	macro	architecture/	
local	and	global	environment.	The	development,	maintenance	and	regulation	of	stem	
cell	 populations	 for	bone-related	 cell	 therapeutic	products	 requires	 the	 very	difficult	
task	of	replicating	this	complex	and	specific	microenvironment	and	the	dynamicity	of	its	
transport	 characteristics.	 Thus,	 the	 design	 of	 adequate	 tailor-made	 bioprocessing	
systems	able	to	achieve	such	high	standards	is	on	demand	(Salgado	et	al.,	2004).	The	
desirable	bioprocessing	should	consider	control,	 reproducibility	and	 the	possibility	 to	
scale	up,	as	well	as	the	routine	good	manufacturing	practices	(GMP)	required	for	clinical	
applications.		
Different	 bioprocessing	 systems	 using	 shear	 stress	 have	 been	 under	 study.	 The	
mechanisms	 in	 which	 shear	 stress	 affects	 cell	 culture	 are	 not	 yet	 established.	
Nonetheless,	 it	 is	clear	that	it	 is	an	important	biophysical	signal,	with	cell	growth	and	
bone	 mechano-transduction	 effect.	 These	 mechanisms	 comprise	 calcium	 signalling,	
mechanical	 force	 transmission	 along	 fibrous	 cytoskeletal	 networks,	 cell-cell	
communication,	and	disruption	of	ligand-receptor	binding,	between	others	(Akins	et	al.,	
1997,	Morrison	et	al.,	1992,	Talbot	et	al.,	2010).		
In	 Figure	 14,	 pictures	 of	 different	 bioprocessing	 systems	 can	 be	 seen,	 they	 will	 be	
discussed	in	detail.	
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Figure	14	Different	bioprocessing	systems	
The	spinner	flask	bioreactor	(SF)	is	a	simple	and	inexpensive	dynamic	culture	system	in	
which,	cell-seeded	scaffolds	are	attached	to	needles	secured	to	the	lid	of	the	vessel	or	
seeded	 into	 microcarriers	 and	 the	 culture	 media	 is	 subjected	 to	 turbulence	 by	 a	
magnetic	 stirrer.	 The	 amount	 of	 shear	 stress	 depends	 on	 the	 stirrer	 speed.	 This	
bioprocessing	has	successfully	been	used	to	generate	bone	constructs.	Sikavitsas	and	
colleagues	 used	 a	 system	 consisting	 of	 murine	 MSCs	 (mMSCs),	 porous	 PLGA	 disks	
(D=12.7	mm	and	 L=6	mm)	 and	 SF,	 they	 found	 that	 proliferation,	mineralisation,	ALP	
activity	and	osteocalcin	expression	are	enhanced	compared	to	static	culture	(Sikavitsas	
et	al.,	2002).	Stiehler	et	al.	found	similar	proliferation	and	mineralisation	results	when	
bioprocessing	hMSC	in	cubic	PLGA	scaffolds	(8x8x5	mm3)	with	a	SF	(Stiehler	et	al.,	2009),	
they	assessed	a	bigger	panel	of	genes,	finding	COL1A1,	BMP2,	OPN,	RUNX2	and	OSX	to	
(Qian et al., 2013)
(Kleinhans et al., 2015)
BSEL in-house design
HARV and STLV synthecon bioreactorstic cultureSpinner flask bioreactor integra-biosciences
Perfusion bioreactors
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be	upregulated	when	compared	to	static	culture.	However,	they	found	OC,	ALP	and	BSP	
expression	to	be	downregulated	(Stiehler	et	al.,	2009).	Jin	and	co-workers	bioprocessed	
murine	pre-osteoblasts	in	porous	PCL-PLPC	microcarriers	(D=0.35	mm)	in	SF,	to	further	
successfully	 assess	 a	mice	 in	 vivo	model	 (Jin	et	 al.,	 2014).	Nonetheless,	 the	 constant	
stirring	of	culture	media	causes	turbulent	flow	around	the	scaffolds	and	the	cells	can	
form	a	dense	 layer	 in	 its	 surface.	Oxygenation	and	nutrition	of	 the	 cells	 in	 the	 inner	
scaffold	will	be	disrupted,	hindering	the	healthy	development	and	differentiation	of	cells	
and	the	tissue	constructs	ultimately	produced.	In	addition,	the	shear	stress	supplied	by	
the	magnetic	stirrer	is	not	homogenous,	causing	heterogeneous	production	of	calcified	
scaffolds	 (Salgado	 et	 al.,	 2004,	 Sikavitsas	 et	 al.,	 2002,	Martin	 et	 al.,	 2004).	 Another	
bioprocessing,	 the	 Rotating	 Wall	 Vessel	 Bioreactors	 (RWV)	 such	 as	 the	 NASA’s	
developed	High	Aspect	Ratio	Vessel	Bioreactor	(HARV)	or	the	Slow	Turning	Lateral	Vessel	
(STLV)	are	fed-batch	culture	systems	able	to	create	a	low	shear	environment	along	the	
horizontal	axis,	which	allows	cells	to	be	cultured	in	static	suspension.	Qiu	and	co-workers	
did	 an	 early	 study	 with	 murine	 MSC/osteosarcoma	 cells	 in	 bioceramic	 hollow	
microspheres	 (D=0.2-0.3)	 bioprocessed	 by	 RWV,	 demonstrating	 the	 production	 of	
calcium	phosphate	crystals,	with	characteristics	comparable	with	HA		(Qiu	et	al.,	1999).	
Botchwey	 et	 al.	 developed	 a	 hollow,	 lighter-than-water	microcarriers	 of	 bioerodible	
PLGA	 (D=0.8	 mm),	 they	 seeded	 the	 scaffold	 with	 human	 osteosarcoma	 cells	 and	
processed	the	cell	constructs	in	RWV.	They	demonstrated	that	the	system	was	able	to	
significantly	enhance	cell	number,	ALPase	activity,	hystochemical	phenotypic	expression	
and	early	mineralised	matrix	synthesis	(Botchwey	et	al.,	2001).	Sikavitsas	et	al.	used	a	
system	consisting	of	murine	MSCs	 (mMSCs),	porous	PLGA	disks	 (D=12.7	mm	and	L=6	
mm)	and	RWV,	they	found	that	mineralisation,	ALP	activity	and	osteocalcin	expression	
are	 enhanced	 compared	 to	 static	 culture.	 However,	 proliferation	 was	 decreased	
(Sikavitsas	et	al.,	2002).	Hwang	et	al.	studied	mMSCs	encapsulated	in	alginate	hydrogels	
(D=3-3.5	 mm)	 and	 differentiated	 in	 suspended	 RWV	 culture,	 showing	 evidence	 of	
differentiation	by	gene	expression	and	assessing	the	material	with	histology,	ATR-FTIR,	
X-ray	microanalysis	and	mechanical	properties	(Hwang	et	al.,	2009).	These	systems	are	
efficient	to	reduce	diffusion	limitations	of	nutrients	and	when	the	scaffolds’	density	is	
similar	or	lower	than	the	density	of	media	they	have	proved	to	be	useful	in	producing	ex	
vivo	 bone,	 achieving	 ECM	 deposition	 and	 mineralisation/	 ALP	 activity/	 Osteocalcin	
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expresion	similar	or	better	than	the	parameters	achieved	in	static	culture.	RWV-based	
bioreactors,	when	working	in	the	right	setting,	have	shown	to	achieve	better	expansion	
and	bone	differentiation	than	the	SF	or	static	culture	(Rauh	et	al.,	2011).	Only	the	work	
from	Sikavitsas	et	al.	with	RWV	bioreactors	shows	decreased	osteogenic	effect.	Their	
findings	suggest	that	when	the	density	of	the	scaffold	is	higher	than	the	density	of	the	
media,	the	scaffolds	crash	against	the	vessel’s	walls	with	the	rotation,	thus	expansion	
and	 differentiation	 are	 hindered,	 achieving	 poor	 mineralisation	 and	 ALP	 activity	
(Venkatesan	et	al.,	2015,	Sikavitsas	et	al.,	2002).	However,	none	of	these	bioprocessing	
has	been	able	to	recapitulate	the	conditions	of	 the	microenvironment	 found	 in	bone	
tissue.	 There	 is	 still	much	 to	do	 to	understand	 the	 complex	 interaction	between	 the	
bioprocessing	and	the	microarchitecture,	i.e.	the	local	and	global	cues	to	produce	bone	
tissue,	thus	further	development	is	critical	to	achieve	bone	mimicry	in	vitro	and	to	be	
able	to	use	this	tissue	in	vivo.			
To	attempt	to	close	the	gap	between	the	bioprocessing	and	the	in	vivo	requirements,	a	
third	 family	of	bioreactors	was	pioneered.	Fed-batch	 feeding	 strategies	 from	spinner	
flasks	and	RWV	bioreactors	is	left	behind,	to	adopt	a	perfusion	feeding	strategy.	
Perfusion	culture	systems	are	diverse	in	design	(containers,	cartridges,	chambers)	but	
they	all	have	 in	common	a	continuous	exchange	of	medium.	By	generating	a	 laminar	
fluid	flow	of	culture	media	through	the	scaffold,	mass	transport	of	nutrients	and	oxygen	
is	enhanced	as	well	as	providing	the	system	with	mechanical	stimuli.	Perfusion	ensures	
supplementing	essential	 nutrients	 to	 all	 the	 cells	 in	 the	 scaffold,	while	 removing	 the	
metabolic	waste	throughout	the	cultivation	process.		
These	systems	are	supplied	with	a	peristaltic	pump	to	drive	culture	media	through	the	
scaffold.	 Media	 can	 flow	 either	 in	 an	 open	 or	 a	 closed	 loop	 system,	 through	 gas	
permeable	silicone	tubes.	The	system	could	be	supplied	of	an	oxygenator	device	and/	
or	gas	permeable	membranes	to	ensure	adequate	oxygenation.	Media	flow	mode	can	
be	controlled	to	be	steady,	pulsatile	or	oscillated,	hence	a	dynamic	shear	stress	can	be	
studied.	 Jacobs	and	colleagues	performed	an	early	study	on	 the	differential	effect	of	
flow	 type	and	bone	mineralisation.	 Their	 findings	 suggest	 that	oscillating	 flow	 is	 less	
potent	stimulator	of	bone	cells	than	either	steady	or	pulsing	flow.	Furthermore,	lower	
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frequencies	were	observed	to	produce	higher	intracellular	calcium	concentration	for	the	
dynamic	 flows.	These	results	coincide	with	 the	net	 fluid	 transport	of	 the	 fluid	profile	
(Jacobs	et	al.,	1998).	Another	report	performed	by	Sinlapabodin	and	colleagues	studied	
the	 effect	 of	 perfusion	 flow	 rate	 (1-3-5	 ml/min)	 in	 cell	 density	 and	 osteogenic	
differentiation.	They	showed	that	high	flow	rates	can	cause	the	detachment	of	cells	and	
limit	ALP	activity	and	intracellular	calcium	content.	As	well,	they	indicated	that	the	lower	
flow	 rate	 gave	better	 expansion,	 but	 less	ALP	 and	 internal	 calcium	content	 than	 the	
intermediate	flow	(Sinlapabodin	et	al.,	2016).	Accordingly,	each	bioreactor-scaffold-cell	
type	will	have	to	be	assessed	for	the	adequate	flow	rate.	Many	studies	have	been	done	
with	 steady	 flow.	 Wang	 and	 colleagues	 cultured	 murine	 osteoblasts	 seeded-β-TCP	
scaffold	 (5x5x5	mm3)	 inside	 a	 perfusion	 chamber,	 achieving	 enhanced	 proliferation,	
calcification	and	ALP/	OC	gene	expression,	with	a	successful	in	vivo	validation	(Wang	et	
al.,	2003).	Gomes	et	al.	and	Hosseinkhani	et	al.	utilised	a	perfusion	cassette-like	system	
to	bioprocess	murine	cells	in	different	scaffolds,	a	starch	fibre	mesh	(D=8	mm,	L=1.5-2	
mm)	and	a	collagen/PGA		(D=8	mm,	L=1.5-2	mm)	respectively.	Both	groups	were	able	to	
produce	bone	constructs	with	enhanced	proliferation	and	gene	expression	compared	to	
static	 culture.	 Additionally,	 Gomes	 group	 did	 in	 vivo	 validation	 with	 positive	 results	
supported	by	histochemistry	(Gomes	et	al.,	2006,	Hosseinkhani	et	al.,	2006).	Different	
cells/scaffold	pairs	with	osteogenic	potential	have	been	successfully	bioprocessed	under	
perfusion	flow	(Bancroft	et	al.,	2003,	Janssen	et	al.,	2006,	Qian	et	al.,	2013,	Gardel	et	al.,	
2014,	 Kleinhans	 et	 al.,	 2015).	 Expansion	 and	 gene	 expression	 have	 been	 shown	
improved	comopared	 to	static	culture	and	 to	SF.	Further,	 these	 in	vitro	 results,	have	
been	frequently	subjected	to	in	vivo	models	validation,	with	posuitive	results	in	terms	
of	osteoinduction	and	osseointegration	to	the	host	animals.	
Several	of	these	reactors	are	already	available	in	the	market	with	differing	ease	of	use,	
cost/efficiency,	and	capability	of	monitoring	and	controlling	biophysical	and	chemical	
parameters.	 However,	 further	 optimization,	 modification,	 or	 the	 design	 of	 new	
bioreactors,	as	well	as	the	full	understanding	of	signalling	and	the	culture	medium,	are	
required	 to	 produce	 the	 proper	 osteoblast-seeded	 biomaterial	 able	 to	 translate	
accurately	from	the	in	vitro	concept,	to	the	in	vivo	neo-tissue	completion.	
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In	 	Table	2:	Current	studies	about	stem	cell	differentiation	towards	bone	tissue	using	
various	bioreactors,	a	summary	of	the	mentioned	publications,	plus	a	selection	of	other	
studies	can	be	found.	
1.2.7 Nutritional	requirements	
hDPSCs	and	MSCs	in	general	are	found	in	low	numbers.	Their	quality	and	quantity	is	age	
and	health	dependent,	and	traditional	 long-term	culture	technique	hinders	their	self-
renewal	and	multipotent	features.	A	scale-up	strategy	to	produce	high	quality	cells	is	on	
demand.		
It	is	necessary	to	understand	the	nutritional	necessities	and	essential	bioactive	factors	
required	 in	culture	medium,	 the	global	system	to	provide	the	adequate	cues	at	 local	
level;	 and	 the	 environmental	 conditions,	 as	 oxygen	 and	 pH,	 which	 directly	 effect	
important	pathways.	These	parameters	are	required	to	be	controlled,	for	the	cells	to	
grow	healthy	and	undifferentiated,	and	are	priority	for	a	successful	culture	strategy	(Ng	
et	al.,	2014).		
Growth	and	differentiation	are	mediated	by	a	number	of	growth	factors,	transcription	
factors	and	extracellular	matrix	proteins.	These	act	as	molecular	switches	to	activate	or	
repress	 specific	 gene	 expression	 programmes	 (Shi	 and	 Gronthos,	 2003,	 Niwa	 et	 al.,	
2000).	Hence,	these	switches	Influence	the	architecture,	intercellular	interactions,	and	
functions	of	the	cells.	
Culture	medium	must	support	cell	attachment	and	expansion	in	primary	and	passaged	
cultures	as	well	as	in	3D	environments	(Jung	et	al.,	2012b).	Micro	and	macro	nutrients	
are	the	substrates	for	metabolism	or	biosynthesis.	If	regulatory	metabolic	pathways	are	
compromised,	 homeostasis	 will	 be	 hindered.	 Hence,	 minerals,	 amino	 acids,	
carbohydrates,	lipids	and	vitamins	normal	to	the	in-vivo	cellular	environment	must	be	
provided	in	the	culture	medium.	Most	micronutrients	for	cell	stability	are	provided	by	
adding	foetal	bovine	serum	(FBS)	to	basal	medium.	If	these	are	not	present	in	either	FBS	
or	basal	medium,	 they	have	to	be	supplemented	to	guarantee	production	of	healthy	
cells	and	genomic	and	phenotypic	stability.	Other	important	component	are	antibiotics	
to	prevent	microbial	and	fungal	contamination	of	the	culture.	
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various	bioreactors	
Bi
or
ea
ct
or
	ty
pe
	
Sc
af
fo
ld
	
Ce
lls
	
Ef
fe
ct
	
Re
fe
re
nc
e	
St
irr
ed
	F
la
sk
	
PL
GA
	d
isc
s	
m
ur
in
e	
M
SC
	
Gr
ow
th
↑
,	C
a↑
,	A
LP
as
e↑
,	O
C↑
	
(S
ik
av
its
as
	e
t	a
l.,
	2
00
2)
	
St
irr
ed
	F
la
sk
	
PL
GA
	cu
be
s	
hu
m
an
	M
SC
	
Gr
ow
th
↑
,	C
a↑
,	A
LP
as
e↑
,	O
C/
AL
P/
BS
P↓
,	
CO
L1
A1
/B
M
P2
/O
PN
/R
UN
X2
/O
SX
↑
	
(S
tie
hl
er
	e
t	a
l.,
	2
00
9)
	
St
irr
ed
	F
la
sk
	
PC
L/
PL
PC
	
m
icr
oc
ar
rie
rs
	
m
ur
in
e	
pr
e	
os
te
ob
la
st
s	
Gr
ow
th
↑
,	C
a↑
,	A
LP
as
e↑
,	O
C↑
,	i
n	
vi
vo
	
(Ji
n	
et
	a
l.,
	2
01
4)
	
Ro
ta
tin
g	
W
al
l	V
es
se
l	
Si
O 2
	b
io
ce
ra
m
ic	
m
ur
in
e	
M
SC
/o
st
eo
sa
rc
om
a	
Ca
↑
,	H
A↑
	
(Q
iu
	e
t	a
l.,
	1
99
9)
	
Ro
ta
tin
g	
W
al
l	V
es
se
l	
PL
AG
A	
m
icr
oc
ar
rie
rs
	
hu
m
an
	o
st
eo
sa
rc
om
a	
Gr
ow
th
↑
↑
,	C
a↑
,	A
LP
as
e↑
,	h
ist
oc
he
m
+	
(B
ot
ch
w
ey
	e
t	a
l.,
	2
00
1)
	
Ro
ta
tin
g	
W
al
l	V
es
se
l	
PL
GA
	d
isc
s	
m
ur
in
e	
M
SC
	
Gr
ow
th
↓
,	C
a↑
,	A
LP
as
e↑
,	O
C↑
	
(S
ik
av
its
as
	e
t	a
l.,
	2
00
2)
	
Ro
ta
tin
g	
W
al
l	V
es
se
l	
Al
gi
na
te
	
m
ur
in
e	
ES
C	
Ca
↑
,	H
A↑
,	R
UN
X2
/O
SX
↑
	
(H
w
an
g	
et
	a
l.,
	2
00
9)
	
Ro
ta
tin
g	
W
al
l	V
es
se
l	
De
m
in
er
al
ise
d	
hu
m
an
		b
on
e	
m
ur
in
e	
os
te
ob
la
st
s	
Gr
ow
th
↑
,	C
a↑
↑
,	A
LP
as
e↓
,	
(S
on
g	
et
	a
l.,
	2
00
8)
	
Ro
ta
tin
g	
W
al
l	V
es
se
l	
Sp
on
ce
ra
m
	c
er
am
ic	
di
sc
s	
hu
m
an
	M
SC
	
Gr
ow
th
↑
,	C
a↑
↑
,	A
LP
as
e↓
,	h
ist
ol
og
y+
	
(D
ie
de
ric
hs
	e
t	a
l.,
	2
00
9)
	
Ro
ta
tin
g	
W
al
l	V
es
se
l	
al
gi
na
te
	
hy
dr
og
el
s/
bi
og
la
ss
	
m
ur
in
e	
ES
C	
Gr
ow
th
↑
,	A
LP
as
e=
,	R
UN
X2
↑
	
(Z
ha
ng
	e
t	a
l.,
	2
00
9)
	
Pe
rfu
sio
n	
ch
am
be
r	
Fl
at
	su
rfa
ce
	
Hu
m
an
	fe
ta
l	o
st
eo
bl
as
ts
	
Ca
↑
↑
	
(Ja
co
bs
	e
t	a
l.,
	1
99
8)
	
Pe
rfu
sio
n	
co
nt
ai
ne
r	
β-
TC
P	
m
ur
in
e	
os
te
ob
la
st
s	
Gr
ow
th
↑
,	C
a↑
,	A
LP
as
e↓
,	h
ist
ol
og
y+
,	A
LP
/O
C↑
,	
in
	v
iv
o	
(W
an
g	
et
	a
l.,
	2
00
3)
	
Pe
rfu
sio
n	
ca
ss
et
te
s	
co
lla
ge
n	
sp
on
ge
	d
isc
s	
m
ur
in
e	
os
te
os
ar
co
m
a	
Gr
ow
th
↑
,	C
a↑
↑
,	A
LP
as
e↑
	
(B
an
cr
of
t	e
t	a
l.,
	2
00
3)
	
Pe
rfu
sio
n	
bi
or
ea
ct
or
	
st
ar
ch
	fi
br
e	
m
es
h	
m
ur
in
e	
M
SC
	
Hi
st
oc
em
+,
	B
M
P2
/T
GF
b1
,F
GF
2/
VE
GF
↑
,	P
DG
F-
A=
,	
in
	v
iv
o	
(G
om
es
	e
t	a
l.,
	2
00
6)
	
Pe
rfu
sio
n	
ca
ss
et
te
	
Co
lla
ge
n/
PG
A	
m
ur
in
e	
M
SC
	
Gr
ow
th
↑
,	C
a↑
,	A
LP
as
e↑
,	O
C↑
,	h
ist
ol
og
y+
	
(H
os
se
in
kh
an
i	e
t	a
l.,
	
20
06
)	
Pe
rfu
sio
n	
ca
ss
et
te
	
ca
lci
um
	p
ho
sp
ha
te
	
go
at
	M
SC
	
Gr
ow
th
↑
,	C
a↑
,	H
A↑
,	h
ist
ol
og
y+
,	i
n	
vi
vo
	
(Ja
ns
se
n	
et
	a
l.,
	2
00
6)
	
Pe
rfu
sio
n	
bi
or
ea
ct
or
	
HA
/p
ol
ya
m
id
e	
m
ur
in
e	
M
SC
	
Gr
ow
th
=,
	C
a↑
,	A
LP
as
e↑
,	O
C↑
	
(Q
ia
n	
et
	a
l.,
	2
01
3)
	
Pe
rfu
sio
n	
cy
lin
de
r	
st
ar
ch
/P
CL
	
go
at
	M
SC
	
Gr
ow
th
=,
	C
a↑
,	H
A↑
,	h
ist
ol
og
y+
,M
icr
oC
T+
,	i
n	
vi
vo
	
(G
ar
de
l	e
t	a
l.,
	2
01
4)
	
Pe
rfu
sio
n	
bi
or
ea
ct
or
	
β-
TC
P	
sh
ee
p	
M
SC
	
Hi
st
ol
og
y+
,	h
ist
om
or
ph
ol
og
y+
	
(L
i	e
t	a
l.,
	2
01
4)
	
Pe
rfu
sio
n	
ca
rt
rid
ge
	
P(
LL
A-
co
-C
L)
	
hu
m
an
	M
SC
	
AL
PL
/C
OL
1A
1↑
,	R
UN
X2
/S
PP
1↑
↑
,	B
GL
AP
↓
,	
hi
st
ol
og
y+
	
(K
le
in
ha
ns
	e
t	a
l.,
	2
01
5)
	
Pe
rfu
sio
n	
ca
rt
rid
ge
	
Si
lk
/g
el
at
in
/H
A	
M
C3
T3
-E
1/
m
ur
in
e	
M
SC
	
Gr
ow
th
↑
,	C
a↑
,	H
A↑
,	A
LP
as
e↑
	
(S
in
la
pa
bo
di
n	
et
	a
l.,
	
20
16
,	L
i	e
t	a
l.,
	2
01
4)
	
	
	 58	
In	vivo,	carbohydrates	supply	the	cellular	energy	requirement.	Through	the	glycolysis	
and	the	Citric	acid	cycle	(also	known	as	TCA	cycle,	Krebs	cycle)	the	cells	metabolise	the	
carbohydrates	and	produces	ATP	to	function.	Hence,	their	uptake	will	be	controlled	by	
the	energy	requirement	characteristic	of	every	different	cell	type.	In	addition,	they	are	
used	for	the	synthesis	of	certain	amino	acids,	fat	and	nucleic	acids	and	for	intracellular	
carbohydrate	 intermediates.	 But	 these	 represents	 a	 small	 proportion	 of	 the	 total	
glucose	 consumption.	 In	 vitro,	 carbohydrates	 will	 be	 provided	 in	 basal	 medium	 as	
glucose.	It	is	known	that	high	glucose	concentrations	could	be	harmful	for	certain	cell	
types	 (Jung	et	al.,	2012b).	Thus	a	 low	glucose	concentration	 is	normally	used	 in	MSC	
culture	(5.5mM).	Lactate,	a	by-product	of	glucose	metabolism,	can	reduce	growth	and	
multipotency	 when	 its	 concentration	 reach	 levels	 higher	 than	 16	 mM,	 so	 its	
concentration	has	to	be	followed	carefully.		
Amino	acids	are	the	raw	material	for	protein	synthesis,	they	are	of	extreme	importance	
for	the	majority	of	the	cellular	processes.	All	cells	need	12	essential	amino	acids	and	they	
come	 as	 part	 of	 basal	media,	 arginine,	 cysteine,	 histidine,	 isoleucine,	 leucine,	 lysine,	
methionine,	phenylalanine,	threonine,	tyrosine,	tryptophan	and	valine.	Particular	amino	
acids	as	glutamine	have	to	be	added	in	specific	concentrations	as	they	play	a	specific	
role,	either	in	growth	or	differentiation.	Glutamine	plays	an	important	role	as	it	provides	
the	nitrogen	of	purine	and	pyrimidine	of	nucleic	acids	and	is	essential	for	the	synthesis	
of	the	mono-,	bi-	and	tri-phosphate	acid	glycosides.	
Lipids	 that	 stimulates	 growth,	 for	 instance,	 cholesterol,	 linoleic	 acid,	 oleic	 acid	 and	
phospholipids	 are	 found	 in	 serum.	 Hence	 media	 with	 serum	 won’t	 require	
supplementation	 of	 lipids.	 In	 contrast,	 serum	 free	 and	 differentiation	 media	 will.	
Hormones	of	lipidic	nature	have	roles	in	growth	and	differentiation	and	require	to	be	
added	to	the	media.	For	instance,	hydrocortisone	is	a	hormone	with	growth	promoting	
properties	its	action	mainly	happens	when	cells	are	in	log	growth	phase	but	has	negative	
osteo-regulatory	characteristics	(Rowe	et	al.,	1977).	Simvastatin	is	a	known	lipoprotein	
with	osteogenic	properties,	acting	through	the	bone	morphogenetic	proteins	pathway	
(Pagkalos	et	al.,	2010a,	Chen	et	al.,	2010).	
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Growth	factors	and	cytokines	are	normally	 from	proteic	or	 lipidic	 (steroid	hormones)	
nature,	they	are	key	for	most	of	the	regulatory	processes	to	maintain	cell	function	and	
their	undifferentiated/	differentiated	state	and	have	to	be	added	to	media.	Serum	will	
have	a	complex	pool	of	them	with	importance	in	growth	and	attachment	of	cells.		
Vitamins	 primarily	 act	 as	 coenzymes	 or	 prosthetic	 groups	 supporting	 enzymatic	
functions	in	metabolic	processes.	Essential	vitamins	required	in	cell	culture	comprise	fat-
soluble	vitamins	such	as	A,	D,	E,	K,	thiamine,	riboflavin,	niacin	pyridoxine,	pantothenic	
acid,	 folate,	 vitamin	 B12,	 biotin.	 Another	 essential,	 Ascorbic	 acid	 (vitamin	 C),	 has	
antioxidant	properties,	and	works	as	a	growth	promoter.	Vitamins	C	and	D	are	reported	
to	have	osteoinductive	properties,	and	play	a	key	role	in	calcium	homeostasis	(Rowe	et	
al.,	1977,	van	Leeuwen	et	al.,	2001).	
Inorganic	salts	play	a	role	 in	retaining	the	osmotic	balance	of	the	cells	and	in	specific	
functions.	Most	mammalians	 have	 a	 plasma	osmotic	 pressure	 of	 260-320	mOsm/kg,	
humans	in	particular,	have	a	plasma	osmotic	pressure	of	290	mOsm/kg	and	cells	grow	
healthy	 when	 maintain	 between	 10%	 of	 this	 value.	 Sodium,	 potassium,	 calcium,	
magnesium,	nitrogen,	chloride,	sulfate,	bicarbonate	and	phosphate	are	included	in	basal	
media.	Other	functions	associated	with	inorganic	salts	are	cell	attachment	aid,	signalling	
transduction	 intermediation,	membrane	potential	regulation	and	 intracellular	charge.	
Inorganic	trace	elements	as	molybdenum,	vanadium,	iron,	zinc	and	selenium,	copper,	
manganese	come	as	part	of	basal	media.	Although	their	function	remains	unclear,	they	
are	known	to	play	a	role	as	enzyme	cofactors.	
Serum	provides	most	of	the	essential	requirements	for	cell	viability	and	clonogenicity	
that	 are	 not	 found	 in	 basal	 medium	 and	 is	 an	 extremely	 complex	 fluid.	 With	 an	
undefined	nature,	it	is	known	to	be	constituted	by	a	comprehensive	range	of	biological	
factors,	 with	 a	 balanced	 action	 in	 growth	 promotion,	 inhibition	 and	 differentiation.	
Growth	factors	found	in	serum	as	PDGF,	EGF,	IGF-1,	IGF-2	are	known	to	be	related	with	
cell	 proliferation	 and	 differentiation.	 Adhesion	 factors	 as	 fibronectin	 support	 cell	
attachment	and	expansion.	The	main	functions	of	serum	comprise	providing:	essential	
nutrients,	 adherence	 and	 expansion	 factors,	 hormones,	 various	 growth	 factors	 and	
binding	proteins.	
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A	table	with	the	approximate	components	and	concentrations	of	serum	published	by	
Jung	and	colleagues	can	be	seen	in	Figure	15.	
The	composition	of	serum	is	unknown	and	jointly	with	other	culturing	reagents	comes	
from	 animal	 origin.	 They	 pose	 numerous	 safety	 issues	 in	 clinical	 therapy,	 including	
possible	 infections	 and	 severe	 immune	 reactions.	 Additionally,	 serum	 composition	
varies	 from	 batch	 to	 batch.	 Hence,	 constant	 attempts	 have	 been	 made	 to	 develop	
defined	 Serum-free	 and	 xeno-free	 culture	 media.	 For	 a	 successful	 serum/xeno-free	
media	to	be	developed,	the	same	essential	requirements	provided	by	serum	must	be	
attained.	A	well-defined	culture	media	will	provision	the	production	of	homogeneous	
culture	enriched	with	a	desired	cell	type,	enhancing	cell	bioprocessing	protocols,	which	
is	essential	for	increasing	clinical	efficiency	of	cell	therapy	devices.	As	serum	is	still	ill-
defined,	most	formulations	developed	on	the	knowledge	gathered	from	serum,	present	
limited	performance,	with	 less	viability	and	slow	rates	being	some	of	their	problems.	
Until	 the	defined	media	does	not	reach	the	culture	conditions	required	to	produce	a	
quality	cell	product,	serum	will	still	be	the	golden	standard	in	culture	media.		
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Figure	15:	Constituents	of	serum	(Jung	et	al.,	2012a)	
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1.2.8 Remarks	and	conclusions	of	this	section	
Cells	are	the	machinery,	growth	factors	the	cues,	scaffold	the	local	microarchitecture,	
while	the	bioprocessing	the	equivalent	of	the	global	interactions.	All	this	factors	require	
to	be	fully	understood	and	orchestrated	for	a	succeeding	osteogenic	bioprocessing	and	
have	to	be	standardised	in	order	to	be	able	to	bring	bone	tissue	engineering	from	the	
laboratory	bench	to	the	clinical	use	in	regenerative	medicine.	
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2 Aims	and	objectives	
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The	use	of	hDPSCs	in	bone	tissue	engineering	and	regenerative	medicine	requires	the	
development	of	an	unambiguous	and	efficient	protocol	for	selectively	directing	MSCs	
differentiation	 towards	 the	 osteogenic	 lineages	 in	 vitro.	 Additionally,	 clinical	
applications	 require	 an	 automated	 and	 scalable	 bioprocessing	 able	 to	 achieve	 the	
required	production,	minimising	sample	manipulation.	Most	of	the	traditional	methods	
for	MSCs	culture	involve	laborious	procedures	and	handling	of	samples,	the	expansion	
of	healthy	undifferentiated	cells	to	the	desired	quantity	and	their	further	differentiation	
to	 produce	 homogenous	 osteogenic	 cells	 in	 the	 adequate	 three-dimensional	
environment	 is	 not	 easily	 achieved.	 Furthermore,	 two-dimensional	 and	 three-
dimensional	 static	 culture	 systems	 are	 not	 suitable	 for	 large	 scale	 production	 and	
differentiation	of	MSCs	and	require	the	use	of	high	concentrations	of	expensive	growth	
factors,	cytokines	and	biological	cues	to	achieve	differentiation.	
The	Aims	of	this	project	are	to	develop	the	effective	methodology	to	produce	bone-like	
tissue	constructs	for	clinical	use.	through	the	lineage	specific	differentiation	of	hDPSCs,	
especially	 into	osteoblasts,	 and	 the	development	of	 three	dimensional	 cost-effective	
bone	constructs	within	a	bioreactor	culture	system	for	clinical	applications.	Specifically,	
this	can	be	achieved	through	the	characterisation	of	hDPSCs	as	MSC-like	cells	 in	a	2D	
environment	 as	 this	 represents	 the	 starting	material	 in	 a	 three-dimensional	 culture.	
Subsequently,	 the	 focus	would	 be	 on	 the	 development	 of	 an	 integrated,	 single	 step	
culture	 process	 for	 direct	 osteogenic	 differentiation	 of	 hDPSCs	 by	 encapsulation	 in	
alginate/	 gelatin	 hydrogels	 and	 the	 use	 of	 perfusion	 of	 culture	 medium	 through	 a	
rotating	wall	vessel	bioreactor,	resulting	in	an	efficient	and	reproducible	culture	system	
for	for	bone	tissue	engineering	applications.	
The	specific	objectives	are:	
a. The	characterisation	of	hDPSCs	as	MSCs-like	stem	cells	in	two-dimensional	static	culture,	
by	 following	 the	 minimal	 criteria	 defined	 by	 The	 International	 Society	 for	 Cellular	
Therapy	(ISCT),	with	the	examination	of	the	undifferentiated	and	proliferative	quality	of	
the	 cells.	 And	 ultimately,	 developing	 of	 an	 in	 vitro	 protocol	 for	 the	 generation	 of	 a	
specific	cell	population	with	high	osteogenic	potential	from	hDPSCs.	
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b. Determination	of	the	effect	of	perfusion	in	dynamic	rotatory	wall	bioreactor	culture	in	
the	expansion	and	osteogenic	differentiation	of	hDPSCs	 in	three-dimensional	culture,	
using	encapsulation	in	alginate/	gelatin	hydrogels	with	the	examination	of	the	quality	of	
the	 bone	 neo-tissue	 constructs	 and	 comparison	with	 Horizontal	 Aspect	 Ratio	 Vessel	
(HARV)	 bioreactor	 and	 three-dimensional	 static	 culture.	 Ultimately,	 generating	 an	 in	
vitro	protocol	for	the	production	of	cell	populations	from	osteoblastic	lineage	with	high	
therapeutic	potential.	
c. To	 investigate	 the	effect	of	Bone	morphogenetic	protein	2	at	physiological	 level	 and	
simvastatin	as	enhancers	of	osteogenesis	 in	perfusion-RWV	bioreactor	system	and	 in	
alginate/	gelatin	scaffolds	with	the	examination	of	the	quality	of	the	bone	neo-tissue	
constructs.	Ultimately,	developing	an	in	vitro	protocol	for	the	generation	of	high	quality,	
homogeneous,	 functional	 and	mature	 cell	 population	 from	 osteoblastic	 lineage	with	
high	therapeutic	potential.	
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3 Materials	and	methods	
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3.1 Overview	of	the	experiments	
This	 study	 addressed	 the	 in	 vitro	 bone	 mimicry	 capacity	 of	 hDPSCs	 from	 donors,	
encapsulated	 in	 3D	 alginate	 beads	 and	 the	 effect	 of	 Rotating	Wall	 Vessel	 bioreactor	
coupled	with	 perfusion	 flow	of	 culture	media;	 following	 cell	 fate	 through	 the	whole	
process.	 The	 study	 was	 structured	 to	 follow	 three	 different	 aspects	 of	 the	 cells	
bioprocessing;		
a) The	characterisation	of	hDPSCs	as	MSCs-like	cells	following	the	minimal	criteria	defined	
by	The	International	Society	for	Cellular	Therapy	(ISCT).	
b) Comparison	 between	 the	 in	 vitro	 osteogenic	 differentiation	 capability	 of	 hDPSCs	
encapsulated	 in	 alginate	 beads	 in	 different	 bioprocessing	 systems:	 3D	 static	 culture,	
High	Aspect	Ratio	Vessel	bioreactor	(HARV)	and	In-house	designed	Perfusion	Rotating	
Vessel	bioreactor.	
c) Enhancement	of	the	differentiation	capabilities	of	Perfusion	Rotating	Vessel	bioreactor	
by	addition	of	Symvastatin	and	physiological	 levels	of	bone	morphogenetic	protein	2	
(BMP-2).	
3.1.1 Culture	media	
• Maintenance	medium:	Minimum	essential	medium	Eagle	-	alpha	modification	(αMEM,	
Gibco,	UK)	with	10%	Fetal	Bovine	Serum	(FBS,	Gibco),	2	mM	L-glutamine	(L-GLu,	Gibco),	
0.1	mM	L-Ascorbic	Acid	2-Phosphate	(L-ASAP,	Sigma),	100	U/ml	Penicillin/Streptomycin	
antibiotics	(Pen/Strep,	Gibco)	and	0.25	ug/ml	fungizone	antimycotic	(amphothericin	B,	
Gibco)*.	
• Osteogenic	 differentiation	 medium:	 maintenance	 medium	 plus	 5	 mM	 β-
glycerophosphate	(β-GP,	Sigma),	0.1	mM	dexamethasone	(Dex,	Sigma),	0.5	mM	ASAP	
(Sigma),	1.8	mM	KH2PO4	(Sigma).	
• Maintenance	 BMP-2	 medium:	 maintenance	 medium,	 plus	 300	 pg/ml	 Bone	 BMP-2	
(Peprotech).	
• Maintenance	 Simvastatin	 medium:	 maintenance	 medium,	 plus	 10	 uM	 Simvastatin	
(Sigma).	
• Osteogenic	differentiation	BMP-2	medium:	osteogenic	medium,	plus	300	pg/ml	BMP-2	
(Peprotech).	
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• Osteogenic	 differentiation	 Simvastatin	 medium:	 osteogenic	 medium,	 plus	 10	 uM	
Simvastatin	(Sigma).	
• Chondrogenic	differentiation	medium:	growth	medium	plus	50	uM	ASAP	(Sigma),	100	
nM	Dex	(sigma),	5	ug/ml	human	insulin	(Sigma	I-9278),	1	ng/ml	TGFb1,	400	uM	proline,	
1x	non-essential	amino	acids	(Sigma)	
• Adipogenic	 differentiation	 medium:	 growth	 medium	 plus	 0.5	 mM	 3-isobutyl-1-
methylxantine	 (IBMX,	 Sigma),	 1	 uM	 Dex	 (Sigma),	 10	 ug/ml	 human	 insulin,	 200	 uM	
indomethacin	(Sigma)	
*	fungizone	anti	mycotic	was	used	only	in	3D	experiments.	For	2D	static	culture,	it	was	
omitted.		
3.1.2 hDPSCs	extraction	
Normal	human	impacted	third	molars	were	collected	from	adults	(19–29	years	of	age)	
under	approved	guidelines	set	by	The	UK	Stem	Cell	Bank	and	Department	of	Health	in	
the	Code	of	Practice	for	the	use	of	human	stem	cell	lines.	Tooth	surfaces	were	cleaned	
and	cut	around	the	cementum-enamel	junction	by	using	sterilized	dental	fissure	burs	to	
expose	the	pulp	chamber.	The	pulp	tissue	was	gently	separated	from	the	Crown	and	
root	and	then	digested	in	a	solution	of	3	mg/ml	collagenase	type	I	and	4	mg/ml	dispase	
for	1	h	at	37°C.	Single-cell	suspensions	are	obtained	by	passing	the	cells	through	a	70-
μm	 strainer.	 The	 extraction	 and	 isolation	 of	 the	 hDPSCs	 was	 done	 in	 Leeds	 Dental	
Institute,	in	collaboration	with	the	University	of	Leeds.	
3.1.3 hDPSCs	maintenance	
hDPSCs	 were	 routinely	 cultured	 on	 tissue	 culture	 flasks	 (T-flasks)	 in	 a	 humidified	
incubator	set	at	37°C	and	5%	CO2.	Single-cell	suspensions	of	naïve	hDPSCs	(<	passage	5)	
were	seeded	into	T-flasks	with	a	density	of	5x103	cells/cm2	and	then	incubated	for	3-4	
days	in	maintenance	medium	to	get	cell	expansion.	When	achieving	80%	confluence	of	
the	T-flask	surface,	cells	were	detached	with	TrypLE	express	(Thermo	Fisher	scientific)	
and	passaged	by	re-plating	at	low	density	(5x103	cells/cm2).	Cells	were	fed	every	3	days	
with	fresh	hDPSC	maintenance	medium.		
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3.1.4 hDPSCs	characterisation	
To	characterise	the	undifferentiated	stage	of	the	cells	prior	to	the	induction	of	3D	bone	
differentiation,	The	International	Society	for	Cellular	Therapy	(ISCT)	defined,	minimal	
criteria	for	cells	to	be	considered	multipotent	stromal	stem	cells	were	followed.	With	
this	purpose,	cells	were	analysed	through	passaging	for	multipotency	markers	in	flow	
cytometry	and	they	were	driven	to	trilineage	mesenchymal	differentiation.	As	well,	
their	clonogenic	potencial	was	measured	by	assessing	fibroblast	colony	forming	units	
(CFU-F).	
3.1.5 hDPSCs	osteogenic	differentiation	in	2D	static	culture	
Single-cell	 suspensions	 of	 naïve	 hDPSCs	 (<	 passage	 5)	were	 seeded	 into	 T-flasks	 in	 a	
humidified	 incubator	 set	 at	 37°C	 and	 5%	 CO2	 with	 a	 density	 of	 5x103	 cells/cm2,	
maintenance	medium	was	used	and	 then	 incubated	 for	3-4	days	until	achieving	80%	
confluence	of	the	T-flask	surface.	After,	osteogenic	differentiation	was	triggered	using	
osteogenic	medium	for	the	next	21	days.	During	this	period,	cells	were	fed	every	3	days	
with	fresh	hDPSC	osteogenic	medium.		
3.1.6 hDPSCs	adipogenic	differentiation	in	2D	static	culture	
Single-cell	 suspensions	 of	 naïve	 hDPSCs	 (<	 passage	 5)	were	 seeded	 into	 T-flasks	 in	 a	
humidified	 incubator	 set	 at	 37°C	 and	 5%	 CO2	 with	 a	 density	 of	 5x103	 cells/cm2,	
maintenance	medium	was	used	and	 then	 incubated	 for	3-4	days	until	achieving	80%	
confluence	of	the	T-flask	surface.	After,	adipogenic	differentiation	was	triggered	using	
adipogenic	medium	for	the	next	21	days.	During	this	period,	cells	were	fed	every	3	days	
with	fresh	hDPSC	adipogenic	medium.		
3.1.7 hDPSCs	chondrogenic	differentiation	in	2D	static	culture	
Single-cell	 suspensions	 of	 naïve	 hDPSCs	 (<	 passage	 5)	were	 seeded	 into	 T-flasks	 in	 a	
humidified	 incubator	 set	 at	 37°C	 and	 5%	 CO2	 with	 a	 density	 of	 5x103	 cells/cm2,	
maintenance	medium	was	used	and	 then	 incubated	 for	3-4	days	until	achieving	80%	
confluence	 of	 the	 T-flask	 surface.	 After,	 chondrogenic	 differentiation	 was	 triggered	
using	chondrogenic	medium	for	the	next	21	days.	During	this	period,	cells	were	fed	every	
3	days	with	fresh	hDPSC	chondrogenic	medium.		
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3.1.8 Alginate	encapsulation	of	hDPSCs	
80%	 confluent	 undifferentiated	 hDPSCs	 were	 detached	 from	 T-flasks	 with	 TrypLE	
express	(Thermo	Fisher	scientific),	dissociated	into	single	cell	suspension,	washed	two	
times	with	phosphate	buffered	saline	(PBS)	and	centrifuged	to	get	a	cell	pellet.	The	cells	
were	counted	and	resuspended	at	a	density	of	2.5	x	106	cells/ml	(20,000	cells/bead)	in	
a	 sterile-filtered	solution	composed	of	1.1%	 (w/v)	alginic	acid	 (Sigma)	and	0.1%	 (v/v)	
gelatin	(Sigma)	in	PBS	(pH	7.4)	as	described	in	our	previous	study	(Randle	et	al.,	2007b).	
The	 cell	 suspension	 was	 driven	 through	 a	 peristaltic	 pump	 (Model	 P-1,	 Amesham	
Biosciences,	U.K.)	 and	dropped	 from	at	 least	30	mm	height	 into	gently	 stirred	cross-
linking	 solution	 (100	 mM	 calcium	 chloride	 (CaCl2)	 and	 10	 mM	 N-(s-hydroxyethyl)	
piperazine-N-(2-ethane	sulfonic	acid)	at	pH	7.4).	The	flow	rate	of	the	pump	was	adjusted	
to	 give	 single	 droplets	 using	 a	 25-gauge	 needle	 (Becton	Dickinson,	Oxfordshire,	UK).	
Upon	 contact	 with	 the	 solution,	 gelling	 of	 the	 alginate	 droplets	 started	 and	 after	 5	
minutes	 in	 the	 solution,	 bead-shaped	gels	with	 an	 approximate	diameter	of	 1.3	mm	
were	obtained.	The	droplets	remained	in	the	solution	being	stirred	for	5	more	minutes	
at	room	temperature	to	allow	the	beads	to	set.	Finally,	the	beads	were	washed	three	
times	 in	 PBS	 and	 placed	 into	 normal	 hDPSC	 growth	 or	 differentiation	 culture	media	
(Randle	et	al.,	2007a)	as	 required	 for	 the	experiment.	To	avoid	contamination,	 tubes	
were	 autoclaved	 and	 washed	 three	 times	 with	 filtered-sterile	 PBS	 before	 the	
encapsulation	process.		
3.1.9 Three-dimensional	culture	of	hDPSCs	for	osteogenic	differentiation	
Encapsulated	cells	were	transferred	to	a	175	T-flasks,	a	55	ml	Perfusion	Rotating	Wall	
bioreactor	(BSEL	in-house	design),	or	a	55	ml	HARV	bioreactor	(Synthecon	RWV-HARV,	
Cellon,	Bereldange,	Luxembourg).	Each	vessel	was	loaded	with	250	alginate	beads.	The	
rotation	rate	of	the	vessels	was	optimized	in	previous	works	in	our	lab,	according	to	the	
cell	growth	kinetics	to	avoid	increasing	shear	stress	in	the	vessel.	Beads	were	collected		
at	each	sample	point	to	further	be	stored,	fixed	or	depolymerized	for	biological	analysis	
of	the	resulting	cells	and	mineralised	scaffolds.	
For	the	first	7	days	of	experiments,	beads	were	seeded	in	175	T-flasks	and	expanded	
undifferentiated	with	maintenance	medium	for	the	next	7	days.	After,	the	beads	were	
transferred	to	either	a	55	ml	Perfusion	Rotating	Wall	bioreactor	(BSEL	in-house	design),	
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a	55	ml	HARV	bioreactor	(Synthecon	RWV-HARV,	Cellon,	Bereldange,	Luxembourg),	or	
left	 in	 a	 175	 T-flask.	 To	 perform	osteogenic	 differentiation,	 the	 seeded	 vessels	were	
loaded	with	any	of	the	differentiation	media	for	another	21	days	of	culture,	according	
to	the	culturing	plan.	The	time	plans	for	3D	bone	differentiation	are	described	in	Table	
3	and	Table	4.	Growing	cells	in	beads	were	photographed	using	a	Leica	DM	IL	microscope	
(Leica,	Wetzlar,	Germany)	and	CellSens	software	(Olympus,	Munich).	
Table	 3:	 Experimental	 plan,	 comparison	 of	 different	 bioprocessing	 for	 bone	 tissue	
engineering.	
Group	 Medium	 		
		 Maintenance	 Osteogenic	
Control	-	flask	 7	 21	
HARV	 7	 21	
Perfusion		 7	 21	
	
Table	4:	Experimental	plan,	enhancing	3D	bone	ontogenesis.	
Group	 Medium	 		 		 		 		
		 Maintenance	 Maintenance		 Maintenance		 Osteogenic		 Osteogenic		
		 		 BMP2	 Simvastatin	 BMP2	 Simvastatin	
Control	 28	 0	 0	 0	 0	
BMP2	only	 7	 14	 0	 0	 0	
Symvastatin	
only	 7	 0	 14	 0	 0	
Osteo	BMP2	 7	 0	 0	 21	 0	
Osteo	
Symvastatin	 7	 0	 0	 0	 21	
3.1.10 Fabrication	of	a	perfusion	RWV	bioreactor	vessel	
A	novel	 in-house	 designed	 computer-controlled	 RWV	bioreactor	was	 used	 in	 the	 3D	
experiments.	Which	is	able	to	deliver	continuous	oxygenation,	supply	of	nutrients,	and	
removal	of	metabolic	wastes.	The	gas	exchange	was	achieved	via	using	a	gas-permeable	
membrane	and	 the	nutrients	 supply/waste	 removal,	 via	perfusion	of	medium	with	a	
peristaltic	pump.	The	design	of	the	bioreactor	was	performed	by	Jae	Min	Cha,	a	previous	
PhD	student	in	BSEL.	The	design	and	fabrication	of	the	bioreactor	system	are	described	
in	chapter	V.	The	materials	specification	for	the	gas-permeable	membrane	and	all	parts	
of	bioreactor	can	be	found	in	Table	5	and	Table	6.	
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Table	5:	Specifications	of	gas	permeable	membranes	
Parameter	 Value	
dimensions	 16x16	cm2	
	
0.004	inch	
polydimethylsiloxane	
membrane	thickness	
0.001	inch	
polytetrafluoroethylene	
		 0.005	inch	total	thickness	
surface	area	of	gas	permeable		
membrane	 6030	cm2	
permeability		 1.1e-2	cm/s	
at	amt	pressure	 		
supplier	information	 Specialty	silicone	products	inc.	
		 3	McCrea	hill	road.	
		 Ballston	spa,	NY	12020,	USA	
	
	
Table	6:	Information	of	materials	
Parts	 Materials	
Base	plate	 White	Delrin/Acetyl	Plastic	
Support	walls	 White	Delrin/Acetyl	Plastic	
Oxygenator	 White	Delrin/Acetyl	Plastic	
Oxygenator	
tubing		 Platinum	Cured	Silicone	Rubber	Tube	(3mm	ID	x	4mm	OD)	
Tubing	 Silicon	tubing,	Tygon	(1.6mm	ID	x	4.8mm	OD)	
Vessel	 Virgin	PTFE	(Teflon)	
Steel	rods	 1/8"	OD	x	0.028"	Wall.	316	Stainless	Steel	Tubing	
supplier	
information	 Metal	&	Plastic	Ltd	(Delrin,	Teflon)	
		 -	PO	Box	432	Watford,	Hertfordshire	WD1	8YP,	UK	
		 		
		 London	Fluid	System	Technologies	Swagelok	London	
		 (St	steel	tubing)	
		
-	Kingley	Park,	Station	Road,	Kings	Langley,	Herts	WD4	8GW	
UK	
		 		
		 Silex	Ltd	(silicon	tubing)	
		 -	Unit	5	Broxhead	Trading	Estate,	Lindford,	Bordon,	
		 Hampshire	GU35	0NY,	United	Kingdom	
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3.1.11 Alginate	decapsulation	of	hDPSCs	
The	 beads	were	 dissolved	 at	 each	 time	 point	 for	 sampling	 using	 a	 depolymerisation	
buffer	consisting	of	50	mM	tri-sodium	citrate	dihydrate,	77	mM	sodium	chloride	and	10	
mM	HEPES	(Magyar	et	al.,	2001).	
3.1.12 Biological	evaluation	techniques	
The	general	approach	was	to	show	the	results	in	a	genetic,	then	in	a	protein	and	finally	
in	a	structural	level.	The	viability	of	cells	in	the	hydrogel	beads	was	measured	by	using	
LIVE/DEAD	assay,	Celltiter-Glo	3D	and	Cell	cunting	kit	8.	The	gene	and	protein	expression	
were	measured	by	means	of	quantitative	real	time	polymerase	chain	reaction	(qPCR)	
and	flow	cytometry	or	immunostainning.	The	structural	analysis	was	done	by	histology,	
scanning	electron	microscopy	(SEM)	with	X-ray	microanalysis	(SEM/EDS)	and	attenuated	
total	 reflectance-Fourier	 transform	 infra-red	 spectroscopy	 (ATR-FTIR).	 	 The	 human	
antibodies	 to	be	used	as	markers	of	 the	 cell	 state	 and	 to	 characterise	 them	by	 flow	
cytometry	or	immunostaining	were:	anti-CD44,	anti-CD73,	anti-CD90,	anti-CD105,	anti-
CD14,	anti-CD11b,	anti-CD34,	anti-CD45,	anti-CD79α,	anti-CD19	and	anti-HLA	class	 II,	
Runt-related	transcription	factor	2	(Runx2	–	early	osteoblasts	marker),	anti-Osteopontin	
(OPN/SPP1	–	mature	osteoblasts	marker),	anti-Osteocalcin	(BGLAP	–	mature	osteoblasts	
marker),	anti-Podoplanin	 (PDPN/E11/gp38	–	early	osteoclast),	anti-Sclerostin	 (SOST	–	
mature	osteocyte)	(Yu	et	al.,	2010,	Sabokbar	et	al.,	1994).	
3.1.13 Live/Dead	assay	
Intracellular	 esterase	 activity	 and	 an	 intact	 plasma	 membrane	 are	 distinguishing	
characteristics	of	 live	cells.	This	assay	discriminates	the	 live	and	dead	cells	within	the	
alginate	 hydrogels,	 by	 staining	 with	 cell	 membrane-permeant	 dye,	 3',6'-Di(O-acetyl-
2',7'-bis[N,N-bis(carboxymethyl)	 aminomethyl]	 fluorescein	 tetraacetoxymethyl	 ester	
(calcein	 AM,	 Invitrogen)),	 to	 produce	 cytoplasmic	 green	 fluorescence	 to	 indicate	
esterase	activity	and	with	membrane-impermeant	ethidium	homodimer-1	(EthD-1)	to	
label	nucleic	acids	of	membrane-compromised	cells	with	red	fluorescence	to	 indicate	
loss	of	plasma	membrane	integrity.	Beads	are	collected	and	washed	with	PBS.	A	4mM	
EthD-1/	2mM	calcein	AM	solution	diluted	in	PBS	was	added	to	beads	and	incubated	at	
37oC	with	gentle	shaking	for	30	minutes	in	the	dark.	A	negative	control	is	produced	by	
using	100%	(v/v)	methanol	for	5	minutes	instead	of	PBS.	After	incubation,	the	solution	
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is	aspirated	and	a	small	amount	of	PBS	is	added	to	the	beads	to	prevent	dehydration.	
Samples	are	then	photographed	for	analysis.	
3.1.14 Celltiter-Glo	3D	cell	viability	assay	
A	quantitative	method	to	determine	 the	number	of	viable	cells	 in	3D	cell	 culture,	by	
determining	the	amount	of	ATP	present,	which	is	a	marker	for	metabolically	active	cells.	
3	hydrogel	beads	were	harvested	(n=3)	and	deposited	in	opaque-walled	96	well	plate	
with	100	uL	of	media.	100	uL	of	Celltiter-Glo	3D	reagent	were	added	to	each	well,	mixing	
vigorously	 for	5	minutes	 to	dissolve	 the	scaffold	and	 induce	cell	 lysis.	 From	this	 step	
onwards,	everything	was	done	in	darkness.	The	plate	was	allowed	to	incubate	at	room	
temperature	 for	 an	 additional	 25	 minutes.	 The	 luminiscence	 was	 measured	 with	 a	
GLoMax	96	microplate	luminometer	(Promega).		
3.1.15 Cell	counting	kit	8	viability	assay	
Cell	counting	kit	8	(CCK-8;	Sigma),	is	a	tetrazolium	salt	based	kit	(as	MTT	or	MTS).	It	uses	
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,	
monosodium	salt	(WST-8),	a	reagent	reduced	by	cellular	dehydrogenases	producing	an	
orange	 formazan	 dye.	 The	 amount	 of	 formazan	 produced	 by	 this	 reaction,	 is	
proportional	 to	 the	 living	 cell	 number.	 3	 hydrogels	 beads	were	 harvested	 (n=3)	 and	
deposited	in	96	well	plate	with	100	uL	of	media.	The	samples	were	pre-incubated	in	the	
incubator	at	37oC	and	with	5%	CO2.	10	uL	of	CCK-8	reagent	were	added	to	each	well	and	
then	 samples	 were	 incubated	 in	 the	 incubator	 for	 4	 hours.	 After,	 the	 supernatant	
absorbance	 at	 450	 nm	 was	 measured	 with	 GLoMax	 96	 microplate	 luminometer	
(Promega).	
3.1.16 Real	Time	Polymerase	Chain	Reaction	(qPCR)	
Total	 RNAs	 from	 the	 samples	 is	 extracted	 by	 using	 RNeasy	 kit	 according	 to	 the	
manufacturer’s	 instructions.	 If	 necessary	 dissolve	 the	 beads	 with	 depolymerisation	
buffer	 for	 20	minutes,	RNA	 is	 reversed	 transcribed	 into	 complementary	DNA	 (cDNA)	
using	the	Reverse	Transcription	System.	Briefly,	cocktail	for	cDNA	synthesis	consisting	of	
1	μg	of	RNA,	4	μl	of	MgCl2	(25	mM),	2	μl	of	dNTPmix	(10	mM),	2	μM	of	RT	10X	Buffer,	
0.5	 μl	 recombinant	 RNasin	 ribonuclease	 inhibitor,	 0.6	 μl	 AMV	 reverse	 transcriptase	
(15U)	and	1	μl	random	primers	(0.5	mg)	in	a	total	volume	of	10,1	μl	per	reaction.	The	
RNA	samples	are	heated	at	70oC	for	10	minutes	and	then	immediately	cooled	on	ice	for	
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5	minutes.	After	the	cocktail	is	added	to	RNA	samples,	they	are	incubated	at	25oC	for	
10min,	 and	 then	 reverse	 transcription	 is	 performed	by	 setting	 the	program	 for	 92oC	
burst	 for	20-40	 cycles	depending	on	 the	 sample.	50	μl	 cDNA	 samples	 containing	 the	
mastermix,	5	μl	10X	PCR	Buffer	(-Mg),	1	μl	dNTP	mixture	(10	mM),	1.5μl	MgCl2	(50mM),	
38,1	 μl	 DEPC-treated	 water.	 Add	 1	 μl	 of	 each	 primer	 (sense	 and	 anti-sense),	 0.4	 μl	
Platinum	Taq	DNA	Polymerase	(5	U/	μl)	and	2	μl	of	cDNA	sample.	Run	the	real	time	PCR	
machine.	The	list	of	genes	and	specific	PCR	conditions	is	indicated	in		Table	7.	
	Table	7:	Primers	for	osteogenic	differentiation	characterisation	
Gene	 Sequence	 		 Size	 AT(oC)	
GAPDH	 Forward	Primer	 GGAGCGAGATCCCTCCAAAAT	 197	 62	
	 Reverse	Primer	 GGCTGTTGTCATACTTCTCATGG	 	
	 	 	 	 	
Runx2	 Forward	Primer	 TGGTTACTGTCATGGCGGGTA	 101	 62	
	 Reverse	Primer	 TCTCAGATCGTTGAACCTTGCTA	 	
	 	 	 	 	
Col1a1	 Forward	Primer	 GAGGGCCAAGACGAAGACATC	 140	 62	
	 Reverse	Primer	 CAGATCACGTCATCGCACAAC	 	 	
	 	 	 	 	
ALPL	 Forward	Primer	 ACCACCACGAGAGTGAACCA	 79	 62	
	 Reverse	Primer	 CGTTGTCTGAGTACCAGTCCC	 	 	
	 	 	 	 	
SOST	 Forward	Primer	 ACACAGCCTTCCGTGTAGTG	 123	 61	
	 Reverse	Primer	 GGTTCATGGTCTTGTTGTTCTCC	 	
	 	 	 	 	
BGLAP	 Forward	Primer	 CACTCCTCGCCCTATTGGC	 112	 62	
		 Reverse	Primer	 CCCTCCTGCTTGGACACAAAG	 		 		
	
3.1.17 Flow	cytometry	analysis	
Cells	were	trypsinised,	counted	and	washed.	Pellets	with	100.000	cells	were	formed	by	
centrifugation.	The	cell	pellets	were	fixed	for	40	minutes	at	room	temperature	 in	4%	
(w/v)	paraformaldehyde	(PFA:	BDH	Laboratory	supplies),	washed	twice	with	cell	staining	
buffer,	consisting	of	1%	bovine	serum	albumin	(BSA,	Sigma)	and	0.02%	sodium	azide	in	
PBS.	and	placed	into	a	tube.	The	samples	were	then	permeabilised	by	incubating	for	45	
minutes	in	0.1%	triton	x-100	(Sigma),	1%	BSA	in	PBS,	washed	with	staining	buffer	and	
then	 blocked	 by	 incubating	 for	 10	minutes	 in	 10%	 serum	 in	 staining	 buffer.	 A	 good	
blocking	 solution	 consists	 of	 serum	of	 the	 same	animal	 species	 than	 the	host	of	 the	
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secondary	antibody.	The	blocking	solution	was	removed	and	samples	were	washed	2	
times	in	staining	buffer.	Cells	were	incubated	overnight	in	a	humid	chamber	with	the	
primary	antibodies	diluted	in	staining	buffer,	for	the	control	sample,	only	the	staining	
buffer	was	added.	The	solution	was	removed	and	washed	twice	with	staining	buffer.	
Samples	then	where	incubated	for	1	hour	in	the	dark	and	at	room	temperature,	with	the	
corresponding	 secondary	 antibodies	 diluted	 in	 PBS	 (including	 the	 control).	 From	 this	
step	onwards,	everything	was	done	in	darkness.	The	secondary	antibody	solution	was	
removed	and	samples	were	washed	in	rinse	buffer	1X.	The	pellet	was	resuspended	in	
300	ml	of	staining	buffer	and	the	samples	were	ready	to	be	measured	in	flow	cytometer	
(BD	 Fortessa	 flow	 cytometer;	 BD	 biosciences/	 Guava	 easyCyte	 8HT	 benchtop	 flow	
cytometer;	Merck	Millipore).	
3.1.18 Immunocytochemical	stainning		
Hydrogels	were	collected	and	 fixed	 for	90	minutes	at	 room	temperature	 in	4%	(w/v)	
paraformaldehyde	(PFA:	BDH	Laboratory	supplies),	washed	twice	with	rinse	buffer	1X,	
consisting	of	20	mM	Tris-HCl	buffer	(Sigma),	0,15%	NaCl	and	0,05%	tween-20	(Sigma)	in	
PBS	and	placed	into	tubes.	The	samples	were	then	permeabilised-blocked	by	incubating	
for	45	in	permeabilisation-blocking	solution.	A	good	blocking	solution	consists	of	serum	
of	the	same	animal	species	than	the	host	of	the	secondary	antibody,	in	this	study,	rabbit	
and	goat	 serum	were	used.	 the	permeabilisation-blocking	solution	was	 removed	and	
samples	were	washed	2	times	in	rinse	buffer	1X.	samples	were	incubated	overnight	in	a	
humid	chamber	with	the	primary	antibodies	diluted	in	0.1%	triton,	1%	BSA	in	PBS,	for	
the	control	sample,	only	the	diluent	was	added.	The	solution	was	removed	and	washed	
twice	with	rinse	buffer	1X.	Samples	then	where	incubated	for	1	hour	in	the	dark	and	at	
room	 temperature,	 with	 the	 corresponding	 secondary	 antibodies	 diluted	 in	 PBS	
(including	the	control).	From	this	step	onwards,	everything	was	done	in	darkness.	The	
secondary	antibody	solution	was	removed	and	samples	were	washed	in	rinse	buffer	1X.	
The	rinse	buffer	was	removed	and	the	samples	were	ready	to	be	observed	under	the	
microscope.	
3.1.19 Alkaline	Phosphatase	(ALPase)	activity	
Although	the	mechanism	is	yet	not	fully	understood,	ALPase	has	a	fundamental	roll	in	
the	deposition	of	the	mineral	salts	and	calcification	of	the	bone	matrix,	thus	making	it	a	
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valued	marker	for	the	bone	mineralisation.	Cellular	ALPase	was	assessed	colorimetrically	
by	 measuring	 ρ-nitrophenol	 phosphate	 (ρNPP)	 content.	 Three	 beads	 (n=3)	 were	
collected	 from	 each	 group	 and	 dissolved	 in	 depolimerisation	 buffer	 for	 20	minutes,	
centrifuged	at	400g	for	10	minutes	and	the	supernatant	was	removed	and	washed	with	
PBS.	200	µL	of	ALPase	buffer	and	200	µL	of	ρNPP	were	added	to	each	sample,	pipetted	
vigorously	and	then	Incubated	at	37oC	for	30	minutes	in	the	dark.	To	stop	the	reaction	
400	µL	of	 0.5N	 sodium	hydroxide	were	added	 to	 the	 samples.	 Finally,	 100	µL	of	 the	
solution	were	analyse	at	410	nm	wavelength	with	ELISA	reader	 (MRX	 II	plate	reader;	
Dynex	technologies,	West	
Sussex,	UK).	
3.1.20 Media	analysis	
The	metabolic	activity	of	 the	cells	 is	directly	 related	 to	 the	metabolic	 stress	 they	are	
living	 and	 will	 impact	 the	 cells	 proliferation	 and	 differentiation.	 The	 concentration	
profile	 of	 nutrients	 (glucose,	 glutamine,	 lactate,	 ammonia,	 glutamate)	 and	 pH	 was	
measured	using	Bioprofile	400	Analyzer	(Nova	Biomedical,	Flintshire,	UK)	taking	1.0	ml	
samples	of	culture	media	supernatant	to	be	harvested	at	several	time	points	during	the	
culture.	Fresh	media	was	used	as	control.	
3.1.21 Paraffin	embedding	and	sectioning	for	histological	analysis	
The	 paraffin	wax	 embedding	 of	 the	 hydrogels	 for	 further	 sectioning	 and	 histological	
analysis	was	done	following	the	same	procedure	for	all	experiments	as	described:	beads	
were	 fixed	 in	 the	 appropriate	 fixative	 depending	 on	 the	 sample	 point	 (see	 Table	 8),	
dehydrated	 through	a	 series	of	 graded	ethanol	baths	 (70%	 for	3	minutes;	 95%	 for	3	
minutes,	2	times;	100%	for	3	minutes,	2	times;	1:1	Paraclear:Ethanol	 for	10	minutes;	
Paraclear	(Polysciences,	Inc)	for	10	minutes,	2	times)	to	displace	water,	then	infiltrated	
with	paraplast	plus	(Sigma)	for	1	hour	to	finally	be	embedded	with	new	paraplast	in	an	
histology	cassette	for	up	to	1	hour	to	form	a	block.	It	is	important	not	to	keep	the	beads	
in	hot	paraffin	too	long	or	samples	could	be	damaged.	Processed	tissues	can	be	stored	
in	the	cassettes	at	room	temperature	indefinitely,	or	serially	sectioned	with	a	thickness	
of	4	um	with	a	microtome	into	glass	slides.	
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Table	8:	Different	fixatives	for	histology	
Ethanol	70%	 First	 2	weeks	 of	 experiment	 (first	week,	
day	 0	 and	 7	 in	 growth	 media,	 and	 first	
week,	day	0	and	7	of	differentiation)	*	
Neutral	buffered	formalin	(Formaldehyde	
4%	in	PBS)	
Last	2	weeks	of	experiment		(day	14	and	
21	of	differentiation)	**	
*	Without	differentiation,	beads	get	dissolved	in	common	fixatives.	 		
**most	commonly	used	fixative.	
3.1.22 Alizarin	red	S	(ARS)	Staining	for	calcium	deposition	
Paraffin-embedded	 slides	 were	 deparaffinised	 and	 rehydrated,	 by	 placing	 them	 in	
paraclear	and	decreasing	concentrations	of	ethanol.	After,	the	slides	were	immersed	in	
a	40	mM	alizarin	red	S	 (Sigma-Aldrich)	solution	(pH	4.2)	 for	up	to	5	minutes	at	room	
temperature,	 checking	 for	 the	 red	 colour	 granules	 forming	 in	 the	 slides	 under	 the	
microscope.	When	 the	 colour	was	 formed,	 the	 solution	was	 removed	 and	 the	 slides	
were	washed	with	running	water.	The	slides	then	were	dried	in	a	series	of	 increasing	
concentrations	of	ethanol,	to	finally	be	mounted	with	10%	(V/V)	glycerol	(Sigma)	and	
observed	in	the	microscope.	
3.1.23 Von	Kossa	staining	for	calcium	deposition	
Paraffin-embedded	 slides	 were	 deparaffinised	 and	 rehydrated,	 by	 placing	 them	 in	
paraclear	 and	 decreasing	 concentrations	 of	 ethanol.	 Slides	 were	 immersed	 and	
incubated	for	20	minutes	in	1%	silver	nitrate	solution	under	ultraviolet	light,	then	rinsed	
in	several	changes	of	distilled	water.	The	unreacted	silver	was	removed	immersing	the	
slides	in	5%	sodium	thiosulfate	for	5	minutes.	Nuclear	fast	red	was	used	as	counterstain.	
The	slides	were	immersed	in	fast	red	for	5	minutes,	rinsed	with	distilled	water	and	then	
dried	in	a	series	of	increasing	concentrations	of	ethanol,	to	finally	be	mounted	with	10%	
(V/V)	glycerol	and	observed	in	the	microscope.	
3.1.24 Haematoxylin	&	Eosin	staining	
Paraffin-embedded	 slides	 were	 deparaffinised	 and	 rehydrated,	 by	 placing	 them	 in	
paraclear	and	decreasing	concentrations	of	ethanol.	To	stain	with	Mayer’s	haematoxylin	
(Sigma),	the	slides	were	immersed	in	haematoxylin	solution	for	3	minutes,	washed	in	
tap	water	for	5	minutes,	dipped	12	times	in	acid	ethanol	(1	ml	of	concentrated	HCl	in	
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400	ml	of	70%	EtOH)	to	destain,	rinsed	2	times	for	1	minute	in	tap	water	and	one	more	
time	in	deionised	water	for	2	minutes.	If	desired,	slides	can	be	left	in	water	over	night.	
To	stain	with	Eosin	Y,	the	remaining	remaining	water	was	blotted	and	the	slides	were	
immersed	 in	eosin	y	solution	(Sigma)	 for	30	seconds.	The	slides	then	were	dried	 in	a	
series	of	 increasing	 concentrations	of	ethanol,	 to	 finally	be	mounted	with	10%	 (V/V)	
glycerol	and	observed	in	the	microscope.	
3.1.25 Scanning	electron	microscopy	with	X-ray	microanalysis	
Hydrogels	were	rinsed	in	PBS	to	remove	any	medium,	fixed	by	submerging	in	warm	3%	
glutaraldehyde	solution	(Sigma)	 in	Sorenson’s	buffer	 (80.4	ml	of	Na2HPO4,	19.6	ml	of	
KH2PO4	and	100	ml	of	dH2O)	for	3	hours,	and	washed	two	times	with	Sorenson’s	buffer	
for	5	minutes.	For	post-fixation,	beads	were	submerged	in	osmium	tetroxide	(Sigma),	
under	 the	 hood	 and	 in	 a	 cold	 bath	 for	 15	 minutes.	 Beads	 were	 rinsed	 carefuly	 in	
Sorenson’s	buffer,	to	avoid	structural	damage	of	the	samples.	Samples	were	dried	in	a	
series	of	increasing	concentrations	of	ethanol	and	mounted	on	stubs.	Mounted	samples	
were	coated	with	gold	in	a	sputter	coater	()	and	then	viewed.	Digital	image	capture	was	
performed	 in	 Jeol	 JSM5610LV	 SEM	 and	 x-ray	 microanalysis	 was	 performed	 in	 Jeol	
JSM6400	SEM	fitted	with	Oxford	Instruments	INCA	energy	dispersive	analytical	system	
(EDS)	for	elemental	x-ray.	
3.1.26 Attenuated	Total	Reflectance-Fourier	Transform	Infra-red	spectroscopy	
Attenuated	total	reflectance	Fourier	transform	infrared	(ATR-FTIR)	spectral	analysis	was	
conducted	using	an	ATR-FTIR	spectrometer	(Varian	7000	FT-IR,	Varian	Inc.	CA,	USA)	with	
Isys	software	(Spectral	Dimension,	Malvern,	Aus).	Sample	beads	were	placed	onto	the	
measuring	surface	of	the	ATR	crystal	(oil	analyser,	Specac	Ltd.,	Kent,	UK).	Excess	water	
was	 removed	and	spectra	was	acquired.	Three	beads	were	measured	per	 treatment,	
and	 the	 relative	 amount	 of	 hydroxyapatite	 in	 each	 of	 the	 bead	 was	 compared	 by	
calculating	 the	 ratio	 between	 wavelength	 values	 at	 1415	 and	 1035	 [cm-1],	 both	
characteristic	 for	 the	 organic	 (mostly	 collagen	 I)	 and	 inorganic	 composition	 of	 bone	
(mostly	hydroxyapatite)	respectively.		
Attenuated	 total	 reflection	 Fourier	 transform	 infrared	 (ATR-FTIR)	 imaging	 was	
performed	using	a	continuous	scan	FTIR	spectrometer	(Varian	7000	FT-IR,	Varian	 Inc.	
CA,	USA)	jointly	to	a	large	sample	compartment	extension	(Varian	LS)	and	a	64	x	64	focal	
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plane	array	(FPA)	detector.	Sample	beads	were	placed	onto	the	measuring	surface	of	
the	ATR	crystal	(oil	analyser,	Specac	Ltd.,	Kent,	UK)	with	the	surface	in	contact	with	the	
crystal.	Excessive	water	was	carefully	removed	and	the	sample	was	sheltered	to	prevent	
further	 evaporation,	 thus	 ensuring	 that	 the	 bead	 remains	 hydrated	 during	
measurements.	Images	were	acquired	with	8	cm-1	spectral	resolution	with	32	co-adding	
scans.	 A	 sample	 measurement	 would	 normally	 require	 less	 than	 1	 minute	 to	 be	
processed.	 Three	 beads	 (n=2)	 were	measured	 from	 each	 sample.	 Spectral	 data	 was	
analysed	using	the	Isys	software	(Spectral	Dimension,	Malvern,	Aus).	Factor	analysis	was	
applied	to	the	spectral	region	of	1110-990	[cm-1].	Results	were	analysed	simultaneously	
by	 concatenating	 all	 images	 together	 before	 the	 factor	 analysis.	 Allowing	 a	 direct	
comparison	 between	 images.	 Image	 showing	 the	 distribution	 of	 hydroxyapatite	
developed	in	the	hydrogels	was	extracted	using	factor	analysis.	Further,	a	binary	image	
was	generated	with	a	threshold	of	10%	to	outline	the	pixels	that	were	considered	to	
detect	hydroxyapatite.	
3.1.27 Statistical	analysis	
Samples	for	quantitative	analyses	were	measured	in	replicates	(two	or	three).	Error	bars	
on	 all	 graphs	 represent	 the	 standard	 deviation	 of	 their	 average	 values.	 Comparable	
values	 from	each	 group	were	 subjected	 to	 statistical	 analysed	with	 student	 t-test	 or	
analysis	 of	 variance	 (ANOVA)	 with	 a	 significance	 of	 p<0.05	 or	 p<0.001	 (*	 or	 **	
respectively).	
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4 Characterisation	of	human	dental	pulp	stem	cells	
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4.1 Introduction	
Adult	MSCs	have	been	found	in	most	of	the	tissues	of	the	human	body,	such	as:	dental	
pulp,	bone	marrow,	peripheral	blood,	adipose	tissue.	In	addition,	MSCs	have	been	found	
in	various	neonatal	tissues,	such	as:	placenta,	amnion,	umbilical	cord	and	cord	blood.	
These	differently	sourced	MSCs,	have	been	seen	to	carry	differences	in	their	genotype	
and	phenotype.	Several	important	surface	SC	markers	in	addition	to	proliferation	rate,	
life	 span	 and	 differentiation	 capacity,	 present	 differences	 ranging	 from	 subtle	 to	
considerable	 (Hass	 et	 al.,	 2011).	Moreover,	 diverse	methodologies	 of	 extraction	 and	
expansion	can	further	 increase	these	differences.	The	scale-up	of	production	of	stem	
cells	requires	Safeguarding	the	resulting	cells	are	sufficiently	akin	and	differentiable	to	
be	consistently	used	in	cell	therapy	procedures.	Hence	characterising	MSCs	represent	
the	first	mile	stone	of	any	stem	cell	strategy	development.	
hDPSCs	differ	from	mesenchyme	as	they	have	an	ectodermal	origin	and	arise	from	the	
neural	 crest.	 Nevertheless,	 these	 cells	 share	 several	 characteristics	 with	 MSCs,	
clonogenic,	 rapidly	 proliferating	 and	 with	 the	 potential	 to	 differentiate	 into	 several	
tissues.	To	define	them	as	ectomesenchyme	with	cell	therapy	potential,	it’s	required	to	
follow	exactly	the	same	criteria	used	to	define	regular	MSCs	and	in	the	process	assess	
their	MSCs	equivalence.	
4.1.1 Minimal	criteria	for	MSCs	
Based	on	currently	available	data,	the	Mesenchymal	and	Tissue	Stem	Cell	Committee	of	
the	International	Society	for	Cellular	Therapy	(ISCT)	issued	a	position	statement	in	2006,	
proposing	a	set	of	standards	defining	the	minimal	criteria	for	cells	to	be	considered	MSCs	
for	laboratory-based	research	and	for	pre-clinical	studies	(Dominici	et	al.,	2006).	They	
propose	three	criteria:	1)	cells	must	be	plastic	adherent	when	grown	under	standard	in	
vitro	culture	conditions,	2)	95%	or	more	of	the	expanded	cells,	must	express	the	surface	
markers	CD73	 (ecto-5’nucleotidase;	 cell-cell	 interactions,	migration	 and	modulation),	
CD90	 (Thy-1	 antigen;	 cell-cell	 interactions)	 and	 CD105	 (Endoglin;	 TGF-β	 receptor	 III)	
when	measured	by	flow	cytometry,	Other	cell	surface	marker	characteristic	of	MSCs	is	
CD44,	 it’s	 thought	 to	 help	 cells	 to	 maintain	 stemness	 and	 the	 ISCT	 recommends	
reporting	its	expression	as	well;	hematopoietic	cells	are	the	most	common	contaminant	
in	MSCs	samples,	cells	must	be	negative	(2%	or	 less	positive)	 for	the	markers:	CD14/	
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CD11b	(monocytes	and	macrophages),	CD34	(primitive	hematopoietic	and	endothelial),	
CD45	 (leukocyte),	 CD79α/	 CD19	 (B	 cells)	 and	 HLA	 class	 II	 (leukocyte).	 3)	 the	 most	
distinctive	property	of	MSCs	is	their	tri-lineage	differentiability	under	standard	in	vitro	
culture	conditions.	Differentiation	to	osteoblasts,	adipocytes	and	chondrocytes	must	be	
demonstrated	and	it	can	be	shown	by	the	following	in	vitro	stainings	Alizarin	red	S,	Oil	
red	O	and	Safranin	O	respectively.	
4.1.2 Clonogenicity	of	MSCs	and	lost	of	multipotency	
MSCs	 are	 highly	 proliferative	 cells	 able	 to	 form	 colonies	 of	 functional	 clones	 under	
normal	culture	conditions.	These	colonies	when	grown	in	incubators	can	be	driven	to	
differentiate	 into	 specific	 cell	 types,	 or	 spontaneously	 differentiate	 into	 osteoblasts,	
adipocytes	and	chondrocytes.	However,	long	term	culturing	has	been	demonstrated	to	
hinder	cell	proliferation	and/or	their	differentiation	capacity,	thus,	primitive	MSC-like	
properties	may	be	lost	through	successive	passaging.	
4.1.3 Tri-lineage	differentiation	of	hDPSCs	
Directed	differentiation	is	a	critical	aspect	for	MSCs,	strategies	and	requirements	for	tri-
lineage	differentiation	of	hDPSCs	have	to	be	studied	before	designing	bioprocessing.	The	
differentiation	in	vitro	of	MSCs	will	depend	largely	on	the	culture	conditions,	the	specific	
inducers	used,	and	the	nutrients	for	biosynthesis.		
4.1.3.1 Osteogenic	differentiation	of	hDPSCs	
Undifferentiated	 hDPSCs	 can	 be	 induced	 to	 Osteogenic	 differentiation	 by	 treatment	
with	BMPs,	a	 family	of	growth	 factors	which	act	as	direct	 cues	 for	differentiation	by	
driving	a	chain	of	events	that	triggers	the	expression	of	runx2	and	causing	the	initiation	
and	propagation	of	genes	in	charge	of	the	development	and	maturation	of	osteoblasts	
(e.g.	 collagen	 I,	 osteopontin,	 alkaline	 phosphatase	 and	 osteocalcin).	 Dexamethasone	
(Dex)	 and	 simvastatin	 are	 two	 drugs	 that	 act	 as	 indirect	 differentiation	 cues,	 by	
interacting	with	 the	 BMP	pathway,	 they	 down-regulate	 the	 effect	 of	 tumor	 necrosis	
factor	(TNF-α),	a	inflammatory	mediator	with	inhibitory	effect	in	osteogenesis.	Dex	has	
been	reported	to	protect	cells	from	apoptosis	in	confluent	culture.		β-glycerol	phosphate	
(β-GP)	 is	 required	 as	 a	 local	 source	 of	 inorganic	 phosphate	 ions	 for	 the	mineralising	
tissue	(forming	part	of	hydroxyapatite)	and	can	cause	differentiation	alone	by	acting	as	
an	intracellular	signal,	or	enhance	the	effect	of	other	cues.	Ascorbic	acid	(ASAP)	which	
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stimulates	 ECM	 secretion	 (collagen	 type	 I)	 is	 a	 vital	 cofactor	 for	 enzymes	 that	
hydroxylate	proline	and	lysine	in	pro-collagen,	in	its	absence,	collagen	is	not	properly	
formed	(Pittenger	et	al.,	1999,	Langenbach	and	Handschel,	2013).	The	most	common	
medium	for	osteogenic	differentiation	was	 first	 reported	 in	1985	by	Tenenbaum	and	
Heersche,	it	uses	Dex,	β-GP	and	ASAP	in	serum	medium	and	it	has	became	the	golden	
standard	for	osteogenic	differentiation	(Tenenbaum	and	Heersche,	1985).			
For	 characterization	 purposes,	 osteogenic	 differentiation	 can	 be	 confirmed	
histologically	by	the	appearance	of	calcium	nodules	and	by	the	expression	of	ALP.		
4.1.3.2 Chondrogenic	differentiation	of	hDPSCs	
Undifferentiated	hDPSCs	can	be	induced		to	Chondrogenic	differentiation	by	treatment	
with	TGF-β,	 	a	family	of	growth	factors	which	act	as	direct	cues	for	differentiation	by	
driving	a	chain	of	events	that	triggers	the	expression	of	SOX9	and	causing	the	initiation	
and	propagation	of	genes	in	charge	of	the	development	and	maturation	of	chondrocytes	
(e.g.	Col2,	Ihh,	Runx2,	Colx,	ALP,	VEGF).	TGF-β1,	TGF-β3,	Dex,	Insulin,	insulin-like	growth	
factor	1	(IGF-I),	or	BMP4	which	acts	as	chondrogenic	inducer	proceeding	through	TGF-β	
signaling	 are	 typically	 used	 in	 chondrogenic	 differentiation	 mediums.	 Although	 the	
mechanism	in	which	insulin	acts	is	still	unidentified,	but	it’s	known	to	be	essential.	If	not	
included,	the	differentiation	is	not	possible	(Mueller	et	al.,	2013).		
For	 characterization	 purposes,	 chondrogenic	 differentiation	 can	 be	 confirmed	
histologically	by	the	appearance	of	proteoglycan-rich	ECM	(Pittenger	et	al.,	1999).		
4.1.3.3 Adipogenic	differentiation	of	hDPSCs	
Undifferentiated	hDPSCs	 can	be	 induced	 	 to	Adipogenic	differentiation	by	 treatment	
with	 transcription	 factors	 cyclic	adenosine	monophosphate	messenger	 (cAMP)	which	
triggers	cAMP	response	element-binding	protein	(CREB),	these	drive	the	expression	of	
CCAAT/enhancer-binding	 proteins	 (C/EBPs)	 and	 of	 transcription	 factor	 peroxisome	
proliferator	 activated	 receptor	 gamma	 (pPAR-δ)	 which	 regulates	 adipose	 tissue	
development	and	maturation	(Rosen	and	MacDougald,	2006).	The	most	common	media	
for	 Adipogenic	 differentiation	 uses	 1-methyl-3-isobutylxanthine	 (IBMX),	 Dex,	 insulin,	
and	 indomethacin,	 this	 cocktail	 enhances	 intracellular	 cAMP	 and	 triggers	 adipogenic	
gene	expression.	Insulin	through	the	Wnt	pathway	induces		β-catenin	in	due	process	it	
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promotes	proliferation	and	differentiation	of	preadipocytes.	Dex	alone	is	known	to	be	
important	 for	 the	 tri-lineage	 differentiation,	 and	 when	 combined	 with	 IBMX	 they	
regulate	pPAR-δ	and	C/EBPs	and	promote	adipogenesis.	
For	 characterization	 purposes,	 adipogenic	 differentiation	 can	 be	 confirmed	
histologically	by	the	appearance	of	lipid-rich	vacuoles	within	the	cells	(Pittenger	et	al.,	
1999).	
4.2 Objectives	
An	efficient	strategy	for	scaling	up	the	production	and	differentiation	of	hDPSCs	for	cell	
therapy,	 requires	 understanding	 the	 behaviour	 of	 cells	 under	 normal	 MSC	 culture	
conditions.	This	chapter	focus	in	the	characterisation	of	the	hDPSCs	as	MSC-like	cells	by	
studying	 the	 undifferentiated	 expansion,	 the	 passaging	 and	 the	 further	 tri-lineage	
differentiation,	as	well	as	the	nutritional	and	environmental	requirements	of	hDPSCs.	
Characterising	 hDPSCs	 by	 the	 ISCT	 defined	 criteria,	 represents	 the	 foundations	 for	
designing	a	bioprocess	for	bone	tissue	engineering.		
	
4.3 Experimental	Process	
Isolated	donor	samples	of	hDPSCs	were	cultured	and	characterised	by	their	ability	to	
proliferate	 in	culture	with	an	attached	well-spread	morphology,	by	the	presence	of	a	
consistent	set	of	marker	proteins	on	their	surface,	and	by	their	extensive	differentiation	
to	multiple	mesenchymal	lineages	under	controlled	in	vitro	conditions.	
Prior	to	the	tri-lineage	differentiation,	hDPSCs	were	passaged	12	times	for	morphologic,	
kinetic	 and	 flow	cytometry	 characterisation,	 to	 assess	which	passage	would	allow	 to	
expand	 sufficient	 cells	 for	 the	 further	 differentiation,	 meanwhile	 maintaining	 the	
stablished	minimal	criteria.	
Clonogenicity,	metabolic	activity	and	tri-lineage	differentiation	were	assessed	 for	 the	
selected	passage	and	were	measured	by	CFU-F,	bioprofiling,	histological	analysis	and	in	
particular	for	bone	differentiation,	runx2	expresion	and	ALP	activity	were	measured.	
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4.4 Results		
4.4.1 hDPSCs	expansion	and	maintenance	
The	 expansion	 and	 maintenance	 of	 undifferentiated	 hDPSCs,	 while	 retaining	 their	
multipotency,	 is	 an	 important	 step	 in	 designing	 a	 bone	 tissue	bioprocessing,	 since	 it	
provides	 the	 starting	 material	 for	 the	 further	 differentiation.	 Establishing	 the	
appropriate	 passage	 that	 will	 retain	 the	 multipotent	 characteristics	 as	 well	 as	 the	
proliferation	rate	of	the	parental	cells,	meanwhile	allowing	to	suffice	the	amount	of	cells	
required,	was	the	first	step	in	this	characterisation.	
To	establish	 the	optimal	 condition	 for	 the	hDPSCs	expansion,	 Passage	4	 cells	 from	2	
donors	(n=6)	were	seeded	with	different	densities	(Low=2000	cells/cm2,	Medium=5000	
cells/cm2,	High=10000	cells/cm2	and	then	allowed	to	expand	for	5	days.	Every	day	cells	
were	counted	to	asses	their	growth.	As	shown	in	Figure	16,	the	medium	initial	density	
of	approximate	5000	cells/cm2	showed	faster	growth	achieving	the	same	cell	number	
than	the	achieved	by	the	high	cell	density	culture.	The	doubling	time	for	low	density	was	
of	1.51	days,	for	medium	density	of	1.475	days	and	for	the	high	density	of	2.21	days.	
Accordingly,	the	medium	cell	seeding	density	was	used	in	all	further	studies.	
	
Figure	16	hDPSCs	expansion	during	120	hours	of	culture	in	function	of	cell	seeding,	cell	
number	was	measured.	For	each	group,	n=3	(*:	significantly	different	compared	to	the	
sample	point,	P<0.05)	
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As	previously	stated,	when	hDPSCs	are	undifferentiated,	the	surface	antigen	CD73,	CD90	
and	CD105	are	highly	expressed.	When	differentiation	starts,	the	expression	is	down-
regulated	until	 totally	disappearing	at	 the	end	of	 the	process.	As	well,	CD14/	CD11b,	
CD34,	CD45,	CD79α/	CD19	and	HLA	class	II	are	always	negative.		
Passage	 1	 cells	 from	2	 donors	were	 plated	 at	 density	 5x103	 cells/cm2	 and	 individual	
attached	cells	were	identified	on	the	culture	dish.	When	80%	confluence	was	achieved,	
cells	were	sub-cultured	into	new	T75	flasks	with	the	same	cell	density.	With	every	new	
passage,	cells	were	counted	for	proliferation	analysis	and	compared	with	the	parental	
cells	 (passage	 1).	 This	 process	 was	 repeated	 for	 12	 successive	 passages.	 Population	
doubling	time,	is	an	important	index	indicating	how	proliferative	the	given	cells	are	in	
culture.	Cells	were	found	to	have	an	average	doubling	time	of	1.568	±	0.29	days	with	a	
minimum	of	28	hours	and	a	maximum	of	48,	with	an	average	 live/dead	ratio	of	21	±	
4.64.	The	proliferation	rates	of	the	first	five	passages	of	the	cells	did	not	show	significant	
differences	compared	with	the	parent	cells.	These	results	can	be	seen	in	Figure	17.	
	
Figure	 17	 Doubling	 times	 and	 live/dead	 ratios	 for	 12	 passages	 of	 undifferentiated	
hDPSCs.	For	each	group	n=3		(*:	significantly	different	compared	to	the	parent	cells,	
P<0.05)	
A	 flow	 cytometry	 characterisation	of	 clonal	 cells	was	performed.	Cells	 from	 selected	
passages	were	analysed	with	flow	cytometry	and	their	multipotency	was	compared	to	
the	parent	cells	(Passage	1).	Cells	were	stained	with	surface	markers	for	CD44,	CD73,	
CD90,	CD105,	CD14,	CD11b,	CD34,	CD45,	CD79α,	CD19	and	HLA	class	II	and	were	found	
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to	be	homogeneous	and	indistinguishable	from	the	parent	culture	until	passage	4	with	
expression	above	98%	for	CD73,	CD90,	CD105	as	well	as	for	the	additional	marker	CD44.	
After	passage	4,	the	markers	presented	fluctuation,	but	with	a	tendency	to	decrease.	
The	 histograms	 and	 percentage	 of	 expression	 of	 CD73,	 CD90	 and	 CD105	 for	 every	
passage	can	be	seen	in	Figure	18	and	Figure	19	respectively.	It	is	important	to	comment	
that	histograms	for	passage	8	and	10,	appear	different,	as	the	measurements	were	done	
by	 different	 flow	 cytometer	 than	 the	 other	 samples	 (Guava	 easyCyte	 8HT	 flow	
cytometer,	Millipore).	
	
Figure	 18	 Histograms	 for	 the	 markers	 CD73,	 CD90	 and	 CD105	 measured	 by	 flow	
cytometry,	where	 the	 red	 line	 indicates	 the	negative	control	and	 the	blue	 line,	 the	
positive	samples.	10,000	events	were	acquired.	
	
Figure	19	Percentage	of	cells	with	positive	expression	for	the	markers	CD73,	CD90	and	
CD105	measured	by	flow	cytometry,	10,000	events	per	sample	were	acquired.	
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The	histograms	and	percentage	of	 expression	of	 CD44	 can	be	 seen	 in	 Figure	20	 and	
Figure	21	respectively.	
	
Figure	20	Histograms	for	the	markers	CD44	measured	by	flow	cytometry,	where	the	
red	line	represents	the	negative	control	and	the	blue	line,	the	positive	samples,	the	
positive	samples.	10,000	events	were	measured.	
	
Figure	21	Percentage	of	cells	with	positive	expression	for	the	marker	CD44	measured	
by	flow	cytometry.	
All	 the	 negative	 hematopoietic	 markers	 were	 grouped	 into	 one	 single	 channel	 and	
analysed.	If	samples	were	negative,	it	meant	all	the	markers	were	negative.	The	results	
for	all	the	selected	analysed	passages	were	negative	can	be	seen	in	Figure	22.	
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Figure	 22	 Histograms	 for	 the	 grouped	 hematopoietic	markers	 CD14,	 CD11b,	 CD34,	
CD45,	CD79α,	CD19	and	HLA	class	 II	 in	one	channel,	 in	each	histogram	the	samples	
(orange),	the	unstained	cells	(red)	and	the	isotypes	can	be	seen	(light	blue).	
These	 results	 confirm	 a	 well-defined	 proliferative	 ability	 through	 all	 the	 passages,	
especially	from	passage	1	to	5,	and	show	how	these	cells	are	suitable	for	long	term	3D	
culture.	
4.4.2 Effect	of	culture	duration	on	surface	markers	
A	 flow	 cytometry	 characterisation	 of	 clonal	 cells	 enduring	 long-term	 culture	 was	
performed.	 Cells	 from	 passage	 4	 were	 seeded	 with	 a	 density	 of	 ≈5000	 cells/cm2,	
cultured	 for	 10	 days	 without	 passaging	 and	 analysed	 with	 flow	 cytometry.	 Their	
multipotency	was	compared	to	cells	from	day	1	of	culture.	The	density	of	cells	at	the	last	
day	achieved	151330	±	14443	cells/cm2	(4.93	doublings).	Cells	were	stained	with	surface	
markers	 for	CD44,	CD73,	CD90,	CD105,	CD14,	CD11b,	CD34,	CD45,	CD79α,	CD19	and	
HLA	 class	 II	 and	 were	 found	 to	 be	 homogeneous	 and	 indistinguishable	 from	 day	 1	
culture,	with	 expression	 above	98%	 for	CD44,	 CD73,	 CD90,	 CD105.	 The	 light	 scatter,	
histograms	and	percentage	of	expression	for	markersCD44,	CD73,	CD90	and	CD105	can	
be	seen	in	Figure	23	and	Figure	24	respectively.		
													P2																						P6																							P9											
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Figure	23	light	scatter	plots	and	histograms	for	long	term	culture	measured	by	flow	
cytometry.	A)	forward	vs	side	scatter,	CD44/CD73	and	CD90/CD105	plots	for	day	1	of	
culture.	B)	forward	vs	side	scatter,	CD44/CD73	and	CD90/CD105	plots	for	day	10	of	
culture.	C)	CD14,	CD11b,	CD34,	CD45,	CD79α,	CD19	and	HLA	class	II	markers	grouped	
in	one	channel	for	day	10	of	culture,	red	colour	for	the	samples,	green	for	the	isotypes	
and	blue	for	the	unstained.	D)	unstained	and	isotype	controls			
		
Figure	24	Percentage	of	 cells	with	positive	expression	 for	 the	markers	CD44,	CD73,	
CD90	and	CD105	for	days	1	and	10	and	cell	density,	measured	by	flow	cytometry.	
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
98
98.5
99
99.5
100
1 10
cd44 cd73 cd90 cd105 cell	density
A)	
B)	
C)	 D)	
	 92	
4.4.3 	Morphology	and	clonogenicity	of	hDPSCs,	CFU-F		
Following	 the	 determination	 of	 the	 surface	 antigen	 expression,	 the	 morphology	 of	
undifferentiated	hDPSCs	was	followed	for	7	days	of	culture.	The	cells	attached	after	3-4	
hours	 to	 the	 flask.	 The	 cells	 grew	attached	 to	 the	plastic	 surface	of	 the	 T-flasks	 and	
started	 single-cell	 spreading	and	 then	 forming	 colonies.	 The	 cells	within	each	 colony	
were	characterised	by	the	typical	fibroblast-like	morphology	analogous	to	the	shape	and	
size	of	BM-MSCs.	The	shape	and	size	was	heterogeneous.	In	the	first	day,	cells	attached	
to	 the	 plastic	 and	 the	 fibroblastic	 shape	 was	 still	 not	 clear.	 By	 day	 2,	 cells	 started	
elongating	and	the	spindle	shape	was	more	clear,	cells	started	growing	and	spreading	
through	the	plate.	Cells	achieved	80%	confluence	by	day	3,	confluence	by	day	4	and	then	
they	started	growing	multi-layered.	
	
Figure	25	Morphology	of	hDPSCs	under	normal	growth	conditions	in	light	microscopy.	
A),	D)	are	pictures	of	cells	by	day	1	of	culture.	B)	and	E)	are	pictures	of	cells	by	days	2.	
C)	and	F)	are	pictures	of	cells	by	days	3.	G)	Displays	a	confluent	plate	and	H)	a	multi-
layered	plate.	Scale	bar=200	µm.	
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Colonogenic	assay	was	performed	to	establish	the	growth	potential	of	hDPSCs	in	vitro.	
This	assay	was	employed	to	determine	the	quality	of	the	isolated	stem	cells	(the	level	of	
SCs	present	in	samples).	Only	true	multipotente	SCs	in	samples	would	adhere	and	form	
colonies	 when	 cultured	 with	 very-low	 density.	 The	 Colony	 forming	 efficiency	 was	
established	by	seeding	cells	 from	3	donors,	with	a	density	of	100	cells/well	 in	6	well	
plates	(»10	cells/cm2)	and	counting	the	colonies	scored	after	14	and	21	days	of	culture.	
The	number	of	colonies	scored	between	14	and	21	days	has	no	significant	differences	
with	a	colony	efficiency	of	16	±	2.16	percent	and	13.3	±	2.62	percent	respectively.	Each	
colony	 originates	 from	 a	 single	 parental	 cell	 and	 displays	 a	 wide	 variation	 in	 cell	
morphology	and	growth	potential.	No	new	colonies	were	formed	in	this	period,	but	the	
size	of	the	colonies	was	very	diverse.	In	Figure	26	pictures	of	the	resulting	colonies	can	
be	seen	as	well	as	close	ups	to	the	colonies	showing	the	maintenance	of	 the	spindle	
shaped	morphology	and	how	the	colonies	grew	in	size.	
4.4.4 Metabolic	activity	of	hDPSCs	
Following	 the	 multipotency	 and	 growth	 kinetics	 assessment,	 in	 order	 to	 evaluate	
indirectly	 the	 proliferative	 capability	 of	 hDPSCs	 in	 2D	 static	 culture,	 the	 metabolic	
activity	 of	 hDPSCs	 cultured	 under	 normal	 conditions	 of	 culture	 was	 evaluated	 by	
measuring	for	3	days	the	time-course	concentration	of	key	substrates	and	metabolites	
in	culture	medium.	Consumption	of	glutamine	and	glucose,	production	of	ammonia	and	
lactate,	concentration	of	oxygen	and	detection	of	pH	were	acquired	every	4	hours	with	
a	bio-profiler.	During	the	whole	culture,	media	was	not	exchanged,	allowing	to	assess	
the	metabolic	stress	that	cells	were	suffering	during	an	entire	medium	exchange	cycle	
(normally	of	3	days).	The	same	quantity	of	media	sampled	(1	ml)	was	restocked	with	
fresh	media	to	maintain	a	constant	volume	in	the	culture.	
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Figure	26	CFU-F	of	hDPSCs	under	normal	growth	conditions.	A)	hDPSCs	colonies	after	
14	days	of	culture	(n=3).	B)	scored	hDPSCs	colonies	after	14	days	of	culture	(n=3).	C)	
scored	hDPSCs	colonies	after	21	days	of	culture	D)	a	close	up	to	a	colony	of	14	days	of	
culture.	E)	a	close	up	of	a	colony	after	21	days	of	culture.	F)	higher	magnification	of	a	
colony	after	21	days	of	culture	
A)	
B)	
C)	
F)	E)	D)	
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Figure	 27	 Change	 with	 culture	 time	 of	 key	 substrates	 and	 metabolites	 in	 culture	
medium.	A)	Consumption	of	glutamine	and	production	of	ammonia.	B)	Consumption	
of	glucose	and	production	of	lactate.	C)	Oxygen.	D)	pH.	
The	glutaminolysis	is	a	key	metabolic	pathway	to	produce	energy	for	proliferative	cells	
and	 as	 glutamine	 is	 lysed	 into	 glutamate	 to	 produce	 ATP,	 it	 releases	 1	molecule	 of	
ammonia.	Glutamine	was	consumed	from	2.83	[mmol/L]	to	1.88	[mmol/L]	and	the	same	
number	of	molecules	of	ammonia	was	produced,	going	from	the	initial	concentration	of	
1.49	[mmol/L]	to	2.43	[mmol/L].	Glutamine	and	ammonia	kinetics	can	be	seen	in	Figure	
27A.	The	glycolysis	is	a	key	metabolic	pathway	to	produce	energy	for	proliferative	cells	
and	as	glucose	is	digested	to	produce	ATP,	it	releases	2	molecules	of	Lactate.	Glucose	
was	consumed	from	5.2	[mmol/L]	to	≈0	[mmol/L]	and	twice	the	number	of	molecules	of	
lactate	 was	 produced,	 going	 from	 the	 initial	 concentration	 of	≈0	 [mmol/L]	 to	 11.67	
[mmol/L].	Glucose	and	lactate	kinetics	can	be	seen	in	Figure	27B.	The	oxygen	tension	in	
the	medium	slowly	decreased,	fluctuating	between	180	[mmHg]	and	150	[mmHg].	The	
oxygen	 kinetics	 can	 be	 seen	 in	 Figure	 27C.	 Cell	 culture	 was	 established	 with	 an	
unadjusted	pH,	ressults	could	improve	if	pH	was	adjusted	to	a	starting	value	of	7.4.	The	
initial	pH	was	7.7	and	gradually	decreasing	to	7.5	as	culture	time	passed.	The	pH	kinetics	
can	be	seen	in	Figure	27D.	
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4.4.5 In	vitro	tri-lineage	differentiation	of	hDPSCs	
Following	 the	multipotency	 and	 kinetic	 studies,	 a	 tri-lineage	 directed	 differentiation	
assay	was	performed.	To	characterise	the	differentiability	of	hDPSCs	and	to	assess	if	they	
comply	 with	 the	 minimal	 criteria,	 cells	 were	 differentiated	 into	 osteoblasts,	
chondrocytes	and	adypocytes.	Passage	4	multipotent	hDPSCs	were	seeded	in	T-flasks	
and	allowed	to	grow	until	80%	confluence,	then	cells	were	 long-term	cultured	for	21	
days,	in	the	presence	of	ASAP,	Dex	and	β-GP	for	osteogenic	differentiation;	ASAP,	Dex,	
human	insulin	and	TGFb1	for	chondrogenic	differentiation;	or	IBMX,	Dex,	human	insulin	
and	indomethacin	for	adipogenic		diferentiationmedia.	The	differentiation	was	assessed	
by	histological	analysis,	following	the	time-course	change	in	the	tainted	tissues.		
Osteogenic	differentiation	was	assessed	by	measuring	the	capacity	to	form	alizarin	red-
positive	 condensed	 nodules,	 by	 staining	 collagen	 with	 picrosirius	 red,	 by	 measuring	
ALPase	activity	and	by	flow	cytometry	analysis	of	Runt-related	transcriptional	factor	2	
(Runx-2).	Positive	staining	of	nodules	started	as	early	as	day	7,	nodules	kept	growing	in	
number	and	size	through	the	whole	experiment	to	finally	conquer	most	of	the	growth	
surface	of	the	plate.	The	start	of	osteogenic	differentiation	is	characterised	by	an	up-
regulation	 of	 Runx-2,	 followed	 by	 its	 subsequent	 down-regulation.	 In	 Figure	 28	 and	
Figure	29,	the	change	in	Runx2	positive	cells	can	be	seen,	and	as	expected,	it	starts	high	
and	goes	down	with	the	time-course	of	the	differentiation.		
Early	 osteogenic	 differentiation	 is	 characterised	 by	 an	 up-regulation	 of	 the	 enzyme	
alkaline	 phosphatase,	 followed	by	 a	 consequent	 down-regulation.	 Flask	 coating	with	
collagen	 and	 gelatine	 has	 been	 reported	 to	 help	 enhance	 attachment	 of	 cells	 and	
differentiation.	Flasks	were	coated	with	collagen	and	gelatine	and	the	resulting	ALPase	
activity	 after	 14	 days	 of	 culture	 was	 compared	 with	 uncoated	 flask.	 The	 enzymatic	
activity	of	ALPase	was	quantified	using	a	colorimetric	assay	and	demonstrated	that	both	
coatings	produced	higher	 enzymatic	 activity	 than	 the	uncoated	 flasks.	 From	 the	 two	
coats,	collagen	gave	better	performance	than	gelatin.	Albeit,	the	differences	were	not	
statistically	significant	and	coating	was	considered	unnecessary.	The	results	can	be	seen	
in	Figure	31.	
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Chondrogenic	differentiation	was	assessed	by	measuring	the	capacity	to	form	safranin	
O-positive	 extracellular	 matrix	 containing	 proteoglycans.	 Positive	 nodules	 started	
appearing	from	day	14	and	then	they	grew	in	number	and	and	size.	
Adipogenic	differentiation	was	assessed	by	measuring	the	capacity	to	deposit	Oil	red	O-
positive	triglycerides	and	lipids.	In	the	first	week	of	differentiation	the	presence	of	lipidic	
expression	was	null.	It	was	after	day	14	when	evidence	of	differentiation	was	found.	In	
unstained	 pictures,	 the	 lipidic	 nodules	 can	 be	 seen	 with	 less	 effort	 as	 well	 as	 the	
adipogenic	morphpology.	Although	scarce	staining,	the	presence	of	nodules	by	day	14	
and	21	is	sufficient	to	support	and	sustain	a	positive	differentiation.		
	
Figure	28	Hystograms	for	Runx-2	expression	measured	by	flow	cytometry	for	A)	day	7,	
B)	 day	 14,	 C)	 day	 21	 and	 D)	 unstained	 and	 isotype	 controls.	 10,000	 events	 were	
acquired.	
	
Figure	29	Runx-2	expression	during	21	days	of	osteogenic	differentiation	measured	by	
flow	cytometry.	n=3,	10,000	events	were	acquired.	
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Figure	 30	 Differentiation	 time-course	 followed	 by	 	 hDPSCs	 during	 21	 days	 of	
differentiation	 into	 adipocytes,	 chondrocytes	 and	 osteoblasts.	 A),	 B)	 C)	 and	D)	 are	
images	of	the	adipogenic	differentiation	stained	with	Oil	red	O	by	day	1,	7,	14	and	21	
respectively.	E),	F),	G)	and	H)	are	images	of	the	chondrogenic	differentiation	stained	
with	Safranin	O	by	day	1,	7,	14	and	21	respectively.		I),	J)	K)	and	L)	are	images	of	the	
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osteogenic	 differentiation	 stained	 with	 Alizarin	 red	 S	 by	 day	 1,	 7,	 14	 and	 21	
respectively.	The	arrows	indicate	in	A,B,C	cartilage	nodules,	in	C,D	and	F	fat	deposition	
and	in	G,	H	and	I,	calcium	deposition.			
In	Figure	30,	the	differentiation	time-course	followed	by	the	cells	during	the	tri-lineage	
differentiation	can	be	seen.	
	
Figure	31	Measurement	Alkaline	Phosphatase	activity	of	hDPSCs	differentiated	for	14	
days	 in	 different	 coatings,	 collagen,	 gelatin	 and	uncoated.	 For	 each	 group	n=3.	No	
significant	differences	were	found.	
To	 assess	 the	 quality	 of	 the	 osteoblasts	 produced	 by	 the	 hDPSCs	 differentiated	 into	
osteoblasts,	 cells	 were	 frozen	 for	 1	 year	 and	 then	 thawed	 and	 expanded	 in	 growth	
medium	 for	 2	 weeks,	 the	 resulting	 cells	 were	 then	 stained	 with	 alizarin	 red	 s	 and	
picrosirius	red	to	assess	the	differentiation	state.	Cells	grew	to	populate	the	flasks,	they	
formed	a	multi-layered	surface	and	produced	bone	extracellular	matrix.	In	Figure	32	the	
resulting	pictures	can	be	seen,	were	A)	shows	the	calcium	nodule	deposition	and	B)	the	
collagen	deposition.		
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Figure	32	Expanded	osteoblasts	in	regular	expansion	medium	for	21	days	after	1	year	
frozen.	A)	and	B)	alizarin	red	S	and	C)	and	D)	picrosirius	red.	Scale	bar=200µm	
4.5 Discussion	
MSCs	 characterisation	 is	 a	 standard	procedure	 to	assess	 the	quality	of	 the	biological	
material	for	further	differentiation	and	developmental	studies	and	plenty	of	information	
can	be	found	in	literature.	However,	as	hDPSCs	come	from	the	ectoderm,	their	MSC-like	
state	has	to	be	assessed.		
hDPSCs	are	clonogenic	multipotent	stromal	cells	that	can	be	obtained	autologously	from	
adult	teeth	with	the	capability	to	differentiate	 into	many	different	specialised	animal	
tissues.	Hence	these	cells	have	been	under	study	to	understand	many	developmental	
processes	with	 the	 aim	of	 developing	 therapeutics	 and	 applications	 for	 regenerative	
medicine	and	tissue	engineering.	However,	they	possess	limited	stemness	and	through	
passaging,	 their	 multipotency	 is	 slowly	 lost	 until	 cells	 became	 quiescent.	 Most	 of	
progenitor	cells	have	a	Hayflick’s	limit	between	50	to	70	doublings.	Additionally,	the	use	
of	donor	cells	comes	associated	with	an	intrinsic	heterogeneity	of	the	biological	material	
in	comparison	with	immortalised	cell	lines.	As	consequence,	the	characterisation	of	the	
cells	in	function	of	their	functionality	and	suitability	is	of	utmost	importance	as	a	starting	
point	to	develop	a	3D	bioprocessing	with	clinical	use.	
For	 a	 successful	 bioprocessing	 of	 hDPSCs	 with	 medical	 purposes	 to	 be	 design,	 it	 is	
essential	 to	 be	 able	 isolate	 and	 enrich	 the	 best	 cell	 populations	 that	 would	 ensure	
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optimal	 functionality,	 cell	 viability	 and	 clinical	 effectiveness,	 capable	 to	 construct	 a	
particular	 tissue	 from	 the	 cellular	 and	 extracellular	 perspective.	 One	 of	 the	 main	
characteristics	of	MSCs	is	their	multipotent	self-renewal	and	hDPSCs	are	similar	to	other	
MSCs	 in	 aspects	 including	 shape	 and	 adherence,	 multipotence	 and	 differentiability,	
however	the	maintenance	of	the	multipotent	capabilities	and	the	differentiability	are	
unique	for	each	MSC	type.	
A	 standardised	 culture	 method	 is	 critical	 to	 understand	 and	 preserve	 the	
undifferentiated	state	of	the	cells	and	support	their	clonogenicity	during	cell	renewal	
and	 expansion.	 	 As	 critical	 as	 a	 preserved	 expansion	 methodology,	 are	 the	 defined	
culture	conditions	for	directing	homogenic	cell	differentiation	into	specific	cell	types.		
The	cell	seeding	density	plays	a	key	roll	in	the	proliferative	capabilities	of	the	cells,	cell-
cell	 interactions	are	managed	by	the	Notch	pathway,	which	controls	cell	proliferation	
and	differentiation.	Albeit	the	mechanism	of	action	is	still	uncertain,	it	is	known	that	low	
density	of	cells	will	hinder	 their	proliferative	capabilities	as	 they	need	 the	contact	 to	
develop	and	form	colonies.	A	high	seeding	density	however,	will	hinder	proliferation	as	
well.	 In	 this	 conditions,	a	 retarded	cell	 growth	 is	produced	by	contact	 inhibition,	 the	
Notch	pathway	prepares	the	cells	for	differentiation	rather	than	for	proliferation,	cells	
go	 to	 the	 non	 proliferative	 phase	 G0/G1	 of	 the	 cell	 cycle	 and	 markers	 of	 early	
differentiation	start	being	expressed	,	such	as	Runx-2	(Galindo	et	al.,	2005).		Our	results	
are	in	correspondence	with	results	of	other	researchers	(Suchánek	et	al.,	2007,	Bressan	
et	al.,	2012)	and	 the	medium	density	of	5000	cells/cm2	gave	 the	better	proliferation	
rates	with	 a	DT	 of	≈	 34	 hours.	 The	medium	density	was	 used	 for	 all	 the	 further	 2D	
experiments.	
The	CFU-F	efficiency	reported	by	us,	with	such	a	low	density	of	starting	cells	is	higher	
than	the	efficiency	reported	for	other	MSCs	and	is	in	conformity	with	results	found	in	
literature	(Gronthos	et	al.,	2000).	These	results	support	the	high	proliferative	quality	of	
hDPSCs.	
Evaluation	 of	 cell	 viability	 and	 proliferation	 rates	 for	 long	 term	 culture	 is	 of	 major	
relevance	in	quality	control	for	cell	therapeutics.	Previous	research	has	assessed	these	
parameters	with	dissimilar	results	(Martin-Piedra	et	al.,	2013,	Kerkis	et	al.,	2006,	Martin-
	 102	
Piedra	 et	 al.,	 2014),	 implying	 that	 further	 analysis	 should	 be	 realised.	 Viability	 and	
proliferation	rates	(measured	as	doubling	time	(DT)	were	assessed	and	followed	through	
12	 passages,	 revealing	 a	 viability	 always	 over	 90%	with	 its	 peak	 at	 passage	 4,	 after	
viability	 started	 slowly	 but	 steadily	 decreasing.	 The	 DT	 steadily	 increased	with	 each	
passage,	 ranging	 from	28	 to	 48	 hours.	Our	 findings	 correspond	 to	 approximately	 25	
population	doublings	per	sample	and	are	in	accordance	with	a	wide	study	realised	by	
Suchánek	et	al.	on	donors	aged	16-66,	they	informed	doubling	times	of	12-50	hours	for	
the	first	40	population	doublings.	After,	DT	increases	to	60-90	hours	(Suchánek	et	al.,	
2007,	 Bressan	 et	 al.,	 2012).	 Statistical	 analysis	 suggests	 that	 there’s	 no	 significant	
difference	between	viability	and	doubling	time	between	parental	cells	and	cells	amid	
passage	1-6.	After,	 the	decrease	 in	quality	becomes	significant.	These	results	suggest	
that	cells	between	passage	1	and	6	are	at	their	optimal	and	should	be	used	preferentially	
in	 therapeutics.	 Albeit,	 cells	 from	 further	 passage	 are	 still	 good	 quality	 and	 their	
multipotency	should	be	studied	to	assure	the	quality	of	the	cells.	
Along	with	the	proliferative	capabilities	of	hDPSCs,	their	long-term	multipotency	hasn’t	
been	fully	studied.	The	assessment	of	the	conserved	undifferentiated	self-renewal	state	
associated	with	 expression	 of	 cell	 surface	molecules	 such	 as	 CD44,	 CD73,	 CD90	 and	
CD105.	As	well	as	the	lack	of	expression	of	CD14,	CD11b,	CD34,	CD45,	CD79α,	CD19	and	
HLA	class	II,	has	to	be	evaluated	to	ensure	the	quality	of	the	cells.	These	markers	were	
studied	for	12	consecutive	passages	of	the	cells	to	assess	the	number	of	passages	it	takes	
for	the	cells	to	get	significantly	different	from	the	parental	cells.	Flow	cytometry	data	
analysis	showed	that	there	is	no	difference	between	the	parental	cells	and	cells	from	
passage	1-4.	After,	with	the	positive	markers	over	98%	and	the	negative	markers	under	
2%,	after	the	positive	markers	started	to	slowly	diminish	fluctuating	and	reaching	the	
lowest	quality	by	passage	12.	Interestingly,	CD105	was	the	first	in	decrease,	this	marker	
has	 been	 previously	 reported	 as	 the	 most	 fluctuating	 MSC	 marker,	 Soncini	 and	
colleagues	demonstrated	that	amnion	mesenchymal	stem	cells	(AMCs)	with	only	40%	of	
the	cell	population	positive	to	CD105	were	able	of	tri-lineage	differentiation	(Soncini	et	
al.,	2007).	These	results	suggest	that	cells	between	passage	1	-	4	are	at	their	optimal	and	
should	 be	 used	 preferentially	 in	 therapeutics.	 Cells	 from	 further	 passage	 will	
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differentiate	 and	will	 have	 potential	 for	 neo-tissue	 formation,	 albeit	 the	 results	 will	
probably	be	heterogenic	and	with	pour	reproducibility.		
Following	the	viability	and	immunophenotypic	analysis	of	the	12	first	passages,	the	same	
scheme	was	 followed	 for	 a	 10	days	 long	 culture	without	passaging.	With	 the	aim	 to	
assess	the	effect	of	contact	inhibition	in	proliferation	and	stemness,	the	parental	cells	
were	compared	with	the	resulting	cells.	Our	results	gave	a	DT	of	2.033	days,	significantly	
higher	 than	 the	 same	 passage	 4	 cells	 sub-cultured	 which	 could	 yield	 approximately	
double	the	amount	of	cells.	Interestingly,	the	stemness	markers	showed	no	significant	
difference	with	 the	parental	 cells,	 retaining	all	 the	positive	clusters	of	differentiation	
above	99%	and	the	negatives	under	2%.	These	results	suggest	that	 long	term	culture	
without	passaging	can	produce	healthy	multipotent	cells,	but	has	a	big	 impact	 in	the	
proliferative	quality	of	the	cells.		
The	two	main	characteristics	of	MSCs	are	self-renewal	and	capability	for	multipotency	
differentiation.	We	 already	 studied	 the	 self-renewal	 of	 the	 hDPSCs	 considering	 their	
proliferation	rate,	their	viability	and	immunophenotype.	However,	their	differentiation	
capability	has	yet	to	be	discussed.	Osteogenic,	chondrogenic	and	adipogenic	neo-tissular	
formation	are	considered	to	be	trademark	of	all	MSCs.	hDPSCs	demonstrated	potential	
for	the	tri-lineage	differentiation	with	results	comparable	with	other	MSCs.	Osteogenic	
differentiation	was	demonstrated	from	the	first	week	with	ALZ	staining	and	the	calcium	
deposition	 was	 well	 established	 by	 days	 14	 and	 21.	 On	 day	 21	 unspecific	 collagen	
deposition	was	seen.	Runx-2	is	a	marker	of	early	osteogenic	differentiation	and	a	typical	
in	vitro	osteogenic	profile,	starts	with	the	up-regulation	of	its	expression,	until	its	peak	
is	reached	by	day	14	of	culture	and	its	subsequent	down-regulation,	when	osteoblast	
maturation	is	achieved	(Compton	and	Lee,	2014).	Our	experiments	are	in	concordance	
with	the	expected	profile	and	this	implies	that	osteoblasts	were	grown	and	started	to	
mature.	ALPase	activity	 found	 its	peak	by	day	14	and	no	significant	differences	were	
found	when	using	different	coating,	these	results	suggest	that	the	use	of	coating	for	the	
differentiation	 won’t	 provide	 significant	 benefits,	 only	 having	 a	 repercussion	 in	
reproducibility,	 as	 one	 extra	 step	 is	 added	 to	 the	 culture.	 Coating	 has	 been	 seen	 to	
enhance	 culture	 when	 cells	 with	 lower	 proliferation	 rates	 are	 in	 use.	 However,	 as	
hDPSCs	are	highly	proliferative	(Gronthos	et	al.,	2002).	The	produced	osteoblasts	were	
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functional	after	a	year	 frozen	and	were	able	to	grow	and	produce	osteoblast	ECM	in	
regular	expansion	medium.	These	 results	 suggest	 the	possibility	 to	 store	 frozen	neo-
tissue	for	clinical	ready-availability.	
Although	 the	adipogenic	 competence	of	hDPSCs	has	not	been	 clearly	demonstrated,	
adipogenic	differentiation	of	hDPSCs	was	confirmed	by	the	formation	of	fat	precipitates	
in	 the	 samples.	 By	 day	 7	 of	 adipogenic	 differentiation,	 adipocytes	 were	
indistinguishable,	 by	 day	 14	 and	 21	 adipocytes	 were	 visible	 by	 their	 morphology.	
Conversely,	little	accumulation	of	lipid	deposition	was	seen.	It	has	been	reported	that	
adipocytes	appear	significantly	 less	frequently	than	the	other	cell	type,	Gronthos	and	
colleagues	found	null	adipogenic	differentiation	and	Pierdomenico	and	colleagues	found	
restricted	adipogenic	differentiation	(Gronthos	et	al.,	2002,	Pierdomenico	et	al.,	2005).		
Chondrogenic	differentiation	of	hDPSCs	was	demonstrated	 from	 the	 second	week	of	
culture	and	onward	with	positive	safranin	s	staining.	In	the	last	week	a	big	portion	of	
ECM	containing	proteoglicans	characteristic	of	chondrocytes	was	found,	denoting	the	
chondrogenic	potential	of	the	cells.	These	results	are	in	accordance	with	research	done	
by	other	groups	(Gronthos	et	al.,	2002,	Pisciotta	et	al.,	2015).	Albeit	Pierdomenico	and	
colleagues	in	their	studies	found	hDPSCs	to	be	negative	for	chondrogenic	differentiaton	
in	long	term	exposure	to	differentiation	media	(6	weeks).	
4.6 Conclusions	
Experimental	and	clinical	data	indicate	that	MSCs	have	potential	for	differentiating	into	
various	tissues	 in	organ	transplantation	and	in	gene	therapy,	owing	to	their	plasticity	
under	 appropriate	 conditions	 and	 their	 immunomodulatory	 properties.	 Through	 our	
experiments	we	have	demonstrated	that	hDPSCs	harbour	a	big	potential	for	bone	tissue	
engineering,	they	have	high	viability	and	proliferation	rate,	meanwhile	maintaining	their	
multipotent	phenotype	through	passaging	and	high	density	culture,	as	well	as	strong	
bone	differentiation	that	can	be	sustained	after	long	term	storage.	From	the	conditions	
studied,	it	was	seen	that	passage	4	cells	are	able	to	produce	the	required	number	of	cells	
for	3D	culture	without	significant	modifications	from	the	paternal	cells	(passage	1)	and	
are	able	to	produce	good	quality	bone	tissue.	Hence,	the	long-term	3D	bioprocess	in	a	
perfusion-RWV	bioreactor	studies	will	be	done	in	passage	4	cells.	Albeit	hDPSCs	are	able	
to	 differentiate	 into	 chondrocytes	 and	 adipocytes,	 their	 potential	 is	 limited	 and	 our	
	 105	
studies	and	literature	found	mixed	results	ranging	from	well	stablished,	to	low	or	even	
null	differentiation.	Hence,	hDPSCs	are	suitable	to	develop	a	 long-term	bioprocessing	
for	bone	tissue	engineering	and	the	conditions	stablished	in	this	chapter	will	be	used	to	
produce	 the	 biological	 material	 for	 the	 next	 chapters.	 A	 further	 study	 specific	 for	
chondrogenic	and	adipogenic	differentiation	should	be	carried	out	in	order	to	establish	
a	proper	protocol	able	to	differentiate	cells	homogeneously.	Until	this	is	not	done,	they	
wouldn’t	be	recommended	for	the	design	of	any	clinical	device	involving	chondro/adipo	
neo-tissue.	
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5 Effect	of	perfusion	in	the	3D	bioprocessing	for	osteogenic	differentiation:	a	comparison	
between	a	novel	perfusion-RWV	bioreactor,	a	fed	batch	RWV	bioreactor		and	3D	static	
culture
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5.1 Introduction	
In	vivo,	bone	cells	are	contained	in	a	three-dimensional	histoarchitectures	that	hosts	the	
cells	and	their	interactions.	Herein,	water,	nutrients,	cytokines	and	growth	factors	are	
delivered	to	the	cells,	and	normal	development/healing	phenomena	are	hosted.		
Traditionally,	 cells	 have	 been	 grown	 in	 two-dimensional	 static	 monolayered	 culture	
systems,	where	cells	are	grown	attached	to	a	plastic	plane	in	their	base	and	are	exposed	
to	 culture	media	 in	 their	 upper	 face.	Within	 regular	 two-dimensional	 static	 culture,	
hDPSCs	have	been	induced	to	differentiate	 into	cells	from	the	osteoblast	 lineage	and	
many	 advances	 have	 been	 done	 in	 understanding	 mammalian	 developmental	
processes.	The	sequence	of	events	followed	by	the	cells,	is	believed	to	recapitulate	the	
in	vivo	developmental	phenomena.	However,	two-dimensional	static	culture	lacks	the	
characteristic	 three	 dimensionality	 found	 in	 the	 normal	 environment,	 resulting	 on	
limiting	the	delivery	of	many	structural,	mechanical	and	biochemical	cues	required	for	
proper	neo-tissue	development.	In	two-dimensional	environment,	cells	in	the	basal	area	
of	the	culture	flasks,	receive	limited	nutrients	and	signals.	Developing	heterogeneously.	
Additionally,	 cells	 become	 flatter,	 divide	 abnormally	 and	 lose	 their	 differentiated	
phenotype	 (Baker	 and	 Chen,	 2012).	 Consequently,	 research	 outcomes	 in	 two-
dimensional	static	culture	are	not	reproducible	in	vivo	or	in	tissue	explants.		
The	efforts	to	tackle	with	the	adimensionality	of	regular	two-dimensional	culture	and	
close	 the	 gap	 between	 the	 traditional	 culture	 technique	 and	 the	 in	 vivo	 tissue	 have	
derived	 into	 the	 development	 of	 three-dimensional	 culture	 systems.	 The	
microenvironment	 of	 regular	 bone	 can	 be	 temporarily	 reproduced	within	 a	 scaffold.	
These	 matrices	 provide	 a	 supporting	 microarchitecture	 for	 the	 cells	 to	 expand	 and	
attach.	Providing	a	template	for	normal	cell-cell	interactions	and	the	mass	transfer	for	
nutrients	and	signalling	delivery.	In	other	words,	the	scaffold	plays	the	role	of	an	artificial	
three-dimensional	ECM	(Hutmacher,	2000,	Sheridan	et	al.,	2000).	A	three-dimensional	
setting	promise	to	be	closer	to	what	really	occurs	in	the	in	vivo	environment.	
The	development,	maintenance	and	regulation	of	hDPSC	populations	for	bone-related	
cell	therapeutic	products,	not	only	requires	such	a	very	difficult	task	of	replicating	the	
complex	 and	 specific	 histoarchitecture	 of	 bone.	 It	 also	 requires	 reproducing	 the	
dynamicity	 of	 its	 transport	 characteristics.	 Accordingly,	 improvement	 of	 culture	
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conditions,	including	the	design	of	adequate	tailor-made	bioprocessing	systems	able	to	
achieve	such	high	benchmarks,	appears	to	be	crucial	(Salgado	et	al.,	2004).		
3D	scaffolds	or	cell	aggregates	cultured	in	a	suspension	inside	a	controlled	environment	
using	bioreactors,	offer	attractive	advantages	of	ready	scalability	and	relative	simplicity	
and	may	influence	cell	viability	and	turnover	of	specific	stages	and	types	of	stem	cells	
(Zandstra	and	Nagy,	2001).		
Several	studies	have	reported	the	use	of	different	scaffolds	and	bioreactors	in	the	three-
dimensional	osteogenic	differentiation	of	ESCs	and	MSCs,	a	list	of	them	can	be	found	in		
Table	 2:	 Current	 studies	 about	 stem	 cell	 differentiation	 towards	 bone	 tissue	 using	
various	 bioreactors.	 Their	 findings	 delivered	 mixed	 results,	 but	 all	 agreeing	 that	
bioreactors	 and	 scaffolds	 provide	 an	 advantageous	 environment	 leading	 to	 obtain	
improved	 production	 of	 cell	 constructs.	 Alginate	 encapsulation	 has	 been	 recurrently	
studied	 as	 a	 biodegradable	 matrix	 which	 is	 adaptable	 to	 three-dimensional	 culture	
systems	for	tissue	engineering.	It	has	been	reported	that	the	jointly	use	of	gelatin	with	
alginate,	 strengthen	 the	hydrogel	 to	be	used	 in	 long	 term	culture,	 as	 alginate	alone,	
when	ionically	cross-linked,	loses	Ca2+	ions	and	could	collapse	(Basmanav	et	al.,	2008).	
Furthermore,	 the	 incorporation	of	gelatin	 to	 the	alginate	hydrogel,	has	been	seen	to	
significantly	improve	cell	adherence	and	proliferation,	compared	with	the	alginate	only	
scaffold.	(Venkatesan	et	al.,	2015).	
Different	bioprocessing	systems	using	shear	stress	have	been	under	development.	TE	
adopted	 this	 technology	 to	overcome	the	 limitations	 from	using	 the	 impeller-type	of	
bioreactor.	Shear	stress	 is	an	important	biophysical	signal,	with	cell	growth	and	bone	
mechano-transduction	 effect.	 It	 is	 involved	 in	 calcium	 signalling,	 mechanical	 force	
transmission	 along	 fibrous	 cytoskeletal	 networks,	 cell-cell	 communication,	 and	
disruption	of	ligand-receptor	binding,	between	others	(Akins	et	al.,	1997,	Morrison	et	
al.,	 1992,	Talbot	et	al.,	 2010).	Example	of	units	utilising	 the	advantages	of	 low	shear	
stress,	 is	 the	 family	 of	 bioreactors	 categorised	 as	 Rotating	 Wall	 Vessel	 (RWV)	
bioreactors.	Originally	designed	by	NASA,	they	are	dynamic	systems	able	to	generate	a	
low	 shear	 environment,	 where	 cells	 grow	 in	 static	 suspension.	 These	 systems	 are	
efficient	to	reduce	diffusion	limitations	of	nutrients	and	useful	in	producing	ex	vivo	bone.	
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Achieving	ECM	deposition	(Qiu	et	al.,	1999)	and	mineralisation/	ALP	activity/	Osteocalcin	
expresion	similar	or	better	than	the	parameters	achieved	in	static	culture	(Botchwey	et	
al.,	2001,	Song	et	al.,	2008,	Hwang	et	al.,	2009).		
	RWV-based	 bioreactors,	 when	 working	 in	 the	 right	 setting,	 have	 shown	 to	 achieve	
enhanced	 expansion	 and	 bone	 differentiation	 (Rauh	 et	 al.,	 2011).	 However,	 none	 of	
these	 bioprocesses	 has	 been	 able	 to	 recapitulate	 the	 conditions	 of	 the	
microenvironment	found	in	bone	tissue.		
To	close	the	gap	between	the	bioprocessing	and	the	in	vivo	requirements,	a	third	family	
of	bioreactors	was	pioneered.	Semi-batch	feeding	strategies	were	left	behind	to	adopt	
a	perfusion	feeding	strategy.	
Perfusion	 bioreactors,	 incorporate	 with	 a	 continuous	 exchange	 of	 medium.	 By	
generating	a	laminar	fluid	flow	of	culture	media	through	the	bioreactor,	mass	transport	
of	nutrients	and	oxygen	is	enhanced	as	well	as	providing	mechanical	stimuli.	A	peristaltic	
pump	 drives	 pre-oxygenated	 medium	 through	 the	 bioreactor/	 scaffold	 and	 ensures	
providing	a	well-mixed	environment	with	essential	 nutrients	 and	oxygen,	meanwhile	
removing	the	metabolic	waste.	Additionally,	different	flow	types	can	be	adopted.	The	
performance	of	flow	type	and	mineralisation	have	been	studied,	the	results	indicate	that	
a	steady	flow	is	a	more	potent	stimulator	of	bone	cells,	producing	higher	intracellular	
calcium	 than	 either	 oscillatory	 or	 pulsing	 flow	 (Jacobs	 et	 al.,	 1998).	 Another	 report	
studied	the	effect	of	perfusion	flow	rate	(1-3-5	ml/min).	The	findings	suggest	that	a	high	
flow	 rate	 can	 cause	 the	 detachment	 of	 cells	 and	 limit	 ALP	 activity	 and	 intracellular	
calcium	content.	Furthermore	,	they	suggest	that	low	flow	rates	give	better	expansion,	
but	less	ALP	and	internal	calcium	content	than	an	intermediate	flow	(Sinlapabodin	et	al.,	
2016).	Accordingly,	each	bioreactor-scaffold-cell	type	will	have	to	be	assessed	for	the	
adequate	flow	rate.	
Bioreactors	are	available	in	the	market	with	differing	ease	of	use,	cost/efficiency,	and	
capability	of	monitoring	and	controlling	biophysical	and	chemical	parameters.	However,	
optimization,	modification,	or	the	design	of	new	bioprocesses,	are	required	to	produce	
the	suitable	osteoblast-seeded	biomaterial	able	to	translate	accurately	from	the	in	vitro	
concept,	to	the	in	vivo	neo-tissue	completion.	
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Oxygen	tension	is	known	to	play	a	role	in	expansion	and	differentiation,	as	well	as	proper	
oxygenation	which	is	important	key	parameter	in	bioreactors	design.	The	significance	of	
oxygen	concentration	control	is	highlighted	by	the	enormous	and	intricate	mechanisms	
used	 to	 maintain	 oxygen	 homeostasis	 in	 the	 body	 (Csete,	 2005).	 Hypoxia	 (Oxygen	
tension	of	≈0-30	mmHg,	≈0-5%),	has	been	reported	to	improve	proliferation	and	yield	
of	undifferentiated	ESCs	and	MSCs	and	reduce	apoptosis,	as	opposed	to	normoxia	(≈150	
mmHg	of	pO2,	≈	20%),	which	has	been	described	to	have	an	impact	on	differentiation	
patterns	 (Sakdee	 et	 al.,	 2009,	 Csete,	 2005)	 and	 in	 particular,	 it	 enhances	 osteogenic	
differentiation	 (He	 et	 al.,	 2010).	 In	 vivo,	 stem	 cells	 normally	 reside	 in	 relatively	 low	
oxygen	 niches,	 and	 local	 oxygen	 is	 increased	 when	 healing	 happens.	 It	 has	 been	
suggested	that	controlling	only	the	oxygen	tension	might	not	be	sufficient	to	improve	
the	general	efficacy	in	stem	cell	cultures.	
Most	bioreactor	currently	being	used	in	the	field	of	TE	are	a	fed-batch.	However,	this	
design	 aspect	 requires	 to	 be	 modified.	 Fed-batch	 operation	 lacks	 control	 of	 the	
parameters	in	culture	medium	such	as	nutrients,	metabolites,	and	oxygen.	Additionally,	
it	 accumulates	 metabolic	 waste,	 which	 can	 be	 toxic	 for	 cells	 at	 inhibitory	 level	
(Abranches	et	al.,	2007).	Moreover,	abrupt	medium	exchange	in	fed-batch	systems	can	
produce	high	stress	to	the	cells.	As	cells	grow	over	the	culture	time,	the	degree	of	stress	
for	 cells	 rises	 due	 to	 increasing	 rates	 of	 nutrient	 and	 oxygen	 consumption,	 and	
metabolite	accumulation	in	a	batch,	a	schematic	diagram	of	this	can	be	seen	in	Figure	
33.	Perfusion	culture	systems	allow	control	and	monitoring	of	the	medium	in	real	time,	
metabolic	waste	removal,	eliminate	medium	exchange	stress	and	reduce	the	loss	of	cell-
secretion,	improving	the	maintenance	of	the	desirable	milieu	that	aids	both	expansion	
and	differentiation	(Bauwens	et	al.,	2005,	Baker	and	Chen,	2012,	Godara	et	al.,	2008).	
Cell-constructs	manufactured	 inside	an	 inadequate	environment;	 lacking	 in	nutrients,	
oxygen	and	biosignals,	with	waste	accumulation;	tend	to	produce	poor	cell-density	and	
development,	 cell-type	heterogeneity,	 ECM-poor	 and	uneven	 spatial	 cell	 distribution	
(Ong	et	al.,	2008).	Cells	closer	to	the	surface	of	the	cell-construct	would	be	preferably	
expanded	 and	 differentiated.	 Cells	 in	 the	 cell-construct	 centre,	 would	 travel	 to	 the	
surface	 to	 fulfil	 their	 nutritional	 requirements.	 Ultimately,	 when	 the	 surface	 is	
excessively	 cell-dense,	 cells	would	 leave	 the	 construct	 to	 adhere	 into	 a	 free	 surface	
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(Sikavitsas	et	al.,	2002).	Cell	constructs	under	these	circumstances,	would	bring	further	
problems	when	implanted	in	vivo	as	its	functionality	would	be	compromised,	the	cell-
dense	 surface	would	 produce	 a	 harder,	 over-calcified	 surface,	 but	 the	 centre	would	
remain	soft,	translating	into	poor	mechanical	properties.	Additionally,	this	over-calcified	
surface	would	present	a	barrier	for	Vascularisation	of	the	healed	bone	defect,	rendering	
the	cell	therapy	to	failure	.	Hence,		adequate	scaffold	size	and	medium	perfusion	in	a	
bioreactor	setting	are	considered	not	only	a	requirement,	but	indispensable	features	for	
the	future	design	of	any	bioprocess	with	the	possibility	of	success	in	cell	therapy.	
	
Figure	 33	 Fed-batch	 vs	 perfusion	 feeding	 strategy.	 It	 can	 be	 seen	 how	 nutrient	
consumption	 and	 metabolites	 production	 accumulate	 in	 the	 bioreactor	 (modified	
from	(Cha,	2010)).	
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Our	 group	 has	 previously	 developed	 a	 simplified,	 integrated,	 and	 reproducible	
bioprocess	 for	 three-dimensional	 osteogenesis	 from	 ESCs	 using	 encapsulation	 with	
alginate/gelatin	 hydrogel	 and	 an	 in-house	 developed	 perfusion-RWV	bioreactor	with	
promising	results	for	therapeutic	uses	(Cha,	2010,	Yeo,	2012,	Randle	et	al.,	2007a).	In	
the	 next	 subsection,	 the	 principia	 behind	 the	 development	 of	 this	 bioprocessing	 are	
summarised.		
5.1.1 Principia	behind	the	design	of	a	perfused	bioreactor	
The	 in-house	 designed	 perfusion	 bioreactor	 incorporates	 an	 outer	 gas-permeable	
membrane	that	covers	the	culture	vessel,	enhancing	gas-exchange,	as	well	as	medium	
perfusion	and	an	oxygenator.	 Inside	the	bioreactor,	cells	are	encapsulated	in	alginate	
hydrogels	that	are	grown	in	a	suspended-like	environment.	This	section	summarises	the	
work	 done	 by	 former	 PhD	 students	 in	 our	 laboratory	 to	 calculate	 the	 bioreactor	
dimensions	(Cha,	2010,	Yeo,	2012).	Additionally,	the	diameter	of	the	hydrogels	for	the	
adequate	oxygenation	of	the	cells	encapsulated	is	described.	Fick’s	second	law	was	used	
to	define	the	optimal	dimensions	of	the	culture	vessel	and	oxygenator.	It	estimates	the	
profile	 in	which	oxygen	diffuses	and	distributes	within	the	vessel	and	the	oxygenator	
tubing	to	have	cells	shortly	exposed	to	the	gaseous	environment	inside	an	incubator.	
Fick’s	law	is	briefly	explained	below.	
Fick's	first	law,	relates	the	diffusive	flux	to	the	concentration	field	under	steady	state.	
The	 flux	 travels	 from	high	 concentration	 regions	 to	 low	concentration	 regions	and	 is	
proportional	to	the	concentration	gradient	(spatial	derivative).	In	one	dimension:	
𝐽 = −𝐷 𝜕𝐶𝜕𝑥 	
Fick's	second	law,	derived	from	the	first	law	by	combining	with	a	mass	balance	to	the	
solute,	predicts	how	diffusion	causes	the	concentration	field	to	change	with	time:	𝜕𝐶𝜕𝑡 = − 𝜕𝜕𝑥 𝐽 = 𝜕𝜕𝑥 𝐷 𝜕𝐶𝜕𝑥 ⟹ 𝜕𝐶𝜕𝑡 = 𝐷 𝜕2𝐶𝜕𝑥2 	
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Where	the	parameters	in	both	equations	are:	J	is	the	diffusion	flux,	amount	of	substance	
that	will	flow	per	unit	of	area	per	unit	of	time,	D	is	the	diffusivity,	which	is	proportional	
to	the	squared	velocity	of	the	diffusing	particles,	C	is	the	concentration	in	ideal	mixtures	
environment	and	x	is	the	position	(diffusion	length).	
Fick’s	second	law	represents	how	far	a	specific	oxygen	density	(C)	has	propagated	in	a	
certain	 direction	 (z)	 by	 diffusion	 in	 time	 (t),	 and	was	used	 to	determine	 the	optimal	
vessel	dimensions	as	well	as	the	length	of	the	oxygenator	tubing.		
The	assumptions	for	the	design	were	as	follows:	Gas	diffusion	is	from	the	air	to	medium	
in	the	vessel.	Well-mixed	medium	and	constant	gas	concentrations	in	air.	Initial	oxygen	
concentration	in	the	medium	is	assumed	zero.	Concentration	at	the	contact	surface	is	
set	as	the	concentration	of	oxygen	in	air.	The	diffusivity	of	oxygen	in	medium	is	assumed	
the	same	value	as	the	H2O–O2	system	at	37oC.	
The	partial	differential	equation	with	all	the	assumptions	can	be	derived	from	the	error	
function.	In	Figure	34,	the	solution	of	the	second	law	considering	the	assumptions	and	
the	 conceptual	 design	 of	 the	 vessel	 can	 be	 seen.	 In	 the	 resulting	 equation,	 oxygen	
concentration	 (CO2),	 Time	 (t)	 and	 length	 of	 diffusion	 (z)	 vary	 together	 (e.g.	 one	 day	
(86400	sec)	after	oxygen	diffusion	starts,	67%	of	the	surface	concentration	of	oxygen	
can	be	achieved	in	a	depth	of	1	cm,	according	to	the	calculation.	
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Figure	 34	 Solution	 of	 Fick’s	 second	 law	 and	 conceptual	 design	 of	 culture	 vessel	
(modified	from	(Cha,	2010)).	
To	 solve	 the	 system,	 the	 desired	 concentration	 inside	 the	 vessel	 is	 set	 in	 order	 to	
estimate	the	relationship	between	length	(z)	and	time	(t).	A	plot	can	be	drawn	by	setting	
the	minimal	oxygen	concentration.	In	our	design,	the	concentration	was	fixed	at	80%	of	
the	surface	concentration	and	from	the	resulting	plot,	it	was	found	that	for	a	distance	z	
=1.5	cm	to	be	80%	saturated,	approximately	3	days	have	to	pass.	Therefore,	the	depth	
from	the	surface	to	the	perfusion	rod	of	the	culture	vessel	(R-r,	see	Figure	35)	can	be	set	
as	 1.5	 cm	 with	 allowing	 3	 days	 of	 the	 oxygen-saturation	 time.	 This	 length	 also	
corresponds	 to	 the	 depth	 of	 a	 55-ml	 High	 Aspect	 Ratio	 Vessel	 (HARV),	 which	 was	
designed	 to	have	 sufficient	 gas-exchange	 through	 the	membrane	on	 the	back	of	 the	
vessel	and	 is	a	 system	 in	used	as	a	comparison	system.	The	other	dimensions	of	 the	
vessel	were	derived	on	basis	of	the	diffusion	length	and	the	volume	(approx.	55ml	size),	
and	further	modified	due	to	technical	reasons	for	fabrication.	The	design	of	the	inner	
cartridge	of	the	cell	culture	vessel	is	confirmed	by	the	calculations	shown	in	Figure	35.		
	
Figure	35	Dimensions	calculation	and	schematics	of	the	vessel	(modified	from	(Cha,	
2010)).	
A	 gas-permeable	membrane	 is	 rolled	 and	 tightly	 fixed	 to	 the	 frame	 of	 the	 vessel,	
allowing	gas-exchange	through	the	wide	surface	area	as	determined	previously.	The	
membrane	 is	 made	 of	 a	 silicon	 material	 coated	 in	 one	 side	 with	
polytetrafluoroethylene	(PTFE,	Teflon),	to	prevent	fouling	by	numerous	bio-molecules	
!"#" = %('() − +(,) ' = 1.5 + + ) = , + 0.2 !"#" = %( 3' − 2.25 ) + 0.2 + − 1.5 ( = 555, 3' − 2.25 ) + 0.2r( = 17.51 if	r	 = 	1	cm	 ⟹ 	R	 = 	2.5	cm	 ⟹ 5.25L	 = 	17.31 L ≈ 3.5	cm l ≈ 3.3	cm Volume ≈ 60	ml 
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present	 in	 culture	medium	 or	 secreted	 by	 cells.	 The	 detailed	 specifications	 of	 the	
membrane	can	be	found	in	Table	5	and	Table	6.	
Table	 5:	 Specifications	 of	 gas	 permeable	membranes,	 in	 the	materials	 and	methods	
section.	
In	 addition	 to	 the	 oxygen	 provided	 through	 the	 membrane,	 the	 culture	 medium	
perfused	 to	 the	 culture	 vessel	 comes	 oxygen-saturated	 by	 the	 use	 of	 an	 external	
oxygenator.	See	figure		
	
Figure	 36	 Culture	 vessel’s	 dual	 supply	 of	 oxygen	 (Cha,	 2010).	 It	 can	 be	 seen	 how	
oxygenated	media	enters	the	system	through	the	annulus	of	the	central	rod,	and	then	
radially	to	the	vessel.	 It	exits	through	the	opposite	central	outlet.	Oxygen	from	the	
environment	enters	the	vessel	through	the	membrane-wall.			
The	external	oxygenator	is	composed	of	a	spiral	roll	of	gas-permeable	silicon	tubing	with	
a	 wall	 thickness	 of	 0.5	 mm.	 The	 length	 of	 the	 tubing	 of	 approximately	 3.4	 m	 was	
designed	 to	 be	 long	 enough	 to	 saturate	 the	 culture	medium	with	 oxygen	whilst	 the	
medium	 passes	 through	 the	 oxygenator.	 The	 calculations	 were	 done	 following	 the	
second	 Fick	 law	with	 the	 same	 boundary	 conditions	 used	 to	 design	 the	 vessel.	 The	
residence	time	of	medium	in	the	oxygenator	would	be	of	600	min	for	a	total	length	of	
3.4	m.	
To	calculate	the	adequate	diameter	of	alginate	hydrogels,	a	similar	strategy	to	the	vessel	
design	 was	 followed.	 To	 describe	 the	 dynamic	 mass	 transfer	 of	 oxygen	 from	 bulk	
solution	into	the	alginate	spheres,	the	transfer	of	the	oxygen	along	the	media	and	the	
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transfer	 from	 the	 medium	 to	 the	 solid	 and	 the	 consumption	 of	 oxygen	 by	 the	
encapsulated	cells	have	to	be	considered.	𝜕𝐶345678𝜕𝑡 = 𝐷9 𝜕2𝐶345678𝜕𝑧2 + 𝑆= 	
Where	De	is	the	effective	oxygen	diffusion	coefficient,	C@45ABC	 is	the	concentration	of	
oxygen	within	the	hydrogels,	C	is	the	concentration	in	ideal	mixtures	environment,	t	is	
time,	Sr	is	the	rate	of	oxygen	consumption	per	unit	volume,	kf	is	the	Liquid-solid	mass	
transfer	coefficient,	as	is	the	surface	area	of	the	spheres	and	r	is	the	position	(diffusion	
radial	position).	
The	assumptions	for	the	design	were	as	follows:	consumption	by	the	cells	is	considered	
to	be	zero,	microcapsules	are	assumed	to	be	homogeneous	spheres	of	equal	size,	well-
mixed	medium	provides	a	constant	oxygen	concentration.	Initial	oxygen	concentration	
in	 the	 sphere	 is	 assumed	 zero.	 Concentration	 at	 the	 contact	 surface	 is	 set	 as	 the	
concentration	of	oxygen	in	the	media.	The	diffusivity	of	oxygen	in	the	hydrogels	has	a	
value	of	1.4x10-5	cm2/s,	this	value	is	obtained	from	literature	(White	et	al.,	2014,	Zhao	
et	al.,	2013).	Additionally,	it	is	considered	that	there	is	no	external	boundary	layer	effect	
and	the	consumption	of	oxygen	by	the	cells	to	be	zero.	
Boundary	conditions:	 				𝐵. 𝐶. 1: 𝐶345678 = 0	𝑎𝑡	𝑡 = 0	𝐵. 𝐶. 2:	𝐶345678 = 𝐶	𝑎𝑡	𝑧 = 0	𝐵. 𝐶. 3:	𝐶345678 = 0	𝑎𝑡	𝑧 = 𝑅	
Where	R	is	the	radius	of	the	alginate	spheres.	
𝐶345678𝐶 = 𝑒𝑟𝑓𝑐 𝑧 4 ∙ 𝐷9 ∙ 𝑡 R2 , 𝐷9 = 1.4𝑥105# 𝑐𝑚2 𝑠	𝑎𝑡	37°𝐶	
⇒ 𝐶345678 = 	𝑒𝑟𝑓𝑐 133.63 ∙ 𝑧𝑡 ∙ 𝐶 𝑍: 𝑐𝑚𝑡: 𝑠𝑒𝑐	
To	solve	the	system,	the	desired	concentration	inside	the	hydrogels	 is	set	 in	order	to	
estimate	the	relationship	between	its	radius	(depth	in	direction	z)	and	time	(t).	A	plot	
can	be	drawn	by	setting	the	minimal	oxygen	concentration.	The	concentration	was	fixed	
at	80%	of	the	surface	concentration	(medium	concentration)	and	from	the	resulting	plot,	
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it	was	 found	 that	 for	 a	 distance	 z	 =	 1.3	mm	 to	 be	 80%	 saturated,	 approximately	 40	
minutes	 have	 to	 pass.	 Table	 9	 shows	 the	 time	 required	 for	 different	 percentages	 of	
saturation	to	be	achieved	by	different	diameters.	Therefore,	the	depth	from	the	surface	
to	centre	of	the	hydrogel	can	be	set	between	0.5	and	2.5	mm,	and	in	less	than	3	hours,	
90%	of	the	medium	concentration	would	be	attained.	
	
Table	9:	Variation	of	oxygen	saturation	times	with	diameter	of	hydrogel	spheres.	
 Time	required	to	achieve		
	 x	percentage	of	saturation	
Diameter	 70%	 80%	 90%	
0,5	mm	 3	min	 5	min	 23	min	
1,0	mm	 10	min	 23	min	 93	min	
1,3	mm	 17	min	 40	min	 158	min	
1,5	mm	 23	min	 52	min	 210	min	
2,0	mm	 40	min	 93	min	 370	min	
2,5	mm	 64	min	 145	min	 585	min	
	
Computational	 Fluid	 Dynamics	 (CFD)	 analysis	 was	 used	 to	 simulate	 the	 transport	 of	
oxygen	in	the	culture	vessel	to	establish	the	time	required	to	achieve	saturation	(Yeo,	
2012).	The	model	considered	the	oxygen	supplied	through	the	membrane	and	through	
perfusion	of	saturated	culture	media	without	cells-seeded	hydrogels	in	the	system.	The	
boundary	 conditions	 used	 were	 the	 same	 as	 stated	 for	 the	 conceptual	 design.	 The	
results	demonstrated	that	this	setting	can	achieve	an	homogeneous	≈	60%	of	saturation	
by	6	hours	and	after	18	hours	saturation	has	reached	the	level	of	oxygen	in	the	surface.	
The	calculations	done	to	design	considered	3	day	of	oxygenation	to	achieve	equilibrium	
with	the	environment.	However,	the	dual-supply	of	oxygen	through	both	the	membrane	
and	medium	perfusion	offers	effective	oxygenation	and	 is	able	to	reduce	the	time	to	
achieve	homogeneous	equilibrium	of	oxygen	tension	with	the	incubator	atmosphere	in	
less	than	24	hours.	
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Figure	37	Oxygenation	within	the	culture	vessel	after	A)	6	and	B)	18	hours.	The	picture	
displays	 CFD	models	 of	 oxygen	 concentration	 distributes	 in	 the	 culture	 vessel,	 the	
model	describes	the	time	required	for	medium	inside	the	vessel	to	achieve	saturation	
(Yeo,	2012).		
The	 perfusion-RWV	 bioreactor	was	 designed	 in	 a	 twin	 setting,	 and	 consist	 of	 2	 pre-
sterilised	hand-assembled	culture	vessels	attached	to	a	rotating	system	with	2	peristaltic	
pumps	to	drive	the	media	from	the	oxygenator	to	the	vessels.	Sealed	bottles	contain	
sterile	fresh	media	and	waste	media	is	disposed	in	sealed	waste	bottles	to	prevent	the	
system	of	contamination.	In	Figure	38	a	CAD	model	of	the	bioreactor	can	be	seen.	
The	 performance	 of	 the	 in-house	 designed	 perfusion-RWV	 bioreactor,	 has	 been	
compared	with	traditional	 two-dimensional	culture	 for	 the	expansion	and	osteogenic	
differentiation	of	ESCs.	Results	demonstrate	enhanced	undifferentiated	expansion,	as	
well	 as	 an	 improved	 osteogenic	 differentiation	 measured	 by	 an	 enhanced	 ALPase	
activity,	mineralisation	and	gene	expression	for	many	important	genes			(Cha,	2010,	Yeo,	
2012,	Randle	et	al.,	2007a).	However,	our	bioprocessing	still	remains	to	be	tested	with	
MSCs	such	as	the	hDPSCs.		
A	 B	
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Figure	 38	 CAD	model	 of	 the	 perfusion-RWV	 bioreactor.	 It	 displays	 the	 twin	 vessel	
setting	of	the	bioreactor,	with	two	bottles	for	fresh	medium,	two	bottles	for	waste	
medium	and	two	peristaltic	pumps,	one	for	each	vessel.		
5.2 Objectives	
An	efficient	strategy	for	the	reproducible	scaling	up	of	the	production	and	osteogenic	
differentiation	of	hDPSCs	for	cell	therapy,	requires	understanding	the	behaviour	of	cells	
under	three-dimensional	conditions	 for	expansion	and	differentiation,	by	 focusing	on	
the	 three-dimensional	 undifferentiated	 expansion	 of	 hDPSCs	 and	 in	 the	 osteogenic	
differentiation	of	hDPSCs	under	perfusion	 flow,	as	 the	nutritional	and	environmental	
requirements	of	hDPSCs	under	this	conditions.	
The	aims	of	this	chapter	are:	1)	to	establish	long-term	three-dimensional	bioprocess	in	
a	 perfusion-RWV	 bioreactor	 for	 the	 undifferentiated	 expansion	 of	 hDPSCs.	 2)	 to	
establish	 the	 efficient	 long-term	 three-dimenssional	 bioprocess	 in	 a	 perfusion-RWV	
bioreactor	for	directing	the	osteogenic	differentiation	of	hDPSCs	and	compare	it	with	
three-dimensional	static	culture	and	a	fed-batch	RWV	bioreactor.	
5.3 Experimental	Process	
Previously	it	was	demonstrated	that	hDPSCs	can	be	long	term	grown	undifferentiated	
under	 normal	 culture	 conditions	 and	 that	 passage	 4	 cells	 are	 able	 to	 produce	 the	
required	number	of	cells	for	3D	culture	without	significant	differences	from	the	paternal	
cells	 (passage	 1),	 these	 cells	 were	 used	 in	 this	 chapter.	 Prior	 to	 the	 osteogenic	
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differentiation,	donor	samples	of	hDPSCs	were	expanded	undifferentiated	until	reaching	
the	desired	number	by	passage	4,	these	cells	were	encapsulated	in	an	alginate/	gelatin	
scaffold	with	a	density	of	20,000	cells/bead.	250	beads	were	seeded	and	cultured	in	the	
perfusion-RWV	bioreactor	with	growth	medium	and	characterised	through	their	ability	
to	 proliferate	 in	 suspended	 culture,	 by	 the	 presence	 of	 a	 consistent	 set	 of	 marker	
proteins	on	 their	 surface	 and	proliferative	 capabilities.	 Perfusion	was	 set	 as	 1	 vessel	
volume	per	day	(55	ml/day	medium).	
For	 the	 osteogenic	 differentiation,	 donor	 samples	 of	 hDPSCs	 were	 expanded	
undifferentiated	 until	 reaching	 the	 desired	 number	 by	 passage	 4,	 these	 cells	 were	
encapsulated	 in	an	alginate/	gelatin	scaffold	with	a	density	of	20,000	cells/bead.	250	
beads	were	seeded	and	expanded	in	175	T-flasks	with	expansion	medium	for	7	days,	
allowing	cells	to	acclimatise	to	the	new	three	dimensional	environment.	Following	the	
process,	beads	were	transferred	to	either,	perfusion-RWV	bioreactor,	HARV	bioreactor	
or	3D	static	culture	and	for	21	days	osteogenic	medium	containing	dexamethasone,	β-
GP,	ascorbic	acid	and	KH2PO4,	was	used	to	drive	undifferentiated	hDPSCs	to	osteogenic	
lineage.	 For	 the	 perfusion-RWV	 bioreactor,	 medium	 perfusion	 was	 set	 to	 1	 vessel	
volume	per	day	(55	ml),	for	the	HARV	bioreactor,	media	was	changed	daily	(55	ml)	and	
for	the	static	culture,	media	was	changed	daily	(25	ml).	Thus	osteogenic	differentiation	
was	assessed	using	various	techniques	such	as,	proliferation	measurement	by	Calcein	
AM/	 ethidium	 homodimer,	 measurement	 of	 ATP	 content	 and	 MTS	 assay,	
characterisation	 of	 mineralised	 bone	 nodules	 by	 alizarin	 red	 and	 von	 Kossa,	 H&E,	
alkaline	 phosphatase	 expression,	 immunocytochemical	 characterisation,	 RT-PCR,	
scanning	electron	microscopy	with	X-ray	microanalysis,	ATR-FTIR	and	ATR-FTIR	imaging.	
The	detailed	explanation	of	these	techniques	can	be	found	 in	Chapter	 III.	The	overall	
experimental	process	is	illustrated	in	Figure	39.	
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Figure	39	Experimental	process	for	the	3D	osteogenic	differentiation	in	A)	perfusion-
RWV	bioreactor,	B)	HARV	bioreactor	and	C)	static	culture.	
5.4 Results	
5.4.1 hDPSCs	cultured	in	three-dimensional	environment	for	expansion	and	maintenance	
It	is	an	important	factor	to	keep	maintaining	multipotency	of	hDPSCs	in	3D	culture	during	
expansion	and	maintenance	of	the	undifferentiated	cells	for	bone	tissue	bioprocessing.	
Since	we	are	developing	a	single	step	bioprocess,	the	cells	are	required	to	be	expanded	
inside	 the	 bioreactor	 with	 the	 minimum	 disturbance	 before	 the	 osteogenic	
differentiation.		
Cells	were	likely	to	show	single	cell	suspension	well	distributed	through	the	hydrogel,	
cell	clumps	can	be	seen.	The	hydrogels	did	not	show	any	signal	of	mineralisation	during	
the	12	days	of	culture.	Pictures	can	be	seen	in	Figure	40.	
	
Figure	 40	 Morphology	 of	 hDPSCs	 encapsulated	 in	 alginate	 beads	 grown	
undifferentiated	in	perfusion-RWV	bioreactor	for	A)	7	days	and	B)	and	C)	day	12.	Scale	
bar	for	picture	A=100	µm	and	200	µm	for	pictures	B	and	C.	
B)
A)
seeding passaging collectingencapsulating differentiationSupplements and factors for 
osteogenic
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encapsulation
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To	assess	the	expansion	of	passage	4	hDPSCs-loaded	hydrogels	grown	in	the	perfusion-
RWV	bioreactor,	their	multipotent	immunophenotype	was	measured	by	flow	cytometry	
during	 12	 days.	 Every	 three	 days,	 cells	were	 stained	with	 surface	markers	 for	 CD44,	
CD73,	CD90,	CD105.	In	the	last	day	of	culture,	the	negative	markers	CD14,	CD11b,	CD34,	
CD45,	CD79α,	CD19	and	HLA	class	II,	were	measured.	As	well,	proliferation	and	ALPASE	
activity	were	assessed	for	28	days	by	measuring	ATP	content	and	by	MTS	activity	assay.	
Cells	were	found	homogenously	positive	and	indistinguishable	from	day	1	cells	for	the	
markers	CD44,	CD73	and	CD90.	However,	cd105	demonstrated	a	tendency	to	decrease	
after	day	6.		The	dot	plots	and	percentage	of	expression	of	CD44,	CD73,	CD90	and	CD105	
every	3	days	can	be	seen	in	Figure	41	and	Figure	42	respectively.		
	
Figure	41	Forward	and	side	scatter	plots	 top	row,	dot	plots	 for	 the	double	positive	
markers	CD105	vs	CD90	mid	row	and	dot	plots	for	double	positive	markers	CD44	vs	
CD73	down	row	measured	by	flow	cytometry	for	A)	day	3,	B)	day	6),	C)	day	9	and	D)	
day	12	of	culture	in	perfusion-RWV	bioreactor,	F)	histogram	of	the	negative	grouped	
MSC	markers	by	day	12,	where	orange	represents	the	sample,	red	the	unstained	cells	
and	violet	the	isotypes.	10,000	events	were	acquired	per	sample.	
A																		B																	C																		D												 F	
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Figure	42	Percentage	of	 cells	with	positive	expression	 for	 the	markers	CD44,	CD73,	
CD90	and	CD105	measured	every	three	days	of	culture	in	perfusion-RWV	bioreactor	
for	a	total	of	12	days	by	flow	cytometry.	10,000	events	were	acquired	per	sample.	
The	growth	kinetic	of	hDPSCs	was	measured	by	the	ATP	content	(CelltiterGlo	3D	assay)	
and	MTS	activity	of	beads	(CCK-8	assay)	(n=6).	The	ATP	content	increased	1.61	times	fold	
by	day	14,	6.74	times	by	day	21	and	13,33	by	day	28,	MTS	followed	a	similar	pattern	
increasing	2.47	times	fold	by	day	14,	5.11	times	by	day	21	and	9.19	times	by	day	28.	
Charts	that	show	these	results	can	be	seen	in	Figure	43	and	Figure	44	for	ATP	content	
and	MTS	activity	respectively.	Both	proliferation	assays	used	have	limitations	as	the	3D	
environment	deviates	from	the	real	cell	number.	The	relationship	between	seeded	cell	
number	 and	 luminescent/	 absorbance	 output	 after	 several	 days	 in	 culture	 is	 often	
curved	due	to	the	effects	of	contact	inhibition	on	cell	proliferation,	as	well	as	reduced	
metabolic	activity	and/	or	necrosis	in	the	centre	of	scaffolds.	The	non-linearity	provides	
a	semi-quantitative/	qualitative	approximation	to	cell	number	rather	than	a	quantitative	
measurement.		
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Figure	43	Measurement	of	hDPSCs	proliferation	by	Celltiter-Glo	3D	cell	viability	assay	
(ATP	content)	for	28	days	of	expansion	in	perfusion-RWV	bioreactor.	For	each	group	
n=6.	
	
Figure	44	Measurement	of	hDPSCs	proliferation	by	CCK-8	cell	viability	assay	for	28	days	
of	expansion	in	perfusion-RWV	bioreactor.	For	each	group	n=6.	
Alkaline	phosphatase	activity	(ALPase)	was	low	during	all	the	culture,	without	significant	
differences	between	the	time	points,	as	cells	did	not	start	bone	differentiation.	it	can	be	
seen	in	Figure	45.	
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Figure	45	Measurement	Alkaline	Phosphatase	activity	of	hDPSCs	expanded	for	28	days	
of	expansion	in	perfusion-RWV	bioreactor.	For	each	sample-point,	n=3.	
5.4.2 Comparison	of	3D	bioprocesses	for	osteogenic	differentiation	
The	3D	expansion	and	acclimatising	of	the	cells	to	the	3D	environment	(first	7	days	of	
culture)	was	performed	in	3D	static	culture	(T175-flasks)	placed	in	a	shaker,	for	all	the	
differentiation	 processes	 to	 start	 from	 the	 same	 conditions.	 However,	 since	 we	 are	
developing	 a	 single	 step	 bioprocess,	 in	 normal	 operation	 conditions,	 the	 bioreactors	
should	be	loaded	from	day	0	with	the	seeded	hydrogels	and	cells	should	not	be	removed	
from	the	reactor	or	be	disturbed	in	any	possible	manner.	By	day	7,	cells	were	placed	in	
one	of	 the	three	bioprocesses	 in	study	and	osteogenic	differentiation	of	hDPSCs	was	
performed	by	exposure	to	osteogenic	media	(Dex,	ASAP,	β-GP)	for	21	more	days.	The	
best	 bioprocess	 for	 3D	 osteogenic	 differentiation	 was	 established	 by	 measuring	
proliferation,	 gene	 expression,	 mineralisation	 through	 different	 techniques,	 and	
qualitatively	by	SEM	microscopy,	histology	and	immunostaining.	
5.4.2.1 Morphology	and	cell	viability	of	hDPSCs	3D	osteogenic	bioprocesses	
Every	hydrogels	containing	osteogenic	cells	after	28	days	of	culture	showing	changing	
colour	 from	 clear	 transparent	 becoming	 white,	 bone	 looking	 and	 appeared	 to	 be	
physically	brittle	in	contrast	to	the	initial	alginate	gel	properties.	As	presented	in	Figure	
46.		
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Figure	46	Images	of	hydrogels	after	28	days	of	culture,	A)	perfusion-RWV	bioreactor,	
B)	HARV	bioreactor	and	C)	3D	static	culture.		
During	 the	 differentiation	 process,	 the	 morphology	 changes	 of	 the	 hydrogels	 were	
followed	by	light	microscopy.	By	day	7	(expansion	and	acclimatising	period),	cells	were	
likely	 to	 show	 single	 cell	 suspension	 well	 distributed	 through	 the	 hydrogel.	 The	
hydrogels	did	not	show	signal	of	mineralisation.	By	day	21	(day	14	of	differentiation),	
mineralisation	started	conquering	the	hydrogels,	and	light	almost	could	not	travel	across	
the	 hydrogels.	 By	 day	 28	 pictures	 showed	 black	 spheres,	 as	 light	 did	 not	 cross	 the	
hydrogels.	 From	 the	 three	 bioprocesses,	 mineralisation	 appears	 to	 be	 higher	 in	 the	
perfusion-RWV	bioreactor,	followed	by	the	flask	and	the	HARV	bioreactor	having	similar	
results.	Morphology	of	the	beads	can	be	seen	in	Figure	47	for	days	7	and	28.	The	other	
days	can	be	found	in	the	supplementary	information	in	the	appendix.	
The	 growth	 kinetics	 of	 hDPSCs	 seeded	 in	 beads	 (n=6)	 showed	 that	 by	 day	 21,	 the	
perfusion-RWV	 bioreactor	 yielded	 significantly	 higher	 cell	 numbers	 than	 the	 other	
bioprocesses,	with	an	enhancement	of	≈7	times	fold,	compared	with	5.8	and	5	times	
achieved	by	the	HARV	bioreactor	and	the	3D	static	culture	respectively.	Albeit	by	day	28	
the	MTS	activity	went	down	for	the	three	bioprocesses,	it’s	believed	that	mineralisation	
of	 the	 beads	 or	 an	 enzymatic	 change	 related	with	 differentiation,	 did	 not	 allow	 the	
reaction	buffer	to	act	on	the	cells	causing	the	down	expression	of	the	MTS	assay.	Cells	
were	 shown	 to	 be	 alive	 and	 healthy	 by	 the	 end	 of	 the	 culture	 by	 Live/	 dead	 assay,	
staining	 live	 cells	with	 Calcein	 AM	 (green)	 and	 dead	 cells	with	 ethidium	homodimer	
(red).	These	results	can	be	seen	in	Figure	48	and	Figure	49.	
Live/	dead	assay	shows	that	cells	are	very	alive,	the	down	expression	of	the	MTS	assay	
could	be	result	of	an	enzymatic	activity	change	after	differentiation.	The	proliferation	
assay	used	have	limitations	as	the	3D	environment	deviates	from	the	real	cell	number.	
The	relationship	between	seeded	cell	number	and	absorbance	output	after	several	days	
A)	 B)	 C)	
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in	culture	is	often	curved	due	to	the	effects	of	contact	inhibition	on	cell	proliferation,	as	
well	as	reduced	metabolic	activity	and/	or	necrosis	in	the	centre	of	scaffolds.	The	non-
linearity	provides	a	semi-quantitative/	qualitative	approximation	to	cell	number	rather	
than	a	quantitative	measurement.	
	
Figure	47	morphology	of	hydrogels	observed	under	light	microscopy	of	A)	Day	7,	B)	
day	 28	 HARV	 bioreactor,	 C)	 day	 28	 static	 culture	 Flask,	 D)	 day	 28	 Perfusion-RWV	
bioreactor.	Scale	bar=200	µm.	
	
Figure	48	Measurement	of	hDPSCs	proliferation	by	CCK-8	cell	viability	assay	scored	by	
HARV	bioreactor,	perfusion-RWV	bioreactor	and	3D	static	culture	through	28	days	of	
culture.	 For	 each	 group	n=3.	 *	 indicates	 statistical	 significance	 comparing	between	
bioprocess	for	each	time-point.	
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Figure	49	 Live	dead	assay	A)	at	day	0,	B)	at	day	7,	C)	 at	day	28	 for	 cells	 seeded	 in	
perfusion-RWV	bioreactor,	D)	at	day	28	for	cells	seeded	in	HARV	bioreactor,	E)	at	day	
28	for	cells	seeded	in	3D	static	culture.	scale	bar=200	µm.	
In	order	to	evaluate	indirectly	the	proliferative	capability	of	hDPSCs	in	3D	culture,	the	
metabolic	activity	of	hDPSCs	cultured	in	perfusion-RWV	bioreactor,	HARV	bioreactor	or	
3D	static	culture	under	osteogenic	differentiation	was	evaluated	by	measuring	for	28	
days	 the	 time-course	 concentration	 of	 key	 substrates	 and	 metabolites	 in	 culture	
medium.	Consumption	of	glutamine	and	glucose,	production	of	ammonia	and	lactate,	
concentration	of	oxygen	and	detection	of	pH	were	acquired	every	7	days	with	a	bio-
profiler.		
For	 the	Perfusion-RWV	bioreactor,	medium	perfusion	was	 set	 to	 the	equivalent	of	 1	
vessel	volume	a	day	(55	ml	of	medium).	For	the	HARV	bioreactor	and	3D	static	culture,	
media	was	exchanged	daily	with	volumes	of	55	and	25	ml	 respectively.	Medium	was	
measured	 before	 exchange,	 allowing	 to	 assess	 the	 metabolic	 stress	 that	 cells	 were	
suffering	during	an	entire	medium	exchange	cycle.	
The	glycolysis	is	a	key	metabolic	pathway	to	produce	energy	for	proliferative	cells	and	
as	glucose	is	digested	to	produce	ATP,	it	releases	2	molecules	of	Lactate.	20	[mmol/l]	of	
lactate	are	limiting	for	the	culture,	above	this	level,	lactate	has	a	harmful	effect	(Ouyang	
et	 al.,	 2007).	 In	 the	 perfusion-RWV	 bioreactor,	 glucose	 was	 consumed	 from	 ≈7.1	
[mmol/L]	to	≈6	[mmol/L].	However,	as	lactate	accumulation	was	too	low,	it	did	not	reach	
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a	 measurable	 concentration.	 Glucose	 and	 lactate	 kinetics	 for	 the	 perfusion-RWV	
bioreactor	can	be	seen	in	Figure	50A.	In	the	HARV	bioreactor,	glucose	was	consumed	
from	≈7.1	[mmol/L]	to	≈5.4	[mmol/L],	lactate	accumulation	in	the	system	was	too	low,	
and	did	not	reach	a	concentration	measurable	by	the	bioprofiler.	Glucose	and	lactate	
kinetics	for	the	perfusion-RWV	bioreactor	can	be	seen	 in	Figure	51A.	 In	the	3D	static	
culture,	 glucose	 was	 consumed	 from	 ≈7.1	 [mmol/L]	 to	 ≈0	 [mmol/L],	 and	 twice	 the	
number	of	molecules	of	lactate	was	produced.	Lactate	production	rise	from	≈0	to	≈12.3	
[mmol/L].	Glucose	and	lactate	kinetics	for	the	perfusion-RWV	bioreactor	can	be	seen	in	
Figure	52A.	
The	glutaminolysis	is	a	key	metabolic	pathway	to	produce	energy	for	proliferative	cells	
and	 as	 glutamine	 is	 lysed	 into	 glutamate	 to	 produce	 ATP,	 it	 releases	 1	molecule	 of	
ammonia,	if	ammonia	concentration	reaches	4	[mmol/L],	it	can	have	a	toxic	effect	for	
the	 cells	 (Chaudhry	 et	 al.,	 2009).	 For	 the	 perfusion-RWV	 bioreactor,	 glutamine	
fluctuated	from	≈4	[mmol/L]	and		≈3	[mmol/L]	and	ammonia	followed	a	similar	trend,	
fluctuating	 between	 	 ≈0.78	 [mmol/L]	 and	 	 ≈1.1	 [mmol/L].	 Glutamine	 and	 ammonia	
kinetics	 for	 the	 perfusion	 RWV-bioreactor	 can	 be	 seen	 in	 Figure	50B.	 For	 the	 HARV	
bioreactor,	glutamine	fluctuated	from	≈4	[mmol/L]	and		≈2.8	[mmol/L]	and	ammonia	
followed	 a	 similar	 trend,	 fluctuating	 between	 	 ≈0.9	 [mmol/L]	 and	 	 ≈1.1	 [mmol/L].	
Glutamine	and	ammonia	kinetics	for	the	HARV	bioreactor	can	be	seen	in	Figure	51B.	For	
the	3D	static	culture,	glutamine	fluctuated	from	≈4.1	[mmol/L]	and		≈2.39	[mmol/L]	and	
ammonia	 followed	 a	 similar	 trend,	 fluctuating	 between	 	 ≈0.8	 [mmol/L]	 and	 	 ≈1.3	
[mmol/L].	Glutamine	and	ammonia	kinetics	for	the	static	culture	can	be	seen	in	Figure	
52B.	
For	the	perfusion-RWV	bioreactor,	the	oxygen	tension	in	the	medium	slowly	decreased,	
fluctuating	 between	 160	 [mmHg]	 and	 140	 [mmHg].	 The	 oxygen	 kinetics	 for	 the	
perfusion-RWV	 bioreactor	 can	 be	 seen	 in	 Figure	 50C.	 For	 the	 HARV	 bioreactor,	 the	
oxygen	tension	in	the	medium	slowly	decreased,	fluctuating	between	160	[mmHg]	and	
130	[mmHg].	The	oxygen	kinetics	for	the	HARV	bioreactor	can	be	seen	in	Figure	51C.	For	
the	3D	static	culture,	the	oxygen	tension	in	the	medium	slowly	decreased,	fluctuating	
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between	160	[mmHg]	and	130	[mmHg].	The	oxygen	kinetics	for	the	3D	static	culture	can	
be	seen	in	Figure	52C.	
The	pH	in	the	perfusion-RWV	bioreactor	culture,	gradually	decreased	from	7.6	to	7.2	as	
culture	time	passed.	The	pH	kinetics	for	the	perfusion-RWV	bioreactor	can	be	seen	in	
Figure	50D.	The	pH	in	the	HARV	bioreactor	culture,	gradually	decreased	from	7.6	to	7.08	
as	culture	time	passed.	The	pH	kinetics	for	the	HARV	bioreactor	can	be	seen	in	Figure	
51D.	The	pH	in	the	3D	static	culture,	gradually	decreased	from	7.6	to	7	as	culture	time	
passed.	The	pH	kinetics	for	the	3D	static	culture	can	be	seen	in	Figure	52D.	
It	is	important	to	mention	that	in	every	time-point,	50	beads	were	removed	for	analysis.	
This	disturbance	 inserted	to	the	system	implies	that	the	resulting	metabolite	kinetics	
would	be	affected.	If	these	samples	were	to	be	maintained	in	the	system,	the	kinetics	
would	 reflect	 it	 and	 by	 the	 end	 of	 culture,	 5	 times	more	 cells	 would	 be	 consuming	
medium,	oxygen	and	producing	waste.	Lactate	and	ammonia	wouldn´t	reach	harmful	
levels,	they	are	limited	by	the	glucose	and	glutamate	concentration.	Nevertheless,	pH,	
glucose,	 glutamate	 and	 oxygen	 concentrations	 could	 reach	 low	 levels,	 and	 have	 a	
negative	repercussion	on	the	culture	quality.	
	
Figure	 50	 Change	 with	 culture	 time	 of	 key	 substrates	 and	 metabolites	 in	 culture	
medium	for	the	perfusion-RWV	bioreactor.	A)	Consumption	of	glucose	and	production	
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of	lactate.	B)	Consumption	of	glutamine	and	production	of	ammonia.	C)	pH.	And	D)	
oxygen.	
	
Figure	 51	 Change	 with	 culture	 time	 of	 key	 substrates	 and	 metabolites	 in	 culture	
medium	 for	 the	 HARV	 bioreactor.	 A)	 Consumption	 of	 glucose	 and	 production	 of	
lactate.	 B)	 Consumption	 of	 glutamine	 and	 production	 of	 ammonia.	 C)	 pH.	 And	 D)	
oxygen.	
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Figure	 52	 Change	 with	 culture	 time	 of	 key	 substrates	 and	 metabolites	 in	 culture	
medium	for	the	3D	static	culture.	A)	Consumption	of	glucose	and	production	of	lactate.	
B)	Consumption	of	glutamine	and	production	of	ammonia.	C)	pH.	And	D)	oxygen	
5.4.2.2 Histological	analysis	and	immunostaining	of	hDPSCs	3D	osteogenic	bioprocesses	
We	addressed	whether	the	hDPSCs	were	capable	of	forming	mineralised	bone	nodule	
in	 3D	 culture	 systems	 using	 alginate	 beads	 and	 any	 of	 the	 three	 bioprocesses	 being	
compared.	 In	 order	 to	 confirm	whether	 these	 tissues	were	mineralised	 bone	 tissue,	
histological	analysis	and	immunostaining	was	done	to	characterize	the	morphology	and	
calcium	deposits	in	tissues.		
The	 resulting	hydrogels	 from	 the	3	bioprocesses	were	 cut	 in	 slices	 and	histologically	
examined	 by	 hematoxylin	 and	 eosin	 staining	 (H&E).	 As	 shown	 in	 Figure	 53,	 samples	
displayed	 a	 heterogeneous	 morphology	 and	 behave	 different.	 However,	 the	 three	
groups	of	osteogenic	 constructs	 showed	gradual	bone	neo-tissue	 formation	over	 the	
time	period.	At	day	0,	most	cells	appear	scattered	and	spread	homogenously	through	
the	beads,	at	this	stage	cells	haven’t	formed	extracellular	matrix	(Figure	53A).	After	7	
days	of	culture	in	expansion	medium,	It	can	be	seen	that	cells	expanded	and	populated	
the	whole	hydrogels	(Figure	53B	).	by	day	14	(7	days	in	differentiation	media),	a	decrease	
in	cell	number	is	observed,	this	is	confirmed	by	the	MTS	measurements	that	show	the	
same	 reduction.	 As	 time	 passed	 by,	 size	 and	 shape	 of	 cells,	 together	 with	 their	
surroundings	 changed,	 ECM	 was	 formed	 and	 approximately-round	 lacunae	 started	
showing	 around	 single	 cells,	 which	 is	 signal	 of	 cells	 differentiation	 into	 osteogenic	
lineage.	 These	 lacunae,	 when	 cells	 matured,	 became	 more	 elongated	 (osteocyte	
lacunae).	The	3D	static	culture	showed	fair	formation	of	round-shaped	lacunae	by	day	
21	and	increased	by	day	28	(see	Figure	53C).	This	suggests	cell	maturation.	Interestingly,	
lacunae	without	cells	started	appearing	by	day	21	and	cells	attached	to	the	flask	surface	
began	growing	(see	Figure	54).	The	HARV	bioreactor	showed	less	differentiation	than	
the	 static	 culture.	 By	 day	 21	 poor	 lacunae	 formation	was	 observed,	 suggesting	 poor	
maturation	of	the	cells.	Additionally,	there	were	not	many	cells	visible	in	the	hydrogels.	
The	 perfusion-RWV	 bioreactor	 showed	 the	 production	 of	 more	mature	morphology	
than	 the	other	bioprocesses.	By	day	21,	 cells	 fully	populated	 the	 scaffold	 and	 round	
lacunae	was	formed	in	all	the	beads	except	from	the	most	inner	area	of	the	beads.	By	
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day	 28	 elongated	 lacunae	 can	 be	 seen	 in	 the	 most	 external	 area	 of	 the	 beads.	
Nonetheless,	the	inner	area	was	not	as	maturated,	showing	heterogeneity	of	the	cell	
product.	 Figure	 53	 displays	 H&E	 pictures	 of	 day	 0,	 7	 and	 28.	 A	 complete	 scenario,	
including	days	14	and	21,	can	be	found	in	the	supplementary	images	in	the	appendix.	
	
Figure	53	H&E	images	showing	the	morphology	of	alginate	beads:	pictures	A)	and	B)	
display	 cells	 grown	 in	 alginate	 beads	 in	 growth	 medium	 in	 static	 culture	 for	
acclimatisation	to	the	3D	environment	by	day	0	and	7	respectively.	Hydrogels	cultured	
with	osteogenic	medium	after	28	days	C)	in	3D	static	culture	D)	in	HARV	bioreactor	
and	E)	in	perfusion	bioreactor.	Scale	bar=200	µm.	
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Figure	54	hDPSCs	adhered	to	culture	flask	by	day	14	of	culture	 in	3D	static	culture,	
these	 cells	 left	 the	 scaffold	 as	 consequence	 of	 mass	 transport	 limitations.	 Scale	
bar=200	µm.		
Calcified	 deposition	 was	 widely	 spread	 in	 the	 osteogenic	 beads	 and	 was	 shown	 by	
alizarin	red	s	staining	(ARS)	and	von	Kossa	staining.	ARS	results	displayed	an	increase	of	
the	 nodules	 in	 time.	 3D	 static	 culture	 and	 perfusion-RWV	 produced	 larger	 nodules	
through	the	28	days,	while	HARV	bioreactor	produced	small	nodules	in	higher	quantity.	
Negative	controls	are	undifferentiated	hDPSCs	grown	in	alginate	beads	and	a	known	to	
be	negative	tissue.	Further	in	this	chapter,	quantitative	analysis	of	ARS	can	be	found.	
Figure	55	displays	the	results	for	3D	static	culture,	HARV	bioreactor	and	perfusion-RVW	
bioreactor	 for	 days	 14	 and	 28	 of	 culture,	 additional	 pictures	 can	 be	 found	 in	 the	
appendix.	
Von	 Kossa	 staining	 was	 done	 for	 day	 28	 and	 albeit	 the	 results	 do	 not	 show	 mass	
deposition	 (black	 colour),	 the	 beads	 produced	 by	 the	 3	 bioprocesses,	 specially	 the	
perfusion-RWV	bioreactor,	produced	plenty	of	dispersed	depositions	of	calcium	(grey	
colour),	compared	with	the	negative	sample	that	produced	a	pink	stain	without	grey	of	
black.	These	results	can	be	seen	in	Figure	56	
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Figure	55	Alizarin	red	staining	of	beads	produced	by:	3D	static	culture,	A)	day	14,	B)	
and	C)	day	28;	HARV	bioreactor,	D)	day	14,	E)	and	F)	day	28;	perfusion-RWV	bioreactor	
G)	day	14,	H)	and	 I)	day	28;	 	F)	undifferentiated	hDPSCs,	G)	negative	control.	Scale	
bar=200	µm.	
	
Figure	56	Von	Kossa	staining	of	beads	after	28	day	bioprocessed	in:	A)	and	B)	3D	static	
culture,	C)	and	D)	HARV	bioreactor,	E)	and	F)	perfusion-RWV	bioreactor;	G)	negative	
control.	Scale	bar=200	µm.	
	
For	further	confirmation	of	osteogenic	neo-tissue	formation,	the	hydrogels	were	stained	
with	anti-osteocalcin	antibody	(Figure	57).	The	three	bioprocesses	by	day	28	produced	
tissue	 positive	 for	 osteocalcin,	 with	 the	 perfusion-RWV	 bioreactor	 showing	 higher	
intensity.	The	other	bioprocesses	showed	a	comparatively	weaker	expression.	
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Figure	 57	 Fluorochrome	 labelling	 of	 bone	 constructs	 for	 Osteocalcin	 of	 beads	
differentiated	after	28	days	of	 cultureof	A)HARV	bioreactor	B)	3D	 static	 culture,	C)	
perfusion-RWV	bioreactor	and	D)	negative	control.	Scale	bar=200	µm.	
5.4.2.3 Quantitative	analysis	of	hDPSCs	3D	osteogenic	bioprocesses	
The	 quantitative	 comparisons	 among	 the	 bioprocesses	 were	 undertaken	 by	 ALPase	
activity	 analysis,	 ARS-based	 quantification,	 chemical	 analysis	 with	 ATR-FTIR	
spectroscopy	analysis	and	X-ray	microanalysis	and	qPCR	with	various	osteogenic	genes.	
ALPase	activities	in	the	3	bioprocesses	increased	through	the	experiment,	however,	the	
differentiation	in	flasks,	showed	poor	increase	compared	with	the	other	bioprocesses,	
additionally,	perfusion-RWV	bioreactor	achieved	significantly	higher	activities	than	the	
other	bioprocesses,	scoring	7.3	times	fold	its	initial	activity.	These	results	can	be	seen	in	
Figure	58.	
The	level	of	mineralisation	of	the	beads	was	measured	by	quantifying	the	ARS	positive	
area	in	stained	slides.	The	three	bioprocesses	demonstrated	a	similar	trend,	with	a	slow,	
but	steady	increase	of	the	positive	area	through	the	28	days.	There	was	not	a	significant	
difference	 in	 the	 increase	experienced	by	 the	2	bioreactors.	After	14	days	of	 culture	
increasing	 from	 5%	 to	 ≈32%.	 However,	 the	 3D	 static	 culture	 had	 a	 positive	 surface	
significantly	lower	after	the	28	days	of	culture.	These	results	can	be	seen	in	Figure	59	
	 137	
	
	
Figure	58	Measurement	of	Alkaline	phosphatase	activity	by	colorimetric	assay,	scored	
by	HARV	bioreactor,	perfusion-RWV	bioreactor	and	3D	static	culture	through	28	days	
of	culture.	For	each	group	n=3.	*	indicates	statistical	significance	between	the	three	
groups	for	each	time-point.	
	
	
Figure	 59	 Semi-quantitative	 indirect	measurement	 of	 Alizarin	 red	 S	 stained	 slides:	
Percentage	of	mineralised	area	of	hydrogels	measured	by	image	analysis	software	of	
stained	slides	(n=3).	*	indicates	statistical	significance	between	the	three	groups	for	
each	time-point.	
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Spectra	 from	 ATR-FTIR	 and	 X-ray	 microanalysis,	 confirmed	 that	 the	 comparison	 of	
mineralisation	in	this	study	was	based	on	the	true	calcified	hydroxyapatite	components	
(Figure	60,	Figure	61,	Figure	65,	Figure	65	and	Figure	65).	They	were	characterised	in	
ATR-FTIR	 by	 the	 specific	 spectral	 bands	 at	 1012	 cm-1	 and	 1445	 cm-1	 which	 are	
comparable	with	pure	hydroxyapatite	and	collagen	of	human	bone	respectively	and	in	
X-ray	microanalysis	by	the	ratio	Ca/P,	as	previously	reported	hydroxyapatite	has	a	ratio	
of	1.62	(Meyer	et	al.,	1972,	Figueiredo	et	al.,	2012).	It	was	seen	that	the	perfusion-RWV	
bioreactor	achieved	better	results	in	both	analysis	during	the	28	days	of	culture.	Having	
stronger	signal	in	the	mentioned	bands	and	showing	an	average	Ca/P	ratio	higher	than	
the	other	bioprocesses.	However,	albeit	Ca/P	ratio	scored	by	the	static	culture	was	in	
the	 same	orders	of	magnitude	as	 the	perfusion-RVW	bioreactor	and	higher	 than	 the	
resulting	 from	 the	 HARV	 bioreactor,	 the	 measurements	 in	 ATR-FTIR	 were	 opposite,	
scoring	lower	than	HRV	bioreactor.		
	
Figure	60	ATR-FTIR	 spectra	 comparison	 for	 the	 three	bioprocesses	after	21	days	of	
culture	
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Figure	61	ATR-FTIR	 spectra	 comparison	 for	 the	 three	bioprocesses	after	28	days	of	
culture	
	
Figure	 62	 ATR-FTIR	 spectra	 normal	 human	 bone	 tissue,	 obtained	 by	 Beasley	 et	 al.		
(Beasley	 et	 al.,	 2014).	 This	 image	 is	 used	 as	 control,	 the	 peaks	 for	 phosphate	 and	
carbonate	can	be	seen	in	the	wavenumbers	1035	and	1415	[cm-1]	respectively	
	
Figure	63	ATR-FTIR	imaging	of	A)	static	culture,	B)	HARV	bioreactor	and	C)	perfusion	
bioreactor	after	28	days	of	culture.	These	images	where	obtained	with	a	field	of	view	
of	 650x580	µm2,	 Factor	 analysis	was	 applied	 to	 the	 region	of	 1110-990	 cm-1.	 Scale	
bar=200	µm.	
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The	C/P	ratio	is	a	characteristic	ATR-FTIR	measurement	of	bone.	Samples	were	analysed	
measuring	the	absorbance	of	the	samples	for	the	wavenumbers	1415	(for	C)	and	1035	
[cm-1]	(for	P),	the	resulting	values	can	be	seen	in	the	Figure	64.	
	
Figure	64	Relationship	between	the		organic	and	inorganic	fraction	of	bone	constructs.	
C/P	ratio	of	hydrogels	for	for	different	sampling	days.	For	each	group	n=3.	*	indicates	
statistical	significance	between	the	three	groups	for	each	time-point.	
	
	
Figure	 65	 Measurement	 of	 hydroxyl	 apatite	 quality	 by	 X-ray	 microanalisis.	
Standardised	Ca/P	ratios	characteristic	of	bone	scored	by	HARV	bioreactor,	perfusion-
RWV	bioreactor	and	3D	static	culture	through	28	days	of	culture	(n=3).	No	significant	
differences	were	seen	in	the	three	groups.	
Following	 the	 evaluation	 of	 the	 enzymatic	 and	 chemical	 characteristics	 of	 the	
biomaterial	constructs	formed	by	the	three	bioprocesses,	osteogenic	differentiation	was	
also	characterized	by	distinct	cellular	phenotypes.	Osteogenic	differentiation	of	hDPSCs	
was	evaluated	by	measurement	of	gene	expression	level	using	qPCR.	The	expression	of	
*
*
*
*
0
0.2
0.4
0.6
0.8
1
21 28
FLASK HARV PERF
P			 Ca
0
0.4
0.8
1.2
1.6
21 28
Ra
tio
	C
a/
P
Days
Standardised	Ratio	Ca/P
PERF
HARV
FLASK
	 141	
genes	Runx2/CBFA1,	osteocalcin	(BGLAP),	alkaline	phosphatase	(ALPL),	collagen	type	I	
(COL1A1)	and	sclerostin	(SOST)	can	be	seen	in	Figure	66.	
The	positive	expression	for	the	five	genes	in	the	three	bioprocesses,	indicates	successful	
osteogenic	differentiation.	Especially,	when	going	from	day	21	of	induction	to	day	28.	
An	enhanced	or	steady	expression	was	seen	in	most	of	the	genes.	Perfusion	culture	had	
a	 steady	 expression	 of	 Runx2	 and	 produced	 an	 enhancement	 in	 the	 expression	 of	
COL1A1,	BGLAP,	ALPL	and	SOST	in	the	last	7	days	of	culture.	HARV	culture	had	a	steady	
expression	of	Runx2	and	produced	a	soft	enhancement	in	all	the	analysed	genes	in	the	
last	7	days	of	culture.	Static	culture	had	a	steady	expression	of	ALPL	and	COL1A1	and	
produced	an	enhancement	 in	the	expression	of	Runx2,	BGLAP	and	SOST	 in	the	 last	7	
days	of	culture.	These	results	indicate	the	progression	of	the	osteogenic	differentiation.	
	
Figure	66		Relative	gene	expression	for	the	osteogenic	markers	A)	RUNX2,	B)	BGLAP,	
C)COL1A1,	D)	ALPL	and	D)	SOST,	for	the	three	bioprocesses	for	28	days	of	culture	under	
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differenciation	bioprocessing	(n=3).	*	indicates	statistical	significance	comparing	day	
21	and	day	28	of	culture.	
5.4.2.4 Surface	analysis	by	scanning	electron	microscopy	of	hDPSCs	3D	osteogenic	
bioprocesses	
When	 viewed	 by	 SEM,	 many	 mineralised	 deposit	 were	 observed	 within	 alginate	
hydrogels	after	osteogenic	culture.	Additionally,	the	lacunae	seen	in	the	histology	are	
clearly	viewed	in	these	pictures,	along	with	the	morphogenesis	of	the	osteoblastic	cells.	
In	the	first	days	of	culture,	cells	were	seen	scattered	homogenously,	additionally,	as	ECM	
was	still	not	produced,	the	hydrogels	were	weak	and	difficult	to	process	for	SEM.	After,	
scaffolds	started	getting	rigid	and	pictures	showed	the	presence	of	non-stoichiometric	
mineralised	 deposits.	 These	 nodules	 were	 mainly	 composed	 of	 calcium	 and	
phosphorous	(proved	by	X-ray	microanalysis).	By	day	28	the	lacunae	were	distributed	in	
large	 portions	 of	 the	 scaffolds	 and	 in	 the	 pictures	 of	 the	 perfusion-RWV	 bioreactor,	
osteocytes	can	be	morphologically	recognised.	The	morphology	of	the	bone	constructs	
produced	by	the	3D	static	culture	can	be	seen	in	Figure	67	A	to	C,	where	the	maturation	
of	the	tissue	can	be	seen.	However,	osteocyte	lacunae	were	found	empty	(in	accordance	
with	 H&E	 pictures).	 The	morphology	 of	 the	 bone	 constructs	 produced	 by	 the	 HARV	
bioreactor	can	be	seen	in	Figure	67	D	to	F,	where	cell	heterogeneity	and	less	mature	
neo-tissue	 can	 be	 seen.	 The	 morphology	 of	 the	 bone	 constructs	 produced	 by	 the	
perfusion-RWV	bioreactor	can	be	seen	in	Figure	67	G	to	L.	In	these	SEM	pictures	it	can	
be	seen	that	cells	 in	the	surface	of	the	beads	resemble	osteocytes	showing	canaliculi	
and	their	surroundings	osteocytes	lacuna.	The	cells	 in	the	inner	area	of	the	scaffolds,	
look	immature,	implying	cell	heterogeneity.		
5.5 Discussions	
Tissue	 engineering	 holds	 the	 keys	 for	 the	 production	 of	 neo-tissue-equivalents	 with	
clinical	use.	Cells,	scaffolds	and	bioreactors	are	the	tools	it	uses,	in	hope	to	produce	fully	
functional	living	tissue-mimicking	biomaterials.	In	due	process,	it	can	provide	the	basis	
for	systemic	and	controlled	in	vitro	studies	of	tissue	development	and	function.	To	date,	
several	studies	in	2D	and	3D	static	platforms	have	been	done,	using	different	cell	sources	
and	scaffold	materials	with	the	aim	to	produce	bone-like	constructs	in	a	laboratory	scale	
(Zhao	 et	 al.,	 2011,	 Karbanova	 et	 al.,	 2010,	 Jensen	 et	 al.,	 2015,	 Heng	 et	 al.,	 2015).	
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Additionally,	 In	 the	 last	 years,	 there	have	been	numerous	 research	 to	develop	 three	
dimensional	 in	 vitro	 bone	 neo-tissue	 constructs	 using	 MSCs,	 3D	 scaffolds,	 growth	
factors/chemical	 cues	 and	 bioreactors,	 showing	 the	 potential	 use	 of	 MSCs	 in	 bone	
regeneration	(Sikavitsas	et	al.,	2002,	Stiehler	et	al.,	2009,	Hwang	et	al.,	2008,	Hwang	et	
al.,	 2009,	Randle	et	al.,	 2007b,	Diederichs	et	al.,	 2009,	 Jung	et	al.,	 2012a)	 .	All	 these	
studies	had	in	common	the	use	of	encapsulated	cells	(or	cells	seeded	into	a	scaffold),	a	
semi-batch	 feeding	 strategy	 and	 shear	 stress	 modulation,	 showing	 successful	
approaches	 for	 osteogenic	 differentiation	 of	 MSCs.	 Nonetheless,	 these	 efforts	 have	
been	 insufficient	 and	 the	 production	 of	 cellular	 constructs	 with	 heterogeneous	
populations	of	cells	is	a	trademark	of	these	bioprocesses.	The	in	vivo	microenvironment	
is	a	rich	in	complexity	and	dynamic	setting,	in	which	transport	of	nutrients	and	physical	
stimuli	happen	naturally	and	optimally.	 In	2D/3D	static	culture,	this	does	not	happen	
and	limited	nutrients	and	oxygen	transport	from	culture	medium	to	the	innermost	layer	
of	the	scaffolds,	along	with	lack	of	proper	physical	cues	represent	the	standards.	The	
histological	pictures	provided,	can	support	these	idea,	as	density	of	cells	in	the	core	of	
the	beads	is	low,	and	as	we	get	closer	to	the	surface,	it	reaches	its	highest	(see	Figure	
53).	These	limitations	hinder	the	cell	culture	outcome	and	produce	this	heterogeneity.		
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Figure	67	SEM	pictures	of	cultured	scaffolds	in	differentiation	medium	after	28	days	
showing	characteristic	bone	features:	Pictures	A	to	C	Display	cell	constructs	produced	
by	 3D	 static	 culture.	 Pictures	 D	 to	 F	 display	 cell	 constructs	 produced	 by	 HARV	
bioprocessing.	Pictures	G	to	L	display	pictures	of	cell	constructs	produced	by	perfusion-
RWV	bioprocessing.	
To	overcome	 these	 strains,	medium	perfusion	 has	 been	 introduced	 to	 the	 design	 of	
culture	vessels.	This	new	layer	of	bioreactor	design,	provides	the	culture	systems	with	
dynamic	exchange	of	nutrients	and	oxygen,	together	with	a	new	source	of	controlled	
shear	stress	and	has	been	developed	in	an	attempt	to	close	the	gap	between	the	in	vitro	
platforms	 and	 the	 in	 vivo	 natural	 environment.	 Therefore,	 we	 developed	 a	 culture	
system	to	create	three-dimensional	bone-like	tissues	based	on	hDPSCs,	alginate/gelatin	
bead,	and	perfusion-RWV	bioreactor.	To	the	best	of	our	knowledge,	this	is	the	first	study	
demonstrating	 the	 three	 dimensional	 bone-like	 tissue	 formation	 from	 hDPSCs	 in	
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alginate/gelatin	 scaffolds,	 grown	 suspended	 in	 a	 perfusion	 bioreactor	 system.	 Thus,	
could	have	widespread	applications	in	bone	tissue	engineering.	
In	this	study,	hDPSCs	were	homogenously	encapsulated	within	1.1%	alginate	mixed	with	
0.1%	gelatin	hydrogels,	afterwards	the	encapsulated	hDPSCs	were	placed	to	culture	in	
suspension	 environment	 within	 vessels	 of	 perfusion-RWV	 bioreactor,	 whereas	 the	
bioreactor	maintains	controlled	in	vitro	culture	conditions	that	permit	tissue	growth	and	
development.	
This	 in-house	 designed	 perfusion-RWV	 bioreactor	 produce	 a	 suspension	 culture	 by	
providing	laminar	flow	of	culture	media	and	rotation	of	the	vessel.	Hence	minimising	cell	
exposure	 to	 shear	 and	 turbulence	 which	 can	 be	 detrimental	 for	 cell	 growth	 and	
differentiation,	while	providing	sufficient	nutrients	and	oxygenation	to	support	3D	neo-
tissue	 growth	 and	 removing	 the	 undesirable	 cellular	 by-products.	 In	 our	 study,	 a	
protocol	 for	 cell	 expansion	 previously	 defined	 by	 our	 group	 for	mESCs	 was	 used	 to	
expand	undifferentiated	cells	in	3D	environment.	However,	the	need	to	design	a	specific	
expansion	 protocol	 for	 hDPSCs,	 considering	 seeding	 density,	 culture	 time	 and	 a	
thorough	 follow	up	of	undifferentiated	state,	 still	 remains	 to	be	done.	The	perfusion	
bioprocess	demonstrated	to	be	good	for	the	expansion	of	hDPSCs,	providing	with	≈13.5	
times	fold	expansion	after	28	days	of	culture.	A	significant	decrease	in	CD105	(endoglin)	
marker	after	6	days	of	culture,	giving	rise	to	2	subpopulations	of	hDPSCs,	one	CD15+	and	
another	CD105-.	This	heterogeneity	was	believed	to	be	due	to	different	stages	of	multi-
lineage	differentiation	(Jin	et	al.,	2009).	However,	more	resent	studies	have	found	that	
CD105+	and	CD105-	MSCs	represent	 independent	subpopulations	that	maintain	their	
properties	upon	several	passages.	These	subpopulations	have	similar	growth	potential	
and	 express	 almost	 identical	MSC	markers,	 but	 their	 differentiation	 capabilities	may	
differ.	 Interestingly,	CD105-	MSCs	were	found	to	be	more	prone	to	differentiate	 into	
osteoblastic	and	adipocytic	 lineages	and	suppressed	 the	proliferation	of	CD4+	T	cells	
(less	 immune	 response)	 more	 efficiently	 compared	 to	 the	 CD105+	 subpopulations	
(Anderson	 et	 al.,	 2013).	 If	 we	 consider	 ALPase	 activity	 as	 a	 measurement	 of	
differentiation,	our	 results	 suggest	 that	 through	 the	 long	 term	culture,	 there	was	no	
differentiation	and	it	could	be	thought	to	be	in	front	of	a	multipotent	CD105-	population.	
A	redefinition	of	the	MSCs	characteristic	phenotype	is	due	to	happen	and	this	CD105-	
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could	represent	an	interesting	source	of	cells	for	bone	tissue	engineering	and	adipose	
tissue	engineering,	particularly	for	hDPSCs	bioprocessing,	as	they	have	been	proven	to	
have	 troubles	with	 the	adipogenic	 lineage	differentiation	 (as	discussed	 in	chapter	4).	
However,	more	research	is	required	to	establish	the	capabilities	of	CD105-	MSCs.	In	the	
mean	time,	more	than	1	week	of	expansion	prior	to	the	differentiation	process	should	
not	be	recommended,	as	it	is	known	with	certainty	that	1	week	of	culture	can	produce	
hDPSCs	 with	 multipotent	 features	 ready	 for	 3D	 differentiation	 and	 with	 high	 cell	
viability.	
Morphological	assay	showed	increased	cell	aggregation	size	in	accordance	with	culture	
time	and	finally	well	developed	cells	within	alginate	beads.	
The	bioprofile	measurements	of	the	expansion	media,	demonstrated	cells	growing	and	
that	 the	 stress	 produced	by	nutrients	 exhaustion	 and	metabolites	 accumulation	was	
limited	 with	 perfusion	 of	 pre-oxygenated	 fresh	 media.	 With	 a	 positive	 influence	 in	
proliferation	of	hDPSCs.	
In	 the	 comparison	 study	 between	 the	 differentiation	 capability	 of	 perfusion-RWV	
bioreactor,	HARV	bioreactor	and	3D	static	culture	of	hDPSCs	within	alginate	beads,	the	
perfusion-RWV	bioreactor	 demonstrated	much	 higher	 cell	 proliferation	 and	 viability.	
The	differences	found	between	the	systems,	may	have	their	roots	in	the	mass	transfer	
characteristics	 of	 every	 system	 as	 well	 as	 the	 mechanical	 stimulation	 caused	 by	
hydrostatic	pressure	and	shear	stress.	 In	case	of	the	static	culture,	the	comparatively	
lower	cell	viability	might	be	produced	by	mass	transfer	 limitations.	 Including	external	
(culture	medium)	and	 internal	 (hydrogel)	mass	transfer	restriction	with	regard	to	the	
supply	of	oxygen	and	nutrients.	If	the	rate	of	nutrient	consumption	from	the	immediate	
vicinity	of	the	cell-construct	is	faster	than	the	replacement	rate	of	those	nutrients,	then	
a	nutrient	concentration	gradient	is	generated	on	the	scaffold's	surface	and	the	seeded	
cells	may	experience	malnutrition	or	decreased	concentrations	of	growth	factors	vital	
for	 their	 long-term	 growth	 and	 differentiation.	 In	 a	 static	 culture	 the	 only	 transport	
mechanism	 of	 nutrients	 is	 molecular	 diffusion,	 which	 cannot	 achieve	 the	 metabolic	
requirement	 of	 hDPSCs,	 while	 in	 both	 bioreactors,	 the	 low	 physiological	 fluid	 shear	
conditions	 enhance	 nutrient	 transport,	 thereby	 decreasing	 the	 existing	 nutrient	
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concentration	gradients	(Sikavitsas	et	al.,	2002,	Mueller	et	al.,	1999).	In	case	of	the	HARV	
bioreactor,	 significant	 differences	with	 static	 culture	were	 not	 found,	 the	 low	 shear	
condition	alone	did	not	produce	the	physiologically	relevant	microenvironment	for	cells	
to	grow,	hence	perfusion	could	deliver	key	mechanical	stimuli	for	the	cells	to	expand	
properly	and	differentiate	properly.	
Cell	growth	and	expression	of	the	osteoblastic	phenotype	in	2D	static	culture	has	three	
distinct	 phases:	 1)	 High	 proliferation	 and	 development	 of	 extracellular	 collagenous	
matrix	(10	to	12	days).	2)	Matrix	maturation,	down-regulation	of	proliferation	and	up-
regulation	 of	 ALPase	 activity	 (12th	 to	 18th	 day).	 3)	 High	 mineralisation	 and	 further	
decrease	of	proliferation,	declination	of	ALPase	activity	and	the	induction	of	osteocalcin	
expression	(16th	to	20th	day).	Similar	behaviour	can	be	seen	in	the	proliferation	of	cells	
in	the	three	platforms	being	assessed	with	a	time	delay,	this	could	be	associated	with	
the	3D	environment.	The	decreased	cellularity	observed	at	the	end	of	the	experiment	
on	the	hydrogels	cultured	in	the	three	bioprocesses,	is	in	accordance	with	the	apoptotic	
behaviour	observed	of	mature	osteoblasts	residing	in	mineralised	nodules	(Sikavitsas	et	
al.,	2002).	Although	the	live/dead	assay	showed	that	by	day	28,	the	scaffolds	were	fully	
populated	of	 living	 cells,	which	 suggests	 that	 the	down	expression	of	 the	MTS	assay	
could	be	result	of	the	mentioned	decrease	in	proliferation	and	enzymatic	activity.	
The	 morphological	 analyses	 by	 light	 microscopy	 showed	 how	 ECM	 formation	 and	
mineral	deposition	happen	through	the	culture.	At	the	beginning	of	the	culture,	beads	
where	transparent	and	cells	were	visible	with	light	microscopy.	However,	through	the	
culture,	for	the	three	bioprocesses,	it	was	seen	how	ECM	formation	and	mineralisation	
started	blocking	the	light	until	light	transmission	through	the	beads	was	not	possible.		
The	bone	neo-tissue	formed	by	cell	growth	within	alginate/	gelatin	hydrogels	consisted	
of	viable	and	metabolically	active	cells,	which	were	evaluated	by	measuring	pH,	glucose,	
glutamine,	lactate,	ammonia	and	oxygen	kinetics	in	osteogenic	medium	during	cultures.	
It	 has	 been	 reported	 that	 the	 profile	 of	 pH	 and	 these	 metabolites	 can	 be	 used	 to	
modulate	 cell	 metabolism,	 for	 instance	 ECM	 deposition	 and	 neo-tissue	 progress	 for	
developing	optimal	 culture	condition	 for	SCs	culture	 (Obradovic	et	al.,	1999).	Animal	
cells	utilize	glucose	and	glutamine	as	vital	energy	sources.	Through	glycolysis,	1	molecule	
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of	glucose	 is	metabolised	and	produces	2	molecules	of	 lactate	as	a	by-product	under	
anaerobic	 condition,	 yielding	 2	 mole	 of	 adenosine	 triphosphate	 (ATP)	 per	 mole	 of	
glucose,	or	C02	and	H20	through	the	TCA	cycle	in	aerobic	condition,	yielding	36	mole	of	
ATP	per	mole	of	glucose.	Through	the	TCA	cycle,	1	molecule	of	glutamine	is	lysed	into	
glutamate	and	produces	1	molecule	of	ammonia	as	by-product.	Hence,	the	amount	of	
ammonia	can	be	used	as	an	indicator	of	glutamine	utilization	and	TCA	cycle	activity.	In	
our	study	of	3D	osteogenesis.	Glucose	consumption	kinetics	showed	both	bioreactors	
had	 similar	 profiles,	 a	 slow	 but	 steady	 decrease	 through	 the	 culture,	 implying	 the	
adequate	 feeding	 strategy	 to	produce	metabolically	 active	 cells	 in	 sustained	 growth.	
However,	the	3D	static	culture	showed	a	rapid	decrease	in	glucose	concentration	of	the	
medium	to	below	measurable	level,	this	might	be	due	to	a	low	initial	concentration	of	
glucose	in	the	medium.	A	high-glucose	minimum	essential	medium	(mem),	could	replace	
the	usage	of	the	low-glucose	mem	utilised	in	the	formulation	of	the	osteogenic	medium.	
This	change	could	represent	a	more	adequate	substrate	for	this	bioprocessing.	However,	
measurements	should	be	taken	if	this	strategy	was	to	be	taken,	as	higher	glucose	would	
produce	more	lactate.	In	lactate	kinetics,	both	bioreactors	produced	below	measurable	
levels,	 this	 reflects	 the	 slow	but	 steady	 glucose	 consumption	 seen.	 3D	 static	 culture	
accumulated	 lactate	 fast,	 reaching	 a	maximum	of	 12	 [mmol/L],	 this	was	 the	 limiting	
concentration	achievable,	as	all	glucose	was	consumed.	A	high	glucose	medium	could	
help	 cell	 proliferation,	 but	 as	 well	 would	 increase	 the	 concentration	 of	 lactate.	 As	
concentrations	of	lactate	above	16	[mmol/L]	can	be	harmful	for	the	cells	(Ouyang	et	al.,	
2007),	lactate	kinetics	should	be	followed	carefully.	Glutamine	showed	a	similar	profile	
for	the	three	bioprocesses,	going	down	for	the	first	21	days	and	then	up	again,	ammonia	
had	a	behaviour	that	mirrors	glutamine	consumption.	We	believe	the	decrease	in	the	
consumption	of	glutamine	 reflects	 the	amount	of	 cells	 sampled	 rather	 than	 the	cells	
consumption.	Ammonia	did	not	 reach	 toxic	 levels	 through	 the	whole	 culture	 for	 the	
three	 bioprocesses,	 with	 values	 between	 1	 and	 2	 [mmol/L]	 (less	 than	 4	 [mmol/L]	
(Chaudhry	 et	 al.,	 2009)).	 Additionally,	 pH	 and	 oxygen	 concentration	 are	 other	
parameters	 to	 consider	 as	 these	 affect	 cell	 viability,	 growth,	 differentiation	 and	
metabolic	activity.	pH	in	osteogenic	medium	decreased	with	culture	time	and	followed	
the	 increase	 of	 lactate	 and	 ammonia	 concentration,	 as	 it	 is	 known	 that	 these	
metabolites	 affect	medium	 pH	 (Barngrover	 et	 al.,	 1985).	 pH	 change	 was	 within	 the	
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proper	pH	 range	 (7.0-7.4)	 of	 cell	 culture	media,	 implying	no	 strong	 influence	on	 cell	
growth	and	function.	Oxygen	has	a	major	role	in	SCs	growth	and	differentiation,	hypoxic	
conditions	 favouring	 undifferentiated	 expansion	 and	 normoxic	 conditions,	
differentiation.	For	the	three	bioprocesses,	oxygen	fluctuated	between	normoxic	values	
through	the	whole	culture.	
For	validation	of	the	3D	osteogenic	differentiation	achieved	by	the	three	bioprocesses,	
the	cell	constructs	during	differentiation	were	characterised	by	histological,	 immuno-
staining	and	SEM	microscopy.	Histological	H&E	staining	of	sectioned	hydrogels	at	day	0,	
showed	 most	 cells	 appear	 scattered	 in	 the	 bead	 without	 having	 form	 extracellular	
matrix.	 After,	 displayed	 well	 distributed	 tissue	 growth	 for	 both	 bioreactors	 and	
heterogeneity	 for	 the	 static	 culture.	 Morphogenesis	 of	 the	 osteogenic	 cells	 until	
achieving	maturation,	can	be	seen	in	both	the	perfusion	and	the	static	culture	by	the	
emergence	of	osteocyte	 lacunae.	This	 is	not	 so	clear	 in	 the	HARV	bioreactor	culture.		
However,	the	presence	of	vacant	lacunae	in	static	culture,	demonstrates	that	cells	are	
leaving	the	scaffold.	Prove	of	this,	is	seen	in	Figure	54,	where	approximately	confluent	
cells	growing	attached	to	the	flask	can	be	found.	A	probable	reason	for	the	cells	to	leave	
the	beads,	would	be	poor	diffusive	transport	of	oxygen	and	nutrients	from	the	media	to	
the	inner	area	of	the	hydrogels,	causing	an	impediment	for	growth	and	differentiation	
and	as	a	consequence,	forcing	cells	from	the	inner	area	of	the	scaffold	to	migrate	to	the	
surface,	and	further	to	the	flask	surface	(Sikavitsas	et	al.,	2002).	This	could	be	another	
probable	 reason	behind	 the	 low	MTS	and	ALPase	activity	achieved	at	 the	end	of	 the	
static	 culture.	 ARS	 staining	 indicated	 a	 progressive	 differentiation	 through	 time,	 a	
gradual	enhancement	in	mineral	deposition	for	the	cell	construct	produced	by	the	three	
bioprocesses	was	seen.	The	ARS	quantitative	analysis	is	consistent	with	the	qualitative	
results	and	both	bioreactors	show	better	performance	than	the	static	culture,	von	Kossa	
confirmed	 the	 mineralisation	 by	 showing	 disperse	 deposits	 of	 calcium	 through	 the	
hydrogels	for	the	three	bioprocesses.	Immunostaining	for	Osteocalcin	was	positive	for	
the	three	bioprocesses,	but	perfusion	culture	had	clearly	higher	expression.	The	surface	
of	the	cell	constructs	was	analysed	with	SEM	microscopy,	here	the	morphogenesis	of	
the	 hDPSCs	 can	 be	 perceived	 in	 different	 levels	 for	 the	 three	 bioprocesses,	 the	
perfusion-RWV	 bioreactor	 showed	 higher	 neo-tissue	 maturation,	 seen	 by	 the	 many	
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hydroxyapatite	crystals	 found,	 the	osteocyte	 lacunae	and	the	presence	of	osteocytes	
with	 developed	 canaliculi.	 Static	 culture	 showed	 more	 maturation	 than	 the	 HARV	
bioreactor.	However	most	of	the	quantitative	analysis	suggests	that	this	maturation	is	
only	 in	 the	 surface	 of	 the	 construct,	 whereas	 the	 HARV	 bioreactor	 produces	 more	
homogeneous	constructs.		
ATR-FTIR	of	human	bone	shows	carbonate	bands	at	wavenumbers	870,	1415	and	1470	
[cm-1],	and	phosphate	bands	at	wavenumber	565,	605	and	1035	[cm-1].	Carbonate	bands	
are	distinctive	of	the	bone	organic	component	(mainly	collagen)	and	phosphate	bands	
of	 the	 inorganic	 fraction	 (hydroxyapatite),	 and	 the	 ratio	 of	 organic	 and	 inorganic	
component,	 C/P	 is	 characteristic	 biogenic	 signature	 for	 human	 bone.	 However,	 it	 is	
recommended	 to	 use	 the	 phosphate	 peak	 of	 1035	 and	 carbonate	 peak	 of	 1415	 to	
calculate	C/P	ratio.	When	these	wavenumbers	are	used,	the	human	bone	C/P	ratio	is	
0.23	 	 (Beasley	 et	 al.,	 2014).	When	differentiation	 starts,	 the	C/P	 ratio	 is	 high,	 and	 it	
decreases	with	differentiation	and	hydroxyapatite	formation.	Static	culture	produced	a	
high	C/P	value,	showing	poor	differentiation.	Both	bioreactors	scored	very	well,	with	
HARV	culture	achieving	≈0.28	and	perfusion	culture	achieving	≈0.23,	 the	exact	value	
described	for	human	bone	in	literature.	ATR-FTIR	imaging	confirms	these	results,	with	
yellow	being	positive	and	blue	negative.	
X-ray	microanalysis	(SEM/EDS)	of	hydroxyapatite	shows	the	elemental	composition	of	
the	analysed	materials,	it	has	been	seen	that	the	Ca/P	ratio	represents	a	characteristic	
biogenic	 signature	 of	 the	 inorganic	 fraction	 of	 bone	 (hydroxyapatite).	 Pure	
hydroxyapatite	has	a	Ca/P	ratio	of	1.67	(Medina	Ledo	et	al.,	2008).	In	our	experiments	it	
can	be	seen	how	values	increase	with	time.	All	the	samples	start	in	a	virtually	null	value,	
after	 28	 days	 of	 culture,	 perfusion	 reaches	 1.23,	 static	 culture	 1.14	 and	 HARV	 0.77.	
Although,	 all	 bioprocesses	 produced	 calcium	 deficient	 hydroxyapatite	 (non-
stoichiometric),	the	increase	is	clear	and	more	research	should	be	done	until	the	proper	
ratio	is	reached.	
3D	 osteogenesis	 was	 characterised	 at	 a	 genetic	 level,	 examining	 the	 expression	 of	
Runx2/CBFA1,	 osteocalcin	 (BGLAP),	 alkaline	 phosphatase	 (ALPL),	 collagen	 type	 I	
(COL1A1)	and	sclerostin	(SOST),	these	genes	are	representative	of	the	entire	MSCs	to	
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osteocyte	ontogenesis.	Osteogenic	ontogenesis	requires	the	precise	and	orchestrated	
activity	 of	 several	 genes	 and	 signals	 (extracellular	 and	 intracellular).	 Runx2	 is	 a	
transcription	 factor	 and	 the	 central	 control	 of	 osteogenic	 differentiation.	 Its	
upregulation	 happens	 early	 in	 the	 ontogenesis,	 and	 is	 believed	 to	 have	 a	 constant	
expression	 through	 the	whole	differentiation	 (Shui	et	al.,	2003).	ALPL	 is	a	ubiquitous	
cellular	protein,	and	its	function	is	ill-defined.	However,	it	is	known	that	its	action	starts	
as	early	as	2	days	after	the	beginning	of	the	osteogenic	drive.	Its	expression	is	increased	
steadily	through	the	differentiation.	Collagen	I	(Col1a1),	is	an	important	component	in	
the	bone	ECM,	with	a	role	in	cell	adhesion,	proliferation	and	osteoblast	phenotype,	its	
upregulation	 is	 characteristic	 of	 osteogenic	differentiation	 and	 can	be	 considered	an	
early	marker	of	differentiation.	Osteocalcin	(BGLAP),	is	an	osteoblast	specific	gene	and	
one	of	the	most	abundant	proteins	in	bone,	its	expression	is	significantly	upregulated	in	
matrix	 synthesis	 and	mineralisation	 (Ryoo	et	 al.,	 1997).	 Sclerostin	 (SOST)	 is	 a	 known	
specific	gene	for	mature	osteocytes,	and	It	is	integral	to	osteocyte	function	as	a	signal	
to	 damp	 the	 action	 of	 osteoblast	 bone	 deposition	 and	 to	 control	 bone	metabolism	
(Compton	and	Lee,	2014).	
MSCs,	preosteoblasts	and	osteoblasts	express	Runx2	together	with	secreting	osteoid,	
when	osteoblasts	mature,	they	express	alkaline	phosphatase.	When	mature	osteoblasts	
become	embedded	in	osteoid,	they	express	osteocalcin	and	start	producing	dendritic	
projections	characteristic	of	osteocytes.	The	only	known	marker	unique	for	osteocytes	
is	 sclerostin	 (Compton	 and	 Lee,	 2014).	 Perfusion	 culture	 showed	 low	 and	 constant	
expression	of	RUNX2	along	with	high	and	almost	constant	expression	of	osteocalcin.	The	
expression	of	these	two	genes,	could	signify	most	of	the	cells	already	went	through	the	
transition	from	immature	to	mature	osteoblast.	The	high	 increase	of	SOST	in	the	 last	
week	 of	 culture	 could	 represent	 the	 further	 transition	 from	 mature	 osteoblasts	 to	
osteocytes.	During	all	this	period,	Col1a1	and	ALPL	were	active	and	positive.	These	genes	
are	 related	 with	 ECM	 formation	 and	 mineralisation,	 and	 are	 indicative	 of	 a	 well	
developed	in	vitro	osteogenesis.	These	results	suggest	that	a	homogeneous	population	
of	cells	was	produced	with	cells	in	the	last	stages	of	maturation.	HARV	culture	showed	
low	 enhancement	 in	 expression	 of	 RUNX2	 along	with	 high	 increase	 in	 expression	 of	
osteocalcin.	The	expression	of	these	two	genes,	could	signify	cells	are	going	through	the	
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transition	of	immature	cells	to	mature	osteoblast.	The	increase	of	SOST	in	the	last	week	
of	culture	could	represent	the	cells	transitioning	from	mature	osteoblasts	to	osteocytes.	
During	all	this	period,	Col1a1	and	ALPL	are	active	and	positive.	These	genes	are	related	
with	ECM	formation	and	mineralisation,	and	are	indicative	of	a	well	developed	in	vitro	
osteogenesis.	 These	 results	 suggest	 that	 a	 heterogeneous	 population	 of	 cells	 was	
produced	with	 cells	 undergoing	maturation	 to	 osteoblasts	 and	 osteocytes.	 3D	 static	
culture	showed	high	increase	in	expression	of	RUNX2	along	with	a	relatively	constant	
expression	of	osteocalcin.	The	expression	of	these	two	genes,	could	signify	the	presence	
of	significant	amount	of	immature	cells.	The	high	increase	of	SOST	in	the	last	week	of	
culture	could	represent	that	most	of	the	cells	that	matured	into	osteoblasts	have	further	
differentiated	 to	 osteocytes.	 During	 all	 this	 period,	 col1a1	 and	 ALPL	 are	 active	 and	
positive.	 These	 genes	 are	 related	 with	 ECM	 formation	 and	 mineralisation,	 and	 are	
indicative	of	a	well	developed	in	vitro	osteogenesis.	These	results	suggest	that,	a	highly	
heterogeneous	population	of	cells	was	produced	with	cells	in	the	early,	middle	and	final	
stages	of	maturation.	
Perfusion	 bioreactor	 showed	 a	 higher	 proliferation,	 calcification	 and	 a	 more	
homogeneous	 bone	 tissue,	 the	 HARV	 bioreactor	 showed	 a	 lower	 differentiation	 in	
comparison	 with	 the	 perfusion	 system	 and	 the	 static	 culture	 showed	 good	
differentiation	 in	 the	 surface	 of	 the	 constructs,	 but	 poor	 in	 the	 inner	 part	 of	 the	
hydrogels,	additionally,	cells	left	the	construct	to	start	growing	on	the	flask	surface.	
Low	proliferation	of	cells	in	HARV	culture	(compared	with	perfusion	culture)	could	have	
damped	 the	 differentiation,	 the	 morphogenetic	 analysis	 validates	 this	 idea,	 other	
authors	have	argued	this	could	happen	as	a	consequence	of	the	collision	of	the	beads	
with	the	wall	of	the	reactor	vessel,	traumatising	the	cells	in	the	surface	of	the	scaffold	
and	retarding	differentiation	(Sikavitsas	et	al.,	2002).	However,	this	is	not	our	case,	as	
cells	are	grown	in	a	free	fall	state.	Static	culture	produces	a	highly	heterogeneous	cell	
construct,	 with	 limited	 mineralisation	 compared	 with	 the	 other	 bioprocesses,	 it	 is	
believed	that	mass	transfer	impediments	produce	poor	nutrition	of	the	cells	and	finally	
hinders	the	quality	of	the	cell	construct.	
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The	enhanced	proliferation,	AP	activity,	OC	secretion,	and	calcium	deposition	observed	
in	the	perfusion	culture	indicates	a	positive	influence	of	the	continuous	feeding	strategy,	
and	 potential	 mitigation	 of	 external	 mass	 transport	 limitations	 on	 the	 growth	 and	
differentiation	of	MSCs	towards	the	osteoblastic	phenotype.	
5.6 Conclusions	
This	study	demonstrated	that	the	bioprocessing	providing	perfusion	flow	of	medium	in	
a	 suspended	 environment	 is	 successful	 in	 the	 mitigation	 of	 nutrient	 and	 oxygen	
transport	limitations,	external	to	three-dimensional	cell/alginate	constructs	and	is	more	
efficient	that	the	HARV	bioreactor	and	the	3D	static	culture,	positively	influencing	the	
proliferation,	differentiation,	mineralisation	and	expression	of	osteoblastic	markers	of	
hDPSCs	cultured	in	the	presence	of	osteogenic	media,	ultimately	enabling	the	formation	
of	 3D	 bone-like	 constructs	 for	 clinical	 purposes.	 Progressive	 differentiation	 was	
confirmed	 for	 the	 three	 different	 bioprocesses	 by	 the	 gene	 expression	 pattern,	 the	
increase	and	further	decrease	in	ALPase	activity,	the	gradual	decrease	of	the	C/P	ratio	
measured	by	ATR-FTIR,	the	increase	in	the	Ca/P	ratio,	measured	by	SEM/EDS	and	the	
ARS	positive	area,	measured	by	 software	analysis;	and	was	qualitatively	validated	by	
immunostaining,	H&E	and	von	Kossa	staining,	SEM	pictures	and	ATR-FTIR.	The	perfusion	
system	achieved	better	results	in	most	of	the	analysis,	producing	a	homogeneous	cell	
construct	with	regenerative	medicine	potential.	On	contrary,	static	culture	produced	a	
highly	heterogeneous	cell	construct	and	due	to	mass	transfer	limitations,	proportioning	
an	 unfavourable	 environment	 for	 cells	 to	 grow	 and	 differentiate.	 The	 HARV	
demonstrated	slower	proliferation	than	the	perfusion	culture,	which	may	have	delayed	
or	dampened	the	normal	differentiation	pattern	of	osteoblastic	cells.		
The	perfusion	culture	system	described	here	would	provide	an	efficient	and	easy	culture	
system	for	applications	in	bone	tissue	engineering	in	the	context	of	macroscopic	bone	
formation.	
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6 Enhancing	the	three-dimensional	perfusion	bioprocessing	for	osteogenic	
differentiation:	Bone	morphogenetic	protein-2	and		Simvastatin
	 155	
6.1 Introduction	
The	 scaled-up,	 ex	 vivo	 production	 of	 three-dimensional	 bone-like	 constructs,	 to	 be	
utilised	in	clinical	settings,	to	augment	bone	repair	and	regeneration	in	patients,	is	on	
demand.	The	tissue	engineering	(TE)	approach,	provides	the	toolset	to	tackle	with	the	
production	of	these	bone	mimics.	By	employing	autologous	bone-forming	cells,	three-
dimensional	 osteoconductive	 scaffold	 materials	 and	 bioreactor	 vessels,	 has	 been	
extensively	 working	 in	 producing	 the	 homogeneous,	 reproducible	 and	 functional	
artefact,	 required	 to	 fulfil	 this	 clinical	need	 (Gaspar	et	al.,	2012,	Godara	et	al.,	2008,	
Hidalgo-Bastida	et	al.,	2012,	Qiu	et	al.,	1999,	Zhang	et	al.,	2009,	Grayson	et	al.,	2011,	
Yeatts	 and	 Fisher,	 2011,	 Salter	 et	 al.,	 2012).	 Cells	 provide	 the	machinery	 to	produce	
bone-tissue,	 being	 able	 to	 produce	 ECM/	 osteoid	 and	 mineralise	 its	 surrounding.	
However,	 they	require	a	3D	environment	to	produce	the	adequate	histoarchitecture.	
Scaffold	provide	the	3D	environment	for	the	cells	to	attach,	spread	and	transform	into	
bone-tissue,	and	in	due	process	being	resorbed	and	replaced	by	ECM	and	calcifications	
for	further	produce	a	full	neo-tissue.	Nonetheless,	scaffolds	provide	an	impeded	mass	
transfer	 for	 cell	 nutrition.	Bioreactors	provide	 the	means	 to	deliver/	 fulfil	 nutritional	
requirements	 of	 the	 cells,	 by	 enhancing	 transport	 properties	 inside	 and	 outside	 the	
scaffold,	while	removing	the	cellular	waste.	A	variety	of	dynamic	3D	bioreactor	concepts	
mimicking	 the	 native	microenvironment	 in	 bone	 tissue,	 for	 example,	 spinner	 flasks,	
rotating	wall	vessel	constructs,	perfusion	bioreactors,	and	systems	based	on	mechanical	
or	electromagnetic	stimulation	of	cell/scaffold	composites,	have	been	developed	(Rauh	
et	 al.,	 2011).	 These	 novel	 setting,	 in	 different	 levels	 being	 successful	 in	 reproducing	
specific	aspects	of	the	in	vivo	milieu,	and	producing	mineralised	constructs,	with	positive	
expression	 of	 osteogenic	 genes	 and	 proteins,	 whilst	 partially	 mimicking	 bone	
microstructure.	Additionally,	bioreactors	allow	automation	and	make	up	for	limitations	
of	 the	 conventional	 cell	 handling	manual	 and	 static	 technique	 (Wendt	 et	 al.,	 2009).	
However,	 these	 setup	 alone	 produces	 heterogeneous	 constructs,	 with	 mixture	 of	
mature	 and	 immature	 cells	 and	 distinguishable	 different	 microscopic	 neo-tissue	
anatomy	(Gaspar	et	al.,	2012,	Godara	et	al.,	2008,	Hidalgo-Bastida	et	al.,	2012,	Qiu	et	
al.,	1999,	Zhang	et	al.,	2009,	Grayson	et	al.,	2011,	Yeatts	and	Fisher,	2011,	Salter	et	al.,	
2012,	Park	et	al.,	2008).	
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The	 engineering	 parameters	 occurring	 and	 controlled	 in	 bioreactors	 are	 equally	
important	 as	 the	 biological	 parameters	 associated	 with	 differentiation.	 Hence,	 the	
adequate	 cues/	 signalling	 for	 bone	 differentiation	 drive	 are	 required	 to	 be	 studied	
together	with	the	3D	bioprocessing.	The	bone	morphogenetic	proteins	(BMPs)	signalling	
pathway	 has	 widely	 been	 recognized	 as	 the	 main	 player	 in	 bone	 developmental	
processes,	and	exhibit	versatile	and	efficacious	 regulatory	 functions	 in	 the	body.	The	
disruption	of	them	has	been	connected	to	a	number	of	bone	diseases	(Chen	et	al.,	2012),	
They	 Induce	and	are	essential	 for	cartilage,	 tooth	and	bone	formation,	crystallization	
and	maturation.		
BMPs	have	major	relevance	in	the	differentiation	of	SCs	into	osteogenic	lineage,		causing	
the	induction	of	the		Runx2	gene	expression	in	early	stage	osteogenesis	(preosteoblasts)	
and	 subsequently	 the	 expression	 of	 	 Osterix	 (OSX)	 in	 late	 state	 osteogenesis	
(osteoblasts)		(Wozney,	2002,	Chen	et	al.,	2004,	Bei	and	Maas,	1998).	
The	BMPs	 family	 is	a	secreted	cytokine/	growth	 factor	subfamily	of	 the	transforming	
growth	factor-β	(TGF-β)	superfamily.	They	are	multifunctional	cytokines	regulators	of	
development,	 proliferation,	 differentiation,	 adhesion	 and	 apoptosis	 in	 different	 cell	
types	at	embryonic	and	adult	ages	(Kirkbride	et	al.,	2008,	Miyazono,	2000).		
BMP2	 has	 been	 approved	 by	 the	 US	 Food	 and	 Drug	 Administration	 (FDA)	 and	 the	
European	Medicines	Agency	(EMEA)	for	the	use	in	certain	types	of	bone	fracture,	making	
this	growth	 factor	 really	 important	 in	 the	regenerative	medicine	 field	 (Ghodadra	and	
Singh,	2008,	Starman	et	al.,	2012).	
BMP	signal	transduction	produces	a	cascade	of	genes	that	will	lead	to	osteogenesis.	It	
starts	inducing	Runt-related	transcription	factor	2	(Runx2,	CBFA1),	followed	by	collagen	
I	(Col1),	osteopontin	(OPN	or	Spp1),	osterix	(OSX)	in	the	preosteoblast	stage	(Komori,	
2010,	Matsubara	et	al.,	2008).	Further,	SP7	and	Wnt	signalling	direct	the	preosteoblast	
to	a	mature	stage	(Komori,	2010).	Mature	osteoblasts	keep	expressing	Col1	and	start	
expressing	osteocalcin	(Bglap),	Runx2	is	kept	constant.	
Committed	cells	express	different	bone	matrix	protein	genes,	depending	on	the	stage	of	
the	cell	development.	Immature	preosteoblasts	weakly	express	collagen	I	(Col1)	and	in	
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a	higher	level	osteopontin	(OPN	or	Spp1)	and	osterix	(OSX),	forming	unpacked	woven	
bone	(Komori,	2010,	Matsubara	et	al.,	2008).	Mature	osteoblasts	strongly	express	Col1	
and	 protein	 1/	 osteocalcin	 (Bglap),	 forming	 densely	 packed	 lamellar	 bone.	 When	
osteoblasts	become	osteocytes,	will	express	Dmp1,	sclerostin	and	podoplanin	(E11).		
Despite	the	fact	that	BMPs	have	been	widely	researched	and	recognised	as	key	factors	
for	osteogenic	differentiation.	The	supra-physiological	doses	used	 in	cell	 therapy,	are	
known	to	produce	ectopic	bone	formation,	increase	risk	of	cancer	and	evidence	suggests	
that	BMP2s	not	only	decide	cancer	cell	fate,	but	they	stimulate	angiogenesis	in	existing	
tumours.	Langenfeld	and	colleagues	demonstrated	in	vitro,	how	using	Noggin,	a	BMPs	
antagonist,	inhibited	proliferation	of	cancer	cells	(Carragee	et	al.,	2013b,	Langenfeld	and	
Langenfeld,	 2004).	 The	 harmful	 effect	 produced	 by	 BMPs	 may	 be	 dose	 dependant	
(DeVine	 et	 al.,	 2012).	 Hence,	 BMPs	 based	 cell	 therapeutics,	 are	 required	 to	 utilise	
minimal	dose	possible.	In	addition	to	the	side	effects,	the	use	and	costs	of	rhBMPs	are	
also	 to	 be	 considered.	 BMPs	 are	 delicate	 to	 handle,	 expensive	 to	 manufacture	 and	
supra-physiological	 doses	 are	 used,	 resulting	 in	 high	 costs.	 The	physiological	 level	 of	
BMP2	 in	humans	 is	of	≈300	[pg/ml]	 (Tosovsky	et	al.,	2014).	Nonetheless,	 in	standard	
conditions	of	culture	and	in	clinical	applications,	the	concentrations	utilised,	range	from	
50	 to	 1000	 times	 fold.	 The	 impact	 of	 pioneer	 bioprocesses	 in	 the	 efficacy	 of	 BMP2	
physiological	concentration,	reminds	to	be	assessed	and	is	a	key	factor	to	reduce	the	
risks	and	costs	of	applications	employing	BMPs.	
Alternatively,	osteogenic	differentiation	pharmacologic	enhancers	able	to	enhance	the	
action	of	the	naturally	occurring	cellular	BMPs,	could	circumvent	these	difficulties.	
A	 less	 direct	mechanism,	 is	 followed	 by	 statins.	 Statins	 are	 inhibitors	 of	 cholesterol	
synthesis.	 However,	 they	 have	 been	 demonstrated	 to	 have	 cholesterol-independent	
anabolic	effects	on	bone	metabolism	and	fracture	healing	(Pagkalos	et	al.,	2010b).	By	
interacting	 with	 both	 canonical	 and	 non	 canonical	 BMP	 pathways,	 they	 upregulate	
BMP2	expression,	along	with	the	cascade	of	genes	associated	with	BMP2	(Chen	et	al.,	
2010).	 Several	 inexpensive	 statins	 are	 available	 with	 different	 molecular	 and	
pharmacokinetic	 properties.	 Simvastatin,	 is	more	 lipophilic	 than	 pravastatin	 and	 has	
higher	affinity	to	phospholipid	membranes	than	atorvastatin,		
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allowing	its	passive	diffusion	through	the	cell	membrane	(Pagkalos	et	al.,	2010b).	Hence	
Simvastatin	represent	an	interesting	alternative	to	direct	BMP	stimuli	of	SCs.		
	
6.2 Objectives	
In	previous	chapters,	hDPSCs	were	shown	to	be	multipotent	highly	proliferative	stem	
cells	with	potential	for	bone	tissue	engineering	and	regenerative	medicine.	Further,	the	
establishment	of	the	efficient	and	reproducible	long-term	three-dimensional	bioprocess	
in	a	perfusion-RWV	bioreactor	for	directing	the	osteogenic	differentiation	of	hDPSCs	was	
developed.	The	expansion	and	osteogenic	differentiation	of	hDPSCs	seeded	in	alginate/	
gelatine	scaffolds	in	a	suspended	environment	and	with	media	perfusion	was	studied	
and	compared	with	commonly	used	bioprocesses,	demonstrating	a	better	performance.		
However,	the	cell	construct	produced	by	this	bioprocess	can	be	additionally	improved	
by	the	use	of	osteoinductive	supplements	as	bone	morphogenetic	proteins	(BMP).	BMPs	
are	expensive	and	are	required	in	high	concentrations	to	have	an	osteogenic	effect	in	
common	culture	systems,	in	the	order	of	100-1000	times	higher	than	physiological	level	
of	 human	 plasma	 (≈300	 [pg/ml])	 (Tosovsky	 et	 al.,	 2014).	 In	 this	 study,	 the	 effect	 of	
supplementing	 with	 BMP2	 at	 physiological	 level	 the	 designed	 bioprocessing,	 was	
assessed	and	compared	with	a	commonly	used	osteogenic	supplement,	Simvastatin.	
The	aims	of	this	chapter	are:	1)	to	pre-assess	the	effect	of	BMP2	at	a	physiological	level	
and	 compare	 with	 simvastatin	 as	 osteo-inducers	 in	 the	 perfusion	 three-dimensional	
bioprocess	previously	designed.	2)	to	establish	the	efficient	long-term	3D	bioprocess	in	
a	 perfusion-RWV	 bioreactor	 for	 directing	 the	 osteogenic	 differentiation	 of	 hDPSCs	
supplemented	with	minimal	concentrations	of	BMP2,	and	compare	it	with	the	effect	of	
simvastatin.	
The	pilot	study	of	 the	supplements	 in	growth	medium	allowed	to	determine	 if	 these	
supplements	 had	 osteogenic	 effect	 under	 3D	 conditions,	 then	 the	 two	 supplements	
were	used	in	long	term	culture	to	assess	the	differentiation	in	full	osteogenic	medium	
to	develop	an	enhanced	bioprocess	for	osteogenic	differentiation.	
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6.3 Experimental	Process	
Previously	 we	 demonstrated	 that	 hDPSCs	 long-term	 cultured	 in	 3D	 scaffolds	 in	 a	
suspended	 environment	 with	 perfusion	 flow	 of	 culture	medium	 could	 produce	 high	
quality	bone	constructs	for	therapeutic	purposes.	For	the	pilot	study	of	the	osteogenic	
supplements,	donor	samples	of	hDPSCs	were	expanded	undifferentiated	until	reaching	
the	desired	number	by	passage	4,	these	cells	were	encapsulated	in	an	alginate/	gelatin	
scaffold	with	a	density	of	40,000	cells/bead.	250	beads	were	seeded	and	cultured	in	the	
perfusion-RWV	bioreactor	with	growth	medium	supplemented	with	either	300	[pg/ml]	
of	BMP2	(experimental	group	BMP2-1),	or	10	uM	of	simvastatin	(experimental	group	
SIMV-1)	for	14	days.	Perfusion	was	set	as	1	vessel	volume	per	day	(55	ml/day	medium).	
Osteogenic	differentiation	was	assessed	using	various	techniques	such	as,	proliferation	
measurement	by	Calcein	AM/	ethidium	homodimer,	measurement	of	ATP	content	and	
MTS	assay,	characterisation	of	mineralised	bone	nodules	by	alizarin	red	and	von	Kossa,	
H&E,	alkaline	phosphatase	expression,	immunocytochemical	characterisation,	scanning	
electron	microscopy	with	X-ray	microanalysis,	ATR-FTIR.	The	detailed	explanation	of	this	
techniques	can	be	found	in	Chapter	3:	Materials	and	methods.		
For	 the	 differentiation	 in	 full	 media,	 donor	 samples	 of	 hDPSCs	 were	 expanded	
undifferentiated	 until	 reaching	 the	 desired	 number	 by	 passage	 4,	 these	 cells	 were	
encapsulated	 in	an	alginate/	gelatin	scaffold	with	a	density	of	20,000	cells/bead.	250	
beads	were	seeded	and	expanded	in	175	T-flasks	with	expansion	medium	for	7	days,	
allowing	cells	to	acclimatise	to	the	new	three	dimensional	environment.	Following	the	
process,	 beads	 were	 transferred	 to	 perfusion-RWV	 bioreactor	 and	 for	 21	 days	
osteogenic	medium	containing	dexamethasone,	β-GP,	ascorbic	acid	and	KH2PO4,	and	
either	 300	 [pg/ml]	 of	 BMP2	 (experimental	 grop	 BMP2-2),	 or	 10	 uM	 of	 simvastatin	
(experimental	group	SIMV-2)	was	used	to	drive	undifferentiated	hDPSCs	to	osteogenic	
lineage.	Medium	perfusion	was	set	to	1	vessel	volume	per	day	(55	ml).	Thus	osteogenic	
differentiation	 was	 assessed	 using	 various	 techniques	 such	 as,	 proliferation	
measurement	by	Calcein	AM/	ethidium	homodimer,	measurement	of	ATP	content	and	
MTS	assay,	characterisation	of	mineralised	bone	nodules	by	alizarin	red	and	von	Kossa,	
H&E,	alkaline	phosphatase	expression,	immunocytochemical	characterisation,	RT-PCR,	
scanning	electron	microscopy	with	X-ray	microanalysis,	ATR-FTIR	and	ATR-FTIR	imaging.	
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The	 detailed	 explanation	 of	 this	 techniques	 can	 be	 found	 in	 Chapter	 III.	 The	 overall	
experimental	process	is	illustrated	in	Figure	39.	
	
Figure	68	Experimental	process	for	the	enhancement	of	perfusion	bioprocess	for	3D	
osteogenic	differentiation.	
6.4 Results	
6.4.1 Pilot	study	of	osteogenic	supplements.	
For	 the	 pilot	 study	 of	 the	 supplements,	 no	 acclimatising	 of	 the	 cells	 to	 the	 3D	
environment	was	performed	and	the	cells	started	the	differentiation	straight	after	being	
encapsulated.	Two	groups	were	studied,	BMP2-1	in	which	cells	were	grown	in	expansion	
medium	supplemented	with	300	pg/ml	of	BMP2	for	14	days	and	SIMV-1,	in	which	cells	
were	grown	in	expansion	media	supplemented	with	10	uM	of	simvastatin	for	14	days.	
The	 osteogenic	 capability	 of	 the	 supplements	 was	 established	 by	 measuring	
proliferation,	 mineralisation	 through	 different	 techniques,	 and	 qualitatively	 by	 SEM	
microscopy,	histology	and	immunostaining.	
The	growth	kinetic	were	measured	by	the	ATP	content	and	MTS	activity	of	beads.	The	
ATP	content	 for	BMP2-1	 increased	1.079	times	 fold	by	day	14	and	 for	SIMV-1,	1.175	
times,	MTS	followed	a	similar	pattern	increasing	for	BMP-2	1.47	times	fold	by	day	14,	
B)
A)
seeding passaging collectingencapsulating differentiationSupplements and factors for 
osteogenic
differentiation
encapsulation
300 [pg/ml] BMP2
10 uM Simvastatin
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and	for	SIMV-1	2.18	times.	Charts	that	show	these	results	can	be	seen	in	Figure	69A	and	
can	be	seen	in	Figure	69B	for	ATP	content	and	MTS	activity	respectively.	
Alkaline	phosphatase	activity	(ALPase)	can	be	seen	in	Figure	69C,	was	positive	for	both	
samples,	with	SIMV-1	showing	a	higher	expression.	However,	 the	difference	was	not	
significantly	different.		
	
	
Figure	69	Measurement	of	proliferation	and	Alkaline	Phosphatase	activity	of	hDPSCs	
in	 growth	 media	 supplemented	 with	 BMP2	 or	 simvastatin	 measured	 by	 CCK-8,	
Celltitter-Glo	3D	and	ALPase	colorimetric	assay	respectively:	A)	Celltiter-Glo	3D	 ,	B)	
CCK-8	and	C)	ALPase	activity	(n=3).	*	indicates	statistical	significance	when	comparing	
between	day	0	and	14	for	proliferation	and	between	treatments	for	ALPase	activity.	
Cells	were	shown	to	be	alive,	healthy	and	well	distributed	by	the	end	of	the	14	days	of	
culture	by	Live/	dead	assay,	staining	live	cells	with	Calcein	AM	(green)	and	dead	cells	
with	ethidium	homodimer	(red).	Live/	dead	assay	shows	that	cells	are	very	alive,	well	
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distributed	and	healthy,	it	is	hard	to	find	dead	cells	in	the	samples,	these	results	can	be	
seen	in	Figure	70.	
	
Figure	70	Live	dead	assay	A)	BMP2-1	at	day	14	of	differentiation,	B)	SIMV-1	at	day	14	
of	differentiation.	Scale	bar=	200	µm.	
6.4.1.1 Histological	analysis,	immunostaining	and	SEM	microscopy	of	hDPSCs	3D	osteogenic	
differentiation,	pilot	study.	
We	addressed	whether	the	hDPSCs	were	capable	of	forming	mineralised	bone	nodule	
in	3D	culture	systems	using	alginate	beads	and	growth	media	supplemented	with	BMP2	
at	physiological	 level	or	 simvastatin.	 In	order	 to	 confirm	whether	 these	 tissues	were	
mineralised	 bone	 tissue,	 histological	 analysis	 and	 immunostaining	 was	 done	 to	
characterize	the	morphology	and	calcium	deposits	in	tissues.		
The	resulting	hydrogels	 from	from	groups	BMP2-1	and	SIMV-1	were	cut	 in	slices	and	
histologically	examined	by	hematoxylin	and	eosin	staining	(H&E).	As	shown	in	Figure	71,	
samples	 displayed	 a	 heterogeneous	 morphology.	 However,	 the	 two	 groups	 of	
osteogenic	constructs	showed	bone	neo-tissue	formation	over	the	time	period.	At	day	
1,	most	 cells	 appear	 scattered	 and	 spread	 homogenously	 through	 the	 beads	 (Figure	
71H).	 After	 14	 days	 of	 culture	 in	 supplemented	 medium,	 It	 can	 be	 seen	 that	 cells	
expanded	and	populated	the	whole	hydrogels	and	differentiation	started		(Figure	71).	
Size	and	shape	of	cells,	together	with	their	surroundings	changed,	ECM	was	formed	and	
approximately-round	lacunae	started	showing	around	single	cells,	which	is	signal	of	cells	
differentiation	into	osteogenic	lineage.	SIMV-1	showed	less	differentiation	than	BMP2-
1.	By	day	14	of	culture,	less	lacunae	formation	was	observed	and	mstly	in	the	surface	
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area,	suggesting	a	 lower	degree	of	maturation	of	 the	cells.	 Interestingly,	 the	BMP2-1	
group	showed	the	appearance	of	lacunae	in	the	inner	area	of	the	beads,	meanwhile	the	
perfusion	 group	 with	 osteogenic	 media	 from	 the	 previous	 chapter	 by	 day	 14	 of	
differentiation	had	 lacunae	allocated	 from	 the	middle	 to	 the	periphery	of	 the	beads	
(Figure	71G).		
Calcified	deposition	started	spreading	in	beads	produced	by	both	experimental	groups	
and	was	shown	by	alizarin	 red	s	staining	 (ARS)	and	by	a	soft	von	Kossa	staining.	ARS	
results	displayed	an	increase	of	the	nodules	in	time.	Both	treatments	displayed	similar	
deposition.	Negative	controls	are	undifferentiated	hDPSCs	grown	in	alginate	beads	and	
a	known	to	be	negative	 tissue.	Figure	72	shows	ARS	 results	 for	both	 treatments	and	
Figure	73,	shows	von	Kossa	results	for	both	treatments.		
Von	kossa	staining	was	done	for	day	14	of	differentiation	and	albeit	the	results	do	not	
show	mass	deposition	(black	colour),	the	beads	produced	by	both	treatment,	especially	
BMP2-1,	produced	dispersed	depositions	of	calcium	(grey	colour),	compared	with	the	
negative	sample	that	produced	a	pink	stain	without	grey	of	black.	
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Figure	71	H&E	images	displaying	the	morphology	of	alginate	beads:	A,	B	and	C)	are	
pictures	of	group	BMP2-1	at	day	14	of	culture.	D,	E	and	F)	are	pictures	of	group	SIMV-
1	 at	 day	 14	 of	 culture,	 G)	 cells	 grown	 in	 osteogenic	 media	 by	 day	 14	 and	 H)	
undifferentiated	day	3	cells.	Scale	bar=200	µm.	
	
Figure	72	ARS	staining	images	showing	the	mineral	deposition	on	alginate	beads:	A,	B	
and	C)	are	pictures	of	group	BMP2-1	at	day	14	of	culture.	D,	E	and	F)	are	pictures	of	
group	SIMV-1	at	day	14	of	culture,	G)	cells	grown	in	osteogenic	media	by	day	14,	H)	
undifferentiated	day	1	cells	and	I)	control.	Scale	bar=200	µm.	
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Figure	73	Von	Kossa	staining	images	calcium	deposition	on	alginate	beads:	A,	B	and	C)	
are	pictures	of	group	BMP2-1	at	day	14	of	culture.	D,	E	and	F)	are	pictures	of	group	
SIMV-1	 at	 day	 14	 of	 culture,	 G)	 cells	 grown	 in	 osteogenic	 media	 by	 day	 28,	 H)	
undifferentiated	day	1	cells	and	I)	control.	Scale	bar=200	µm.	
For	further	confirmation	of	osteogenic	neo-tissue	formation,	the	hydrogels	were	stained	
with	anti-osteocalcin,	anti-osteopontin,	anti-sclerostin	and	anti-podoplanin	antibodies	
(Figure	 74	 and	 Figure	 75).	 The	 two	 experimental	 groups	 by	 day	 14	 of	 culture	 under	
differentiation	 medium,	 produced	 tissue	 positive	 for	 osteopontin,	 osteocalcin,	
podoplanin	 and	 sclerostin,	 with	 the	 BMP2-1	 group	 showing	 higher	 intensity	 for	
osteocalcin	 and	 podoplanin,	 but	 showing	 weak	 expression	 of	 osteopontin.	 SIMV-1	
showed	a	comparatively	weaker	expression	of	osteocalcin	and	podoplanin,	but	showing	
higher	osteopontin.	The	intensity	of	sclerostin	expression	was	similar	in	both	groups.	
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Figure	 74	 Fluorochrome	 labelling	 of	 bone	 constructs	 for	 Osteocalcin	 (green)	 and	
Osteopontin	(red):	A,	B	and	C)	are	pictures	of	group	BMP2-1	at	day	14	of	culture.	D,	E	
and	F)	are	pictures	of	group	SIMV-1	at	day	14	of	culture.	Scale	bar=200	µm.	
	
Figure	 75	 Fluorochrome	 labelling	 of	 bone	 constructs	 for	 Sclerostin	 (green)	 and	
Podoplanin	(red):	A	and	B)	are	pictures	of	group	BMP2-1	at	day	14	of	culture.	C	and	D)	
are	pictures	of	group	SIMV-1	at	day	14	of	culture.	Scale	bar=200	µm.	
When	observed	by	SEM,	many	mineralised	deposit	were	detected	within	the	alginate	
hydrogels	 of	 both	 experimental	 groups	 after	 osteogenic	 culture.	 Additionally,	 the	
lacunae	seen	in	the	histology	are	seen	in	these	pictures,	along	with	the	morphogenesis	
of	 the	 osteoblastic	 cells.	 Pictures	 showed	 the	 presence	 of	 non-stoichiometric	
mineralised	 deposits.	 By	 day	 14	 the	 lacunae	 were	 distributed	 in	 some	 areas	 of	 the	
scaffolds	 and	 in	 the	 pictures	 of	 both	 groups,	 osteocytes	 can	 be	 morphologically	
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recognised.	The	morphology	of	 the	bone	constructs	produced	by	group	BMP2-1	and	
SIMV-1	by	day	14	can	be	seen	in	Figure	76,	where	the	maturation	of	the	tissue	can	be	
seen.	The	morphology	of	the	bone	constructs	produced	by	both	experimental	groups	
appears	immature.	In	some	pictures,	it	can	be	seen	that	cells	in	the	surface	of	the	beads	
resemble	osteocytes	and	their	surroundings	osteocytes	lacuna.	
	
Figure	76	SEM	pictures	of	cultured	scaffolds	in	differentiation	medium	after	28	days	
showing	characteristic	bone	features	for	experimental	groups:	A),	B)	and	C)	BMP2-1,	
D),	E)	and	F)	SIMV-1	by	day	14	of	culture.	
6.4.2 Enhancing	the	three-dimensional	perfusion	bioprocessing	for	osteogenic	
differentiation:	Bone	morphogenetic	protein	2	and	Simvastatin	
For	the	enhancement	of	the	previously	established	perfusion	bioprocess,	expansion	and	
acclimatising	 of	 the	 cells	 to	 the	 3D	 environment	was	 performed	 for	 7	 days	 in	 static	
culture	 placed	 in	 a	 shaker.	 By	 day	 7,	 hydrogels	 were	 placed	 in	 the	 perfusion-RWV	
bioreactor.	Following	the	pilot	study,	two	new	experimental	groups	were	established	
and	studied,	BMP2-2	in	which	osteogenic	differentiation	of	hDPSCs	was	performed	by	
exposure	 to	osteogenic	medium	 (Dex,	ASAP,	β-GP)	 supplemented	with	300	pg/ml	of	
BMP2	for	21	more	days	and	SIMV-2,	in	which	osteogenic	differentiation	of	hDPSCs	was	
performed	by	exposure	to	osteogenic	medium	(Dex,	ASAP,	β-GP)	supplemented	with	10	
uM	of	 simvastatin	 for	 21	more	days.	 The	osteogenic	 capability	 of	 the	 supplemented	
osteogenic	 media	 was	 established	 by	 measuring	 proliferation,	 gene	 expression,	
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mineralisation	 through	 different	 techniques,	 and	 qualitatively	 by	 SEM	 microscopy,	
histology	and	immunostaining.	
Every	hydrogels	containing	osteogenic	cells	after	28	days	of	culture	showing	changing	
colour	 from	 clear	 transparent	 becoming	 white,	 bone	 looking	 and	 appeared	 to	 be	
physically	brittle	in	contrast	to	the	initial	alginate	gel	properties.	As	presented	in	Figure	
77.		
	
Figure	77	Images	of	hydrogels	after	28	days	of	perfused	culture,	A)	group	BMP2-2,	B)	
group	SIMV-2.		
During	 the	 differentiation	 process,	 the	 morphology	 changes	 of	 the	 hydrogels	 were	
followed	by	light	microscopy.	By	day	7	(expansion	and	acclimatising	period),	cells	were	
likely	 to	 show	 single	 cell	 suspension	 well	 distributed	 through	 the	 hydrogel.	 The	
hydrogels	did	not	show	signal	of	mineralisation.	By	day	21	(day	14	of	differentiation),	
mineralisation	started	conquering	the	hydrogels,	and	light	almost	could	not	travel	across	
the	 hydrogels.	 By	 day	 28	 pictures	 show	 black	 spheres,	 as	 light	 did	 not	 cross	 the	
hydrogels.	From	the	two	experimental	groups,	mineralisation	appears	to	be	higher	 in	
the	BMP2-2	group.	Morphology	of	the	beads	can	be	seen	in	Figure	78.	
The	 growth	 kinetics	 of	 hDPSCs	 seeded	 in	 beads	 (n=6)	 for	 both	 experimental	 groups	
followed	a	simoid	growth	profile	with	the	appearance	of	distinct	lag,	exponential	and	
stationary	phases.	They	showed	that	by	day	28,	the	experimental	group	SIMV-2	yielded	
higher	 cell	numbers	 than	group	BMP2-2,	with	an	 increase	of	≈	 6.3	 times	 fold	 in	ATP	
content,	compared	with	5.6	times	achieved	by	the	experimental	group	BMP2-2.	MTS	
assay	followed	a	similar	trend,	with	SIMV-2	having	2.92	times	fold	increase	and	BMP2-
2,	a	2.61increase.	Albeit	the	difference	between	the	results	for	the	two	groups	was	not	
significant	 for	 the	 ATP	 content,	 it	 was	 for	 the	MTS	 asay.	 By	 day	 21	 of	 culture,	 cells	
reached	a	plateau	in	both	groups	and	expansion	was	decelerated.	Cells	were	shown	to	
A)	 B)	
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be	alive	and	healthy	by	the	end	of	the	culture	by	Live/	dead	assay,	staining	live	cells	with	
Calcein	AM	(green)	and	dead	cells	with	ethidium	homodimer	(red).	These	results	can	be	
seen	in	Figure	79	and	Figure	80.	Both	proliferation	assays	used	have	limitations	as	the	
3D	environment	deviates	from	the	real	cell	number.	The	relationship	between	seeded	
cell	number	and	luminescent/	absorbance	output	after	several	days	in	culture	is	often	
curved	due	to	the	effects	of	contact	inhibition	on	cell	proliferation,	as	well	as	reduced	
metabolic	activity	and/	or	necrosis	in	the	centre	of	scaffolds.	The	non-linearity	provides	
a	semi-quantitative/	qualitative	approximation	to	cell	number	rather	than	a	quantitative	
measurement.	
	
Figure	78	Morphology	of	hydrogels	observed	under	light	microscopy	of	A)	Day	7,	B)	
day	28	BMP2-2	and	C)	day	28	SIMV-2	group.	Scale	bar=100	µm.	
	
Figure	79	Measurement	of	proliferation	for	the	enhanced	osteogenic	differentiation	
of	 hDPSCs,	where	A)	 CelltiterGlo	 3D	 and	B)	 CCK-8	 assay	 results	 scored	 by	 the	 two	
experimental	groups	(n=6).	*	indicates	statistical	significance	between	groups	for	each	
time-point.	
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Figure	80	Live	dead	assay	A)	day	28	group	BMP2-2	and	B)	day	28	group	SIMV-2.	Scale	
bar=200	µm.	
In	order	to	evaluate	indirectly	the	proliferative	capability	of	hDPSCs	in	the	enhanced	3D	
bioprocess,	 the	 metabolic	 activity	 of	 experimental	 groups	 BMP2-2	 and	 SIMV-2	 was	
evaluated	by	measuring	for	28	days	the	time-course	concentration	of	key	substrates	and	
metabolites	in	culture	medium.	Consumption	of	glutamine	and	glucose,	production	of	
ammonia	and	lactate,	concentration	of	oxygen	and	detection	of	pH	were	acquired	every	
7	days	with	a	bio-profiler.	For	both	experimental	groups,	medium	perfusion	was	set	to	
the	equivalent	of	1	vessel	volume	a	day	(55	ml	of	medium)	and	samples	were	taken	from	
the	waste	medium	line,	hence	not	disrupting	the	culture.		
The	glycolysis	is	a	key	metabolic	pathway	to	produce	energy	for	proliferative	cells	and	
as	glucose	is	digested	to	produce	ATP,	it	releases	2	molecules	of	Lactate.	20	[mmol/l]	of	
lactate	are	limiting	for	the	culture,	above	this	level,	lactate	has	a	harmful	effect.	In	the	
experimental	 group	 BMP2-2,	 glucose	 was	 consumed	 from	 ≈6.7	 [mmol/L]	 to	 ≈1.6	
[mmol/L]	and	approximately	twice	the	number	of	molecules	of	lactate	was	produced.	
Lactate	 accumulation	 was	 low	 through	 the	 experiment,	 only	 achieving	 readable	
measurements	by	 last	week	of	culture,	reaching	≈10.1	[mmol/L].	Glucose	and	lactate	
kinetics	for	experimental	group	BMP2-2	can	be	seen	in		Figure	81A.	In	the	experimental	
group	 SIMV-2,	 glucose	 was	 consumed	 from	 ≈6.7	 [mmol/L]	 to	 ≈1.7	 [mmol/L]	 and	
approximately	 twice	 the	 number	 of	 molecules	 of	 lactate	 was	 produced.	 Lactate	
accumulation	was	low	through	the	experiment,	only	achieving	readable	measurements	
by	 last	 week	 of	 culture,	 reaching	 ≈10	 [mmol/L].	 Glucose	 and	 lactate	 kinetics	 for	
experimental	group	SIMV-2	can	be	seen	in	Figure	81A.		
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The	glutaminolysis	is	a	key	metabolic	pathway	to	produce	energy	for	proliferative	cells	
and	 as	 glutamine	 is	 lysed	 into	 glutamate	 to	 produce	 ATP,	 it	 releases	 1	molecule	 of	
ammonia,	 if	ammonia	concentration	reaches	4[mmol/L],	 it	can	have	a	toxic	effect	for	
the	cells.	For	BMP2-2	group,	glutamine	fluctuated	from	≈4	[mmol/L]	and		≈1	[mmol/L]	
and	ammonia	followed	a	similar	trend,	fluctuating	between		≈0.9	[mmol/L]	and		≈1.7	
[mmol/L].	Glutamine	and	ammonia	kinetics	for	the	BMP2-2	group	can	be	seen	in	Figure	
81B.	For	SIMV-2	group,	glutamine	fluctuated	from	≈4	[mmol/L]	and		≈0.89	[mmol/L]	and	
ammonia	 followed	 a	 similar	 trend,	 fluctuating	 between	 	 ≈0.9	 [mmol/L]	 and	 	 ≈1.68	
[mmol/L].	Glutamine	and	ammonia	kinetics	for	group	SIMV-2	can	be	seen	in	Figure	82B.		
For	BMP2-2,	the	oxygen	tension	in	the	medium	slowly	decreased,	fluctuating	between	
≈160	[mmHg]	and	≈107	[mmHg].	The	oxygen	kinetics	for	BMP2-2	can	be	seen	in	Figure	
81C.	 For	 SIMV-2,	 the	 oxygen	 tension	 in	 the	 medium	 slowly	 decreased,	 fluctuating	
between	≈160	[mmHg]	and	≈106	[mmHg].	The	oxygen	kinetics	for	SIMV-2	group	can	be	
seen	in	Figure	82C.		
The	pH	in	experimental	group	BMP2-2,	gradually	decreased	from	≈7.6	to	≈7.1	as	culture	
time	passed.	The	pH	kinetics	for	BMP2-2	group	can	be	seen	in	Figure	81D.	The	pH	in	
experimental	group	SIMV-2,	gradually	decreased	from	≈7.6	to	≈7	as	culture	time	passed.	
The	pH	kinetics	for	the	HARV	bioreactor	can	be	seen	in	Figure	82D.		
As	seen	in	Figure	81and	Figure	82,	both	groups	followed	a	very	similar	bioprofile.	
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Figure	 81	 Change	 with	 culture	 time	 of	 key	 substrates	 and	 metabolites	 in	 culture	
medium	 for	 the	 experimental	 group	 BMP2-2.	 A)	 Consumption	 of	 glucose	 and	
production	of	lactate.	B)	Consumption	of	glutamine	and	production	of	ammonia.	C)	
pH	and	D)	oxygen.	
	
Figure	 82	 Change	 with	 culture	 time	 of	 key	 substrates	 and	 metabolites	 in	 culture	
medium	 for	 the	 experimental	 group	 SIMV-2.	 A)	 Consumption	 of	 glucose	 and	
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production	of	lactate.	B)	Consumption	of	glutamine	and	production	of	ammonia.	C)	
pH.	And	D)	oxygen.	
6.4.2.1 Histological	analysis	and	immunostaining	of	hDPSCs	3D	osteogenic	bioprocesses	
We	addressed	whether	the	hDPSCs	were	capable	of	forming	mineralised	bone	nodule	
in	3D	culture	systems	using	alginate	beads	and	supplemented	differentiation	medium.	
In	order	 to	 confirm	whether	 these	 tissues	were	mineralised	bone	 tissue,	 histological	
analysis	 and	 immunostaining	was	 done	 to	 characterize	 the	morphology	 and	 calcium	
deposits	in	tissues.		
The	 resulting	 hydrogels	 from	 two	 experimental	 groups	 were	 cut	 in	 slices	 and	
histologically	examined	by	hematoxylin	and	eosin	staining	(H&E).	As	shown	in	Figure	83,	
samples	from	both	experimental	groups	displayed	a	more	homogeneous	morphology	
compared	 to	 the	 un-supplemented	 samples	 (Figure	 83F),	 however,	 the	 morphology	
looks	 less	mature.	 Both	 groups	 showed	 gradual	 bone	 neo-tissue	 formation	 over	 the	
time-period.	As	time	passed	by,	size	and	shape	of	cells,	together	with	their	surroundings	
changed,	ECM	was	formed	and	approximately-round	lacunae	started	showing	around	
single	cells,	which	is	signal	of	cells	differentiation	into	osteogenic	lineage.	These	lacunae,	
when	cells	matured,	became	more	elongated	(osteocyte	lacunae).	
Our	previous	experiments	demonstrated	that	un-supplemented	samples	differentiated	
from	the	surface	to	 the	 inner	area	of	 the	beads.	However,	both	SIMV-2	and	BMP2-2	
showed	 lacunae	 starting	 to	 form	 from	 the	 core	 area	 to	 the	 surface,	 suggesting	 that	
differentiation	 started	 earlier	 in	 the	 centre	 of	 the	 beads.	 BMP2-2	 resulted	 in	
homogeneous	 beads,	 totally	 populated	 by	 cells	 and	 their	 lacunae.	 By	 day	 21,	 fair	
formation	of	round-shaped	lacunae	was	seen,	and	increased	by	day	28	(see	Figure	83).	
This	 suggests	 cell	 maturation.	 SIMV-2	 group	 showed	 less	 differentiation	 than	 group	
BMP2-2.	By	day	21	less	lacunae	formation	was	observed,	suggesting	inferior	maturation	
of	 the	 cells.	 Additionally,	 hydrogels	 appear	 fully	 and	homogeneously	 populated	with	
cells.	Group	BMP2-2	showed	the	production	of	mature	morphology,	however,	most	of	
the	lacunae	is	circle-shaped	and	elongated	lacunae	was	scarce.	
Calcified	 deposition	 was	 widely	 spread	 in	 the	 osteogenic	 beads	 and	 was	 shown	 by	
alizarin	red	S	staining	(ARS)	and	von	Kossa	staining.	ARS	results	displayed	an	increase	of	
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the	nodules	in	time.	Through	time	nodules	were	growing	in	size	and	number	for	both	
experimental	groups.	Negative	controls	are	undifferentiated	hDPSCs	grown	in	alginate	
beads	and	a	known	to	be	negative	tissue.	Further	in	this	chapter,	quantitative	analysis	
of	ARS	can	be	found.	Figure	84	shows	the	results	for	both	experimental	groups	for	day	
14,	21	and	28	of	culture.	
Von	 kossa	 staining	 was	 done	 for	 day	 28	 and	 albeit	 the	 results	 do	 not	 show	 mass	
deposition	 (black	 colour),	 the	 beads	 produced	 by	 the	 two	 groups,	 produced	 visible	
dispersed	depositions	of	calcium	(grey	colour),	compared	with	the	negative	sample	that	
produced	a	pink	stain	without	grey	of	black.	These	results	can	be	seen	in	Figure	85.	
	
Figure	83	H&E	images	display	the	morphology	of	alginate	beads:	pictures	A)	and	B)	
experimental	group	BMP2-2	at	day	28,	C)	and	D)	experimental	group	SIMV-2	at	day	
28,	E)	day	28	differentiation	in	regular	osteogenic	medium,	F)	undifferentiated.	Scale	
bar=200	µm.	
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Figure	84	Alizarin	red	staining	of	beads	,	A)	day	14	BMP2-2,	B)	day	28	BMP2-2,	C)	day	
14	SIMV-2,	D)	day	28	SIMV-2,	E)	undifferentiated	hDPSCs	and	F)	negative	control.	Scale	
bar=200	µm.	
	
Figure	85	Von	Kossa	staining	of	beads	by	day	28.	A),	B)	and	C)	BMP2-2	group,	D),	E)	
and	 F)	 SIMV-2,	 G)	 day	 28	 osteogenic	 differentiation	 without	 supplements,	 H)	
undifferentiated	hDPSCs	and	I)	negative	control.	Scale	bar=200	µm.	
For	further	confirmation	of	osteogenic	neo-tissue	formation,	the	hydrogels	were	stained	
with	anti-osteocalcin,	anti-osteopontin,	anti-sclerostin	and	anti-podoplanin	antibodies	
(Figure	 86	 and	 Figure	 87).	 The	 two	 experimental	 groups	 by	 day	 28	 of	 culture	 under	
	 176	
differentiation	medium,	produced	tissue	with	positive	expression	for	anti-osteopontin,	
anti-osteocalcin,	anti-podoplanin	and	anti-sclerostin	antibodies,	with	the	BMP2-2	group	
showing	higher	intensity	for	all	antibodies.	SIMV-2	showed	a	positive	but	comparatively	
weaker	expression	for	all	the	antibodies.	The	negative	controls	can	be	found	in	Figure	
88.	
	
Figure	86	Fluorochrome	labelling	of	bone	constructs	obtained	by	experimental	group	
BMP2-2	A)	Anti-osteocalcin	(green)	and	anti-osteopontin	(red)	and		B)		anti-sclerostin	
(green)	and	anti-podoplanin	(red).	Scale	bar=200	µm.	
	
Figure	87	Fluorochrome	labelling	of	bone	constructs	obtained	by	experimental	group	
SIMV-2	 A)	 anti-osteocalcin	 (green)	 and	 anti-osteopontin	 (red),	 B)	 	 anti-sclerostin	
(green)	and	anti-podoplanin	(red).	Scale	bar=200	µm.	
	
	 177	
	
Figure	 88	 Immunostaining	 for	 controls	 A)	 anti-osteocalcin	 (green)	 and	 anti-
osteopontin	 (red)	 undifferentiated	 beads,	 B)	 anti-sclerostin	 (green)	 and	 anti-
podoplanin		(red)	of	undifferentiated	beads	and	C)		anti-osteocalcin	(green)	and	anti-
osteopontin	 (red)	 negative	 control,	 B)	 anti-sclerostin	 (green)	 and	 anti-podoplanin		
(red)	of	negative	control.	
6.4.2.2 Quantitative	analysis	of	hDPSCs	3D	osteogenic	bioprocesses	
The	 quantitative	 comparisons	 among	 the	 supplements	 was	 undertaken	 by	 ALPase	
activity	 analysis,	 ARS-based	 quantification,	 chemical	 analysis	 with	 ATR-FTIR	
spectroscopy	analysis	and	X-ray	microanalysis	and	qPCR	with	various	osteogenic	genes.	
ALPase	activities	in	both	groups	increased	through	the	experiment.	Additionally,	both	
groups	showed	a	similar	increase,	with	the	BMP2-2	group	having	higher	expression,	but	
without	significant	differences,	by	day	28,	BMP2-2	achieved	an	increase	of	14.6	times	
fold	and	SIMV-2,	12.6	times	fold.	Both	treatments	seem	to	have	reached	a	plateau	by	
day	21	of	differentiation.	These	results	can	be	seen	in	Figure	89.	
The	level	of	mineralisation	of	the	beads	was	measured	by	quantifying	the	ARS	positive	
area	 in	 stained	 slides.	 Experimental	 group	 BMP2-2	 showed	 higher	 expression	 in	 the	
sample	 times,	 achieving	 a	 significantly	 higher	 positive	 stained	 area	 of	 ≈30	 percent,	
A)
B)
D)
C)
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whereas	SIMV-2	only	achieved	≈20	percent.	Both	groups	showed	a	big	increase	between	
day	21	and	28	of	culture.	These	results	can	be	seen	in	Figure	90.	
	
	
Figure	89	Measurement	of	Alkaline	phosphatase	activity	by	colorimetric	assay,	scored	
by	 experimental	 groups	 BMP2-2	 and	 SIMV-2	 through	 28	 days	 of	 culture.	 For	 each	
group	n=3.	*	indicates	statistical	significance	between	the	three	groups	for	each	time-
point.		
	
Figure	 90	 Semi-quantitative	 indirect	measurement	 of	 Alizarin	 red	 S	 stained	 slides:	
Percentage	of	mineralised	area	of	hydrogels	achieved	by	experimental	groups	BMP2-
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2	and	SIMV-2,	measured	by	image	analysis	software	of	stained	slides	(n=3).	*	indicates	
statistical	significance	between	the	three	groups	for	each	time-point.		
Spectra	from	ATR-FTIR,	ATR-FTIR	imaging	and	X-ray	microanalysis,	confirmed	that	the	
comparison	 of	 mineralisation	 in	 this	 study	 was	 based	 on	 the	 true	 calcified	
hydroxyapatite	components	(Figure	91,	Figure	92,	Figure	93,	Figure	94	and	Figure	95).	
They	were	characterised	 in	ATR-FTIR	by	 the	specific	 spectral	bands	at	1012	cm-1	and	
1445	cm-1	which	are	comparable	with	pure	hydroxyapatite	and	collagen	of	human	bone	
respectively	 and	 in	 X-ray	 microanalysis	 by	 the	 ratio	 Ca/P,	 as	 previously	 reported	
hydroxyapatite	has	a	ratio	of	1.62	(Meyer	et	al.,	1972,	Figueiredo	et	al.,	2012).	It	was	
seen	that	BMP2-2	experimental	group	achieved	better	results	 in	both	analysis	during	
the	28	days	of	culture,	having	a	significantly	stronger	signal	in	the	mentioned	bands	and	
showing	an	average	Ca/P	ratio	higher	than	SIMV-2.	However,	Ca/P	ratios	scored	by	both	
groups	were	lower	than	values	achieved	by	the	perfusion	bioprocessing	under	normal	
differentiation	 conditions.	 These	 low	 ratios	 represent	 non-stoichiometric	
hydroxyapatite	 formation.	 ATR-FTIR	 has	 a	 penetration	 depth	 between	 0.5	 to	 5	 µm	
depending	on	the	wavenumber,	which	allows	a	spectral	contribution	to	be	measured	
and	seen	from	subsurface	material,	while	elemental	analysis	has	a	penetration	depth	of	
1-2	µm.	The	lower	Ca/P	values	obtained	for	the	supplemented	groups	in	comparison	to	
the	 unsupplemented,	 could	 be	 a	 result	 of	 a	 cell-dense	 surface	 producing	 a	 more	
crystallised	 surface	 in	 the	 unsupplemented	 group.	 However,	 the	 better	 C/P	 ratios,	
suggest	the	more	homogeneous	calcification	of	the	supplemented	groups,	as	ATR-FTIR	
is	able	of	subsurface	meassurements	and	X-ray	microanalysis	is	not.		
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Figure	91	ATR-FTIR	spectra	comparison	for	the	two	experimental	groups	21	days	of	
culture.	
	
Figure	92	ATR-FTIR	spectra	comparison	for	the	two	experimental	groups	after	28	days	
of	culture.	
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Figure	93	ATR-FTIR	imaging	comparison	for	A)	SIMV-2	and	B)	BMP2-2,	after	28	days	of	
culture.	Scale	bar=200	µm.	
The	C/P	ratio	 is	a	characteristic	ATR-FTIR	measurement	of	bone,	with	values	of	0.23.	
Samples	were	analysed	measuring	the	absorbance	of	the	samples	for	the	wavenumbers	
1415	(for	C)	and	1035	(for	P)	[cm-1],	the	resulting	values	can	be	seen	in	the	Figure	64.	
	
Figure	94	Relationship	between	the		organic	and	inorganic	fraction	of	bone	constructs.	
C/P	ratio	of	hydrogels	for	for	different	sampling	days.	For	each	group	n=3.	*	indicates	
statistical	significance	between	the	three	groups	for	each	time-point.	
	
Figure	 95	 Measurement	 of	 hydroxyl	 apatite	 quality	 by	 X-ray	 microanalisis.	
Standardised	Ca/P	ratios	scored	by	Experimental	groups	BMP2-2	and	SIMV-2	by	day	
28	 days	 of	 culture	 (n=3).	 *	 indicates	 statistical	 sigbnificance	 comparing	 the	
experimental	groups.	
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Following	 the	 evaluation	 of	 the	 enzymatic	 and	 chemical	 characteristics	 of	 the	
biomaterial	 constructs	 formed	 by	 the	 two	 experimental	 groups,	 osteogenic	
differentiation	 was	 also	 characterized	 by	 distinct	 cellular	 phenotypes.	 Osteogenic	
differentiation	of	hDPSCs	was	evaluated	by	measurement	of	gene	expression	level	using	
qPCR.	The	expression	of	genes	Runx2/CBFA1,	osteocalcin	(BGLAP),	alkaline	phosphatase	
(ALPL),	collagen	type	I	(COL1A1)	and	sclerostin	(SOST)	can	be	seen	in	Figure	96.	
The	positive	 expression	 for	 the	 five	 genes	 in	 the	 two	experimental	 groups,	 indicates	
successful	osteogenic	differentiation.	Particularly,	when	going	from	day	21	of	induction	
to	day	28.	An	enhanced	or	steady	expression	was	seen	in	most	of	the	genes.	BMP2-2	
experimental	group	had	a	steady	expression	of	Runx2	and	produced	an	enhancement	in	
the	expression	of	COL1A1,	BGLAP,	ALPL	and	SOST	in	the	last	7	days	of	culture.	SIMV-2	
group	produced	a	enhancement	in	all	the	analysed	genes	in	the	last	7	days	of	culture.	
These	results	indicate	the	progression	of	the	osteogenic	differentiation.	
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Figure	96	Relative	gene	expression	for	the	osteogenic	markers	A)	RUNX2,	B)	BGLAP,	
C)COL1A1,	D)	ALPL	and	D)	SOST,	for	the	two	experimental	groups	for	28	days	of	culture	
(n=3).	*	indicates	statistical	significance	comparing	day	21	and	day	28	of	culture.		
6.4.2.3 Surface	analysis	by	scanning	electron	microscopy	of	hDPSCs	3D	osteogenic	
bioprocesses	
When	observed	by	SEM,	many	mineralised	deposit	were	detected	within	the	alginate	
hydrogels	 of	 both	 experimental	 groups	 after	 osteogenic	 culture.	 Additionally,	 the	
lacunae	 seen	 in	 the	 histology	 are	 clearly	 viewed	 in	 these	 pictures,	 along	 with	 the	
morphogenesis	 of	 the	 osteoblastic	 cells.	 In	 the	 first	 days	 of	 culture,	 cells	were	 seen	
scattered	 homogenously,	 additionally,	 as	 ECM	was	 still	 not	 produced,	 the	 hydrogels	
were	weak	and	difficult	 to	process	 for	SEM.	After,	 scaffolds	 started	getting	 rigid	and	
pictures	 showed	 the	 presence	 of	 non-stoichiometric	 mineralised	 deposits.	 These	
nodules	 had	 an	 important	 proportion	 of	 calcium	 and	 phosphorous	 (proved	 by	 X-ray	
microanalysis).	By	day	28	the	lacunae	are	distributed	in	large	portions	of	the	scaffolds	
and	in	the	pictures	of	both	groups,	osteocytes	can	be	morphologically	recognised.	The	
morphology	of	the	bone	constructs	produced	by	group	BMP2-2	can	be	seen	in	Figure	97	
A	 to	 C,	 where	 the	 maturation	 of	 the	 tissue	 can	 be	 seen.	 A)	 displaying	 whole	
differentiated	beads,	B)	and	C)	mineralisation,	lacunae	and	mineralising	osteocytes.	
The	morphology	of	the	bone	constructs	produced	by	group	SIMV-2	can	be	seen	in	Figure	
97	D	to	F.	Where,	D)	shows	whole	beads,	E)	and	F)	mineralisation,	osteoid	osteoblasts,	
osteocytes	and	lacunae	being	mineralised	(mineralising	osteocytes).	
The	morphology	of	the	bone	constructs	produced	by	both	experimental	groups	appears	
immature.	In	these	SEM	pictures,	it	can	be	seen	that	cells	in	the	surface	of	the	beads	
resemble	osteocytes	and	their	surroundings	osteocytes	lacuna.	
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Figure	97	SEM	pictures	of	cultured	scaffolds	in	differentiation	medium	after	28	days	
showing	characteristic	bone	features	for	experimental	group	BMP2-2	A),	B),	C),	D),	E),	
F),	G),	H)	and	I)	day	28	and	J)	day	7.	
6.5 Discussions	
The	standard	procedure	for	the	osteogenic	differentiation	of	multipotent	stem	cells	has	
been	 treatment	 of	 a	 confluent	 monolayer	 with	 a	 cocktail	 of	 dexamethasone	 (Dex),	
ascorbic	acid	(Asc)	and	β-glycerophosphate	(β-GP)	(Langenbach	and	Handschel,	2013).	
However,	monolayer	culture	has	been	demonstrated	to	confront	severe	difficulties,	the	
in	vivo/in	vitro	environment	disparity,	the	mismatching	cell	phenotypes	produced,	and	
the	lack	of	adaptability	to	the	three	dimensional	environment,	mainly	because	of	mass	
transfer	limitations.	Tissue	engineering	drives	the	revolution	to	close	the	gap	between	
the	 in	 vivo-in	 vitro	 environments,	 for	 the	 production	 of	 neo-tissue-equivalents.	 Its	
strategy	involves	studying	cells,	3D	scaffolds/biomatrixes	and	the	design	of	bioreactors.	
In	due	process,	elaborating	the	framework	for	systemic	and	controlled	in	vitro	studies	
of	 tissue	development	and	 function.	To	date,	 several	 studies	 in	2D	and	3D	platforms	
have	been	done,	refining	the	technique	to	a	complex	bioprocess	to	produce	bone-like	
constructs	 in	 a	 laboratory	 scale,	 involving	 different	 MSCs,	 3D	 scaffolds,	 growth	
factors/chemical	cues	and	bioreactors	(Zhao	et	al.,	2011,	Karbanova	et	al.,	2010,	Jensen	
et	al.,	2015,	Heng	et	al.,	2015,	Sikavitsas	et	al.,	2002,	Stiehler	et	al.,	2009,	Hwang	et	al.,	
2008,	Hwang	et	al.,	2009,	Randle	et	al.,	2007b,	Diederichs	et	al.,	2009,	Jung	et	al.,	2012a),	
showing	 the	 potential	 use	 of	 MSCs	 in	 bone	 regeneration.	 The	 different	 strategies,	
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encapsulated	 cells	 (or	 cells	 seeded	 into	 a	 scaffold),	 semi-batch	 or	 perfused	 feeding	
strategies	 and	 shear	 stress	 modulation,	 showing	 successful	 results	 for	 osteogenic	
differentiation	 of	 MSCs.	 Nonetheless,	 these	 efforts	 have	 been	 insufficient	 and	 the	
production	of	cellular	constructs	with	heterogeneous	populations	of	cells	is	a	trademark	
of	these	bioprocesses.	With	the	novelty	of	perfused	vessels,	the	gap	between	in	vivo	and	
in	vitro	has	never	been	closer	 to	be	 tight.	Bioprocesses	with	medium	perfusion	have	
been	 introduced,	 providing	 culture	 systems	with	dynamic	 exchange	of	 nutrients	 and	
oxygen,	together	with	a	new	source	of	controlled	shear	stress.	Previously,	we	developed	
a	 culture	 system	 to	 create	 three-dimensional	 bone-like	 tissues	 based	 on	 hDPSCs,	
alginate/gelatin	bead,	and	perfusion-RWV	bioreactor	and	tested	its	performance	with	
regular	 osteogenic	 differentiation	 medium.	 Its	 comparative	 results	 exceeded	 the	
performance	obtained	with	static	culture	and	a	commercially	available	HARV	bioreactor.	
However,	 the	 transition	 from	 laboratory	 to	 the	clinic,	 requires	 the	production	of	 the	
homogeneous	and	constant	production	of	cellular	constructs,	cell	therapy	requires	the	
highest	quality	production.		Therefore,	we	studied	the	capability	of	supplement	BMP2	
at	 physiological	 level	 and	 compared	 it	 with	 simvastatin,	 a	 commonly	 used	 bone	
differentiation	supplement.		
To	the	best	of	our	knowledge,	this	is	the	first	study	demonstrating	the	three	dimensional	
bone-like	tissue	formation	from	hDPSCs	in	alginate/gelatin	scaffolds,	grown	suspended	
in	a	perfusion	bioreactor	system	using	BMP2	at	a	physiological	level.	Most	of	the	studies	
on	BMPs	use	100	 to	1000	times	higher	concentrations.	Thus,	could	have	widespread	
applications	in	bone	tissue	engineering.	
In	this	chapter,	a	pilot	study	was	done,	hDPSCs	were	homogenously	encapsulated	within	
1.1%	alginate	mixed	with	0.1%	gelatin	hydrogels,	afterwards	the	encapsulated	hDPSCs	
were	 placed	 to	 culture	 in	 suspension	 environment	 within	 vessels	 of	 perfusion-RWV	
bioreactor	for	14	days	of	culture,	whereas	the	bioreactor	maintains	controlled	in	vitro	
culture	 conditions	 that	 permit	 tissue	 growth	 and	 development.	 Each	 day	 of	 culture,	
BMP2	 and	 simvastatin	 were	 supplemented	 to	 the	 perfused	 culture	 media	 to	 avoid	
degradation	of	the	supplements.	
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This	bioprocess	provides	a	suspension	culture.	The	laminar	flow	of	medium,	minimise	
cell	 exposure	 to	 shear	 and	 turbulence	which	 can	 negatively	 affect	 the	 cell	 construct	
produced,	while	providing	sufficient	nutrients	and	oxygenation,	as	well	as	osteogenic	
supplements	to	support	three	dimensional	bone	neo-tissue	growth	and	removing	the	
undesirable	cellular	by-products.		
In	 the	 performed	 pilot	 study	 of	 the	 supplements,	 both	 supplements,	 BMP2	
(experimental	 group	 BMP2-1)	 and	 simvastatin	 (experimental	 group	 SIMV-1)	 in	
expansion	 medium,	 demonstrated	 to	 be	 able	 to	 produce	 bone	 differentiation.	
Experimental	group	SIMV-1	revealed	higher	cell	proliferation	and	viability.	Simvastatin	
has	 been	 seen	 to	 protect	 cells	 from	 cellular	 senescence	 induced	 by	 long-term	
cultures/passages	in	vitro	(Zanette	et	al.,	2015),	and	this	effect	could	be	the	underlying	
cause	 of	 the	 differences	 in	 viability.	 Implying	 that	 although	 differentiation	 inhibits	
proliferation,	 simvastatin	 could	 yield	 more	 cells	 than	 other	 bone	 differentiation	
supplements.		
Cell	growth	and	expression	of	the	osteoblastic	phenotype	in	2D	static	culture	has	three	
distinct	 phases:	 1)	 High	 proliferation	 and	 development	 of	 extracellular	 collagenous	
matrix	(10	to12	days).	2)	Matrix	maturation,	down-regulation	of	proliferation	and	up-
regulation	 of	 ALPase	 activity	 (12th	 to	 18th	 day).	 3)	 High	 mineralisation	 and	 further	
decrease	of	proliferation,	declination	of	ALPase	activity	and	the	induction	of	osteocalcin	
expression	(16th	to	20th	day).	Similar	behaviour	can	be	seen	in	the	proliferation	of	cells	
in	the	two	experimental	groups	(BMP2-1	and	SIMV-1)	being	assessed	with	a	time	delay,	
this	could	be	associated	with	the	3D	environment.		
The	bone	neo-tissue	formed	by	cell	grown	within	alginate/	gelatin	hydrogels	consisted	
of	viable	and	metabolically	active	cells,	which	were	evaluated	by	The	 live/dead	assay	
and	 ALPase	 activity.	 It	 showed	 that	 by	 day	 14,	 the	 scaffolds	 produced	 by	 the	 two	
experimental	groups	were	fully	populated	of	living	cells	and	presented	positive	ALPase	
activity.	The	two	groups	did	not	present	significant	differences	in	their	level	of	ALPase	
activity.	 However,	 SIMV-2	 had	 slightly	 higher	 activity.	 Both	 groups	 shown	 higher	
expression	compared	with	the	unsupplemented	system,	SIMV-2	presented	98%	higher	
ALPase	activity	and	BMP2	71%	higher.	
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For	validation	of	the	3D	osteogenic	differentiation	achieved	by	the	two	experimental	
groups,	 the	 cell	 constructs	 during	 differentiation	 were	 characterised	 by	 histological,	
immuno-staining	and	SEM	microscopy.	Histological	H&E	staining	of	sectioned	hydrogels	
at	 day	 0,	 showed	 most	 cells	 appear	 scattered	 in	 the	 bead	 without	 having	 form	
extracellular	 matrix.	 After,	 displayed	 well	 distributed	 tissue	 growth	 for	 both	
experimental	groups.	Morphogenesis	of	the	osteogenic	cells	until	achieving	maturation,	
can	be	seen	in	both	experimental	groups	by	the	emergence	of	osteocyte	lacunae.	ARS	
staining	 indicated	 positive	 differentiation	 after	 the	 14	 day-long	 culture,	 a	 gradual	
enhancement	 in	 mineral	 deposition	 for	 the	 cell	 constructs	 produced	 by	 both	
experimental	groups	was	seen.	Von	Kossa	staining	was	poor	but	slightly	positive,	and	
confirmed	 the	 mineralisation	 by	 showing	 disperse	 deposits	 of	 calcium	 through	 the	
hydrogels	 for	 both	 groups.	 Immunostaining	 for	 osteopontin,	 osteocalcin,	 podoplanin	
and	sclerostin	was	positive	for	both	groups,	showing	cells	undergoing	bone	ontogenesis	
from	early	osteoblasts	to	mature	osteocytes.	
The	 surface	 of	 the	 cell	 constructs	 was	 analysed	 with	 SEM	 microscopy,	 here	 the	
morphogenesis	 of	 the	 hDPSCs	 can	 be	 perceived	 in	 different	 levels	 for	 the	 two	
experimental	 groups,	 BMP2-1	 showed	 higher	 neo-tissue	 maturation,	 seen	 by	 the	
hydroxyapatite	 crystals	 found,	 the	 osteocyte	 lacunae	 and	 the	 presence	 of	 immature	
osteocytes.	
The	 results	of	 the	pilot	 study	suggest	 that	both	 supplements	have	osteogenic	effect.	
Hence,	their	differentiability	in	full	osteogenic	media	was	further	assessed.	
Further	to	the	short	pilot	study,	we	investigated	the	capability	of	supplement	BMP2	at	
physiological	 level	 (experimental	 group	 BMP2-2)	 and	 compared	 with	 simvastatin	
(experimental	group	SIMV-2)	in	full	osteogenic	medium	for	long-term	culture.		hDPSCs	
were	 homogenously	 encapsulated	 within	 1.1%	 alginate	 mixed	 with	 0.1%	 gelatin	
hydrogels,	afterwards	the	encapsulated	hDPSCs	were	placed	to	culture	 in	suspension	
environment	 within	 vessels	 of	 perfusion-RWV	 bioreactor	 for	 28	 days,	 whereas	 the	
bioreactor	maintains	controlled	in	vitro	culture	conditions	that	permit	tissue	growth	and	
development.	
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Both	supplements,	BMP2	and	simvastatin	in	osteogenic	medium,	demonstrated	to	be	
able	to	produce	bone	differentiation.	Experimental	group	SIMV-2	revealed	higher	cell	
proliferation	 and	 viability,	 similar	 to	what	was	 seen	 in	 the	pilot	 study.	However,	 the	
difference	was	significant	only	in	MTS	assay,	but	not	in	ATP	content,	and	after	21	days	
of	culture.	As	previously	stated,	simvastatin	has	been	seen	to	protect	cells	from	cellular	
senescence	induced	by	long-term	cultures/passages	in	vitro	(Zanette	et	al.,	2015),	this	
could	be	the	underlying	cause	of	the	difference.	Simvastatin	could	yield	more	cells	than	
other	bone	differentiation	supplements	by	partially	abrogating	 the	negative	effect	of	
differentiation	in	proliferation.		
Cell	growth	and	expression	of	the	osteoblastic	phenotype	in	2D	static	culture	follows	a	
three	 staged	pattern	 previously	 described,	 and	 	 a	 similar	 behaviour	was	 seen	 in	 the	
proliferation	of	cells	in	both	experimental	groups,	but	with	a	time	delay,	this	could	be	
associated	 with	 the	 3D	 environment.	 The	 plateau	 observed	 in	 the	 cell	 proliferation	
profiles	 at	 the	 end	 of	 the	 experiment,	 is	 in	 accordance	 with	 a	 typical	 cell	 culture	
sigmoidal	curve,	and	cells	have	reached	a	stationary	phase,	with	the	apoptotic	behaviour	
observed	of	mature	osteoblasts	residing	in	mineralised	nodules	(Sikavitsas	et	al.,	2002).	
The	live/dead	assay	showed	that	by	day	28,	the	scaffolds	were	fully	populated	of	living	
cells.	
The	 morphological	 analyses	 by	 light	 microscopy	 showed	 how	 ECM	 formation	 and	
mineral	deposition	happen	through	the	culture.	At	the	beginning	of	the	culture,	beads	
where	transparent	and	cells	were	visible	with	light	microscopy.	However,	through	the	
culture,	it	was	seen	how	ECM	formation	and	mineralisation	began	blocking	the	light	until	
light	transmission	through	the	beads	was	not	possible.		
The	bone	neo-tissue	formed	by	cell	growth	within	alginate/	gelatin	hydrogels	consisted	
of	viable	and	metabolically	active	cells,	which	were	evaluated	by	measuring	pH,	glucose,	
glutamine,	lactate,	ammonia	and	oxygen	kinetics	in	osteogenic	medium	during	cultures.	
It	 has	 been	 reported	 that	 the	 profile	 of	 pH	 and	 these	 metabolites	 can	 be	 used	 to	
modulate	 cell	 metabolism,	 for	 instance	 ECM	 deposition	 and	 neo-tissue	 progress	 for	
developing	optimal	 culture	condition	 for	SCs	culture	 (Obradovic	et	al.,	1999).	Animal	
cells	utilize	glucose	and	glutamine	as	vital	energy	sources.	Through	glycolysis,	1	molecule	
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of	glucose	 is	metabolised	and	produces	2	molecules	of	 lactate	as	a	by-product	under	
anaerobic	 condition,	 yielding	 2	 mole	 of	 adenosine	 triphosphate	 (ATP)	 per	 mole	 of	
glucose,	or	C02	and	H20	through	the	TCA	cycle	in	aerobic	condition,	yielding	36	mole	of	
ATP	per	mole	of	glucose.	Through	the	TCA	cycle,	1	molecule	of	glutamine	is	lysed	into	
glutamate	and	produces	1	molecule	of	ammonia	as	by-product.	Hence,	the	amount	of	
ammonia	can	be	used	as	an	indicator	of	glutamine	utilization	and	TCA	cycle	activity.	In	
our	study	of	supplemented	3D	osteogenesis.	Glucose	consumption	kinetics	showed	both	
experimental	 groups	 had	 similar	 profiles,	 a	 slow	 but	 steady	 decrease	 through	 the	
culture,	implying	the	adequate	feeding	strategy	to	produce	metabolically	active	cells	in	
sustained	growth.	In	lactate	kinetics,	both	groups	produced	concentrations	below	toxic	
levels,	reaching	a	maximum	of	10	[mmol/L],	 this	reflects	the	slow	but	steady	glucose	
consumption	 seen.	 As	 metabolites	 are	 removed,	 if	 glucose	 were	 to	 reach	 zero,	 the	
limiting	concentration	of	lactate	achievable,	would	be	12	[mmol/L],	never	reaching	toxic	
levels	(>16	[mmol/L]).A	high	glucose	medium	could	help	cell	proliferation,	but	as	well	
would	increase	the	concentration	of	lactate	produced	and	with	it,	the	risk	of	damaging	
the	cells	would	arise.	Glutamine	showed	a	similar	profile	for	both	groups,	going	down	
for	the	first	14	days	and	then	rising	up	again,	ammonia	had	a	behaviour	that	mirrors	
glutamine	 consumption.	 We	 believe	 the	 decrease	 in	 the	 consumption	 of	 glutamine	
reflects	 proliferation	 reaching	 stationary	 phase	 and	 the	 amount	 of	 cell	 constructs,	
sampled	rather	than	the	cells	consumption.	Ammonia	did	not	reach	toxic	levels	through	
the	whole	culture	for	both	groups,	with	values	between	1	and	2	[mmol/L]	(less	than	4	
[mmol/L]).	Additionally,	pH	and	oxygen	concentration	are	other	parameters	to	consider	
as	 these	 affect	 cell	 viability,	 growth,	 differentiation	 and	 metabolic	 activity.	 pH	 in	
osteogenic	medium	decreased	with	culture	time	and	followed	the	 increase	of	 lactate	
and	ammonia	concentration,	as	 it	 is	known	that	these	metabolites	affect	medium	pH	
(Barngrover	et	al.,	1985).	pH	change	was	within	the	proper	pH	range	(7.0-7.4)	of	cell	
culture	media,	implying	no	strong	influence	on	cell	growth	and	function.	Oxygen	has	a	
major	 role	 in	 SCs	 growth	 and	 differentiation,	 hypoxic	 conditions	 favouring	
undifferentiated	 expansion	 and	 normoxic	 conditions,	 differentiation.	 For	 both	
experimental	groups,	oxygen	fluctuated	between	normoxic	values	through	the	whole	
culture.	
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For	 validation	 of	 the	 3D	 osteogenic	 differentiation	 achieved	 by	 both	 experimental	
groups,	 the	 cell	 constructs	 during	 differentiation	 were	 characterised	 by	 histological,	
immuno-staining	and	SEM	microscopy.	Histological	H&E	staining	of	sectioned	hydrogels,	
showed	how	undifferentiated	cells	at	the	beginning	of	the	culture,	appear	scattered	in	
the	beads	without	having	form	extracellular	matrix.	After,	displayed	well	distributed	and	
homogeneous	 tissue	 growth	 for	 both	 experimental	 groups.	 Morphogenesis	 of	 the	
osteogenic	cells	until	achieving	maturation,	can	be	seen	by	the	emergence	of	osteocyte	
lacunae.	Interestingly,	BMP2-2	group	shows	better	neo-tissue	formation,	with	lacunae	
spreading	homogeneously	through	the	whole	bead.	SIMV-2	shows	lacunae	forming	from	
the	 core	 to	 the	 surface,	 but	 not	 reaching	 the	 surface,	 as	 opposed	 with	 the	
unsupplemented	 culture	which	 produced	 lacunae	 from	 the	 surface	 to	 the	 core	 (see	
Figure	53).	ARS	staining	indicated	a	progressive	differentiation	through	time,	a	gradual	
enhancement	 in	 mineral	 deposition	 for	 the	 cell	 construct	 produced	 by	 both	
experimental	 groups.	 The	ARS	quantitative	 analysis	 is	 consistent	with	 the	qualitative	
results	 and	BMP2-2	group	 shows	better	performance	 than	SIMV-2	group.	Von	Kossa	
confirmed	 the	 mineralisation	 by	 showing	 scarce	 but	 positive	 disperse	 deposits	 of	
calcium	 through	 the	 hydrogels.	 Immunostaining	 for	 osteopontin,	 osteocalcin,	
podoplanin	and	sclerostin	was	positive	for	both	groups,	showing	cells	undergoing	bone	
ontogenesis	 from	early	 osteoblasts	 to	mature	 osteocytes.	 BMP2-2	 group	 had	 clearly	
higher	expression.	Meanwhile	osteopontin	(marker	of	early	osteoblasts)	and	osteocalcin	
(marker	of	mature	osteoblasts)	positive	regions	can	be	seen	through	the	whole	bead,	
podoplanin	(marker	of	early	osteocyte)	and	sclerostin	(marker	of	mature	osteocyte)	are	
positive	selectively	in	the	inner	or	outer	areas	of	the	scaffold	respectively,	showing	how	
osteocyte	maturation	is	dependant	of	the	surrounding	osteoid	and	hydroxyapatite.	The	
surface	 of	 the	 cell	 constructs	 was	 analysed	 with	 SEM	 microscopy,	 here	 the	
morphogenesis	 of	 the	 hDPSCs	 can	 be	 perceived	 in	 different	 levels	 for	 both	 groups,	
where	osteoid	osteoblasts	and	mineralising	osteocytes	are	clearly	distinguished,	but	not	
mature	osteocytes	with	dendritic	processes	(canaliculi).	Both	groups	showed	high	neo-
tissue	 maturation,	 seen	 by	 the	 many	 hydroxyapatite	 crystals	 found,	 the	 osteocyte	
lacunae	and	the	presence	of	osteoid	osteoblasts	and	mineralising	osteocytes,	however,	
the	unsupplemented	culture,	showed	more	mature	structure	and	terminal	osteocytes.	
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ATR-FTIR	of	human	bone	shows	carbonate	bands	at	wavenumbers	870,	1415	and	1470	
[cm-1],	and	phosphate	bands	at	wavenumber	565,	605	and	1035	[cm-1].	Carbonate	bands	
are	distinctive	of	the	bone	organic	component	(mainly	collagen)	and	phosphate	bands	
of	 the	 inorganic	 fraction	 (hydroxyapatite),	 and	 the	 ratio	 of	 organic	 and	 inorganic	
component,	 C/P	 is	 characteristic	 biogenic	 signature	 for	 human	 bone.	 However,	 it	 is	
recommended	 to	 use	 the	 phosphate	 peak	 of	 1035	 and	 carbonate	 peak	 of	 1415	 to	
calculate	C/P	ratio.	When	these	wavenumbers	are	used,	the	human	bone	C/P	ratio	is	
0.23	 	 (Beasley	 et	 al.,	 2014).	When	differentiation	 starts,	 the	C/P	 ratio	 is	 high,	 and	 it	
decreases	with	differentiation	and	hydroxyapatite	formation.	BMP2-2	group	produced	
a	significantly	higher	C/P	value	by	day	21,	but	by	day	28,	it	decresed	to	a	significantly	
lower	value,	achieving	≈0.23,	the	exact	value	described	for	human	bone	in	literature,	
showing	good	differentiation.	SIMV-2	culture	achieving	≈0.3.	ATR-FTIR	imaging	confirms	
these	results,	with	yellow	being	positive	and	blue	negative.	
X-ray	microanalysis	(SEM/EDS)	of	hydroxyapatite	shows	the	elemental	composition	of	
the	analysed	materials,	it	has	been	seen	that	the	Ca/P	ratio	represents	a	characteristic	
biogenic	 signature	 of	 the	 inorganic	 fraction	 of	 bone	 (hydroxyapatite).	 Pure	
hydroxyapatite	has	a	Ca/P	ratio	of	1.67	(Medina	Ledo	et	al.,	2008).	In	our	experiments,	
both	 groups	 scored	 low	 ratios,	 demonstrating	 the	 production	 of	 calcium	 deficient	
hydroxyapatite	(non-stoichiometric).	BMP2-2	group	scored	a	significantly	higher	value.	
Further	analysis	demonstrated	the	quality	of	the	bone	construct	achieved,	and	the	low	
scores	for	Ca/P	ratio,	could	be	product	of	the	more	homogeneous	cell	construct,	while	
values	 presented	 in	 the	 previous	 chapter,	 show	 a	 surface	 differentiation	 front	 with	
highly	calcified	surface,	less	calcified	interior.	More	research	should	be	done	until	the	
proper	 ratio	 is	 reached.	 This	 statement	 can	 be	 confirmed	with	 the	ATR-FTIR	 results,	
whish	measure	with	a	depth	of	penetration	of	up	to	5	[um],	against	the	0.1-2	[nm].	
3D	 osteogenesis	 was	 characterised	 at	 a	 genetic	 level,	 examining	 the	 expression	 of	
Runx2/CBFA1,	 osteocalcin	 (BGLAP),	 alkaline	 phosphatase	 (ALPL),	 collagen	 type	 I	
(COL1A1)	and	sclerostin	(SOST),	these	genes	are	representative	of	the	entire	MSCs	to	
osteocyte	ontogenesis.	Osteogenic	ontogenesis	requires	the	precise	and	orchestrated	
activity	 of	 several	 genes	 and	 signals	 (extracellular	 and	 intracellular).	 Runx2	 is	 a	
transcription	 factor	 and	 the	 central	 control	 of	 osteogenic	 differentiation.	 Its	
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upregulation	 happens	 early	 in	 the	 ontogenesis,	 and	 is	 believed	 to	 have	 a	 constant	
expression	 through	 the	whole	differentiation	 (Shui	et	al.,	2003).	ALPL	 is	a	ubiquitous	
cellular	protein,	and	its	function	is	ill-defined.	However,	it	is	known	that	its	action	starts	
as	early	as	2	days	after	the	beginning	of	the	osteogenic	drive.	Its	expression	is	increased	
steadily	through	the	differentiation.	Collagen	I	(Col1a1),	is	an	important	component	in	
the	bone	ECM,	with	a	role	in	cell	adhesion,	proliferation	and	osteoblast	phenotype,	its	
upregulation	 is	 characteristic	 of	 osteogenic	differentiation	 and	 can	be	 considered	an	
early	marker	of	differentiation.	Osteocalcin	(BGLAP),	is	an	osteoblast	specific	gene	and	
one	of	the	most	abundant	proteins	in	bone,	its	expression	is	significantly	upregulated	in	
matrix	 synthesis	 and	mineralisation	 (Ryoo	et	 al.,	 1997).	 Sclerostin	 (SOST)	 is	 a	 known	
specific	gene	for	mature	osteocytes,	and	It	is	integral	to	osteocyte	function	as	a	signal	
to	 damp	 the	 action	 of	 osteoblast	 bone	 deposition	 and	 to	 control	 bone	metabolism	
(Compton	and	Lee,	2014).	
MSCs,	preosteoblasts	and	osteoblasts	express	Runx2	together	with	secreting	osteoid,	
when	pre-osteoblasts	 go	 through	maturation,	 the	expression	alkaline	phosphatase	 is	
increased.	 When	 mature	 osteoblasts	 become	 embedded	 in	 osteoid,	 they	 express	
osteocalcin	 and	 start	 producing	 dendritic	 projections	 characteristic	 of	 osteocytes.	
Through	all	the	ontogenesis,	collagen	1	is	secreted.	BMP2-2	experimental	group	showed	
a	constant	expression	of	Runx2	along	with	high	10	times	fold	increase	in	expression	of	
osteocalcin.	The	expression	of	these	two	genes,	could	signify	most	of	the	cells	already	
went	through	the	transition	from	immature	to	mature	osteoblast.	The	increase	of	SOST	
in	 the	 last	 week	 of	 culture	 could	 represent	 the	 further	 transition	 from	 mature	
osteoblasts	 to	 osteocytes.	 During	 all	 this	 period,	 Col1a1	 and	 ALPL	 were	 active	 and	
positive	with	a	6-time	fold	and	a	3	times	fold	increase.	These	genes	are	related	with	ECM	
formation	 and	 mineralisation,	 and	 are	 indicative	 of	 a	 well	 developed	 in	 vitro	
osteogenesis.	 These	 results	 suggest	 that	 a	 homogeneous	 population	 of	 cells	 was	
produced	 with	 cells	 in	 a	 mature	 osteoblastic	 and	 early	 osteocytic	 stage.	 SIMV-2	
experimental	 group	 showed	 high	 increase	 in	 expression	 of	 Runx2	 (10	 times	 fold),	
Galindo	and	coleagues	sugest	that	an	increase	in	Runx2	is	related	with	the	the	cessation	
of	cell	growth	(i.e.	G0/G1	transition)	(Galindo	et	al.,	2005),	this	could	be	 linked	to	cell	
growth	achieving	stationary	phase.	A	high	expression	of	osteocalcin	was	seen	by	day	21,	
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but	by	day	28,	the	increase	was	low.	The	expression	of	these	two	genes,	could	signify	
cells	are	going	through	late	stages	of	maturation	and	are	becoming	osteocytes.	The	high	
increase	of	 SOST	 in	 the	 last	week	of	 culture	 could	 sustain	 this	 idea	of	maturation	 to	
osteocytes.	During	all	this	period,	Col1a1	was	low	positive,	meanwhile	ALPL	was	highly	
expressed.	 These	 genes	 are	 related	 with	 ECM	 formation	 and	 mineralisation,	 col1a1	
being	 an	 early	 marker,	 and	 ALPL	 a	 more	 mature	 and	 are	 indicative	 of	 late	 stage	
differentiation.	These	results	suggest	that	a	homogeneous	mostly	osteocytic	population	
of	cells	was	produced.		
BMP2-2	 group	 showed	 lower	 proliferation,	 higher	 calcification	 and	 a	 more	
homogeneous	bone	tissue	with	what	we	believe	to	be	population	of	mature	osteoblasts	
and	a	smaller	fraction	of	osteocytes.	SIMV-2	group	showed	a	higher	proliferation,	less	
calcified,	 with	 a	 less	 homogeneous	 construct,	 populated	 with	 what	 we	 believe	 is	 a	
mixture	of	osteoblasts	and	higher	fraction	of	early	osteocytes.	
The	 viability	 and	 proliferation,	 AP	 activity,	 gene	 expression,	 immunostaining,	 and	
calcium	 deposition	 observed	 in	 the	 BMP2-2	 group,	 along	 with	 the	 morphological	
analyses	done,	suggest	that	this	group	produced	a	homogeneous	construct	of	mature	
osteoblasts.	these	cells	are	active	cells	capable	of	proliferate,	secrete	osteoid,	calcify	and	
merge/	 consolidate	 with	 the	 in	 vivo	 environment.	 The	 more	 mature	 cell	 construct	
product	of	SIMV-2	group,	are	a	functional	cell	construct	rather	than	a	developmental	
cell	 construct.	 Hence,	 the	 merge/	 consolidation	 with	 in	 vivo	 tissue	 would	 be	 more	
difficult	to	achieve.	Sclerostin	producing	osteocytes	have	a	negative	effect	in	osteoblast	
proliferation	 and	 increase	 bone	 resorbing	 osteoclast	 presence	 and	 activity	 in	 the	
surrounding	 in	 vivo	 areas.	 However,	 the	 SIMV-2/osteocyte	 construct	 would	 be	 very	
useful	to	research	osteocyte	phenotype	and	function.	
	
6.6 Conclusions	
This	study	demonstrated	that	the	bioprocessing	providing	perfusion	flow	of	medium	in	
a	 suspended	 environment	 is	 successful	 in	 the	 mitigation	 of	 nutrient	 and	 oxygen	
transport	limitations,	external	to	three-dimensional	cell/alginate	constructs,	positively	
influencing	 the	 proliferation,	 differentiation,	 mineralisation	 and	 expression	 of	
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osteoblastic	markers	of	hDPSCs	cultured	in	the	presence	of	osteogenic	media,	and	the	
supplementation	with	either	BMP2	or	SIMV,	provide	successful	enhancing	strategies	for	
the	homogeneous	production	of	bone	mimics,	ultimately	enabling	the	formation	of	3D	
bone-like	constructs	for	clinical	and	research	purposes.	Additionally,	we	demonstrated	
that	 this	 bioprocessing	 positively	 influences	 the	 proliferation,	 differentiation,	
mineralisation	and	expression	of	osteoblastic	markers	of	hDPSCs	cultured	in	the	absence	
of	 osteogenic	 osteoinductive	 supplements,	 apart	 from	 BMP2	 or	 SIMV.	 Through	 the	
analyses	followed	to	characterise	these	constructs,	the	capability	of	the	bioprocess	to	
reproduce	the	whole	osteogenic	lineage	ontogenesis	was	established.		
Progressive	differentiation	was	confirmed	for	both	experimental	groups,	by	the	gene	
expression	pattern,	the	ALPase	activity,	the	gradual	decrease	of	the	C/P	ratio	measured	
by	ATR-FTIR	and	the	ARS	positive	area,	measured	by	software	analysis.	However,	the	
increase	 in	 the	 Ca/P	 ratio,	 measured	 by	 SEM/EDS	 was	 poor	 and	 demonstrated	 the	
production	of	non-stoichiometric	hydroxyapatite,	previously	we	showed	better	results	
with	the	unsupplemented	bioprocess,	this	constructs	had	a	surface	differentiation	front,	
and	 produced	 a	 highly	 mineralised	 surface.	 Both	 experimental	 groups	 presented	 a	
homogeneous	 differentiation	 front,	 hence	 producing	 less	mineralised	 surface.	 These	
were	 qualitatively	 validated	 by	 immunostaining,	 H&E	 and	 von	 Kossa	 staining,	 SEM	
pictures	and	ATR-FTIR	imaging.	Experimental	group	BMP2-2	achieved	better	results	in	
most	of	the	analysis,	producing	a	well	mineralised	homogeneous	cell	construct,	mainly	
populated	by	osteoblasts,	 hence	 showing	big	potential	 in	 regenerative	medicine	and	
clinic.	Interestingly,	experimental	group	SIMV-2	produced	a	mineralised	homogeneous	
cell	construct,	mainly	populated	by	osteocytes,	hence	showing	big	potential	for	research	
in	bone	functionality.	The	perfusion	culture	system	supplemented	with	either	BMP2	or	
simvastatin	 described	 here,	 would	 provide	 an	 efficient	 and	 easy	 culture	 system	 for	
applications	in	bone	tissue	engineering	in	the	context	of	macroscopic	bone	neo-tissue	
formation.	In	particular,	the	successful	use	of	physiological	BMP2	promises	to	have	an	
impact	 in	 cell	 therapy,	 as	 this	 low	 dosage,	 could	 help	 to	 avoid	 the	 negative	 dose	
dependent	risk	product	of	BMP2	therapeutics.			
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7 Summary	and	conclusions
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Mesenchymal	 stem	 cells	 from	 most	 tissues	 of	 the	 body	 have	 arisen	 as	 attractive	
therapeutic	tools	with	high	potential	in	regenerative	medicine.	Their	capability	to	give	
raise	to	a	variety	of	cell	types,	made	them	the	focus	of	extensive	research	to	produce	
biological	 substitute	 devices.	 hDPSCs	 are	 a	 particular	 source	 for	 adult	mesenchymal	
stem	cells.	They	present	ease	in	access	and	extraction,	high	proliferative	characteristics,	
bone	 tissue	 differentiability	 and	 they	 do	 not	 elicit	 ethical	 considerations,	 as	 their	
extraction	is	one	of	the	less	invasive	between	SCs.		
Tissue	 engineering	 encompasses	 the	 required	 toolset	 to	 process	 SCs	 into	 tissue	
constructs.	Through	the	crosstalk	between	cellular	biology	and	engineering,	it	attempts	
to	discover	the	missing	link	between	cells	and	the	 in	vivo	environment.	Ultimately,	to	
generate	 a	 bridge	 for	 ex	 vivo	 cellular	 constructs	 to	 fuse	 with	 living	 organisms.	 Its	
approach	has	been	to	find	the	proper	tools	to	bioprocess	SCs	and	produce	neo-tissue	
able	to	mimic	and	replace	their	in	vivo	counterparts.	Tissue	engineering	researches:	a)	
the	cellular	factor,	their	 interactions	and	the	developmental	processes	they	follow	to	
produce	 neo-tissue.	 b)	 the	 bio-signalling	 factor,	 comprising	 the	 cues	 and	 stimuli	 to	
sustain	 cells	 and	 drive	 their	 differentiation	 to	 the	 adequate	 lineage.	 C)	 the	
environmental	factor,	the	three	dimensional	area,	where	cells	inhabit	and	develop,	able	
to	 be	 converted	 into	 the	 tissue	 itself,	 with	 all	 the	 extracellular	 components	 and	
structures	found	in	a	regular	tissue,	along	with	the	functionality	required.	and	finally,	d)	
the	bioprocessing	factor,	the	design	of	bioreactors	able	provide	the	platform	to	deliver	
nutrients	and	oxygen	for	the	cells	to	develop	appropriately.	Additionally,	the	physical	
stimuli,	along	with	the	macro	environment	for	all	the	previous	factors	to	interact.		
Bone	 tissue	engineering,	would	be	 the	particular	 field	 researching	bone	healing.	The	
cells	able	to	differentiate	into	functional	osteogenic	cells,	producing	the	characteristic	
extracellular	 matrix.	 The	 required	 physical	 and	 chemical	 cues	 to	 drive	 bone	
differentiation.	The	 fabrication	of	 resorbable	 scaffolds	displaying	 suitable	mechanical	
and	 biological	 properties	 to	 replace	 large	 bone	 defects,	 and	 able	 to	 undergo	 neo-
vascularisation	 when	 implanted	 in	 vivo.	 The	 design	 and	 fabrication	 of	 tailor-made	
bioreactors	able	to	supply	homogeneous	medium	environment,	efficient	mass	transport	
characteristics,	together	with	the	physical	stimuli,	during	the	culture	process.		
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Before	the	bioreactor	era,	most	research	was	done	in	2D	monolayered	static	culture.	
However,	 this	 system	 was	 not	 appropriate	 for	 tissue	 development.	 Bone	 cells	 are	
enclosed	 in	 a	 3D	 complex	 histoarchitecture	 not	 reproducible	 in	 2D.	 Thus,	 in	 vivo	
reproducibility	 of	 the	 2D	 in	 vitro	 development	 is	 unfeasible.	 To	 confront	 the	
adimensionality	of	this	system,	3D	scaffolds	where	incorporated	into	the	system	and	TE	
continued	 to	 evolve	 towards	 the	 production	 of	 functional	 tissue	 substitutes.	
Nonetheless,	this	setting	provided	the	cells,	with	nutritional	diffusion	constrains,	hence	
requiring	 an	 adequate	 delivery	 system.	 Dynamic	 suspended	 culture	 bioreactors,	
wherein	the	cell/	scaffold	constructs	are	processed	under	controlled	conditions,	such	as	
nutritional	 requirements,	 temperature,	 pH	 and	 dissolved	 gases,	 appear	 to	 be	 the	
solution	to	this	hindrance	and	to	long-term	stem	cell	culture.	
In	this	thesis,	a	bioprocess	for	the	homogeneous	undifferentiated	expansion	and	further	
bone	 differentiation	 was	 established.	 The	 in-house	 designed	 perfusion	 system	
incorporated	 to	a	RWV	unit	provided:	a	convenient	gas-permeable	membrane	vessel	
casing	and	an	oxygenator	to	ensure	the	homogeneous,	efficient	and	constant	supply	of	
oxygen,	medium	perfusion	 to	 ensure	 adequate	nutrient	 supply	 and	metabolic	waste	
removal,	 and	 the	 avoidance	 of	 experimental	 error	 from	 manual	 operation	 by	 an	
automation	 system.	 These	 novel	 features,	 consequently,	 resulted	 in	 an	 effectively	
maintained	 culture	 condition	 throughout	 the	 entire	 long-term	 culture.	 Additionally,	
showing	 to	 be	 a	 convenient	 adaptation	 culture	 environment	 by	 controlling	 culturing	
factors	at	real	time.		
The	 bioprocess	 has	 successfully	 proven	 to	 be	 a	 significant	 improvement	 for	
maintenance,	expansion	and	osteogenic	differentiation	of	hDPSCs,	in	comparison	to	fed-
batch	 bioreactors	 and	 2D	 static	 culture.	 It	 was	 effective	 in	 producing	 the	 complete	
osteogenic	lineage	ontogenesis,	producing	cells	ranging	from	the	early	and	mature	stage	
osteoblasts,	to	further	produce	the	early	and	mature	stage	osteocytes.	Additionally,	the	
characteristic	bone-extracellular	matrix	and	mineral	deposition	produced,	was	found	to	
successfully	 replace	 the	 scaffold	 architecture.	 Hence,	 producing	 a	 bone-mimicking	
construct.	Ultimately,	a	bioprocess	for	the	production	of	homogeneous	reproducible	3D	
bone	neo-tissue	was	established.	
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Hence,	it	was	concluded	that	this	bioprocessing,	providing	perfusion	flow	of	medium	in	
a	 suspended	 environment	 is	 successful	 in	 the	 mitigation	 of	 nutrient	 and	 oxygen	
transport	limitations,	external	to	three-dimensional	cell/alginate	constructs	and	is	more	
efficient	that	the	HARV	bioreactor	and	the	3D	static	culture,	positively	influencing	the	
proliferation,	differentiation,	mineralisation	and	expression	of	osteoblastic	markers	of	
hDPSCs	cultured	in	the	presence	of	osteogenic	media,	ultimately	enabling	the	formation	
of	3D	bone-like	constructs	for	clinical	purposes.	However,	this	setup	alone	still	produces	
a	level	of	heterogeneity	in	the	constructs,	with	mixture	of	mature	and	immature	cells	
and	distinguishable	different	microscopic	neo-tissue	anatomy.		
These	 enhanced	 culture	 conditions	 successfully	 proven	 to	 significantly	 improve	 the	
designed	 three-dimensional	 hDPSCs	 bioprocess.	 Consequently,	 resulted	 in	 further	
enhanced	maintenance	condition	throughout	the	entire	long-term	culture.	Additionally,	
both	biologics	showing	to	be	an	effective	solution	to	the	homogeneous	production	of	
bone	cell	constructs.	
Studies	 describing	 the	 3D	 undifferentiated	 expansion	 of	 hDPSCs	 in	 3D	 environment,	
under	 long-term	 culture	 have	not	 been	 found	 in	 Pubmed,	 EBSCO	or	Google	 scholar.	
Albeit	this	was	not	the	main	scope	of	this	research	project,	a	first	approximation	has	
been	 done	 and	 it	 could	 lead	 to	 further	 research.	 There	 is	 the	 need	 to	 design	 the	
appropriate	protocol	specifically	for	hDPSCs	expansion,	addressing	cell	seeding	density	
that	would	yield	the	optimal	number	of	cells	while	maintaining	their	multipotency,	as	
well	as	the	seeding	density	for	the	better	differentiation	is	still	on	demand.	The	mass	
production	 of	 undifferentiated	 hDPSCs	 for	 its	 further	 banking	 could	 provide	 ready-
availability	of	cells	for	any	cell	therapy	when	required,	and	the	impact	 in	the	medical	
market	 could	 be	 significant.	 Additionally,	 the	 proper	 control	 of	 cell	 density	 for	 cell	
differentiation	 could	 produce	 the	 rich	 in	 cells	 cell-construct	 required	 for	 a	 fast	
integration	when	implanted	in	vivo.				
Prior	to	this	project,	similar	settings	have	been	used	to	bioprocess	bone-like	constructs	
with	interesting	results	(Cha,	2010,	Bancroft	et	al.,	2003,	Janssen	et	al.,	2006,	Qian	et	al.,	
2013,	Gardel	et	al.,	2014,	Li	et	al.,	2014,	Sinlapabodin	et	al.,	2016,	Kleinhans	et	al.,	2015,	
Wang	 et	 al.,	 2003,	 Gomes	 et	 al.,	 2006,	 Hosseinkhani	 et	 al.,	 2006,	 Gao	 et	 al.,	 2016).	
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However,	 the	positive	 results	 shown,	were	 limited	by	 the	difficulties	 inherent	 to	 SCs	
processing,	heterogeneous	production	of	cells	and	an	ill-characterised	bone	construct	
(Sheehy	et	al.,	2015).	Most	of	 the	studies	done	 in	 this	 field,	procure	 to	demonstrate	
osteogenic	 differentiation	 with	 a	 limited	 number	 of	 widespread	 analyses:	 ALPase,	
proliferation,	 SEM	 microscopy,	 OC	 expression	 and	 histology	 and	 occasionally,	
mechanical	 loading	and;	but	 lack	 the	 thorough	characterisation	a	product	of	medical	
nature	requires.	Producing	bone	implants	for	humans,	requires	the	fully	characterisation	
of	the	cellular	biomaterial	produced.	Not	only	is	it	required	to	assess	biological	aspects,	
as	cell	types	with	the	analysis	of	a	number	of	protein	and	gene	expression;	but	also	by	
the	composition	and	physical	aspects	of	the	biomaterial.	X-ray	microanalysis	and	FTIR	
are	 effective	 for	 characterising	 composition	 of	 the	 biomaterial.	 Mechanical	 loading	
testing	 should	be	performed	 in	 vitro	 and	 in	 vivo	 to	 assess	 the	materials	 response	 to	
vibration,	 fluid	 shear,	 substrate	 deformation	 and	 compressive	 loading	 compared	 to	
regular	bone.	These	aspects	of	the	biomaterial	should	match	the	bone	tissue	they	would	
replace.	Bone	tissue,	as	previously	described,	is	comprised	by	bone-forming	cells,	bone-
resorbing	cells	and	functional	cells.	It	is	required	to	be	able	to	describe	the	ontogenesis	
of	 the	 produced	 tissue,	 which	 stage	 of	 differentiation	 is	 accomplished	 and	 how	
homogeneous	 the	 cell	 constructs	 are.	 The	 cell-types	 will	 be	 determining	 of	 the	
applicability	 of	 the	 therapy.	 In	 this	 project,	 that	 extra	 layer	 of	 characterisation	 was	
applied	 to	 the	 validation	 of	 the	 cell-constructs	 produced	 by	 the	 in-house	 designed	
bioreactor.	Spotting	structural	features,	as	well	as	specific	markers	(genes	and	proteins)	
of	bone	turnover	unique	to	each	stage/	cell	type,	measuring	viability,	enzymatic	activity	
and	 composition	 of	 the	 cell	 constructs.	 Additionally,	 the	 nutritional	 aspects	 of	 the	
system	were	 assessed	 following	metabolic	 kinetics	 of	 key	 nutrients	 and	 cellular	 by-
products.	Mechanical	 testing	was	 not	 performed,	 but	 future	work	 should	 include	 its	
measurement.	 By	 following	 this	 characterisation,	 the	 production	 of	 homogeneous	
mineralised	 tissue,	 rich	 in	 either	 osteoblasts	 or	 osteocytes	 was	 established.	 Cell	
construct	 Homogeneity	 plays	 a	 key	 role,	 as	 fully	 matured	 osteocytes,	 would	 bring	
difficulties	 for	 the	cell	construct	 to	 fuse	with	the	treated	bone	defect.	To	accomplish	
these	homogenous	histo-constructs,	the	use	of	minimal	growth	factors	was	assessed.	
Utilising	BMP2	at	physiological	level,	as	well	as	a	common	osteogenic	signal,	simvastatin.	
To	our	knowledge,	this	is	the	only	successful	study	showing	positive	effect	of	BMP2	at	
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such	 low	 level	 (300	 pg/ml),	 demonstrating	 significant	 differences	 with	 regular	
differentiation	media.	Normal	 studies	 involving	BMP2,	utilise	concentrations	50-1000	
times	higher	to	be	able	to	obtain	comparable	results	(Nguyen	et	al.,	2016,	Lysdahl	et	al.,	
2014).	Supra-physiological	doses	have	been	proved	to	produce	ectopic	bone	formation.	
Additionally,	 there	 is	 a	 significant	 association	 between	 treatment	 with	 BMP2	 and	
incidence	of	cancer	(Carragee	et	al.,	2013b).	Ultimately,	the	expensive	administration	
makes	low	dosing	not	only	valuable	for	stem	cell	bioprocessing,	but	a	requirement.	
If	the	variability	of	MSCs-constructs	was	controlled,	3D	bioprocessing	could	score	better	
results.	Hence,	the	knowledge	obtained	over	this	investigation	puts	the	clinical	setting	
at	a	glance.	However,	more	validation	is	required	for	a	safety	product	to	be	achieved.	
Good	manufacturing	practices	(GMP)	should	be	adopted	and	in	vivo	validation	should	
be	followed.	GMP	require	quality	control	of	collection,	processing,	storage	and	release	
of	 cell	 therapy	 products	 and	 of	 the	 facilities,	 equipment,	 materials	 and	 quality	
assurance:	control,	validation,	qualification	and	documentation	(Giancola	et	al.,	2012).	
It	 would	 require	 for	 the	 culture	 media	 to	 be	 fully-defined	 and	 not	 containing	 any	
exogenous	materials,	a	single	step	closed	setup	bioprocess	in	a	clinical	setup.	
For	validation	and	assessment	of	the	neotissue	constructs	efficacy	and	safety,	an	in	vivo	
model	 should	 be	 done.	 A	 preclinical	 study	 to	 assess	 bone	 union	 after	 implantation	
(osseointegration),	osteoconduction,	vascularisation	and	the	physical	properties	of	the	
resulting	implant	should	be	performed.	Critical-size	defects	should	be	treated	with	cell	
therapy	 and	 then	 assessed	 for:	 biochemical	 markers	 of	 bone	 turnover,	 bone/mass	
density	 measurement,	 analysis	 of	 bone	 architecture/histology,	 and	 biomechanical	
testing	 of	 bone	 strength.	 Preclinical	 studies	 in	 animal	models	 are	 key	 to	 ensure	 the	
quality	required	to	start	clinical	studies	and	essential	in	the	medical	devices	production	
pipeline.	Without	fulfilling	these	requirements,	the	product	would	fail	at	the	arrival	to	
the	clinical	platform.	Furthermore,	in	vivo	models	represent	the	only	true	assessment	to	
compare	cell	constructs	between	different	bioprocess	platforms.	
Research	in	perfusion	is	taking	new	directions,	from	perfusing	media	directly	through	
scaffolds,	with	3D	printed	microfluidic	systems	(Mohanty	et	al.,	2015),	to	scaffold	free	
3D	systems	with	cell	aggregates	(Ong	et	al.,	2008).	Although	these	strategies	promise	to	
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provide	 new	 advantages	 in	 the	 field,	 it	 is	 arguable	 that	 they	 would	 bring	 higher	
processing	complexity	for	the	operators	and	set	back	the	possibility	of	automation.		
In	 the	 future,	 the	 adequate	bioprocess	would	be	 a	 single	 step	 closed	 setup.	Able	 to	
process	patient	cells	in	a	fully	automated	routine.	Starting	from	scaffold	seeding,	until	
the	 fully	 differentiated	 bone	 neo-tissue	 construct	 is	 ready	 to	 be	 transplanted.	 This	
strategy,	would	allow	minimal	handling	of	operators,	avoiding	disruptions,	variability,	
contamination	of	the	samples.	The	system	should	allow	the	production	of	critical	size	
implants	able	to	vascularise	when	transplanted,	here	microfluidics	will	play	an	important	
role.	 Additionally,	 producing	 tissue	 implants	 in	 hospitals	 would	 elude	 logistical	
complication,	as	transferring	specimens	amid	different	locations.	Good	manufacturing	
practices	should	be	tightly	followed.	Additionally,	the	tissue	mimics	should	be	amenable	
for	 long	 term	 storage,	 allowing	 the	 prompt	 availability	 of	 tissue	 for	 emergency	
transplants	when	a	patient	custom	made	cell	construct	is	not	possible,	or	is	not	timely	
feasible.	Research	is	still	on	demand	to	reach	a	point	where	safety	cell	constructs	are	
fabricated	and	cell	 therapy	becomes	 the	standard	procedure	 in	hospitals.	Until	 then,	
development	will	keep	pioneering	new	bioprocesses.	
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8 Future	work
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Although	 numerous	 major	 progresses	 have	 been	 introduced	 in	 the	 bone	 tissue	
engineering	field,	current	bioprocessing	still	faces	many	shortcomings,	and	no	adequate	
substitutes	have	been	developed.	Bone	tissue	is	complex,	its	development	and	healing	
involves	 an	 entangled	 network	 of	 growth	 factors,	 working	 in	 joint	 effort	 with	
multipotent	cells	 in	a	characteristic	environment.	Knowledge	 is	 limited	and	unknown	
factors	yet	need	to	be	discovered.	
Development	 in	 cell	 sources,	 signalling	 molecules,	 scaffolds	 and	 bioreactor	 could	
provide,	 the	 means	 to	 close	 the	 in	 vitro/	 in	 vivo	 gap,	 and	 help	 the	 transfer	 of	 the	
mimicking	 devices	 developed,	 to	 a	 clinical	 setting.	 Additionally,	 the	 tight	 good	
manufacturing	practices	are	required	to	be	followed.		
Future	studies	in	our	perfusion	system,	to	produce	the	homogeneous	bone	replacement	
while	 shortening	 culture	 time	 could	 be	 achieved	 by	 the	 incorporation	 of	 biologically	
active	molecules	into	the	scaffold	structure	(rather	than	in	the	culture	medium).	Hence,	
providing	more	cues	to	cell	attachment,	expansion	and	differentiation.	BMP2,	TGF-β1,	
PDGF,	VEGF,	or	other	known	osteogenic	factors	could	be	dispersed	or	covalently	linked	
to	alginate/	gelatin	hydrogels.	Pharmacokinetics,	 life-span	of	the	biologics	in	use,	and	
the	 interactions	with	the	cells,	would	require	to	be	studied.	Long-term	culture	would	
affect	 integrity,	 effectiveness	 and	 the	 availability	 of	 growth	 factors	 for	 bone	
differentiation	in	long	periods	of	culture.	
Determining	 the	 optimal	 operational	 conditions	 of	 the	 perfusion-RWV	 bioreactor.	
Different	stages	of	differentiation	could	require	different	perfusion	rates.	The	metabolic	
activity	of	undifferentiated	cells,	immature	cells	and	mature	cells,	are	different.	Hypoxic	
culture	has	been	reported	to	yield	higher	proliferation,	keeping	cells	undifferentiated,	
even	under	confluent	conditions.	On	the	contrary,	normoxia	has	been	seen	to	support	
cell	differentiation.	These	conditions	are	easily	modified	with	the	appropriate	incubator	
where	 the	 perfusion	 system	 resides.	 Finding	 the	 adequate	 strategy	 for	 hypoxic	
expansion	 and	 normoxic	 differentiation,	 could	 yield	 a	 better	 bone	 construct.	
Additionally,	osteogenic	tissue	is	acknowledged	to	be	sensitive	to	mechanical	stimuli	in	
vivo	 and	 in	 vitro,	 numerous	 studies	 have	 incorporated	 mechanical	 stimuli	 to	 their	
designs,	with	interesting	results.	Suggesting	that	incorporating	a	convenient	ultrasound	
	 204	
prove	 to	 the	 existing	 perfusion-RWV	 system,	 could	 yield	 enhanced	 bone	 construct	
production.	Alternatively,	it	has	been	reported	that	low	level	light	irradiation	(LLLI)	and	
pulsed	electro-magnetic	field	(PEMF)	have	an	effect	on	the	proliferation	and	osteogenic	
differentiation	 of	 MSCs.	 Attaching	 a	 red-light	 light	 emitting	 diode	 (LED)	 irradiation	
system	to	the	vessel	wouldn’t	be	difficult,	as	the	membrane	case	is	suitably	transparent	
and	 radiation	 could	 travel	 through.	 Two	 round	 solenoid	 electromagnets	 forming	 a	
Helmholtz	coil	could	be	allocated	surrounding	the	vessel	to	produce	an	electro-magnetic	
field.	Both	systems	should	be	accounted	for	their	pulsed	strategy	effect.	
	
Figure	98	Ultrasound	probe	perfusion-RWV	bioreactor	vessel	
	
Figure	99	Red	LED	perfusion-RWV	bioreactor	vessel	
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Figure	100	PEMF	perfusion-RWV	bioreactor	vessel	
Serum	 free,	 xeno	 free	 and	 chemically	 defined	 medium	 experiments	 should	 be	
performed.	 Bioprofiling	 of	 different	 culture	 conditions	 should	 be	 taken,	 to	 further	
develop	computational	models	of	the	culture,	to	assist	and	optimise	the	supplements	to	
be	added	in	the	medium.	Serum	and	other	culturing	reagents	of	animal	origin,	part	of	
traditional	undefined	culture	media,	pose	numerous	safety	issues	in	clinical	therapy	(e.g.	
infections,	 immune	 reactions).	 Serum	 and	 xeno	 components	 are	 not	 allowed	 when	
working	under	GMP	conditions.	This	technology	requires	the	use	of	fully	defined	and	
non	animal	materials	to	reach	clinical	relevance.	The	perfusion-RWV	system	is	a	suitable	
platform	to	stablish	the	required	parameters	to	achieve	GMP	conditions.	
	
Figure	101	GMP	facility	
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Donor/	cell	dependent	computational	models	should	be	developed.	Clinical	efficacy	is	
variable	 and	 it’s	 unclear	 how	 the	 phenotypes	 defining	 MSCs	 as	 well	 as	 donor	
characteristics	(e.g.	age,	gender)	affect	their	functional	properties.	Studying	the	intrinsic	
variability	 produced	 by	 donor	 specific	 characteristics,	 should	 be	 assessed	 and	
bioprocessing,	determining	the	parameters	to	be	controlled	to	minimise	heterogeneous	
production.	
All	the	mentioned	parameters	would	help	to	improve	the	bioprocessing	of	MSCs	and	aid	
the	optimal	 production	of	 clinically	 utilisable	 bone	 cell	 devices.	However,	 the	 ready-
availability	 of	 cellular	 constructs	 is	 as	 vital	 as	 the	 quality	 of	 the	 constructs.	 Hence,	
studying	 the	 long	 term	 storage	 of	 scaffolds	 loaded	 with	 cells	 undifferentiated	 and	
differentiated,	would	pose	 invaluable.	Methodologies	 of	 storage,	 along	with	 viability	
and	maintenance	of	undifferentiated	and	differentiated	phenotype	of	cells	should	be	
studied.	 Currently	 there	 are	 different	 storage	 methodologies,	 some	 use	
cryopreservation	 (e.g.	 in	 serum	 and	DMSO,	 in	 sperm	 freezing	medium,	 vitrification).	
Hence,	freezing	and	thawing	processes	have	to	be	accounted.	others	do	not	(e.g.	sub-
zero	non	freezing	storage,	cryoprotectants).		
Finally,	more	focus	on	in	vivo	studies	is	unavoidable	and	there	is	need	for	more	research	
on	composite	scaffolds	in	realistic	biological	systems.	All	the	mentioned	settings	should	
reach	in	vivo	pre-clinical	and	clinical	testing,	to	ensure	safety	of	the	produced	constructs.		
All	these	studies	would	be	expected	to	produce	the	homogeneous,	highly	mineralised	
and	functional	tissue.	However,	cell	proliferation,	quality	and	time	of	culture	would	be	
modified.	Probably	getting	us	closer	to	the	day	when	bone	TE	bioprocessing	reaches	the	
clinical	field	and	synthetically	produced	osteo-bio-neo-tissues	start	aiding	people.		
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Figure	102	morphology	of	hydrogels	observed	under	light	microscopy	of	A)	Day	7,	B)	
day	 28	 HARV	 bioreactor,	 C)	 day	 28	 static	 culture	 Flask,	 D)	 day	 28	 Perfusion-RWV	
bioreactor.	Scale	bar=200	µm.	
	
	
	
Figure	103	Live	dead	assay	A)	at	day	0,	B)	at	day	7,	C)	at	day	28	for	cells	seeded	in	
perfusion-RWV	bioreactor,	D)	at	day	28	for	cells	seeded	in	HARV	bioreactor,	E)	at	day	
28	for	cells	seeded	in	3D	static	culture.	scale	bar=200	µm.	
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Figure	104	Alizarin	red	staining	of	beads	produced	by	3D	Static	culture	A)	day	14,	B)	
day	21,	C)	and	D)	day	28	
	
	
Figure	105	Alizarin	red	staining	of	beads	produced	by	HARV	bioreactor	A)	and	D)	day	
14,	B)	and	E)	day	21,	C)	and	F)	day	28	
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Figure	106	Alizarin	red	staining	of	beads	produced	by	perfusion-RWV	bioreactor	A),	B)	
and	 C)	 day	 14,	 D)	 and	 E)	 day	 21,	 G)	 and	 H)	 day	 28,	 F)undifferentiated	 hDPSCs,	
G)negative	control	
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